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Abstract 
 
Coronary atherosclerosis and plaque rupture leads to acute coronary thrombosis and 
myocardial infarction. Current treatment involves re-establishing vessel patency, but 
no treatments have been developed to target post-infarction inflammatory pathways. 
Such treatments may reduce cardiomyocyte injury, attenuate adverse remodelling 
and improve clinical outcome.  
Inflammation within the infarcted myocardium is associated with chemotaxis of 
neutrophils and monocytes to the site of injury. Early reperfusion therapy amplifies 
this inflammatory cell influx. Neutrophil release a variety of pro-inflammatory 
factors, including human neutrophil elastase (HNE). HNE has a wide range of 
substrates. Preclinical studies have demonstrated that neutrophil depletion or 
inhibition of neutrophil elastase attenuates post-ischemic inflammatory reperfusion 
injury within the myocardium. Recruitment of monocytes into the infarcted 
myocardium is followed by maturation and differentiation into macrophages. 
Macrophages play a key role in orchestrating inflammation and repair. Therapeutic 
manipulation of this healing process will only come from understanding mechanisms 
and targeting reparative pathways.  
 “Ultrasmall superparamagnetic iron oxide particles” (USPIOs) extravasate through 
capillaries and are phagocytosed by tissue inflammatory cells. These cells are 
predominately macrophages, but neutrophils have also been shown to take up 
USPIOs. USPIO-enhanced MRI can identify areas of inflammation in models 
inflammation in various tissues. Therefore we hypothesised that USPIO enhanced 
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MRI could identify and assess cellular inflammation of the myocardium. 
During coronary artery bypass graft surgery (CABG), the myocardium receives an 
immediate ischaemic insult that is exacerbated by post-ischaemic reperfusion 
inflammatory responses leading to increased myocardial injury. CABG surgery can 
therefore be used as a clinical model of myocardial infarction and inflammation. We 
investigated this with blood markers of inflammation, MRI scanning and USPIO. 
Elafin inhibits the destructive and inflammatory HNE enzyme. Beyond this elafin 
inhibits inflammatory cytokines and modulates the innate and adaptive immune 
systems. In preclinical studies elafin treatment is associated with reduced myocardial 
injury. As such, elafin has a marked potential for the treatment of cardiovascular 
disease involving inflammation. Therefore, we hypothesised that elafin will reduce 
perioperative ischaemic myocardial injury and inflammation in patients undergoing 
elective coronary artery bypass graft surgery.  
We demonstrated for the first time that USPIOs are taken up by the infarct tissue in 
patients with recent myocardial infarction and by the peri-infarct myocardium to a 
lesser degree. This represents a novel non-invasive method to further study cardiac 
inflammation and therapeutic interventions. 
All patients undergoing CABG surgery demonstrated >10-fold elevation above the 
99th centile of cardiac troponin by high sensitivity assay (hs-cTnI) indicating the 
current universal definition of type 5 myocardial infarction lacks specificity. A peak 
hs-cTnI at 6 hours following CABG surgery appears to be related to the surgical 
process and non-specific myocardial injury whilst a continuing increase at 24 hours 
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suggests myocardial infarction. We would suggest hs-cTnI sampling at 6 and 24 
hours post CABG surgery together with ECG assessment for the routine detection 
and diagnosis of type 5 MI. Differing levels of humoral makers inflammation post 
CABG surgery occurred, and did not correlate directly with the length of 
cardiopulmonary bypass time or hs-cTnI release. For the first time we identified 
differing levels of inflammatory cell infiltrate into the myocardium post CABG. This 
varied from none to levels similar to infarcted myocardial tissues. 
Elafin did not attenuate myocardial ischemia-reperfusion injury and inflammation. 
Post-hoc analysis identified reduced cTnI concentrations at 6 hours in Elafin treated 
patients and it is possible that a bigger dose would have conferred protection out to 
48 hours. Elafin did not attenuate the cellular infiltration into the myocardium post 
CABG surgery, but did appear to reduce inflammation in renal tissue. USPIO 
enhanced CMR holds major promise in the non-invasive assessment of myocardial 
inflammation post surgery. 
  
 
Detection, assessment and modulation of myocardial inflammation 5 
Contents 
Abstract ....................................................................................................................... 2 
Contents ...................................................................................................................... 5 
Table of Figures ........................................................................................................ 11 
Table of Tables ......................................................................................................... 13 
Abbreviations ........................................................................................................... 15 
Declaration ................................................................................................................ 18 
Preface ....................................................................................................................... 19 
Acknowledgements ................................................................................................... 20 
Chapter 1: myocardial inflammation following ischaemia-reperfusion injury . 22 
1.1 Overview ................................................................................................ 22 
1.2 Myocardial infarction ............................................................................. 23 
1.2.1 Troponin biology and kinetics ........................................................... 23 
1.2.2 Myocardial cellular inflammation post infarction.............................. 24 
1.3 Coronary artery bypass surgery ............................................................. 28 
1.3.1 Myocardial inflammation post cardiac surgery.................................. 28 
1.4 Role of the endogenous elastase in cardiovascular inflammation and 
injury ...................................................................................................... 30 
1.4.1 Neutrophil-derived elastases and vascular inflammation .................. 30 
1.4.2 Modulation of thrombosis and fibrinolysis and potential involvement 
in acute coronary syndromes .............................................................. 33 
1.4.3 Regulation of inflammatory signalling .............................................. 34 
1.5 Neutrophil elastase activity regulation ................................................... 36 
1.5.1 endogenous inhibitors ........................................................................ 36 
1.5.2 Potential clinical application of biological and synthetic inhibitors of 
HNE ................................................................................................... 37 
1.6 Modification of inflammation by Elafin ................................................ 39 
1.6.1 Elafin as a potent endogenous inhibitor of neutrophil elastase .......... 39 
1.6.2 Tissue distribution and regulation of elafin ....................................... 40 
1.6.3 Inhibition of inflammatory cytokine production ................................ 41 
1.7 Neutrophil mediated injury as a potential target for attenuation of 
inflammation .......................................................................................... 43 
1.7.1 Neutrophil-mediated ischemia-reperfusion injury ............................. 43 
1.8 Therapeutic application of elafin in cardiovascular disease .................. 46 
 
Detection, assessment and modulation of myocardial inflammation 6 
1.9 Magnetic Resonance Imaging of the myocardium ................................. 48 
1.10 Imaging inflammation using Ultrasmall Superparamagnetic Particles of 
Iron Oxide .............................................................................................. 49 
1.10.1 Imaging Methodology .................................................................... 52 
1.10.2 Assessing myocardial inflammation. ............................................. 56 
1.11 Summary ................................................................................................ 59 
1.12 Aim and Hypotheses .............................................................................. 61 
Chapter 2: Methods ................................................................................................. 62 
2.1 Ethical And Regulatory Considerations ................................................. 62 
2.2 Subject Recruitment ............................................................................... 63 
2.2.1 Patients With Myocardial Infarction .................................................. 63 
2.2.2 Healthy Volunteers ............................................................................. 63 
2.2.3 Patients Undergoing CSBG Surgery: The EMPIRE study ................ 64 
2.3 Blood Sampling And Testing ................................................................. 65 
2.3.1 Venepuncture ..................................................................................... 65 
2.3.2 Assays ................................................................................................. 65 
2.4 Elafin ...................................................................................................... 66 
2.4.1 Study Drug Identification ................................................................... 66 
2.4.2 Study Drug Manufacturer ................................................................... 66 
2.4.3 Labelling ............................................................................................. 67 
2.4.4 Storage ................................................................................................ 67 
2.4.5 Study Drug Preperation And Administration ..................................... 67 
2.4.6 Randomisation .................................................................................... 68 
2.5 Placebo ................................................................................................... 69 
2.6 Participant Compliance .......................................................................... 69 
2.7 Overdose................................................................................................. 69 
2.8 Additional Outcomes.............................................................................. 70 
2.9 Cardiac Magnetic Resonance ................................................................. 71 
2.9.1 Contrast Agents - Gadolinium............................................................ 71 
2.9.2 Contrast Agents - USPIO ................................................................... 71 
2.9.3 Imaging Methodology ........................................................................ 71 
2.9.4 Cine And Late Enhancement Imaging ............................................... 73 
2.9.5 Uspio Scanning Protocol .................................................................... 73 
 
Detection, assessment and modulation of myocardial inflammation 7 
2.9.6 Timing Of USPIO MRI Scans ........................................................... 74 
2.9.7 Analysis Of Ejection Fraction And Volume Of Infarction ................ 74 
2.9.8 USPIO Enhanced MRI Image Preperation ........................................ 75 
2.10 Study Protocols for the Assessment Of Cellular Inflammation Following 
Acute Myocardial Infarction  (Chapter 3) .............................................. 77 
2.10.1 Subjects .......................................................................................... 77 
2.10.2 Ultrasmall Superparamagnetic Particles Of Iron Oxide ................. 78 
2.10.3 Magnetic Resonance Imaging ........................................................ 78 
2.10.4 Image Analysis ............................................................................... 78 
2.10.5 Data And Statistical Analysis For Chapter 3 ................................. 81 
2.11 Elafin Myocardial Protection From Ischemia Reperfusion (EMPIRE) 
Trial – Chapters 4, 5 & 6 ........................................................................ 82 
2.11.1 Clinical Study And Recruitment .................................................... 82 
2.11.2 Coronary Artery Bypass Graft Surgery.......................................... 83 
2.11.3 Electrocardiogram .......................................................................... 83 
2.11.4 Blood Biomarkers .......................................................................... 84 
2.11.5 Cardiac Magnetic Resonance Imaging ........................................... 84 
2.11.6 Development Of Uspio Uptake Analysis Protocols ....................... 85 
2.11.7 Data And Statistical Analysis For Chapter 4 ................................. 86 
2.11.8 Data And Statistical Analysis For Chapter 5 ................................. 87 
2.11.9 Data And Statistical Analysis For Chapter 6 ................................. 87 
Chapter 3: Ultrasmall Superparamagnetic Particles Of Iron Oxide Detect 
Cellular Inflammation In Patients With Acute Myocardial Infarction .............. 89 
3.1 Summary ................................................................................................ 89 
3.2 Introduction ............................................................................................ 91 
3.3 Results .................................................................................................... 93 
3.3.1 USPIO uptake in healthy volunteers .................................................. 93 
3.3.1.1 Myocardium ................................................................................... 93 
3.3.1.2 Other organs ................................................................................... 95 
3.3.1.3 USPIO & Iron the in blood pool .................................................... 97 
3.3.2 Completion Of Protocol For Patients With Myocardial Infarction .. 101 
3.3.3 Repeatability .................................................................................... 103 
3.3.4 Effect of USPIO Administration ...................................................... 108 
3.3.5 Non-Specific Effects Of USPIO ...................................................... 111 
 
Detection, assessment and modulation of myocardial inflammation 8 
3.4 Discussion ............................................................................................ 113 
Chapter 4: Peri-Operative Elafin For Ischemia-Reperfusion Injury During 
Coronary Artery Bypass Graft Surgery: A Randomised Controlled Trial ...... 118 
4.1 Summary .............................................................................................. 118 
4.2 Introduction .......................................................................................... 120 
4.3 Results .................................................................................................. 122 
4.3.1 Patient Characteristics And Intra-Operative Details ........................ 122 
4.3.2 Elafin And Elastase Activity ............................................................ 125 
4.3.3 Troponin I ......................................................................................... 127 
4.3.4 CMR ................................................................................................. 130 
4.3.5 Humoral inflammatory markers ....................................................... 132 
4.3.6 Clinical Outcomes ............................................................................ 134 
4.4 Discussion ............................................................................................ 136 
Chapter 5: Assessment Of Cellular Inflammation Post Coronary Bypass 
Grafting Surgery – Empire Sub-study ................................................................. 143 
5.1 Summary .............................................................................................. 143 
5.2 Introduction .......................................................................................... 145 
5.3 Methods ................................................................................................ 148 
5.4 Results .................................................................................................. 149 
5.4.1 Completion of scanning protocol ..................................................... 149 
5.4.2 USPIO Uptake: Elafin Vs Placebo ................................................... 150 
5.4.2.1 Myocardium ................................................................................. 150 
5.4.2.2 Skeletal Muscle and Reticuloendothelial System  Uptake ........... 155 
5.4.2.3 Kidneys ......................................................................................... 157 
5.4.3 USPIO Uptake: Pooled Results ........................................................ 160 
5.4.3.1 Myocardial uptake post CABG surgery ....................................... 160 
5.4.3.2 Skeletal Muscle and Reticuloendothelial System. ....................... 167 
5.5 Discussion ............................................................................................ 171 
Chapter 6: Myocardial Inflammation, Injury And Infarction During On-Pump 
Coronary Artery Bypass Graft Surgery .............................................................. 178 
6.1 Summary .............................................................................................. 178 
6.2 Introduction .......................................................................................... 180 
6.3 Results .................................................................................................. 182 
6.3.1 Recruitment And Baseline Characteristics ....................................... 182 
 
Detection, assessment and modulation of myocardial inflammation 9 
6.3.2 Humoral Inflammation ..................................................................... 187 
6.3.3 Myocardial Injury............................................................................. 190 
6.3.4 Myocardial Infarction....................................................................... 192 
6.3.4.1 Electrocardiogram ........................................................................ 192 
6.3.4.2 Cardiac Magnetic Resonance ....................................................... 194 
6.4 Discussion ............................................................................................ 198 
Chapter 7: Conclusions and Future Directions ................................................... 202 
7.1 Background .......................................................................................... 202 
7.1.1 Myocardial infarction ....................................................................... 202 
7.1.2 Myocardial Inflammation following ischaemia and infarction ........ 203 
7.1.3 Magnetic Resonance Imaging in Tracking Cellular Inflammation .. 205 
7.1.4 Coronary Artery Bypass Surgery ..................................................... 205 
7.1.5 Elafin ................................................................................................ 206 
7.2 Summary of thesis findings .................................................................. 207 
7.2.1 Changes in R2* in USPIO enhanced MRI scans detect cellular 
inflammation post myocardial infarction ......................................... 207 
7.2.2 Myocardial injury post coronary artery bypass surgery can be assessed 
with blood markers of inflammation and infarction. ....................... 207 
7.2.3 Elafin, the neutrophil elastase inhibitor, did not modify post coronary 
artery bypass surgery myocardial injury and inflammation ............. 208 
7.2.4 Cellular inflammation post coronary artery bypass surgery can be 
detected and assessed using USPIO enhanced MRI scanning. ........ 208 
7.3 Future directions .................................................................................. 210 
7.3.1 Proposed continuation of research from chapter 3 ........................... 210 
7.3.1.1 IRNMAN Trial ............................................................................. 210 
7.3.2 Proposed continuation of research from chapter 4 ........................... 212 
7.3.2.1 Elafin in the modulation of cardiovascular inflammation ............ 212 
7.3.3 Proposed continuation of research from chapter 5 ........................... 213 
7.3.3.1 DECIFER-HEART Trial .............................................................. 215 
7.3.3.2 Detection & Modulation of inflammation in renal tissue ............ 218 
7.3.4 Proposed continuation of research in chapter 6 ............................... 220 
7.3.4.1 Hypothesis .................................................................................... 220 
7.3.4.2 Expected Value of Results ........................................................... 221 
References ............................................................................................................... 222 
 
Detection, assessment and modulation of myocardial inflammation 10 
Appendix A: Elafin Review Paper ................................................................... 244 
Appendix B: USPIO Review Paper ................................................................. 285 
Appendix C: USPIO To Detect Inflammation In Patients With Acute MI . 320 
Consent form for active group (Figure 1) ........................................................ 320 
GP information  - Active Group (Figure 2)...................................................... 322 
Patient Information – Active Group ................................................................. 324 
Consent form for control group (figure 3)  ...................................................... 335 
GP information for Control Group ( Figure 4) ................................................. 336 
Patient Information – Control Group ............................................................... 337 
Study Protocol .................................................................................................. 347 
Appendix D: EMPIRE Trial ............................................................................ 361 
Consent form (Figure 1) ....................................................................................... 362 
GP Letter (Figure 2) ............................................................................................. 363 
EMPRIRE Study – Patient Information ............................................................... 365 
Trial Protocol ........................................................................................................ 373 
Appendix E: USPIO in Myocardial Infarction Publication .......................... 431 
Appendix F: Heart Publication ....................................................................... 461 
Appendix G: Animal Studies ............................................................................ 496 
USPIO enhanced CMR in rodent model of myocardial infarction ...................... 497 
Background ...................................................................................................... 497 
Methods ............................................................................................................ 497 
Results .............................................................................................................. 500 
Conclusion ........................................................................................................ 504 
Nanoparticle enhanced MRI scanning to detect cellular inflammation in 
experimental chronic renal allograft rejection. .................................................... 505 
Abstract ............................................................................................................ 505 
Introduction ...................................................................................................... 506 
Materials And Methods .................................................................................... 508 
Results .............................................................................................................. 513 
Discussion ........................................................................................................ 522 
Appendix H: Future Studies ............................................................................. 562 
IRNMAN Trial ................................................................................................. 562 
DECIFER-HEART Trial .................................................................................. 568 
 
Detection, assessment and modulation of myocardial inflammation 11 
Table of Figures 
Figure 1.1 Inflammatory effects of HNE and proteinase 3. ....................................... 31 
Figure 1.2 Elafins’ effects on inflammation .............................................................. 42 
Figure 1.3 Elafins’ effects on cardiovascular pathologies. ........................................ 47 
Figure 1.4 USPIO concentrating in lysosome in macrophage. .................................. 51 
Figure 1.5 Creation of T2* map from multiple echo times. ...................................... 54 
Figure 1.6 T2* decay curve and time constant with and without USPIO. ................. 55 
Figure 2.1 Object map creation .................................................................................. 80 
Figure 3.1 Correlation between R2* increase in the myocardium, skeletal muscle or 
blood pool in healthy volunteers. ....................................................................... 98 
Figure 3.2 R2* Increase in myocardium in vivo & ex vivo blood & increase in iron 
content ................................................................................................................ 99 
Figure 3.3 Tissue R2* Values .................................................................................. 104 
Figure 3.4 Comparison of R2* colour maps in patients with myocardial infarction105 
Figure 3.5 Bland-Altman plot - Differences versus average of R2* values in all 
patients. ............................................................................................................ 106 
Figure 3.6 Medullary and extramedullary R2* value post myocardial infarction ... 112 
Figure 4.1 Patient flow chart .................................................................................... 123 
Figure 4.2 Perioperative plasma Elafin concentration (A) and plasma elastase activity 
(B) between groups. ......................................................................................... 126 
Figure 4.3 Myocardial injury. .................................................................................. 128 
Figure 4.4 Perioperative hsCRP (A) and inflammatory cytokines IL-6 (B) and IL-8 
(C) release between groups. ............................................................................. 133 
Figure 5.1 Myocardial USPIO uptake ...................................................................... 153 
Figure 5.2 Increase in R2* values in renal tissue ..................................................... 159 
Figure 5.3 Left – Pan-myocardium R2* increase in healthy volunteers (n=10) and 
post-coronary artery bypass graft (CABG) surgery. ........................................ 161 
Figure 5.4 R2* increase in the myocadium of patients suffering MI, undergoing 
CABG surgery and healthy volunteers compared to skeletal muscle uptake. . 162 
 
Detection, assessment and modulation of myocardial inflammation 12 
Figure 5.5 Number of myocardial segments with significant USPIO uptake. ......... 164 
Figure 5.6 hsCRP vs R2* increase in the myocardium. ........................................... 166 
Figure 6.1 Study flow diagram ................................................................................. 183 
Figure 6.2 Perioperative cytokine, high-sensitivity c-reactive protein (hsCRP) 
concentrations and circulating white blood cell (WBC) count. ....................... 189 
Figure 6.3 Perioperative high-sensitivity cardiac troponin. ..................................... 191 
Figure 6.4 Troponin versus CMR & ECG changes. ................................................ 193 
Figure 6.5 Change in ejection fraction ..................................................................... 196 
Figure 6.6 Associations between area under the curve high-sensitivity cardiac 
troponin I and LGE & maximum hs-CRP ........................................................ 196 
Figure 7.1 Comparison of myocardial R2* values post surgery, infarction and in 
controls.  ........................................................................................................... 214 
 
 
 
 
Detection, assessment and modulation of myocardial inflammation 13 
Table of Tables 
Table 1-1 Iron oxide nanoparticle preparations ......................................................... 50 
Table 3-1 R2* values of myocardium in healthy volunteers ..................................... 94 
Table 3-2 R2* increase of various tissues in healthy volunteers ............................... 95 
Table 3-3 Iron content and R2* values in ex vivo & in vivo blood and the 
myocardium of healthy volunteers. .................................................................. 100 
Table 3-4 Characteristics of trial participants. ......................................................... 102 
Table 3-5 R2* value (s-1) in infarct region of interest (ROI) of control patients ..... 107 
Table 3-6 R2* value (s-1) in regions of interest (ROI) of patients receiving USPIO.
 .......................................................................................................................... 109 
Table 4-1 Baseline characteristics and intra-operative details by treatment group.  
Data are number of patients (%) or mean ± SD ............................................... 124 
Table 4-2 Post-hoc analysis of plasma cardiac troponin I (cTnI) concentration to 48 
hours. ................................................................................................................ 129 
Table 4-3 Magnetic resonance imaging analysis of postoperative ejection fraction, 
left ventricular mass and infarct volume. ......................................................... 131 
Table 4-4 Post-operative complications and outcomes by treatment. ..................... 135 
Table 5-1 USPIO uptake from all myocardial segments ......................................... 151 
Table 5-2 USPIO uptake from all myocardial segments excluding the apex .......... 152 
Table 5-3 R2* increase in skeletal muscle post CABG (Elafin vs Placebo). .......... 156 
Table 5-4 Increase in R2* in the reticuloendothelial system (Elafin vs Placebo). The 
data was not normally distributed. ................................................................... 156 
Table 5-5 Change in creatinine levels and creatinine clearance pre and post CABG 
surgery in Elafin group. ................................................................................... 158 
Table 5-6 Change in creatinine levels and creatinine clearance pre and post CABG 
surgery in Placebo group. ................................................................................. 158 
Table 5-7 Increase in R2* from pre to post surgery in skeletal muscle. .................. 168 
Table 5-8 Increase in R2*in the reticuloendothelial system in CABG patients 
compared to healthy ......................................................................................... 169 
 
Detection, assessment and modulation of myocardial inflammation 14 
Table 6-1 Baseline patient characteristics. ............................................................... 184 
Table 6-2 Clinical outcomes. ................................................................................... 186 
Table 6-3 Cardiac troponin and cytokine concentrations. ........................................ 188 
  
 
Detection, assessment and modulation of myocardial inflammation 15 
Abbreviations 
 
cTnT  - Cardiac Troponin T 
cTnI  - Cardiac Troponin I 
cTnC  - Cardiac Troponin C 
IL  - Interleukin 
MCP  -  Monocyte chemoattractant protein 
HNE  _ Human neutrophil elastase 
M-CSF - Macrophage colony stimulating factor 
TNF  - Tumour necrosis factor 
CABG  - Coronary artery bypass surgery 
CPB  - Cardio-pulmonary bypass 
CMR  - Cardiac magnetic resonance 
WHO  - Who health organisation 
MMP  _  Matrix metallo-proteinases 
TIMP  - Tissue inhibitor of metallo-proteinases 
TFPI  - Tissue factor pathway inhibitor 
LPS  - Lipopolysaccharide 
PAR  - Protease activated receptor 
SLPI    - Secretory leukocyte protease inhibitor 
 
Detection, assessment and modulation of myocardial inflammation 16 
α1-PI  - Alpha-1 antitrypsin 
NF-κB - Nuclear factor kappa-light-chain-enhancer of B cells 
KDa  - Kilo-Daltons 
Pg   - Picogram 
MRI  - Magnetic resonance imaging 
USPIO - Ultrasmall superparamagnetic iron oxide particles 
MI  - Myocardial Infarction 
ROI  - Region of Interest 
LV  - Left Ventricle 
hs-TnI  - Troponin I by high sensitivity assay 
hs-CRP - C-reactive protein by highly sensitive assay 
AUC  - Area under the curve 
ECG  - Electrocardiogram 
TWI  - T-wave Inversion 
BBB   - Bundle branch block 
SEM  - Standard error of mean 
MPO  - Myeloperoxidase 
95% CI  - 95% Confidence Interval 
IQR  - Inter-quartile range 
mL  - Millilitre 
 
Detection, assessment and modulation of myocardial inflammation 17 
ng   - Nanogram 
mg  - Milligram 
CAD  - Chronic allograft damage 
NGAL  - Neutrophil gelatinase-associated lipocalin  
AKI   - Acute kidney injury 
ICAM  - Intercellular adhesion molecule  
VCAM - Vascular cell adhesion protein 
 
 
  
 
Detection, assessment and modulation of myocardial inflammation 18 
Declaration 
 
This thesis represents research that I have undertaken in the British Heart Foundation 
University of Edinburgh Centre for Cardiovascular Science and the Edinburgh Heart 
Centre, Royal Infirmary of Edinburgh between August 2011 and August 2014. 
I was personally involved in composition and every aspect of the work presented in 
this thesis. In keeping with the collaborative nature of this work, assistance was 
received and is acknowledged. Dr Ninian Lang & Miss Jennifer Richards undertook 
the preliminary design of the study presented in Chapter 3. Dr Peter Henriksen 
conceived and undertook the preliminary design of the study presented in Chapter 4. 
This thesis has not been submitted elsewhere in application for a university degree, 
and all sources of information have been acknowledged. All studies were undertaken 
in accordance with the regulations of the Scotland Research Ethics Committee, 
the Lothian Local Research Ethics Committee, the Medicines and Healthcare 
products Regulatory Agency and the Declaration of Helsinki of the World Medical 
Association. The written informed consent of each participant was obtained before 
entry into the studies. 
The British Heart Foundation funded myself through a Clinical Research 
Training Fellowship (FS/12/83/29781). This work was funded by the Medical 
Research Council (G1001339) and Chest Heart and Stroke Scotland (R11/A135).  
The Wellcome Trust Clinical Research Facility and Clinical Research Imaging 
Centre are supported by NHS Research Scotland (NRS) through NHS Lothian. The 
work was greatly aided by Lynsey Milne, Samantha Thomas and Ronald Harkess. 
 
Detection, assessment and modulation of myocardial inflammation 19 
Preface 
 
 
 
IN THE NAME OF ALLAH, THE ENTIRELY MERCIFUL, THE ESPECIALLY 
MERCIFUL 
MY LORD, ENABLE ME TO BE GRATEFUL FOR YOUR FAVOUR WHICH YOU 
HAVE BESTOWED UPON ME AND UPON MY PARENTS AND TO WORK 
RIGHTEOUSNESS OF WHICH YOU WILL APPROVE AND MAKE RIGHTEOUS 
FOR ME MY OFFSPRING. INDEED, I HAVE REPENTED TO YOU, AND 
INDEED, I AM OF THE MUSLIMS. 
 
Detection, assessment and modulation of myocardial inflammation 20 
Acknowledgements 
 
I would like to thank all the people who have both tolerated and supported me during 
this time of research.  
Most of all my parents Sabiha and Khursheed Alam who worked so hard and 
sacrificed so much to allow me to become a doctor. 
My fellow researchers - Nikhil Joshi, Anoop Shah, Gareth Barnes and Amanda 
Hunter. To this day, friendships formed during the time have endured. 
Professor Dave Newby gave me the opportunity to undertake this period of research, 
and this intervention rescued me from a career in anaesthetics, and allowed me to 
pursue cardiology. For this I am grateful and am indebted.  
Dr Andrew Flapan has mentored me throughout my clinical career, and has 
continually encouraged me to finally write up this thesis. I greatly value his 
friendship and support. 
The Medical Research Council is thanked for their grant. The British Heart 
Foundation and Chest, Heart & Stroke also funded my position and this research. I 
am grateful to every person who donated to these charities, without such selfless 
people no research would be possible. 
I would particularly like to thank Dr Peter Henriksen, who has been invaluable as a 
supervisor. He has supported me in clinical medicine, in research and in all manner 
of problems I encountered during this time. He has gone far beyond the usual remit 
 
Detection, assessment and modulation of myocardial inflammation 21 
of a supervisor to help me, and without these interventions I may well have left 
clinical medicine. As an academic, he is a researcher of the highest intelligence and 
creativity. As a friend and colleague, he has proven himself to be a man of integrity, 
generosity and the highest character. I hope and pray for the best for him and his 
family. 
Chapter 1: Myocardial Inflammation Following Ischaemia-Reperfusion Injury 
Detection, assessment and modulation of myocardial inflammation 22 
Chapter 1: MYOCARDIAL INFLAMMATION FOLLOWING 
ISCHAEMIA-REPERFUSION INJURY 
 
1.1 OVERVIEW 
Ischemia-reperfusion injury occurs when blood flow is restored to organs and tissues 
that have sustained a period of interrupted blood supply. This occurs following 
therapies for acute myocardial infarction, and during cardiac surgery. Inflammation 
follows in order to remove necrotic cellular debris and allow tissue remodelling. 
Excessive inflammation may follow reperfusion therapy, and can have detrimental 
effects on healing and left ventricular remodelling (Nahrendorf et al., 2010). 
Mechanisms of cell and tissue injury include a neutrophil-mediated post-ischaemic 
inflammatory response and activation of cellular death pathways following 
reperfusion (Hansen, 1995). Protecting organs from ischaemia-reperfusion injury to 
improve clinical outcome is a high priority. Despite intense research efforts and huge 
promise from pre-clinical and early phase clinical trials, there are currently no 
effective therapies that can limit this injurious response.  
With the aim of improving outcomes following acute myocardial infarction, novel 
drugs are increasingly focusing on optimisation of myocardial repair and 
regeneration, and include anti-inflammatory interventions (Bonvini et al., 2005, 
Frangogiannis, 2006, Gonzalez et al., 2011, Steffens et al., 2009). There is therefore 
a need for non-invasive methods to assess in vivo myocardial inflammation following 
myocardial infarction both to define the healing process and to measure the potential 
efficacy of novel therapeutic interventions. Such interventions include targeting the 
neutrophil mediated inflammatory cascade. 
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1.2 MYOCARDIAL INFARCTION 
Coronary atherosclerosis is responsible for the initiation of acute myocardial 
infarction with plaque rupture leading to acute coronary thrombosis and myocardial 
infarction. Current treatment in the acute phase involves re-establishing vessel 
patency by percutaneous coronary intervention supported by anti-thrombotic therapy. 
Thereafter, statins, angiotensin-converting enzyme inhibitors and beta-blockade all 
have prognostic benefit but no treatments have been successfully developed to target 
post-infarction inflammatory pathways.  
Necrotic cardiac muscle elicits an inflammatory cascade that serves to clear the 
infarct of dead cells and matrix debris. Human cardiac muscle has negligible 
regenerative capacity and ultimately inflammation leads to replacement of damaged 
tissue with a fibrotic scar. Enhancing reparative mechanisms following the 
inflammatory reaction to myocardial infarction may reduce cardiac myocyte injury, 
attenuate adverse remodelling and improve clinical outcome. A better understanding 
of the early post-infarct healing phase will also facilitate cell therapy strategies to 
engraft stem cells or stimulate regeneration. In order to achieve this goal, we must 
better characterise the inflammatory processes that follow infarction and myocardial 
necrosis in humans.  
 
1.2.1 TROPONIN BIOLOGY AND KINETICS 
Troponin is a protein complex involved in cardiac muscle contraction, and is used in 
clinical practice to detect myocardial infarction. There are a number of forms of 
troponin.  Cardiac troponin T (cTnT) and troponin I  (cTnI) are derived from genes 
specific to the myocardium (Coudrey, 1998, Katus et al., 1992) whereas troponin C 
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(cTnC) is present in both cardiac and skeletal muscle with no specific isoform for 
cardiac tissue (Coudrey, 1998). Whilst most of the cardiac troponin complex 
(troponin I, T and C) is bound within the cytoskeletal structure of the cardiac 
myocyte, approximately 7% and 3.5% of troponin T and I respectively is present 
within the cytosolic pool (Katus et al., 1991, Wu et al., 1998).   There are also 
important differences in the size of troponin I and T with troponin T being twice the 
size (37 kiloDaltons [kDa]) of troponin I (22 kDa) (Mair et al., 1992). 
Wu et al showed that there remains significant differences in the release of troponin 
following acute myocardial injury (Wu et al., 1998). Following acute myocardial 
infarction troponin was released in three forms; a ternary complex (cTn T-I-C), a 
binary complex (cTn I-C) and free troponin T (Wu et al., 1998). Wu et al also 
showed significant heterogeneity in the cross-reactivities of antibodies to various 
forms of troponin I reflecting the assay differences in absolute troponin I 
measurements between assays (Wu et al., 1998).  
 
1.2.2 MYOCARDIAL CELLULAR INFLAMMATION POST INFARCTION 
Inflammation within the infarcted myocardium is associated with induction of 
endothelial adhesion molecules and enhanced permeability of the microvasculature. 
Up regulation of chemokines including interleukin (IL)-8 and monocyte 
chemoattractant protein (MCP)-1 attracts neutrophils and monocytes to the site of 
injury (Hammond et al., 1995, Kumar et al., 1997). Early reperfusion therapy 
amplifies this inflammatory cell influx and accelerates the healing response through 
proliferative and maturation phases. Neutrophil adhesion to endothelium of infarcted 
myocardium occurs within minutes of reperfusion (Weyrich et al., 1995). Ischaemic 
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cardiomyocytes are further injured by adherent neutrophils that release reactive 
oxygen species and destructive proteases including human neutrophil elastase (HNE) 
and proteinase 3 (Borregaard and Cowland, 1997). HNE has a wide range of 
substrates including matrix components elastin, fibronectin, and collagen types III 
and IV (Lee and Downey, 2001, Si-Tahar et al., 1997). Activated neutrophils also 
occlude microvessels and increase endothelial permeability contributing to 
myocardial oedema. Capillary plugging and obstruction by activated neutrophils 
contributes to failure of microvascular perfusion and increased infarct size within the 
‘no-reflow’ zone. Neutrophil depletion reduces this phenomenon and infarct size 
following reperfusion in pre-clinical models (Romson et al., 1983b). 
Recruitment of monocytes into the infarcted myocardium is followed by maturation 
and differentiation into macrophages: a process dependent on growth factors such as 
macrophage-colony stimulating factor (M-CSF) (Okazaki et al., 2007, Yano et al., 
2006). Macrophages have multiple roles within the infarct including (i) phagocytic 
clearance of dead cells and debris, (ii) production of growth factors and cytokines 
that stimulate fibroblast growth and angioneogenesis, and (iii) matrix turnover 
through the production of matrix metalloproteases and their inhibitors (Lambert et 
al., 2008). Macrophages are resident within 24 hours of infarction and persist for up 
to 4 weeks. During this period, macrophages regulate infarct healing with the initial 
development of granulation tissue and subsequent scar formation. Murine studies 
suggest that distinct monocyte subsets regulate these different processes. Monocytes 
arriving within the first 3 days mature into macrophages that scavenge necrotic 
debris through inflammatory mediator expression, proteolysis and phagocytosis. 
Monocytes arriving later on give rise to macrophages which promote reparative 
processes such as angioneogenesis and extracellular matrix deposition (Nahrendorf et 
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al., 2007a). Apoptosis is the primary mechanism determining longevity of 
neutrophils within sites of inflammation and infarction. Engulfment and clearance of 
apoptotic neutrophils by macrophages produces potent anti-inflammatory signals 
including release of transforming growth factor (TGF)-. Combined with clearance 
of pro-inflammatory matrix fragments, these processes drive the switch to tissue 
repair and resolution of the post-infarct inflammatory response.  
MCP-1 expression is increased in ischaemic myocardium following reperfusion and 
this accounts for a substantial proportion of the monocyte chemotactic activity 
(Kumar et al., 1997). MCP-1 knockout mice exhibit delayed macrophage infiltration 
in the healing infarct with a prolonged inflammatory phase and delayed replacement 
of injured cardiomyocytes with granulation tissue (Dewald et al., 2005). The MCP-1 
deficient mice have similar size infarcts but attenuated remodelling compared to wild 
types. MCP-1 mRNA levels are increased 40-fold within non-infarcted myocardium 
(Hayashidani et al., 2003) and blockade of MCP-1 signalling with a deletion mutant 
of MCP-1 markedly reduced macrophage infiltration both within the infarct and non-
infarcted myocardium. Widespread myocardial inflammatory cell infiltration beyond 
the non-infarcted zone has been observed in human autopsy specimens (Abbate et 
al., 2004). Blockade of MCP-1 signalling is associated with improved survival rates 
and reduced left ventricular dilatation as well as reduced tumour necrosis factor 
(TNF)- gene expression in the non-infarcted myocardium. These studies indicate 
that macrophage activity outside the infarct zone may contribute to adverse 
myocardial remodelling following myocardial infarction. 
The inflammatory response to myocardial infarction is necessarily complex to 
coordinate the development of a healing scar from infarcted tissue. The role of the 
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macrophage differs depending on differentiation and location within the 
myocardium. Therapeutic manipulation of this healing process will only come from 
understanding mechanisms and targeting reparative pathways. Indiscriminate 
immunosuppressive therapy in this setting may result in harm as observed in trials 
with methylprednisolone in acute myocardial infarction (Mannisi et al., 1987). 
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1.3 CORONARY ARTERY BYPASS SURGERY 
Over 300 000 coronary artery bypass graft (CABG) operations are performed each 
year in the United States of America (Diodato and Chedrawy, 2014). Myocardial 
inflammation and injury follows surgery. During coronary artery bypass graft 
surgery, the myocardium receives an immediate ischaemic insult that is exacerbated 
by post-ischaemic reperfusion inflammatory responses leading to increased 
myocardial injury. Coronary artery bypass graft surgery can therefore be used as a 
clinical model of myocardial infarction and inflammation (Steuer et al., 2004c, 
Anselmi et al., 2004). 
 
 
1.3.1 MYOCARDIAL INFLAMMATION POST CARDIAC SURGERY 
Cardiopulmonary bypass (CPB) contributes to systemic and coronary inflammation 
(Zahler et al., 1999, Paparella et al., 2002). Inflammatory cytokines depress cardiac 
function after CPB (te Velthuis et al., 1995) and plasma IL-6 and IL-8 concentrations 
in the postoperative period correlate with myocardial injury and apoptosis (Wan et 
al., 2002). Although elevations in circulating markers of cellular inflammation are 
seen to rise during CPB, in vivo cellular infiltration into the myocardium has not 
been demonstrated (Ascione et al., 2000). 
Plasma cTnI concentrations increase in all patients undergoing CABG surgery (van 
Gaal et al., 2011). The magnitude of cTnI concentration increase correlates with 
major adverse cardiac events within 30 days as well as long-term mortality (Nesher 
et al., 2008, Croal et al., 2006). However cardiac magnetic resonance (CMR) 
evidence of myocardial necrosis is only evident in a minority, suggesting that cTnI 
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release may result from additional mechanisms such as post ischaemia-reperfusion 
inflammation (Noora et al., 2005). It has been demonstrated that concentrations 
below the 99th centile detected with this assay provide major prognostic information 
in patients with non ST-elevation myocardial infarction (Shah et al., 2015a). The 
components for defining a myocardial infarction include the presence of symptoms, 
electrocardiographic evidence of myocardial ischaemia and / or biomarker evidence 
of myocardial necrosis. This definition has not substantially changed from the initial 
MONICA World Health Organisation (WHO) statement. What has, however, 
changed significantly over the last few decades is our ability to measure and quantify 
myocardial necrosis.  
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1.4 ROLE OF THE ENDOGENOUS ELASTASE IN CARDIOVASCULAR INFLAMMATION AND 
INJURY 
1.4.1 NEUTROPHIL-DERIVED ELASTASES AND VASCULAR INFLAMMATION 
Neutrophils lead the early phase of the inflammatory response gathering at sites of 
inflammation, and transmigrating through the endothelium to release granule 
contents and generate oxygen-derived free radicals that serve the host defence by 
providing microbicidal activity. Human neutrophil elastase (HNE) and proteinase-3 
are amongst the contents of neutrophil azurophilc granules (Borregaard and 
Cowland, 1997). These enzymes degrade components of the extracellular matrix and 
the list of substrates for HNE is extensive (Lee and Downey, 2001) including fibrin, 
fibronectin, collagen, the glycoprotein IIb/IIIa receptor (Si-Tahar et al., 1997), elastin 
and cadherins (Carden et al., 1998) (Figure 1.1).  
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Figure 1.1 Inflammatory effects of HNE and proteinase 3.  
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HNEs’ action on extracellular matrix components exposes recognition sites that bind 
cellular integrin and tyrosine kinase receptors. These signals direct the cellular 
response to injury. Recognition of elastin-derived fragments by the elastin receptor 
results in migration and chemotaxis of monocytes and vascular smooth muscle cells 
(Robert et al., 1998, Houghton et al., 2006).  
Endothelial cells are susceptible to detachment when cultured with activated 
neutrophils or HNE (Westlin and Gimbrone Jr, 1993). Anchorage of cells to the 
extracellular matrix is necessary for survival and cleavage of matrix components and 
cadherins responsible for adhesion results in apoptosis (Frisch and Francis, 1994, 
Mtairag et al., 2002). HNE is joined by the matrix metalloproteinase (MMP) and the 
cathepsin family of proteases in modulating endothelial extracellular matrix 
degradation during acute inflammation (Garcia-Touchard et al., 2005). There is 
considerable overlap of substrates between these protease families leading to 
apparent redundancy. HNE is distinct in having both a broad range of substrates and 
the ability to be released rapidly and in high concentration from neutrophil granules 
at sites of inflammation. By contrast, many of the extracellular MMP and cathepsin 
proteases are regulated by gene expression and MMPs are activated in a cascade of 
proteolytic steps (Chakraborti et al., 2003). HNE also modulates the activity of 
vascular extracellular proteases. It directly activates MMPs and inactivates their 
inhibitors (tissue inhibitors of metalloproteases: TIMPs) (Okada and Nakanishi, 
1989, Okada et al., 1988). A complex interplay between extracellular proteases that 
share common substrates occurs during inflammatory endothelial injury. HNE’s 
broad ranging activity and modulating activity over other proteolytic pathways 
suggest a central role at the onset of the proteolytic cascade in pathologies where 
neurophil degranulation is present.  
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1.4.2 MODULATION OF THROMBOSIS AND FIBRINOLYSIS AND POTENTIAL INVOLVEMENT 
IN ACUTE CORONARY SYNDROMES 
The capacity of HNE to degrade components of the coagulation and fibrinolytic 
pathways has been demonstrated in vitro. Cleavage of plasminogen activator 
inhibitor type -1 (PAI-1) shortens clot lysis time in vitro (Wu et al., 1995). 
Plasminogen is degraded to miniplasminogen by HNE. This plasminogen fragment is 
more readily activated and the resulting miniplasmin retains fibrinolytic activity but 
may be relatively resistant to inhibition by -2 antiplasmin (Duboscq et al., 1997). 
More recently, the role of neutrophil-derived elastases in thrombus formation has 
been demonstrated in knockout mice (Massberg et al., 2010). Compared to wild type 
mice the animals deficient in neutrophil elastase had markedly reduced fibrin 
formation in response to chemical injury on intravital videomicroscopy. The 
mechanism involved proteolytic inactivation of an endogenous anticoagulant, tissue 
factor pathway inhibitor (TFPI). TFPI and neutophil elastase were observed to co-
localise on the external surface of neutrophils in nucleosomes facilitating TFPI 
degradation. The formation and externalisation of nucleosomes is increased by 
neutrophil interaction with activated platelets. The combination of human neutrophils 
and platelets generates pro-coagulant activity measured by the production of active 
factor X and this was markedly reduced in the presence of HNE inhibitors (Massberg 
et al., 2010). These observations point to a hitherto unappreciated role for neutrophils 
and HNE in triggering coagulation and stabilising thrombus formation. Massberg et 
al suggested an innate immunity role for neutrophil elastase generated thrombosis 
promoting retention of invading pathogens within liver microvessels (Massberg et 
al., 2010). This work demonstrated the capability of neutrophils to promote thrombus 
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formation in larger vessels in the absence of infection. The circulating neutrophil 
count is associated with clinical events including myocardial infarction (Madjid et 
al., 2004). Neutrophils from patients with acute coronary syndromes exhibit evidence 
of activation and degranulation (Buffon et al., 2002).  Together these finding suggest 
a more direct pro-thrombotic role for neutrophils in coronary disease. 
 
1.4.3 REGULATION OF INFLAMMATORY SIGNALLING  
HNE and proteinase-3 modulate cytokine signaling. HNE and Proteinase-3 can 
proteolytically activate or process the inflammatory cytokines TNF-, IL-1, IL-8 
and IL-18 (Carroll et al., 2005, Coeshott et al., 1999, Padrines et al., 1994, Sugawara 
et al., 2001).  HNE is capable of degrading IL-1 and TNF- possibly acting as a 
negative regulator of inflammation. Chemerin is a chemoattractant protein that 
promotes recruitment of antigen presenting cells such as macrophages and dendritic 
cells (Wittamer et al., 2003). HNE activates chemerin from prochemerin by 
proteolytically cleaving its C-terminal peptide. This provides one mechanism 
whereby initial infiltration of neutrophils may orchestrate subsequent antigen 
presenting cell recruitment at inflammatory sites (Wittamer et al., 2005).  
HNE mediated cleavage of the CD14 receptor on monocytes and fibroblasts reduces 
responsiveness and TNF- production in response to LPS (Nemoto et al., 2000) as 
well as impairing recognition and clearance of apoptotic cells by phagocytosis 
(Vandivier et al., 2002). HNE mediated cleavage of the complement receptor 1 from 
the surface of erythrocytes generates a fragment that acts as an inhibitor of 
complement (Sadallah et al., 1999).  These findings indicate divergent effects on 
inflammatory signalling and may reflect changing roles for neutrophil derived 
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elastases depending on variables such as local concentration, stage of inflammation 
and signalling context. 
HNE stimulates production of the neutrophil chemokine IL-8 and augments 
endothelial cell production of IL-8 in response to other stimuli such as 
lipopolysaccharide (Henriksen et al., 2004b). The observation that HNE stimulates 
cytokine production from a variety of cell types has raised the possibility of receptor 
interaction.  Devaney et al demonstrated that HNE up-regulation of IL-8 mRNA and 
protein was dependent on expression of the toll-like receptor 4 in a kidney cell line 
(Devaney et al., 2003). HNE and proteinase-3 also activate the protease activated 
receptors (PAR) (Uehara et al., 2003, Uehara et al., 2002) that influence a wide range 
of physiological responses including platelet activation, intimal hyperplasia and the 
maintenance of vascular tone and barrier function (Leger et al., 2006). Activation of 
PAR-1, PAR-2 and PAR-4 stimulates IL-6, IL-8 and prostaglandin E2 release 
(Asokananthan et al., 2002). Selective activation of PAR-1 and PAR-2 by HNE 
results in increased epithelial permeability and transepithelial migration of 
neutrophils. This effect is blocked by PAR antagonists and is not related to cleavage 
of gap junctions (Chin et al., 2008). Recently, HNE has been shown to activate PAR-
2 through cleavage of the N-terminus (Ramachandran et al., 2011). This results in 
selective activation of downstream MAP kinase signaling pathways, and PAR-2 
dependent calcium signaling is silenced. This recent observation of interaction with 
specific cell surface receptors indicates the potential for discriminate signaling by 
HNE. 
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1.5 NEUTROPHIL ELASTASE ACTIVITY REGULATION  
1.5.1 ENDOGENOUS INHIBITORS 
Neutrophil derived elastases have wide ranging inflammatory effects on a broad 
range of substrates. Endogenous serine protease inhibitors (serpins) block activity by 
complexing with the elastase molecule. α1-antitrypsin (α1-PI) is the major 
circulating serpin produced in the liver with inhibitory activity against HNE. α1-PI is 
present at saturating levels within the circulation providing systemic inhibitory 
activity against HNE. Elafin and secretory leucocyte protease inhibitor (SLPI) are 
serpins produced locally at sites of inflammation by epithelial cells in response to 
inflammatory stimuli such as TNF-α and HNE. The ability to raise this local defence 
of ‘alarm’ antiproteases illustrates the extent to which epithelial tissues have evolved 
mechanisms to respond to, and contain, neutrophil-mediated inflammation 
(Sallenave, 2000b).  Cardiovascular tissues do not express these alarm antiproteases 
and are more vulnerable to HNE mediated injury as a result. 
 
HNE can evade high local concentrations of inhibitors through a series of 
mechanisms. Large quantities of oxidants and proteases released by leukocytes 
recruited to the site of inflammation can overwhelm and inactivate protease 
inhibitors. Adhesion of neutrophils to the extracellular matrix leads to the 
compartmentalisation of the released proteases between the neutrophil and matrix, 
and this microenvironment excludes the large circulating protease inhibitors such as 
α1-PI (Korkmaz et al., 2005). A large proportion of the serine proteases released 
from azurophil granules bind to the plasma membrane with catalytic activity 
preserved. Owen and colleagues suggested that this tight binding of extracellular 
neutrophil serine proteases to the cell membrane makes them inaccessible, and 
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therefore resistant, to circulating, high-molecular-weight, endogenous inhibitors such 
as α1-PI (Owen et al., 1995). Surface bound HNE is inhibited by small molecule 
inhibitors including SLPI suggesting a specific locale for alarm antiproteases to 
control HNE (Owen et al., 1995). This local antiprotease shield is not present within 
the cardiovascular system and strategies to introduce or mimic it will reduce HNE 
mediated tissue injury and inflammation.  
 
 
1.5.2 POTENTIAL CLINICAL APPLICATION OF BIOLOGICAL AND SYNTHETIC INHIBITORS OF 
HNE  
Endogenous and synthetic small molecule inhibitors have been developed to combat 
the pro-inflammatory activity of HNE. Clinical studies with elastase inhibitors have 
focussed on inflammatory lung disease. 
SLPI belongs to the same family of four disulphide core proteins as elafin. It shares 
many properties including inhibition of HNE and interference with 
lipopolysaccharide signalling, transcription factor NF-κB activation and TNF-α 
production. Delivery of recombinant SLPI was protective in rat and murine models 
of ischaemia reperfusion injury (Lentsch et al., 1999). A clinical study examining the 
effect of aerosolised SLPI in cystic fibrosis patients demonstrated reduced elastase 
activity, IL-8 and neutrophil levels in treated patients (McElvaney et al., 1992). α1-PI 
is regarded as the major inhibitor of HNE in the lung and intravenous formulations 
derived from human plasma (Prolastin; Talecris Corporation, Aralast; Alpha 
Therapeutic Corporation and Zemaira; CSL Behring) have been trialled in patients 
with α1-antitrypsin deficiency with minimal impact on disease progression 
(Silverman and Sandhaus, 2009). DX-890 (Depelstat; Dyax 
Corporation/Debiopharm) is a potent HNE inhibitor derived from human inter-α-
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inhibitor. It may have application as an aerosol elastase inhibitor in the treatment of 
cystic fibrosis.  
Several synthetic neutrophil elastase inhibitors have been developed. Preclinical 
studies have shown promise in demonstrating reduced neutrophil elastase injury and 
inflammation but clinical translation has been frustrated by lack of efficacy and 
concerns over toxicity. Sivelestat (Ono Pharmaceutical) is a low molecular weight 
reversible competitive inhibitor of HNE. In observational studies, administration was 
associated with reduced mortality in critically ill patients and attenuated pulmonary 
dysfunction in patients with acute respiratory distress syndrome (Hoshi et al., 2005, 
Okayama et al., 2006). In prospective double-blinded controlled trials, it has been 
shown to reduce IL-8 production and reduce acute lung injury after cardiopulmonary 
bypass, and reduce duration of ventilation in intensive care (Ryugo et al., 2006, 
Tamakuma et al., 2004). The only multi-centre double-blind placebo-controlled trial 
of sivelestat failed to show a decrease in mortality or reduced ventilator requirement 
in critically ill patients (Zeiher et al., 2004). ONO-6818 (Ono Pharmaceutical) is a 
non-peptide selective neutrophil elastase inhibitor that reduced IL-8 production and 
complement activation in a simulated cardiac bypass circuit (Yoshimura et al., 2003). 
Clinical studies in patients with lung disease were halted because of liver injury 
associated with the drug. Mr889 is a less potent, reversible and slow-binding 
competitive inhibitor of HNE developed by Medea Research. Clinical evaluation 
demonstrated the drug to be safe but ineffective in modifying biochemical markers of 
lung destruction (Luisetti et al., 1996).                                                                                         
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1.6 MODIFICATION OF INFLAMMATION BY ELAFIN 
1.6.1 ELAFIN AS A POTENT ENDOGENOUS INHIBITOR OF NEUTROPHIL ELASTASE 
Elafin is an endogenous inhibitor of human neutrophil elastase (HNE) and 
proteinase-3 that was first isolated from psoriatic skin and human bronchial 
secretions.(Wiedow et al., 1990, Sallenave and Ryle, 1991b). Cloning of elafin 
cDNA indicates that initial transcription produces a protein of 117 amino acid 
residues, which undergoes intracellular cleavage of an N-terminal hydrophobic 
signal sequence to produce pro-elafin (Molhuizen et al., 1993, Sallenave and Silva, 
1993, Schalkwijk et al., 1999). The pro-elafin protein is composed of 2 domains: a 
C-terminus consisting of 57 amino acids and an N-terminus consisting of 60 amino 
acids also known as the cementoin domain (Francart et al., 1997, Nara et al., 1994). 
The N-terminus contains VKGQ sequences that provide the substrate for 
transglutaminase, with glutamine and lysine acting as acyl donors and acceptors in 
formation of isopeptide inter-protein cross-links (Nara et al., 1994). 
Transglutaminisation allows elafin to be cross-linked to the extracellular matrix 
where it may persist as a tissue bound inhibitor of HNE. Sumi et al demonstrated 
elafin immunoreactivity within the intima of human coronary arteries in association 
with transglutaminase (Sumi et al., 2002). The C-terminus is responsible for the 
elastase inhibition. It has a four-disulphide core and shows structural similarity with 
the whey acidic protein (WAP) family (Nara et al., 1994, Tsunemi et al., 1996). This 
combination of a transglutaminase substrate area and a WAP/four-disulphide core 
has similarities with other proteins that have been named “trappins” (Schalkwijk et 
al., 1999). Elafin has 40% sequence homology with SLPI and is more specific in its 
spectrum of activity exhibiting potent inhibition of HNE and proteinase-3. It has 
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equilibrium dissociation constants for these enzymes of 0.8 x 10-10 M and 1.2 x 10-10 
M respectively (Zani et al., 2004).  
 
1.6.2 TISSUE DISTRIBUTION AND REGULATION OF ELAFIN  
Elafin is secreted constitutively by the squamous epithelium of the skin, with 
expression raised in inflammatory skin conditions such as psoriasis (Wiedow et al., 
1990, Nara et al., 1994). It has also been isolated in other epithelia such as sweat 
glands, hair follicles, tongue, tonsils, gingiva, epiglottis, esophageal lining, the 
vagina, the pharynx (Pfundt et al., 2000), submandibular glands (Lee et al., 2002), 
trachea, stomach, intestine (Nara et al., 1994), and mammaries (Zhang et al., 1995). 
More recently leucocyte expression has been identified within human endometrial 
neutrophils and alveolar macrophages of the respiratory system (King et al., 2003, 
Sallenave et al., 1993). The detection of elafin within human coronary arteries in 
association with atherosclerosis raises the question over whether it has originated 
from infiltrating inflammatory cells or free protein entering from the circulation. 
IL-1 and TNF- together with HNE are major inducers of elafin expression in 
human airway epithelial cells and keratinocytes (Sallenave et al., 1994, Pfundt et al., 
2000). Regulation by these inflammatory cytokines highlights the role elafin may 
play in the early orchestration of the inflammatory response as an ‘alarm’ 
antiprotease secreted by local cells.  
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1.6.3 INHIBITION OF INFLAMMATORY CYTOKINE PRODUCTION 
It has been demonstrated that there is attenuated inflammatory cytokine production 
by human endothelial cells and macrophages following elafin overexpression using 
adenoviral vectors (Henriksen et al., 2004b). Endothelial cell IL-8 production was 
reduced in response to bacterial lipopolysaccharide (LPS), TNF-α and oxidised low-
density lipoprotein, a key inflammatory stimulus and driver of atherosclerotic plaque 
development. Overexpression in monocyte-differentiated human macrophages 
reduced TNF-α production in response to low concentrations of LPS (Henriksen et 
al., 2004b). SLPI has similar properties reducing TNF-α and matrix metalloprotease 
production in response to LPS (Jin et al., 1997, Zhu et al., 1999).  An intracellular 
mechanism was suggested by the finding that transfection of a non-secreted form of 
SLPI but not addition of recombinant SLPI to cultured macrophages suppresses the 
response to LPS (Zhu et al., 1999). NF-κB upregulates many inflammatory genes 
associated with the inflammatory response including IL-8 and TNF-α. 
Overexpression or incubation of elafin and SLPI with monocytes reduces LPS 
responsiveness (Butler et al., 2006, Henriksen et al., 2004b). This effect is seen in 
association with reduced proteolytic degradation of NF-κBs’ inhibitory subunits 
IκBα and IκBβ suggesting an action by elafin and SLPI on the ubiquitin-proteosome 
pathway (Figure 1.2). 
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Figure 1.2 Elafins’ effects on inflammation 
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1.7 NEUTROPHIL MEDIATED INJURY AS A POTENTIAL TARGET FOR ATTENUATION OF 
INFLAMMATION 
1.7.1 NEUTROPHIL-MEDIATED ISCHEMIA-REPERFUSION INJURY  
The role of the neutrophil in myocardial-reperfusion injury following myocardial 
infarction has been reviewed by Hansen and Jordan et al (Jordan et al., 1999, 
Hansen, 1995). Cardiomyocyte injury is exacerbated following reperfusion and 
neutrophils are pivotal mediators determining post-ischemic inflammatory 
reperfusion injury. Neutrophils accumulate within the reperfused myocardium 
releasing HNE and reactive oxygen species that further effect microvascular and 
myocardial injury. Preclinical studies have demonstrated that neutrophil depletion or 
inhibition of neutrophil elastase attenuates post-ischemic inflammatory reperfusion 
injury within the myocardium (Romson et al., 1983a, Tiefenbacher et al., 1997).   
Plasma HNE and myeloperoxidase concentrations increase following myocardial 
infarction providing evidence of neutrophil activation (Dinerman and Mehta, 1990, 
Mocatta et al., 2007). Neutrophils are activated by a vast array of mediators released 
from endothelial cells, mast cells and myocytes within the myocardium following 
ischemia. The complement fragment C5a, IL-8 and platelet activating factor act as 
chemoattractants and stimulate adherence to the endothelium. TNF-α released from 
mast cells and IL-6 from ischemic cardiomyocytes further stimulate neutrophil 
superoxide production, transendothelial migration and degranulation (Richter et al., 
1990).  
Coronary occlusion without reperfusion is associated with infarction and restricted 
infiltration of neutrophils into the border area of the infarcted zone over 24 hours 
(Reimer et al., 1989). The goal of therapy in acute myocardial infarction is timely 
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restoration of perfusion and whereas this reduces infarct size, it is associated with 
accelerated accumulation of neutrophils within the reperfused myocardium (Dreyer 
et al., 1991, Zhao et al., 2001). Neutrophil adhesion to the endothelium occurs within 
minutes of reperfusion (Sheridan et al., 1996, Murohara et al., 1994). Release of 
proteases and reactive oxygen species cause cardiomyocyte necrosis. Neutrophils 
also occlude microvessels and cause changes in endothelial permeability that 
contribute to myocardial oedema (Engler et al., 1983). Capillary plugging and 
obstruction by activated neutrophils contributes to failure of microvascular perfusion 
and increased infarct size within the “no-reflow” zone. Neutrophil depletion reduced 
this phenomenon and infarct size in a pre-clinical model (Litt et al., 1989). 
Neutrophil mediated inflammation generates production of further chemokines and 
adhesion molecule expression that amplify inflammatory cell recruitment. The goal 
of therapy is both to reduce neutrophil-mediated injury and to break the vicious cycle 
of further neutrophil recruitment. 
Administration or over-expression of elafin was associated with reduced infarct size 
and neutrophil infiltration in several models of ischemia-reperfusion injury. 
Tiefenbacher et al investigated cardiac reperfusion injury in a rat model inducing 
repeated ischemia and reperfusion with ligation of the left coronary artery 
(Tiefenbacher et al., 1997). The animal received a bolus of recombinant elafin by tail 
vein injection prior to ischemia. Myocardial function measured by systolic fractional 
thickening was better in animals receiving elafin or a synthetic elastase inhibitor. 
Systolic fractional thickening of the myocardium measured by pulsed Doppler was 
reduced by 50% in the controls compared to 22% in elafin treated animals. Mice 
expressing human elafin under the control of the preproendothelin promoter exhibit 
better cardiac function compared to littermates following myocardial infarction. Left 
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ventricular dimensions in diastole were significantly increased in the wild-type mice 
(mean 4.75 mm) compared to sham operated mice (mean 3.95 mm).  Elafin 
expressing mice had some increase in cavity size (mean 4.30 mm), which was not 
significantly different from sham operated mice. Elafin expressing mice had reduced 
infarct expansion and less scar thinning. The increases in myocardial tissue elastase 
and matrix metalloprotease activity following infarction were effectively suppressed 
in elafin transgenic animals compared to wild type littermates (Ohta et al., 2004b). 
Tissue myeloperoxidase content can be used as a measure of neutrophil infiltration. 
In the rat myocardial infarction model myeloperoxidase levels increased 14-fold in 
control animals compared to only a 3-fold rise in elafin treated animals 
(Tiefenbacher et al., 1997). Similar reductions in neutrophil infiltration were 
observed in the elafin transgenic mice and following elafin administration prior to 
arterial ligation in a rodent limb ischemia model (Crinnion et al., 1994). In the latter 
study, elafin attenuated the acceleration in neutrophil infiltration (myeloperoxidase 
content) following reperfusion and was associated with reduced myocyte necrosis.  
Elafin administration or overexpression was consistently associated with reduced 
myocyte death and preserved function following ischemia and reperfusion across 
different models.  The reduction in neutrophil infiltration suggests that elafin 
interrupts the positive feedback loop signaling further neutrophil recruitment during 
reperfusion. This may be through combined direct inhibitory action on HNE and 
proteinase 3 mediated tissue injury and suppression of the potent neutrophil 
chemokine IL-8. 
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1.8 THERAPEUTIC APPLICATION OF ELAFIN IN CARDIOVASCULAR DISEASE 
Elafin augmentation protects the cardiovascular system from a range of diseases 
characterized by neutrophil-mediated inflammation (Figure 1.3). Elafin provides the 
endothelium and myocardium with protection against the damaging effects of 
neutrophil-derived elastases. This suggests that intravenous elafin administration or 
gene overexpression can provide inhibition by reaching elastase enzyme that is not 
suppressed by the high circulating concentrations of larger molecular weight elastase 
inhibitors. Elafin attenuates disease progression in chronic injury models including 
atherosclerosis and pulmonary hypertension (Zaidi et al., 2002b) and provides 
survival benefit in a murine model of viral myocarditis (Zaidi et al., 1999). The 
neutrophil does not have a prominent role in these pathologies indicating alternative 
mechanisms for elafin’s effect beyond inhibition of elastase through suppressing NF-
κB activation or modulating the adaptive immune response. Recombinant elafin has 
very low toxicity with short plasma and activity half-lives. It is possible to maintain 
circulating activity with intravenous infusion and this approach is used routinely with 
antithrombotic drugs in acute coronary syndrome patients. Translating the efficacy of 
elafin in pre-clinical models to diseases, such as acute myocardial infarction, will 
depend on achieving adequate concentrations of active protein at the site of tissue 
injury. In most pre-clinical models, elafin is delivered before or at the point of 
vascular injury. This advantageous position is not generally feasible in the clinic. The 
complexities of human disease over animal models have seen many promising 
therapies for ischemia reperfusion fail at translation (Bolli et al., 2004).  
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Figure 1.3 Elafins’ effects on cardiovascular pathologies. 
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1.9 MAGNETIC RESONANCE IMAGING OF THE MYOCARDIUM 
Magnetic resonance imaging (MRI) is a well-established clinical imaging modality 
offering excellent soft tissue contrast and spatial resolution, whilst avoiding ionizing 
radiation. Standard gadolinium-based contrast agents are paramagnetic and are 
infused into the blood pool with variable organ extraction rates, although subsequent 
extravasation and redistribution can be used to identify the interstitial and 
extracellular spaces. Gadolinium is commonly used as an MRI contrast agent after 
acute myocardial infarction (MI) to identify areas of tissue infarction and fibrosis 
(Lima et al., 1995, Schelbert et al., 2010). Tissue oedema and rupture of cell 
membranes with consequent diffusion of gadolinium into the inter- and intra-cellular 
spaces (Lima et al., 1995) results in a “delayed gadolinium enhancement” effect in 
infarcted regions. This is also known as late gadolinium enhancement (LGE). Recent 
interest has turned to novel agents that provide additional structural and functional 
cellular information. Such ‘smart’ contrast agents include iron oxide nanoparticles. 
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1.10 IMAGING INFLAMMATION USING ULTRASMALL SUPERPARAMAGNETIC PARTICLES OF 
IRON OXIDE 
Particles of iron oxide are divided into classes based on their size (Table 1-1). 
Ultrasmall superparamagnetic particles of iron oxide (USPIOs) consist of 
nanoparticles with a diameter of <50 nm and include ferumoxtran-10 (Sinerem, 
Guerbet) and ferumoxytol (Rienso, Takeda; Feraheme, AMAG Pharmaceuticals).  
USPIOs can be used as a blood pool contrast agent but it is their ability to be taken 
up by inflammatory cells that has distinguished them (Christen et al., 2012). Cellular 
uptake of USPIOs occurs through a variety of mechanisms. Phagocytosis and 
receptor-mediated endocytosis are important for uptake of larger particles, whilst 
smaller particles are internalized by pinocytosis. Although the avidity of macrophage 
uptake is strongly influenced by particle size and charge, the surface coating is 
particularly important (Saito et al., 2012, Tsuchiya et al., 2013). As a result of their 
smaller size, USPIOs are less readily recognized by phagocytic cells and persist in 
the circulation for longer than other iron particles (plasma half-life 14-30 h in 
humans) (Landry et al., 2005, Hunt et al., 2005). They are capable of passing through 
capillary walls, to be taken up by tissue-resident macrophages and neutrophils 
(Ruehm et al., 2001b, Dousset et al., 1999, Gellissen et al., 1999a). These 
characteristics allow USPIOs to detect and highlight cellular inflammation within 
tissues using MRI. 
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Table 1-1 Iron oxide nanoparticle preparations 
Particle Size 
(Diameter) 
Plasma Half-
life (h) 
Application 
Microparticles of 
iron oxide (MPIOs) 
1 µm  1-2 min Readily endocytosed and detected with MRI (Shapiro et al., 
2005b). Need immediate scan following infusion.  
Can be combined with ligands for cellular targets allowing 
molecular imaging (McAteer et al., 2011).  
Large size means they remain in the blood pool and are 
suitable for endovascular imaging t (Yang et al., 2010).   
Superparamagneti
c particles of iron 
oxide (SPIOs) 
80-150 nm 2-3 h Ferumoxide (Endorem, Guerbet, France) and ferucarbotran 
(Resovist, Bayer-Schering Pharma, Germany).  
Recognised by cells of the reticuloendothelial system. Have 
been used for oncological imaging including liver studies 
where they are taken up by Kuppfer cells in normal tumour-
free liver .(Margolis et al., 2007) 
Mesenchymal stem cell, monocyte/macrophage labelling  
(Richards et al., 2012a).  
Ultrasmall SPIO 
(USPIOs) 
<50 nm Ferumxytol: 
9-15 h 
Ferumoxtran
-10: 25-30 h 
Ferumoxtran-10 (Sinerem, Guerbet, France) and ferumoxytol 
(Rienso, Takeda, United Kingdom).  
Very small 
superparamagnetic 
iron oxide particles 
(VSOPs) 
<10 nm  1 h Alternative blood pool agents with longer circulating half-life 
than gadolinium based agents (Schnorr et al., 2012, Wagner 
et al., 2011).  
Potential as cell tracking agents (Ludwig et al., 2013). 
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Figure 1.4 USPIO concentrating in lysosome in macrophage. 
 
 
Image from animal study, see “Nanoparticle enhanced MRI scanning to detect 
cellular inflammation in experimental chronic renal allograft rejection” in 
6.1.1.1.1.1.1.1Appendix G: (page 505).  
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1.10.1 IMAGING METHODOLOGY 
USPIOs induce local magnetic field inhomogeneities that shorten T2 and T2* 
relaxations times resulting in a signal deficit on magnetic resonance images. USPIOs 
also have a T1 shortening effect, particularly at low concentrations, and appear bright 
on T1 weighted images.  
A range of approaches have been used to evaluate USPIO accumulation in tissues. 
Most simply, images may be qualitatively assessed for signal deficits. However this 
approach is subjective, and signal deficits due to calcification or other artefacts may 
be misinterpreted.  Manually drawn regions of interest have been used to allow 
comparison of signal intensity of the target tissue with that of control tissue although 
discrete focal areas of USPIO accumulation, and thus focal inflammation, may be 
missed. 
Tissue properties, such as the presence of oedema or haemorrhage, can alter image 
intensities on T2* sequences, and so pre- and post-contrast images need to be 
compared to delineate the impact of USPIO accumulation. This requires accurate co-
registration of these paired scans and adjustments for differences in baseline 
intensity. A specific region of interest (ROI) map can be drawn and subsequently 
transferred to each subsequent co-registered image, thus ensuring the signal intensity 
can be compared for identical sample regions in different scans from the same 
patient. 
Rather than assessing focal image brightness at a single echo time, the T2* time 
constant can be calculated from the exponential decay curve using multiple echo 
times (Figure 1.5). This method provides greater reproducibility, broad applicability 
throughout the field of view, and independence from T1 effects and a range of 
imaging variables. In the presence of USPIO, the T2* relaxation rate is increased 
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thus giving a lower T2* value, or higher R2* value (R2* is the inverse of T2*, R2* = 
1/T2*). Calculation of these values permits the generation of T2* or R2* maps 
indicative of USPIO accumulation (Figure 1.6).  
  
Chapter 1: Myocardial Inflammation Following Ischaemia-Reperfusion Injury 
Detection, assessment and modulation of myocardial inflammation 54 
Figure 1.5 Creation of T2* map from multiple echo times. 
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Figure 1.6 T2* decay curve and time constant with and without USPIO. 
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Various authors have used different techniques to calculate USPIO uptake in tissues, 
and have reported results using T2, T2* or R2*. This can cause confusion since 
higher values infer diminished USPIO uptake in T2/T2* weighted images, but higher 
uptake in R2* maps. Therefore for simplicity, imaging techniques can be described 
but results reported in terms of “increased USPIO uptake”, or increased R2* value 
(indicating increased USPIO uptake). In order to account for native R2* values, 
various authors have used the delta increase in R2* value from successive scans, or 
factor increase. When pre-USPIO scans have not been performed, it must be 
assumed that non-inflamed tissue has similar R2* values to pre-USPIO native R2* 
values.  
Finally, it must be noted that USPIO also shorten T1, and so cause signal 
enhancement of T1 weighted imaging (Small et al., 1993). However, at high 
concentration USPIO can cause signal loss with such imaging limiting its use with 
T1 weighted sequences (Fananapazir et al., 2014). 
 
1.10.2 ASSESSING MYOCARDIAL INFLAMMATION. 
The USPIO NC100150 (Clariscan; Nycomed Imaging, Oslo, Norway) has been 
evaluated as a blood pool contrast agent in a porcine model of MI, and does identify 
areas of non-perfused myocardium (Bjerner et al., 2000). This agent was again 
studied as a blood pool agent in a rodent model of reperfusion after MI (Krombach et 
al., 2002). USPIO T1-weighted hyper-enhancement was larger than the area of 
infarction after reperfusion, but was smaller than the area at risk. Thus UPSIO 
seemed to estimate the spatial extent of microvascular injury, with associated leakage 
into the extravascular space. 
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Monocytes infiltrate the myocardium following infarction or reperfusion injury, and 
differentiate into macrophages as described above. They are initially involved in a 
pro-inflammatory response, whereas monocytes arriving later promote reparative 
processes (Nahrendorf et al., 2007a). Non-invasive imaging using USPIO 
enhancement may provide insights into the dynamics of inflammatory cell 
recruitment in the peri-infarct region, and is ideally suited to evaluate future therapies 
aimed at modifying the inflammatory process. 
Several rodent models of MI have demonstrated excellent histological co-localisation 
of USPIOs with macrophages within infarcted myocardium (Montet-Abou et al., 
2010). Moreover anti-inflammatory interventions reduce USPIO uptake within the 
infarct zone and this corresponds to lower macrophage infiltration on histology. Thus 
USPIO-enhanced MRI tracks myocardial inflammation following MI and can be 
used to assess response to therapeutic intervention. 
Allograft rejection is a potential complication of cardiac transplantation with patients 
requiring life-long monitoring including invasive cardiac biopsy. It is a condition 
where myocardial inflammation causes significant clinical injury. During transplant 
rejection, antigen presenting cells stimulate lymphocytes to release cytokines that 
recruit and activate macrophages that are the main effector cells (Suzuki et al., 2010). 
Macrophage and monocyte infiltration correlate with rejection in biopsies from 
cardiac transplant recipients (Lones et al., 1995).  Rodents with allografts undergoing 
rejection exhibit large USPIO uptake in the myocardium, with rodents treated with 
anti-rejection treatment exhibiting an intermediate reduction in uptake (Penno et al., 
2007).  This is mirrored by myocardial macrophage count that is largest in the 
allograft group, reduced in the treatment group and smallest in controls. Indeed, 
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higher USPIO accumulation is identified with increasing rejection grade (Wu et al., 
2009). USPIO-enhanced MRI indicates a heterogeneous distribution of the 
inflammatory change throughout the myocardium.  This underlines the limitations of 
single-site endomyocardial biopsy, widely regarded as the gold standard for 
diagnosing rejection. USPIO-enhanced MRI may therefore prove to be a more 
sensitive method to monitor graft status with the additional advantage that it is non-
invasive. However translational studies in man are now awaited.  
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1.11 SUMMARY 
Inflammation occurs following acute myocardial infarction due to ischaemic-
reperfusion injury. Inflammation within the infarcted myocardium is associated with 
induction of endothelial adhesion molecules and enhanced permeability of the 
microvasculature. Up regulation of chemokines including interleukin (IL)-8 and 
monocyte chemoattractant protein (MCP)-1 attracts neutrophils and monocytes to the 
site of injury. Recruitment of monocytes into the infarcted myocardium is followed 
by maturation and differentiation into macrophages: a process dependent on growth 
factors such as macrophage-colony stimulating factor (M-CSF). Early reperfusion 
therapy amplifies this inflammatory cell influx and accelerates the healing response 
through proliferative and maturation phases.  
During  coronary artery bypass graft (CABG) surgery and cardiopulmonary bypass, 
coronary blood flow is interrupted and the heart is put into circulatory arrest. This 
also causes ischemia-reperfusion injury. This is exacerbated by adverse neutrophil-
mediated myocardial inflammation and injury (Vinten-Johansen, 2004, Butler et al., 
1993, Wakayama et al., 2007). CABG surgery therefore represents a programmed 
clinical model of ischemia-reperfusion injury that lends itself to testing the efficacy 
of potential therapeutic interventions (Hausenloy et al., 2007). 
Iron oxide particles can be used as a contrast medium in magnetic resonance imaging 
since they alter the T2* relaxation time of tissues in which they accumulate. 
Ultrasmall superparamagnetic particles of iron oxide (USPIO) are taken up by cells 
of the liver, spleen, bone marrow and lymph nodes. As a result of their small size 
(approximately 30 nm) they extravasate freely through capillaries and are 
phagocytosed by tissue-resident inflammatory cells of the reticuloendothelial system 
(Ruehm et al., 2001b). These cells are predominately macrophages (Dousset et al., 
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1999, Gellissen et al., 1999a). T2*-weighted MRI has been validated as a method of 
detecting hepatic and myocardial iron accumulation in patients with thalassemia and 
transfusion-related iron overload. This method could be adapted for the detection of 
focal USPIO accumulation (Anderson et al., 2001, Westwood et al., 2005), and thus 
assess myocardial inflammation in the myocardium. 
Elafin is an endogenous anti-inflammatory protein that was first isolated in the 
search for inhibitors of neutrophil elastase activity in the lung and skin (Sallenave 
and Ryle, 1991a, Wiedow et al., 1991). It has inhibitory activity against both human 
neutrophil elastase and proteinase-3 as well as suppressing production of 
inflammatory cytokines such as interleukin-8 (IL-8) and tumor necrosis factor alpha 
(TNF-α) (Henriksen et al., 2004b). Elafin is produced locally at sites of 
inflammation, raising a local defence of ‘alarm’ antiproteases in order to contain and 
inhibit neutrophil-mediated inflammation (Sallenave, 2000a). Cardiovascular tissues 
do not express elafin or other neutrophil elastase inhibitors, and are therefore more 
vulnerable to neutrophil-mediated injury. Elafin augmentation therefore may protect 
the cardiovascular system from a range of conditions characterized by neutrophil 
elastase-mediated inflammation and injury.  
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1.12 AIM AND HYPOTHESES 
The aim of this thesis is firstly to perform a proof-of-concept study to investigate the 
feasibility of using USPIO enhanced cardiac MRI to identify and assess myocardial 
cellular inflammation. This technique will then be utilised in conjunction with blood 
and conventional MRI markers of inflammation and injury to assess the impact of 
anti-inflammatory Elafin in a randomised controlled trial of patients undergoing 
coronary artery bypass surgery. The detailed characterisation of myocardial injury 
occurring during CABG surgery provided by this study will be used to assess the 
performance of the current universal definition of Type V myocardial infarction. 
 
The following novel hypothesis will be addressed: 
 
1. Changes in R2* in USPIO enhanced MRI scans will detect cellular inflammation 
post myocardial infarction. 
2. Myocardial injury post coronary artery bypass surgery can be assessed with 
blood markers of inflammation and infarction. 
3. Elafin, the neutrophil elastase inhibitor, can modify post coronary artery bypass 
surgery myocardial injury and inflammation 
4. Cellular inflammation post coronary artery bypass surgery can be detected and 
assessed using USPIO enhanced MRI scanning. 
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Chapter 2: METHODS  
 
2.1 ETHICAL AND REGULATORY CONSIDERATIONS 
The studies were undertaken with the approval of the Scotland A Research Ethics 
Committee and Lothian Local Research Ethics Committee 03 (REC 10/S1 103/50), 
who approved the use of the MRI contrast agent ferumoxytol (Feraheme, AMAG 
Pharmaceuticals) to investigate patients.  
The Elafin Myocardial Protection from Ischemia Reperfusion (EMPIRE) randomised 
controlled clinical trial was performed with the approval of the national research 
ethics committee (11/MRE00/5), under a Clinical Trial Authorization 
(27586/0015/001-0001) from the Medicine and Healthcare products Regulatory 
Authority (MHRA, United Kingdom). The Medicines and Healthcare Products 
Regulatory Agency (MHRA) approved the use of the MRI contrast agent 
ferumoxytol (Rienso, Takeda; Feraheme, AMAG Pharmaceuticals) to investigate 
patients. All studies were conducted in accordance with the Declaration of Helsinki. 
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2.2 SUBJECT RECRUITMENT 
All participants gave written informed consent before participating in the study. An 
information sheet was provided and participants’ general practitioners were informed 
in writing (Appendix C: page 320). 
 
2.2.1 PATIENTS WITH MYOCARDIAL INFARCTION 
Patients who had suffered an acute ST-elevation myocardial infarction were 
approached to take part in the proof of concept study investigating if USPIO could 
detect myocardial cellular inflammation. Patients were identified in the coronary care 
unit at the Royal Infirmary of Edinburgh. Inclusion criteria were age 18-80 years, 
recent (within 48 hours) myocardial infarction defined by the universal definition of 
myocardial infarction and plasma troponin I concentration in excess of 10 µg/L at 12 
hours from the onset of chest pain (Thygesen et al., 2007a). Exclusion criteria were 
known critical stenosis (≥95%) of left main stem, ongoing symptoms of unstable 
angina, atrial fibrillation, heart failure (Killip class ≥II), hepatic failure (Childs-Pugh 
grade B or C) or renal failure (estimated glomerular filtration rate <25 mL/min), 
contraindication to magnetic resonance imaging, past history of systemic iron 
overload or hemochromatosis, and patients with known allergy to dextran- or iron-
containing compounds.  
 
2.2.2 HEALTHY VOLUNTEERS 
Healthy volunteers (aged >18 years) were recruited by local advertisement through 
the Edinburgh Heart Centre. Volunteers were excluded from participation in the 
study on the same criteria outlined in section 2.2.1. 
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2.2.3 PATIENTS UNDERGOING CORONARY ARTERY BYPASS SURGERY: THE EMPIRE 
STUDY 
The Elafin Myocardial Protection from Ischemia RepErfusion injury (EMPIRE) 
study examined the effect of Elafin, an endogenous neutrophil elastase inhibitor on 
myocardial injury occurring during coronary artery bypass surgery. The full study 
protocol is attached in 5.1.1.1.1.1.1.1Appendix D: (page 373). Consecutive patients 
referred for elective CABG surgery were recruited from two clinics at Edinburgh 
Heart Centre. Patients were 18 years or older, and were referred for isolated CABG 
surgery requiring 2 or more grafts. Exclusion criteria included patients with recent 
myocardial infarction (within 1 month of surgery), emergency or concomitant valve 
surgery, significant renal impairment (estimated glomerular filtration rate <40 
mL/min), severe respiratory disease (maintenance corticosteroid therapy or forced 
expiratory volume in one second <50% predicted), severe left ventricular impairment 
(ejection fraction <40%), contraindication to magnetic resonance scanning, treatment 
for chronic inflammatory disease, women of child-bearing potential and inability to 
provide consent. For analysis of USPIO uptake in the myocardium, patients who had 
evidence of acute graft or coronary artery occlusion peri-operatively were excluded 
since this would not be representative of standard patients undergoing CABG 
surgery. 
All participants gave written informed consent before participating in the study. An 
information sheet was provided and participants’ general practitioners were informed 
in writing (5.1.1.1.1.1.1.1Appendix D: page 362). 
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2.3 BLOOD SAMPLING AND TESTING 
2.3.1 VENEPUNCTURE 
Venesection was performed on a peripheral vein using standard aseptic technique. 
Whole venous blood (up to 240 mL) was obtained from a vein in the antecubital 
fossa using a 17-21 gauge needle. In the post-operative period, an arterial or centrally 
placed cannula was available for blood sampling.  
 
2.3.2 ASSAYS 
The prototype ARCHITECT STAT high sensitive Troponin-I (TnI) assay (Abbott 
Diagnostics, Abbott Park, IL) is a two-step assay in which plasma TnI is bound by an 
anti-TnI antibody (amino acids 24-40)-coated paramagnetic microparticles and then 
sandwiched with an acridinium-labeled anti-TnI antibody (amino acids 41-49). The 
limit of detection and limit of quantification are 1.0 and 4.1 pg/mL respectively. The 
mean±SD of an apparently healthy population (n=300) is 1.58±3.07 pg/mL and the 
99th percentile was determined to be 16.8 pg/mL with the 10% co-efficient of 
varation (CV) determined as <5.5 pg/mL. Within run, between run, between day and 
total precision (CV) ranged respectively from 1.9-6.2%, 0.0-4.2%, 0.0-3.2% and 2.4-
7.0%. The age specific 99th centile upper reference limit (URL) were 34 ng/L (men) 
and 16 ng/L (women) (Shah et al., 2015c).  
Plasma concentrations of high-sensitive C-reactive protein (hsCRP), interleukin (IL)-
6, IL-8, myeloperoxidase and elastase were quantified using enzyme-linked 
immunosorbant assays (ELISAs; R&D Systems, U.K.; Elastase ELISA, Cambridge 
Biosciences, U.K.). Plasma elastase activity and serum Elafin concentrations were 
measured by the Department of Dermatology, University of Kiel, Germany. Samples 
of plasma for Elafin concentration and elastase activity were sent to Proteo Biotech 
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AG for analysis. The quantification method was propriety information, therefore 
validation data was not available. However, Elafin concentration and elastase activity 
were not used for primary and secondary endpoints nor post hoc analysis.  
 
2.4 ELAFIN 
2.4.1 STUDY DRUG IDENTIFICATION 
Elafin CAS number: 820211-82-3. “Recombinant human Elafin” is produced in yeast 
with a structure identical to the 57 amino acid human form and with 95% purity. It 
was prepared and infused as aqueous solution in 0.9% saline.  
Amino acid sequence (SwissProt accession number: P19957): 
Ala-Gln-Glu-Pro-Val-Lys-Gly-Pro-Val-Ser-Thr-Lys-Pro-Gly-Ser-Cys-Pro-Ile-Ile-
Leu-Ile-Arg-Cys-Ala-Met-Leu-Asn-Pro-Pro-Asn-Arg-Cys-Leu-Lys-Asp-Thr-Asp-
Cys-Pro-Gly-Ile-Lys-Lys-Cys-Cys-Glu-Gly-Ser-Cys-Gly-Met-Ala-Cys-Phe-Val-
Pro-Gln 
 
2.4.2 STUDY DRUG MANUFACTURER 
Elafin, the investigational medicinal product, was manufactured, packaged and 
labelled by Eurogentac S.A. (Biologics, Liege Science Park, 4102 Seraing, Belgium) 
as a subcontractor of Proteo Biotech AG in accordance with Good Manufacturing 
Practice (GMP) guidelines. 
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2.4.3 LABELLING 
The pharmacy department at the Royal Infirmary of Edinburgh and the research 
nurses within the Welcome Trust Clinical Research Facility shared the responsibility 
for the preparation of 200 mg of Elafin in 250 mL of 0.9% saline or matched placebo 
0.9% saline solution, as well as labelling the infusion for blinding the study to 
investigators and participants. 
 
2.4.4 STORAGE 
The study drug was kept in the pharmacy department as per product label. 
 
2.4.5 STUDY DRUG PREPERATION AND ADMINISTRATION 
Intravenous recombinant human Elafin (Proteo Biotech AG, Germany) 200 mg was 
prepared and infused as aqueous solution of 250 mL 0.9% saline.  
Intravenous Elafin 200 mg causes complete inhibition of plasma elastase activity for 
2 hours and >50% inhibition for 8 hours (Bellemare et al., 2008). This dosage regime 
was selected to cover the increased elastase activity following CABG that peaks at 
the time of weaning from cardiopulmonary bypass and has returned to baseline by 6-
7 hours. The study drug was administered to the patient through a central venous 
cannula over a period of 30 minutes. The intravenous infusion was started at first 
skin incision and completed at least 20 minutes before cardiopulmonary bypass 
commenced. 
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2.4.6 RANDOMISATION 
Patients were randomised (1:1) to receive Elafin or matched placebo by Edinburgh 
Clinical Trials Unit to ensure allocation concealment.  No member of the clinical 
team or research team had randomisation information. Subsequent clinical 
management and trial protocol investigation were identical.  Communication of 
randomisation to the pharmacy department was web-based. 
 
 
The minimisation technique incorporated the following binary criteria: 
• Age; ≥ 65 or < 65 years 
• Sex; male or female 
• Diabetes Mellitus; present or absent 
• Extent of coronary artery disease; 2 or 3 vessel coronary disease 
• Estimated glomerular filtration rate (eGFR mL/min); 40- 59 or ≥60  
• Surgeon; Surgeon 1 or Surgeon 2 
  
Chapter 2: Methods 
Detection, assessment and modulation of myocardial inflammation 69 
2.5 PLACEBO 
Placebo consisted of 250 mL of 0.9% saline. Identical to the study drug, this was 
administered to the patient through a central venous cannula over a period of 30 
minutes. The intravenous infusion was started at first skin incision and completed at 
least 20 minutes before cardiopulmonary bypass commenced. 
 
2.6 PARTICIPANT COMPLIANCE 
Responsibility for infusion was with the anaesthetic team. Timing and dose was 
noted on anaesthetic chart as per usual clinical practice. This information was entered 
into the study database. 
 
2.7 OVERDOSE 
From previous studies, a dose of 400 mg was not associated with any relevant safety 
concerns. The only side effects of nausea and headache were attributed to the 
investigational procedure. The study drug infusion was prepared with no other source 
of Elafin being available for clinicians or the research team to administer additional 
amounts. Therefore each patient did not receive more than 200 mg of Elafin. 
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2.8 ADDITIONAL OUTCOMES 
The following data was collected as expected events in the care of patients post 
coronary bypass surgery, but not reported as adverse events related to the study. 
They were included in the primary or secondary end point analysis. 
Postoperative complications related to coronary artery bypass surgery between 0 
(time of first skin incision) and 48 hours including; 
• Wound infection; sternotomy and vein harvest sites 
• Respiratory complications; chest infection, pleural effusion requiring 
drainage 
• Administration of antibiotics for any infection 
• Atrial fibrillation (sustained for more than 5 minutes) 
• Stroke 
• Renal function measured by creatinine/GFR 
• Low cardiac output syndrome and inotrope requirement 
• Red blood cell transfusion 
• Re-operation for bleeding 
 
Death was reported as a serious complication of CABG surgery, and registered as an 
adverse event. 
The patient was quoted an individualised risk of these complications within the 
cardiothoracic surgery using the Euroscore algorithm (Nashef et al., 1999).  
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2.9 CARDIAC MAGNETIC RESONANCE 
2.9.1 CONTRAST AGENTS - GADOLINIUM 
Gadolinium is commonly used as an MRI contrast agent after acute myocardial 
infarction (MI) to identify areas of tissue infarction and fibrosis (Lima et al., 1995, 
Schelbert et al., 2010). Tissue oedema and rupture of cell membranes with 
consequent diffusion of gadolinium into the inter- and intra-cellular spaces (Lima et 
al., 1995) results in a “delayed gadolinium enhancement” effect in infarcted regions. 
Intravenous administration of gadolinium contrast agent (0.1 mmol/kg; Gadovist, 
Bayer Plc, Germany) was used to quantify infarct mass. 
 
2.9.2 CONTRAST AGENTS - ULTRASMALL SUPERPARAMAGNETIC PARTICLES OF IRON 
OXIDE 
Ultrasmall superparamagnetic particles of iron oxide (USPIOs) consist of 
nanoparticles with a diameter of <50 nm. USPIOs can be used as a blood pool 
contrast agent but it is their ability to be taken up by inflammatory cells that has 
distinguished them (Christen et al., 2012). Ferumoxytol (Rienso, Takeda; Feraheme, 
AMAG Pharmaceuticals) was used to investigate inflammatory cell infiltration of the 
myocardium. Each vial contained 510 mg of elemental iron in 17 mL (30 mg/mL).  
 
2.9.3 IMAGING METHODOLOGY 
USPIOs induce local magnetic field inhomogeneities that shorten T2 and T2* 
relaxation times resulting in a signal deficit on magnetic resonance images. USPIOs 
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also have a T1 shortening effect, particularly at low concentrations, and appear bright 
on T1 weighted images.  
Manually drawn regions of interest were used to quantify USPIO uptake in areas of 
interest, such as the infarct zone. Pan-myocardial USPIO uptake was assessed by 
creating regions of interest covering the entire heart. Specific methods are detailed 
below. 
Tissue properties, such as the presence of oedema or haemorrhage, can alter image 
intensities on T2* sequences, and so pre- and post-contrast images were used to 
delineate the impact of USPIO accumulation. This required accurate co-registration 
of these paired scans. A specific region of interest (ROI) map was drawn and 
transferred to each subsequent co-registered image, thus ensuring accurate 
comparison of identical sample regions in different scans from the same patient. 
The T2* time constant was calculated from the exponential decay curve using 
multiple echo times. In the presence of USPIO, the T2* relaxation rate is increased 
thus giving a lower T2* value, or higher R2* value (R2* is the inverse of T2*, R2* = 
1/T2* and represents the rate constant). Calculation of these values permits the 
generation of T2* or R2* maps indicative of USPIO accumulation. R2* maps and 
values were used since the higher the USPIO accumulation, the higher the R2* value. 
In order to account for native R2* values, we used the delta increase in R2* value 
from successive scans.  
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2.9.4 CINE AND LATE ENHANCEMENT IMAGING 
Magnetic resonance imaging was performed using a combination of body matrix and 
spine coil matrix coil elements of a 3-Tesla Verio scanner (Siemens Medical, 
Germany). Standard cardiac breath-held ECG-gated true-FISP sequences were used to 
acquire vertical long axis, horizontal long axis and short axis views of the heart to 
determine cardiac ejection fraction and mass. 
Breath-held inversion recovery sequences in the short-axis, and horizontal and vertical 
long-axis planes were used to acquire late enhancement images 10-15 min following 
an intravenous administration of gadolinium contrast agent (0.1 mmol/kg; Gadovist, 
Bayer Plc, Germany).  Optimal TI was determined on a slice-by-slice basis using 
standard late enhancement protocols.  The inversion recovery late enhancement short 
axis slices were acquired with the same slice position as the short axis T2*-weighted 
slices (see below).  
 
2.9.5 USPIO SCANNING PROTOCOL 
USPIO imaging was performed using established T2*-weighted multi-gradient-echo 
sequences, breath-held and cardiac-gated after a volumetric shim had been applied 
over the entire heart volume. Standard cardiac slice width (6 mm width with 4 mm 
gap) and echo times (2.1-17.1 ms range) with matrix size of 256x115. The in-plane 
resolution differed as required for larger or smaller objects, generally a field of view 
of 400x300 was used with an in-plane resolution of 2.6x1.6. Quantitative analysis of 
USPIO accumulation was achieved by calculation of T2* relaxation times before and 
after administration of USPIO.(Richards et al., 2011a). In order to optimise image 
analysis and prevent degradation due to “T2*-blooming” artefacts, USPIO images 
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were quantitatively analysed using a susceptibility gradient mapping post-processing 
technique previously used in SPIO imaging to quantitate USPIO accumulation using 
changes in calculated T2* relaxation times (Dahnke et al., 2008). 
The inversion recovery late enhancement short axis slices were acquired with the 
same slice position as the short axis T2*-weighted slices. The T2*-weighted short-axis 
acquisitions included views of abdominal organs including through the liver and 
spleen, and allowed quantification of USPIO uptake within the reticuloendothelial 
system via changes in these tissues’ R2* value. 
 
2.9.6 TIMING OF USPIO MRI SCANS 
Each patient underwent baseline cardiac magnetic resonance imaging, and USPIO 
was infused immediately after. USPIO enhanced scan were performed as closed to 
24 hours after the baseline scan as possible.  
 
2.9.7 ANALYSIS OF EJECTION FRACTION AND VOLUME OF INFARCTION 
Quantification of left ventricular mass, ejection fraction and late gadolinium 
enhancement infarct size were determined using established protocols and dedicated 
cardiac analysis software by two trained independent blinded observers.  Late 
enhancement analysis was performed using QMass software (Medis medical imaging 
systems, Netherlands), allowing quantification of infarct size using the full-width, 
half-maximum criterion. The change in mass of infarcted tissue was determined by 
the difference in LGE from the preoperative and first postoperative CMR scans. The 
infarct size was given in mass unless specifically stated. The absolute change in 
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ejection fraction from pre to post surgery was calculated and an arbitrary value of 5% 
change was used to categorize patients into increased, decreased or no change.  
 
2.9.8 USPIO ENHANCED MRI IMAGE PREPERATION 
Baseline and post-USPIO T2*-weighted multi-gradient-echo images for each patient 
were spatially co-registered using ANALYZE software (AnalyzeDirect Software, 
United States). The four echoes (TE = 2.13, 4.27, 6.41, 8.55 ms) in a multi-echo 
T2*-weighted sequence were combined to generate a T2* map, in which the data 
represented the T2* value (S(t) = S(0)exp- (t/T2*)) for each voxel. This was 
achieved using in-house software developed in Matlab (Mathworks, US). The T2* 
value is the decay constant for the exponential decay of signal intensity with time. In 
the presence of USPIO, the signal decays more rapidly due to local field 
inhomogeneities and the T2* value is reduced. A 3x3 voxel Gaussian filter was 
applied to the individual echoes to reduce noise. By minimising the sum of the 
squares of errors between the data and an exponential function, the decay constant 
(i.e. T2*) was obtained. An experimentally determined threshold for the co-efficient 
of determination (r2>0.85) was used to exclude data that did not have an acceptable 
exponential decay when SI was plotted against echo time. The inverse of T2*, R2*, 
was then calculated to assess USPIO uptake. In our laboratory, we have previously 
assessed the repeatability of the measurement of the R2* value by comparing data 
from two T2*W sequences (run 1 versus run 2) performed in quick succession 
without moving the patient. This was performed on a voxel-by-voxel basis with a 
total of 32,936 data points, of which 1.2% were affected by artifact and discarded. 
Using the Bland and Altman method, (Bland and Altman, 1986) there was no 
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evidence of mean difference (0.99±21.9 s-1) with a coefficient of repeatability of 42.9 
s-1.  
The transformation matrix of the co-registration was then applied to the subsequent 
T2*-weighted echoes and R2* was calculated on a voxel-by-voxel basis to generate 
co-registered R2* ‘maps’ at baseline, and subsequent scans. The late enhancement 
short-axis images were also spatially co-registered with the R2* images for each visit 
in case of lack of reproducibility of patient breath-holding between scans.  
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2.10 STUDY PROTOCOLS FOR THE ASSESSMENT OF CELLULAR INFLAMMATION 
FOLLOWING ACUTE MYOCARDIAL INFARCTION  (CHAPTER 3) 
This study investigated the feasibility of using USPIO enhance CMR to detect 
myocardial inflammation following myocardial infarction (Chapter 3: page 89). 
 
2.10.1 SUBJECTS 
This study was an open-label pilot proof-of-concept study in 16 patients who 
suffered a recent myocardial infarction defined by the universal definition of 
myocardial infarction (Thygesen et al., 2007a). For inclusion & exclusion criteria, 
see section 2.1.3. Healthy volunteers, to define the R2* changes following USPIO 
administration in normal tissues, were recruited via local advertising. 
All patients suffered an acute ST-elevation myocardial infarction. One patient in 
each group received thrombolytic therapy with tenecteplase, followed by 
percutaneous coronary angioplasty and stent placement. One patient in the control 
group re-perfused spontaneously followed by percutaneous coronary angioplasty and 
stent placement. All other patients were treated by primary percutaneous coronary 
intervention. 
All patients gave written informed consent and the study was conducted with the 
approval of the local research ethics committee. 
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2.10.2 ULTRASMALL SUPERPARAMAGNETIC PARTICLES OF IRON OXIDE 
Intravenous infusion of USPIO was performed immediately following the initial 
baseline magnetic resonance scan. USPIO (Ferumoxytol; Advanced Magnetics Inc, 
Cambridge, MA) was administered via a peripheral venous cannula at a dose of 4 
mg/kg at a rate of up to 1 mL/s. Hemodynamic and electrocardiographic monitoring 
was conducted throughout. 
 
2.10.3 MAGNETIC RESONANCE IMAGING 
 
Sequential imaging was performed at baseline (24-72 h after admission), and 24 and 
48 h thereafter. In 10 patients, USPIO was administered immediately after the 
baselines scan. Six patients received no infusion and acted as control subjects. 
Magnetic resonance imaging was performed as per 2.9.5. 
 
2.10.4 IMAGE ANALYSIS 
Late enhancement analysis was performed using QMass software (Medis medical 
imaging systems, Netherlands), allowing quantification of infarct size and location 
for correlation with USPIO-related signal changes.  
Baseline, and 24 and 48 hours T2*-weighted multi-gradient-echo images for each 
patient were spatially co-registered using ANALYZE software (AnalyzeDirect 
Software, United States) as described in section 2.4.8. Subsequently, R2* maps were 
generated and used for analysis. 
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The late enhancement short-axis images were also spatially co-registered with the 
R2* images for each visit in case of lack of reproducibility of patient breath-holding 
between scans. Regions of interests (ROIs) were selected on the late enhancement 
images and applied to the co-registered R2* maps corresponding to: (i) micro-
vascular obstruction if present, (ii) infarct area (defined by late gadolinium 
enhancement), (iii) peri-infarct area (adjacent to late gadolinium enhancement), (iv) 
myocardium remote from the infarct zone (distant from late gadolinium 
enhancement), (v) skeletal muscle, (vi) blood pool, (vii) liver and (viii) spleen 
(Figure 2.1). The ROIs were mapped to the first T2* echo before being applied to 
R2* maps to ensure there was coherence to the corresponding areas on all 3 scans, 
and no overlap with the blood pool or extra-cardiac structures. Two investigators 
created and quantified ROIs for all scans independently in order to assess 
reproducibility of the technique. 
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Figure 2.1 Object map creation 
Following registration with late gadolinium enhancement (LGE) images, an “object 
map” (OM) was defined from regions of interest of specific tissues and subsections: 
skeletal muscle (light blue), spleen (dark blue), liver (yellow), blood pool (lilac) and 
heart subdivided into areas of infarction (red), peri-infarction (white) and remote 
myocardium (green). The object map was spatially co-registered with the R2* map 
(R2*) to measure specific R2* values (R2*+OM). 
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2.10.5 DATA AND STATISTICAL ANALYSIS FOR CHAPTER 3  
 
All statistical analysis was performed with GraphPad Prism version 4.00 (GraphPad 
Software, San Diego California USA), except the Intraclass Correlation (ICC) which 
was performed with SPSS (IBM Version 20.0.0, USA) using a one-way random 
effects model. Repeatability was assessed by the method of Bland and Altman and 
coefficient of repeatability defined as twice the standard deviation of the mean of the 
differences (Bland and Altman, 1986). Patient characteristics were compared using 
unpaired non-parametric Mann-Whitney test. R2* values at baseline, 24 hours and 48 
hours for each ROI were compared using repeated measure one-way ANOVA 
(Friedman test). If significant, Dunn’s multiple comparison post-test was performed 
comparing R2* value at baseline to 24 hours, and baseline to 48 hours. Statistical 
significance was defined as two-sided P<0.05. 
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2.11 ELAFIN MYOCARDIAL PROTECTION FROM ISCHEMIA REPERFUSION (EMPIRE) 
TRIAL – CHAPTERS 4, 5 & 6 
 
This study investigated whether Elafin, a neutrophil elastase inhibitor, could reduce 
myocardial inflammation following cardiac surgery (Chapter 4: page 118). As sub-
studies, detection of cellular inflammation by USPIO enhanced CMR in the 
myocardium and other organs following surgery, and its modulation by Elafin was 
investigated (Chapter 5: page 143). Myocardial injury & inflammation following 
surgery was analysed with detection and of type 5 myocardial (Chapter 6: page 178).  
 
2.11.1 CLINICAL STUDY AND RECRUITMENT 
Myocardial inflammation and injury  (see Chapter 6: page 178) was characterised as 
a sub-study of the “Elafin Myocardial Protection from Ischemia Reperfusion” 
(EMPIRE, ISRCTN 82061264) randomized controlled clinical trial (see Chapter 4: 
page 118)(Alam et al., 2015). This investigated the effect of Elafin, a neutrophil 
elastase inhibitor, on myocardial injury during on-pump CABG surgery. As a further 
substudy of the EMPIRE trial, cellular inflammation was investigated using USPIO 
(Chapter 5: page 143). 
Patients referred for elective CABG surgery were recruited at Edinburgh Heart 
Centre between June 2011 and September 2013. Key inclusion & exclusion criteria 
are described in section 2.2.3, page 64. 
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2.11.2 CORONARY ARTERY BYPASS GRAFT SURGERY 
Routine clinical monitoring included an arterial line, central venous line, urinary 
catheter, electrocardiogram and trans-esophageal echocardiography. Anaesthesia 
included opiate analgesia, induction with propofol and muscle relaxation with a non-
depolarizing agent. The trachea was intubated and mechanical ventilation 
commenced. General anaesthesia was maintained with isoflurane propofol infusion 
during bypass. Surgical approach was via a median sternotomy and cardiopulmonary 
bypass was started after heparin administration with a non-pulsatile flow and a 
membrane oxygenator. Cardioprotection was provided by cold-blood cardioplegia 
(1:4), which was administered antegradely, after cross-clamping the aorta, into the 
coronary arteries or by cross clamp fibrillation. Where possible the left internal 
mammary artery was used for grafting. Other conduits were chosen from saphenous 
vein, radial artery or the right internal mammary artery. After grafting, 
cardiopulmonary bypass was discontinued and protamine was given to reverse the 
heparin. Patients received usual postoperative care within the intensive care unit. 
 
2.11.3 ELECTROCARDIOGRAM 
An ECG was performed prior to surgery, and then immediately post-surgery, 24 
hours, 48 hours and at discharge. Additional ECGs were performed only if clinically 
indicated. Ischemia or infarction by ECG was defined as at least 2 mm ST deviation 
in the chest leads or 1 mm in the limb leads, development of new pathological Q 
waves or new bundle branch block. Other ECG categories included T-wave inversion 
(TWI) with no signs of ischemia or infarction, concave ST elevation with or without 
PR segment depression and no changes.  
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2.11.4 BLOOD BIOMARKERS 
Blood samples were taken at baseline (time 0 hours, skin incision) and at 2, 6, 24 and 
48 h post-operatively. Stored plasma samples were analysed using the high-sensitive 
troponin I assay. Plasma concentrations of high-sensitive C-reactive protein (hsCRP), 
interleukin IL-6, IL-8, tumour necrosis factor (TNF)-α, myeloperoxidase and elastase 
were quantified. 
 
2.11.5 CARDIAC MAGNETIC RESONANCE IMAGING  
Each patient underwent cardiac magnetic resonance imaging thrice: baseline CMR 
was performed 6 weeks before surgery. The first post-operative CMR was performed 
from 5 days after surgery, and a further USPIO enhances scan performed 24 hours 
after this. Patients were scanned as described in section 2.4. Quantification of left 
ventricular mass, ejection fraction and late gadolinium enhancement infarct size were 
determined using established protocols and dedicated cardiac analysis software by 
two trained independent blinded observers.   
Healthy volunteers underwent CMR at baseline and 24 hours post USPIO infusion. 
In addition, there was USPIO enhanced scanning carried out immediately after 
infusion. Ex-vivo blood was scanned pre-USPIO infusion, 1 hour post USPIO 
infusion and 24 hours post infusion. 
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2.11.6 DEVELOPMENT OF USPIO UPTAKE ANALYSIS PROTOCOLS 
The inflammation following CABG surgery may not be confined to areas of new 
infarction, and would be expected to be distributed diffusely in the myocardium. In 
order to develop a robust technique to analyse USPIO enhanced scans, the 
myocardium was divided into the standard 17-segment model and a R2* value 
calculated for each segment (Cerqueira et al., 2002). After calculating the increase in 
R2* value between the second and third scans, three methods for USPIO uptake 
quantification where used. Firstly, a pan-myocardial R2* value calculated from the 
mean of all segments. Secondly, since inflammation in the myocardium was likely to 
be non-uniform, a mean of the highest three segments was also calculated. Thirdly, 
the sum of the R2* values for the highest three segments was calculated for 
comparison. Since the apex of the myocardium is relatively thin and difficult to 
apply ROIs to accurately, these three methods of analysis were repeated excluding 
the apex. 
Finally the median, 25th & 75th percentile of the R2* increase per segment of 
myocardium for healthy volunteers (from chapter 3) was calculated (non-parametric 
data). An increase in R2* over the 75th percentile was arbitrarily defined as 
significant USPIO uptake in the study population. The number of “segments with 
significant USPIO uptake” was calculated for each patient.  
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2.11.7 DATA AND STATISTICAL ANALYSIS FOR CHAPTER 4  
Recruitment power calculations were based on a study of patients in a U.K. centre 
undergoing remote ischemic preconditioning before coronary artery bypass surgery 
(Hausenloy et al., 2007). Mean area under the troponin T release curve in control 
patients was 36.12 µg/L (s.d. 26.08) and 20.58 µg/L (s.d. 9.58) in treated patients. No 
contemporary AUC data were available for cTnI release in this patient group but the 
measurements are equivalent in terms of quantifying myocardial injury. With a 
sample size of 80 patients we had 90% power to detect this 40 % difference with a 
significance level of 5%, using a t-test with unequal variances and allowing for 4 
dropouts in each arm. 
The primary outcome variable was the 48-h area under the curve (AUC) for plasma 
cTnI concentration. It was analysed using a generalized linear model, including terms 
for the treatment allocation and the variables on which the randomization was 
minimised. Log transformations were applied as the data were skewed, and the 
results have been unlogged and presented as geometric means. Secondary outcome 
measures involving area under the curve (hs-CRP, IL-6, IL-8, myeloperoxidase and 
elastase) were analysed similarly, taking log transformation if the data were skewed. 
Left ventricular ejection fraction and mass were analysed using QMass software 
(Medis medical imaging systems, Netherlands). The change in volume of infarction 
from preoperative and first postoperative magnetic resonance scans was categorized 
as increased, no change or reduced according to detection threshold based on inter-
observer variability.  Post hoc analyses of individual time points used Wilcoxon 
tests. 
The primary analysis included all randomized patients on an intention-to-treat basis 
regardless of compliance with allocated treatment, and post randomization events. A 
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secondary pre-specified exploratory analysis of AUC cTnI release excluded patients 
who had myocardial infarction or a cardiac arrest resulting in loss of cardiac output 
for >1 min. Type V myocardial infarction was defined according to the third 
universal definition (Thygesen et al., 2012b). Finally, post hoc, we examined 
treatment effect for each time point using the high-sensitive cTnI assay. 
 
2.11.8 DATA AND STATISTICAL ANALYSIS FOR CHAPTER 5 
Parametric data was presented as mean with 95% confidence intervals, and non-
parametric data as median with inter-quartile range as appropriate. Categorical data 
were compared using the Pearson's chi-square test. Parametric R2* data were 
analysed with unpaired t-test, and non-parametric with the Mann-Whitney U-test as 
appropriate. Multiple comparisons for USPIO uptake were compared using Kruskal-
Wallis. If significant, Dunn’s multiple comparison post-test was performed 
comparing R2* value across groups. Statistical significance was defined as two-sided 
P<0.05. 
 
2.11.9 DATA AND STATISTICAL ANALYSIS FOR CHAPTER 6  
Chapter 4 reports that Elafin had no significant effect on primary and secondary 
outcome measures with the exceptions of increased circulating Elafin concentrations 
and a reduction in circulating elastase activity in Elafin treated patients. In chapter 6, 
data from patients in placebo and active treatment arms were aggregated to provide 
an assessment of myocardial injury post CABG surgery.  
Plasma hs-cTnI, hs-CRP, IL-6, IL-8 and MPO concentrations at each time point were 
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expressed as median [inter-quartile range], mean ± standard error of mean or mean 
(95% confidence intervals) as appropriate.  Forty-eight hour area-under-the-curve 
(AUC) was calculated for plasma hs-cTnI, hsCRP and cytokines.   
The change in mass of infarcted tissue was determined by the difference in LGE 
from the preoperative and first postoperative CMR scans. This was categorized as 
increased, no change or reduced according to detection threshold based on inter-
observer variability and agreement between both independent analysers.  The 
absolute change in ejection fraction from pre to post surgery was calculated and an 
arbitrary value of 5% change was used to categorize patients into increased, 
decreased or no change. 
Categorical data were compared using the Pearson's chi-square test. Non-parametric 
R2* data were analysed with the Mann-Whitney U-test. Multiple comparisons for 
USPIO uptake were compared using Kruskal-Wallis. If significant, Dunn’s multiple 
comparison post-test was performed comparing R2* value across groups. Statistical 
significance was defined as two-sided P<0.05.  
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Chapter 3: ULTRASMALL SUPERPARAMAGNETIC 
PARTICLES OF IRON OXIDE DETECT CELLULAR 
INFLAMMATION IN PATIENTS WITH ACUTE MYOCARDIAL 
INFARCTION 
 
3.1 SUMMARY 
Inflammation following acute myocardial infarction has detrimental effects on 
reperfusion, myocardial remodelling and ventricular function. Magnetic resonance 
imaging using ultrasmall superparamagnetic particles of iron oxide (USPIO) can 
detect cellular inflammation in tissues. We designed a proof of concept study to 
explore its utilisation in acute myocardial infarction in humans. 
Sixteen patients within five days of ST-segment elevation myocardial infarction 
underwent 3 sequential magnetic resonance scans at -1, 24 and 48 hours following no 
infusion (controls; n=6) or intravenous infusion of USPIO (n=10; 4 mg/kg). T2*-
weighted multi-gradient-echo sequences were acquired and R2* values calculated for 
specific regions of interest.  
In the control group, R2* remained constant in all tissues throughout all scans with 
excellent repeatability (bias of  -0.208, s-1, coefficient of repeatability of 26.96, s-1; 
intra-class coefficient 0.989). Consistent with uptake by the reticuloendothelial 
system, R2* increased in the liver (84±49.5 to 319±70.0 s-1; p<0.001) but was 
unchanged in skeletal muscle (54±8.4 to 67.0±9.5 s-1; p>0.05) 24 hours after USPIO 
administration. In the myocardial infarct, R2* increased from 41.0±12.0 (baseline) to 
155±45.0  (p<0.001) and 124±35.0 s-1 (p<0.05) at 24 and 48 hours respectively.  
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Following acute myocardial infarction, USPIO uptake occurs within the infarct zone. 
This technique is as a potential method of assessing cellular myocardial 
inflammation and left ventricular remodelling that may have a range of applications 
in patients with myocardial infarction and other inflammatory cardiac conditions. 
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3.2 INTRODUCTION 
Inflammation occurs in the acutely infarcted myocardium in order to remove necrotic 
cellular debris and allow tissue remodelling. Excessive inflammation may follow 
reperfusion therapy, and can have detrimental effects on healing and left ventricular 
remodelling (Nahrendorf et al., 2010). With the aim of improving outcomes 
following acute myocardial infarction, novel drugs are increasingly focusing on 
optimisation of myocardial repair and regeneration, and include anti-inflammatory 
interventions (Bonvini et al., 2005, Frangogiannis, 2006, Gonzalez et al., 2011, 
Steffens et al., 2009). There is therefore a need for non-invasive methods to assess in 
vivo myocardial inflammation following myocardial infarction both to define the 
healing process and to measure the potential efficacy of novel therapeutic 
interventions. As such, this method could be utilised to detect myocardial 
inflammation post CABG surgery and assess modulation by Elafin (Chapter 6: page 
178). 
Magnetic resonance imaging is ideally suited for the serial examination of the heart 
as it is non-invasive, does not involve ionizing radiation and has excellent soft tissue 
contrast and spatial resolution. Cardiac magnetic resonance, using T2-weighted 
imaging, has previously been used to detect myocardial oedema associated with 
myocardial infarction as it may help delineate the “area at risk” from the infarcted 
region (Garcia-Dorado et al., 1993). However there are major differences in the 
diagnostic performance of oedema imaging and there have been conflicting results 
regarding its utility as a prognostic marker or guide to therapeutic intervention 
(Viallon et al., 2012) (Eitel et al., 2010, Larose et al., 2010). One explanation for this 
is that magnetic resonance imaging of oedema does not directly assess the more 
dynamic cellular inflammatory processes.  
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Iron oxide particles can be used as a contrast medium in magnetic resonance imaging 
since they alter the T2* relaxation time of tissues in which they accumulate. USPIO 
are taken up by cells of the liver, spleen, bone marrow and lymph nodes. As a result 
of their small size (approximately 30 nm) they extravasate freely through capillaries 
and are taken up by tissue-resident inflammatory cells of the reticuloendothelial 
system (Ruehm et al., 2001b). These cells are predominately macrophages, but 
neutrophils may also take up USPIOs (Dousset et al., 1999, Gellissen et al., 1999a). 
It has been established that USPIOs can be used to assess vascular cellular 
inflammation in patients with abdominal aortic aneurysms (Richards et al., 2011a). 
Histological examination of aneurysm tissue confirmed co-localization and uptake of 
USPIO in areas with macrophage infiltration and mural USPIO uptake was 
associated with a 3-fold increase in the rate of abdominal aortic aneurysm expansion 
(Richards et al., 2011a). T2*-weighted MRI has been validated as a method of 
detecting hepatic and myocardial iron accumulation in patients with thalassemia and 
transfusion-related iron overload, and this method could be adapted for the detection 
of focal USPIO accumulation (Anderson et al., 2001, Westwood et al., 2005). 
We hypothesised that we could use USPIO to track inflammatory cell infiltration 
within the myocardium of patients who had recently sustained an acute myocardial 
infarction. The aims of the study were therefore to investigate the proof-of-principle 
that USPIO could be used to assess cellular myocardial inflammation following acute 
myocardial infarction in humans. Healthy volunteers were also scanned non-
contemporaneously in order to investigate the changes in R2* values in normal 
tissues and in the bloods pool. 
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3.3 RESULTS 
3.3.1 USPIO UPTAKE IN HEALTHY VOLUNTEERS 
There were 10 healthy volunteers (mean age 26±5 years, 5 male and 5 female) who 
completed the scanning protocol. 
 
3.3.1.1 MYOCARDIUM 
The mean R2* increase was 41.2±11.3 (95% CI 33.1 to 49.3) s-1. The median 
increase was 41.2 [interquartile range 32.6 to 50.7] s-1 (Table 3-1). As such a 
“segments with significant USPIO uptake increase” was defined as an R2* increase 
over 50 s-1. 
 
  
Chapter 3: USPIO Detect Cellular Inflammation in Patients with Acute MI 
Detection, assessment and modulation of myocardial inflammation 94 
 
Table 3-1 R2* values of myocardium in healthy volunteers 
 
R2* Value  Pre-
USPIO (s-1) 
R2* Value Post-
USPIO (s-1) 
 
R2* Value 24 hours 
Post-USPIO  
(s-1) 
Number of values 10 10 10 
25% Percentile 39.9 121.0 80.7 
Median 42.7 132.4 85.3 
75% Percentile 48.2 152.8 99.4 
Mean 44.2 133.6 88.4 
Std. Deviation 5.6 23.6 11.9 
Std. Error of Mean 1.8 7.5 3.8 
Lower 95% CI of mean 40.2 116.7 79.9 
Upper 95% CI of mean 48.3 150.5 97.0 
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3.3.1.2 OTHER ORGANS 
R2* increase 24 hours post USPIO infusion of other organs are given in Table 3-2. 
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Table 3-2 R2* increase of various tissues in healthy volunteers 
 
 
Liver 
Smooth 
Muscle Spleen Renal 
Bone 
Marrow 
Mean R2* (s-1) 229 19.7 311 58.9 272 
Std. Deviation (s-1) 25.2 17.9 93.0 10.3 83.8 
Std. Error of Mean (s-1) 8.0 5.7 29.4 3.3 26.5 
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3.3.1.3 USPIO & IRON THE IN BLOOD POOL 
In healthy volunteers mean R2* values rose in the blood pool from 14.5±6.7 s-1 to 
294.2±40.1 s-1 immediately post USPIO infusion, and 89.5±13.6 s-1 24 hours post 
infusion (Table 3-3). There was a correlation with R2* increase in the myocardium 
and the blood pool (r=0.76, p=0.01). Skeletal muscle was used as a marker of blood 
pool perfusion, and R2* rose from 49.6±5.2 s-1 to 69.2±16.11 s-1. There was a 
correlation with skeletal muscle R2* increase and that of the myocardium (r=0.68, 
p=0.03) (Figure 3.1). Ex vivo blood mean R2* value rose from 148.0±38.5 s-1 to 
264.0±76.0 s-1 immediately post USPIO infusion, and 111.0±45.3 s-1 24 hours post 
infusion (Figure 3.2).   
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Figure 3.1 Correlation between R2* increase in the myocardium, skeletal 
muscle or blood pool in healthy volunteers. 
 
Skeletal muscle – left 
Blood pool - right 
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Figure 3.2 R2* Increase in myocardium in vivo & ex vivo blood & increase in 
iron content 
R2* - left y-axis 
Iron content - Right y-axis 
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Table 3-3 Serum iron concentration and R2* values in ex vivo & in vivo blood 
and the myocardium of healthy volunteers. 
 Baseline to 1 
hour 
Correlation 
between Fe 
Concentration 
1 hour to 24 
hours 
Correlation 
between Fe 
Concentration 
Fe Concentration  
Increase (mg/l) 
50.3 ± 16.8  8.7 ± 27.6  
Ex vivo Blood R2* 
increase (s-1) 
142.0 ± 73.3 Nil  
p=0.80 
-180.0 ± 73.8 Nil  
p=0.50 
In vivo Blood R2* 
increase (s-1) 
277.7 ± 42.8 Nil  
p=0.30 
-200.3 ± 35.2 Nil  
p=0.78 
Myocardial R2* 
increase (s-1) 
88.6 ± 26.3 Nil  
p=0.69 
-32.6 ± 18.5 Nil  
p=0.57 
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Five healthy volunteers had iron concentration of blood measured at each time point. 
Mean values were 473.1 mg/l at baseline, 540.1mg/l 1-hour post infusion, and 547.6 
mg/l 24 hours post infusion. There was no correlation with iron concentration and 
change in R2* values at any time course in ex vivo & in vivo blood or the 
myocardium (Table 3-3).  
 
3.3.2 COMPLETION OF PROTOCOL FOR PATIENTS WITH MYOCARDIAL INFARCTION 
All patients sustained an acute myocardial infarction with a substantial area of 
myocardial necrosis (Table 3-4). All patients underwent three scans (baseline, and 24 
and 48 h) including T2*-weighted multi-gradient-echo sequences and late 
gadolinium enhancement. Late enhancement reconfirmed myocardial infarction in all 
patients.  
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Table 3-4 Characteristics of trial participants.  
CAD – coronary artery disease; SD – standard deviation.  
 USPIO CONTROL  p Value 
Number 10 6  
Age (yr (range)) 52 (38-65) 55 (48-65) 0.5622 
Male 10 5 0.1824  
    
Risk Factors    
      Hypercholesterolemia 5 2 0.5153 
      Hypertension 4 0 0.7897 
      Family History of CAD 6 3 0.6963 
      Diabetes Mellitus 0 0 1.0 
      Current Smoker (Ex-smoker) 4 (2) 3 (1) 0.6963 
    
Myocardial Infarction    
      Symptoms to reperfusion time (min; meanSD) 300218   18192 0.2198 
      Plasma Troponin I concentration (µg/L) 33.0415.5 45.2710.63 0.1120 
      Infarct Volume (mL (95% confidence intervals)) 35.1 (8.0, 62.2)  43.2 (14.9, 71.7) 0.1471 
    
Site of Infarction    
      Anterior Infarct 3 3 0.4237 
      Lateral Infarct 1 3 0.0736 
      Inferior Infarct 6 0 0.0164 
    
Left Ventricular Variables    
      Ejection Fraction (%, meanSD) 5415 48 11  0.5622 
      Myocardial Mass (g, meanSD) 7619 67 15 0.3676 
    
Timing of Scanning    
      Reperfusion to Baseline Scan (h (meanSD)) 4930 4416 0.8749 
      Reperfusion to Scan 2 (h (meanSD)) 7330 6817 0.9578 
      Reperfusion to Scan 3 (h (meanSD)) 9530 9238 0.7925 
      USPIO Infusion to Scan 2 (h (meanSD)) 222 NA  
      USPIO Infusion to Scan 3 (h (meanSD)) 443 NA  
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3.3.3 REPEATABILITY 
Data from patients who did not receive USPIO administration were used to assess 
any potential changes in R2* attributable to acute myocardial infarction alone. There 
were no changes in R2* value within the myocardium or the infarct zone itself 
(Figure 3.3, Figure 3.4; Table 3-5; p>0.05). Similar findings were also observed in 
other organs such as the liver, spleen and skeletal muscle. Moreover, we were able to 
demonstrate excellent repeatability for the assessment of R2* value with a mean bias 
of -0.208,s-1, coefficient of repeatability of 26.96 s-1 and intra-class coefficient 0.989 
(Figure 3.5). 
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Figure 3.3 Tissue R2* Values  
R2* value in regions of interest from the different tissues in control patients (blue) 
and patients who received an infusion of ultrasmall supraparamagnetic particles of 
iron oxide (USPIO; red). Asterisk denotes a significant increase from baseline. 
 
  
Chapter 3: USPIO Detect Cellular Inflammation in Patients with Acute MI 
Detection, assessment and modulation of myocardial inflammation 105 
Figure 3.4 Comparison of R2* colour maps in patients with myocardial 
infarction  
(i) Baseline and (ii) 24 hours after no infusion (3A, upper panels) or after an infusion 
of ultrasmall supraparamagnetic particles of iron oxide (USPIO; 3B, lower panels). 
R2* values did not change in the liver (blue) or myocardium (remote myocardium, 
green; infarct, red; microvascular obstruction, purple) of the control patient (3A iii) 
but did rise in the patient who received USPIOs (3B iii). 
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Figure 3.5 Bland-Altman plot - Differences versus average of R2* values in all 
patients. 
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Table 3-5 R2* value (s-1) in infarct region of interest (ROI) of control patients 
  Baseline Day 2 Day 3 
Micro-Vascular 
Obstruction 
(When present) 
Mean 63.3  53.33 66.7  
S.D. 32.2 23.1 30.6 
Min, Max 40, 100 40, 80 40, 100 
Infarct ROI Mean 45.0  43.33 41.7  
S.D. 13.8 8.2 14.7 
Min, Max 30, 70 40, 60 30, 70 
Peri-Infarct ROI Mean 40.0 38.3  36.7  
S.D. 6.3 7.5 5.2 
Min, Max 30, 50 30, 50 30, 40 
Remote 
Myocardium 
ROI 
Mean 43.3 41.7 43.3 
S.D. 5.2 4.1 5.2 
Min, Max 40, 50 40, 50 40, 50 
Liver ROI Mean 56.7 58.3 56.7 
S.D. 10.3 9.8 8.2 
Min, Max 40, 70 40, 70 40, 60 
Skeletal Muscle Mean 51.67 51.67 51.67 
S.D. 75.3 75.3 9.8 
Min, Max 40, 60 40, 60 40, 70 
Spleen Mean  68.3 75.0 70.0 
S.D. 28.6 37.8 32.3 
Min, Max 40, 100 40, 120 40, 120 
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3.3.4 EFFECT OF USPIO ADMINISTRATION 
All patients tolerated the infusions well with no significant adverse events or 
arrhythmia. In the area of myocardial infarction, R2* increased from 41.0±12.0 s-1 at 
baseline to 155±45.0 (p<0.001) and 124±35.0 s-1 (p<0.05) at 24 and 48 h respectively 
following USPIO administration (Figure 3.3, Figure 3.4, Table 3-6). 
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Table 3-6 R2* value (s-1) in regions of interest (ROI) of patients receiving 
USPIO. 
 
 
  Baseline Day 2 Day 3 
Micro-Vascular 
Obstruction 
(When Present) 
Mean 66.7 173.3  143.3  
S.D. 55.1 68.1 41.6 
Min, Max 30, 130 120, 250 100, 190 
Infarct ROI Mean 41.0  155.0  124.0  
S.D. 12.0 45.0 35.0 
Min, Max 30, 70 110, 250 80, 180 
Peri-Infarct ROI Mean 43.0 130.0  95.0  
S.D. 8.2 30.2 19.0 
Min, Max 30, 60 100, 200 80, 140 
Remote 
Myocardium 
ROI 
Mean  39.0 80.0 67.0 
S.D. 3.2 14.9 15.7 
Min, Max 30, 40 50, 100 50, 100 
Liver ROI Mean 84.0 319.0 243.0 
S.D. 49.5 70.0 63.6 
Min, Max 50, 220 230, 420 160, 370 
Skeletal Muscle Mean  54.0 67.0 65.0 
S.D. 8.4 9.5 14.2 
Min, Max 40, 70 50, 80 50, 100 
Spleen Mean  65.0 293.0 250.0 
S.D. 23.7 172.1 162.6 
Min, Max 20, 100 10, 500 10, 460 
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continued 
 
  
Bone Marrow 
(Ribs) 
Mean  247.0 276.0 274.0 
S.D. 92.6 140.4 164.9 
Min, Max 80, 360 100, 500 60, 570 
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3.3.5  NON-SPECIFIC EFFECTS OF USPIO 
To determine whether there was a non-specific effect of USPIO enhancing R2* 
values in muscle, we assessed regions of interest within skeletal muscle. We were 
able to confirm that there was no change in R2* value of skeletal muscle (Figure 3.4, 
Figure 3.5, Table 3-6). Given that USPIO are taken up by cells of the 
reticuloendothelial system, both the liver and spleen were expected to develop 
marked changes in R2* values and act as positive controls. In the liver, there was a 
large increase in R2* from 84.0±49.5 s-1 at baseline to 319±70.0 (p<0.001) and 
243.0±63.6 s-1 (p<0.001) at 24 and 48 h respectively following USPIO 
administration. A similar pattern was also seen in the spleen (Figure 3.6). The remote 
non-infarcted myocardium also demonstrated an increase from a baseline of 39.0±3.2 
to 80.0±14.9 (p<0.001) and 67.0±15.7 s-1 (p<0.05) at 24 and 48 h respectively 
(Figure 3.3, Figure 3.4, Table 3-6).   
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Figure 3.6 Medullary and extramedullary R2* value post myocardial infarction  
There is a significant increase in R2* value of hepatic and splenic tissues at 24 hours, 
that later fall. The R2* value of rib bone marrow does not increase significantly.  
* P<0.05 versus baseline 
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3.4 DISCUSSION 
For the first time, we have demonstrated that USPIO are taken up into the 
myocardium of patients with a recent myocardial infarction. The increase of R2* by 
USPIO was highest within infarcted tissue, although we did observe a more modest 
increase within myocardium remote from the site of infarction. This suggests early 
macrophage and inflammatory cell infiltration predominantly occurs within the 
infarcted myocardium but appears to be associated with a more global influx of these 
cells that extends beyond the area at risk. However no histological quantification of 
macrophage infiltration was performed, and so the degree of inflammation cannot be 
correlated to MRI changes. Our preliminary findings need further confirmation in 
larger cohorts but this technique does appear to hold major promise in the 
investigation of myocardial inflammation following myocardial infarction and could 
be applied to other inflammatory cardiac diseases such as cardiac sarcoidosis, 
myocarditis or transplant rejection. 
There was no correlation between the iron content of blood and the R2* value in the 
blood pool of healthy volunteers. Only 10 healthy volunteers were scanned, and half 
of these had the iron content analysed. Therefore it is possible the lack of correlation 
was due to an insufficient sample size. However, a CMR sequence would be 
susceptible to flow and motion artefact from a moving blood pool. The T2* sequence 
utilised to detect USPIO accumulation depends on static field non-uniformity within 
each voxel including magnetic susceptibility effects in the patient. In this study, the 
iron within haemoglobin itself exacerbated by the iron load from USPIOs would 
have affected this susceptibility. This would in turn be affected by the patients’ heart 
rate, rhythm, systolic and diastolic function. All these factors would make 
determining the blood pool signal by sampling the ventricular cavity highly variable 
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and inaccurate. This accounts for the different R2* values at baseline and after 
USPIO infusion in healthy volunteers as compared to CABG patients, as well as the 
disparate R2* values in ex-vivo and in vivo blood. However there was a correlation 
between cardiac R2* increase and that of the blood pool, suggesting some of the 
increase seen in the study was due to organ perfusion by USPIO.  
USPIO are actively taken up by inflammatory phagocytic cells, especially 
macrophages. They have been used to explore a number of inflammatory conditions 
including atherosclerotic plaques and abdominal aortic aneurysms (Kooi et al., 
2003b, Trivedi et al., 2006b) (Richards et al., 2011a). Histological examination of 
excised clinical tissue has confirmed co-localisation of USPIO with macrophages 
(Kooi et al., 2003b, Trivedi et al., 2006b, Schmitz et al., 2001, Ruehm et al., 2001b). 
More specifically, pre-clinical models have demonstrated the uptake of magnetic 
nanoparticles into macrophages of infarcted myocardium by both fluorescence 
microscopy and immunohistochemistry (Sosnovik et al., 2007). We were unable to 
obtain tissue confirmation of USPIO uptake into macrophages in our cohort of 
patients. It is possible that other cell types with phagocytic capacity such as 
neutrophils may contribute to the increase in R2* value (Gellissen et al., 1999a). 
However, we have no reason to believe that uptake would differ from previous 
studies and, indeed, phagocytosis into macrophages is 4-6 times greater with 
ferumoxytol than with ferumoxtran-10, a previously used USPIO agent (Yancy et al., 
2005). Moreover, we have demonstrated that organs of the reticuloendothelial 
system, such as the liver and spleen, demonstrate marked increases in R2* consistent 
with monocyte and macrophage uptake.  
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We found that there was an increase in R2* in the remote myocardium and this 
finding is intriguing. It has been demonstrated that increased numbers of 
macrophages in the myocardium remote from the area of infarction both in murine 
models and autopsies of patients who have died from myocardial infarction (Lee et 
al., 2012). Expression of cytokines is not confined to the infarct or peri-infarct zone, 
but is also expressed by myocardium remote from the infarct (Irwin et al., 1999). 
Furthermore, when myocardial infarction is induced in an abdominal heterotopic 
transplanted rodent heart, the native heart demonstrates a decrease in left ventricular 
(LV) fractional shortening and increased in LV end-diastolic dimension accompanied 
by increased TNF- (Nakamura et al., 2003). Thus the post-infarct inflammatory 
process may induce cytokine production and inflammatory cell infiltration in remote 
“normal myocardium”. This is reflected by our finding of an almost three-fold 
increase in R2* in remote myocardium.  It is possible that increased macrophage 
infiltration is not a post- or peri-mortem artefact but a real pathophysiological 
phenomenon (Lee et al., 2012). However there is no histo-pathological confirmation 
or remote macrophage infiltration. USPIOs persist in the circulation with a plasma 
half-life of 14-30 h in humans (Landry et al., 2005, Hunt et al., 2005). At 24 hours 
post infusion, there would be circulating USPIO capable of increasing R2* when 
perfusing the myocardium. This was also seen in the healthy volunteer (Table 3-1, 
page 94). 
R2* was decreasing in myocardial, splenic and hepatic tissues by 48 h post-infusion. 
The decrease in R2* in the blood pool is to be expected given efficient USPIO 
uptake by reticuloendothelial cells leading to rapid clearance (Yancy et al., 2005). 
However pre-clinical findings suggest that monocyte tissue residence in infarcted 
myocardium is brief despite high recruitment rates (Leuschner et al., 2012).  
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Consistent with this study, we found evidence of high extra-medullary activity in 
terms of high USPIO uptake in the liver and spleen in contrast with minimal uptake 
in the bone marrow (Figure 3.6). However, post hoc analysis of bone marrow uptake 
was performed using a ROI in the ribs since CMR protocols to scan extra-medullary 
sites had not been planned. As such analysis is liable to error. The decrease in R2* 
value in the splenic tissues at 48 hours may represent mobilisation of the splenic 
reservoir of monocytes (Swirski et al., 2009b, Nahrendorf et al., 2010).  In addition, 
the decrease in tissue R2* will reflect clearance of extravasated particles by 
phagocytic cells through efflux of USPIO laden inflammatory cells. The time course 
of monocyte and macrophage recruitment into the myocardium is unclear from our 
study and would require USPIO administration at differing time points following 
myocardial infarction. This would help define the peak influx and time course of 
macrophage trafficking into the myocardium.  
We have applied this technique to patients who have recently sustained a myocardial 
infarction. However, this approach could be applied to other cardiac conditions that 
involve intense inflammatory processes. This could include viral myocarditis, giant 
cell myocarditis, anthracycline-induced cardiotoxicity and sarcoidosis. Indeed, it may 
also have a role in detecting cardiac transplant rejection in a non-invasive manner. 
However, this needs further careful validation in well phenotyped clinical subgroups.  
Limitations to our study included the lack of histo-pathological confirmation of 
macrophage uptake. However we performed the same scanning protocol on a rodent 
model of infarction, and obtained myocardial tissue for histological analysis 
(6.1.1.1.1.1.1.1Appendix G: , page 497). This confirmed USPIO were taken up by 
monocytes infiltrating the infarcted myocardium. Other limitations are the longer 
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reperfusion time in the USPIO group potentially resulting in more inflammation and 
the injection of USPIOs at variable time points post MI. However, given the previous 
evidence that USPIO are taken up by macrophages, our study provides proof of 
principle that cellular inflammation may be tracked post myocardial infarction. 
In conclusion, we have demonstrated for the first time that USPIO is taken up by the 
infarct tissue in patients with recent myocardial infarction and by the peri-infarct 
myocardium to a lesser degree. Given previous pre-clinical and clinical studies, this 
is likely to correspond to cellular inflammation. This represents a novel non-invasive 
method to further study cardiac inflammation and therapeutic interventions. It may 
also provide prognostic information or provide a diagnostic tool for the investigation 
of inflammatory cardiac conditions such as myocarditis and transplant rejection, as 
well as a potential biomarker for therapeutic interventions targeted at improving left 
ventricular remodelling following infarction. 
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Chapter 4:  PERI-OPERATIVE ELAFIN FOR ISCHEMIA-
REPERFUSION INJURY DURING CORONARY ARTERY BYPASS 
GRAFT SURGERY: A RANDOMISED CONTROLLED TRIAL 
 
4.1 SUMMARY 
Elafin is a potent endogenous neutrophil elastase inhibitor that protects against 
myocardial inflammation and injury in pre-clinical models of ischemic-reperfusion 
injury. We investigated whether Elafin could inhibit myocardial ischemia-
reperfusion injury induced during coronary artery bypass graft (CABG) surgery. 
In a randomised double blind placebo controlled parallel group clinical trial, 87 
patients undergoing CABG surgery were randomized 1:1 to intravenous Elafin 200 
mg or saline placebo after induction of anaesthesia and prior to sternotomy. 
Myocardial injury was measured with area under the curve (AUC) troponin I release 
over 48 h and quantification of macro-infarction by magnetic resonance imaging. 
Post-ischemic inflammation was measured by plasma markers including AUC high-
sensitive c-reactive protein (hs-CRP), and myeloperoxidase (MPO). 
Elafin infusion was safe and resulted in >3000-fold increase in plasma Elafin 
concentrations with associated >50% inhibition of elastase activity in the first 24 h. 
AUC myocardial injury was not significantly reduced by Elafin (ratio of geometric 
means (Elafin/placebo) of 48h AUC troponin I 0.74 (95% CI 0.47 to 1.15), P=0.18) 
although post-hoc analysis of highly sensitive assay revealed a lower troponin I 
concentration at 6 hours in Elafin treated patients (median 2.4 versus 4.1 μg/L, 
P=0.035). Elafin had no effect on macro-infarction (Elafin, 7/34 versus placebo, 5/35 
patients) or markers of inflammation: mean differences for AUC hs-CRP of 499 
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mg/L/48-h (95% CI -207 to 1205, P=0.16), and AUC MPO of 238 ng/mL/48-h (95% 
CI -235 to 711, P=0.320).  
There was no strong evidence that neutrophil elastase inhibition with a single dose 
Elafin treatment reduced myocardial injury and inflammation following CABG-
induced ischemia-reperfusion injury. 
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4.2 INTRODUCTION 
Ischemia-reperfusion injury occurs when blood flow is restored to organs and tissues 
that have sustained a period of interrupted blood supply. This occurs following 
therapies for acute myocardial infarction and ischemic stroke, and is a necessary 
consequence of solid organ transplantation. Mechanisms of cell and tissue injury 
include a neutrophil-mediated post-ischemic inflammatory response and activation of 
cellular death pathways following reperfusion (Hansen, 1995). Protecting organs 
from ischemia-reperfusion injury to improve clinical outcome is a high priority. 
Despite intense research efforts and huge promise from pre-clinical and early phase 
clinical trials, there are currently no effective therapies that can limit this injurious 
response.  
Coronary artery bypass graft (CABG) surgery improves symptoms and survival, and 
remains the treatment of choice for patients with complex multi-vessel coronary 
artery disease. During CABG and cardiopulmonary bypass, coronary blood flow is 
interrupted and the heart is put into circulatory arrest. This causes ischemia-
reperfusion injury that is exacerbated by adverse neutrophil-mediated myocardial 
inflammation and injury (Vinten-Johansen, 2004, Butler et al., 1993, Wakayama et 
al., 2007). CABG surgery therefore represents a programmed clinical model of 
ischemia-reperfusion injury that lends itself to testing the efficacy of potential 
therapeutic interventions (Hausenloy et al., 2007).  
Elafin is an endogenous anti-inflammatory protein that was first isolated in the 
search for inhibitors of neutrophil elastase activity in the lung and skin (Sallenave 
and Ryle, 1991a, Wiedow et al., 1991). It has inhibitory activity against both human 
neutrophil elastase and proteinase-3 as well as suppressing production of 
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inflammatory cytokines such as IL-8 and TNF-α (Henriksen et al., 2004b). Elafin is 
produced locally at sites of inflammation, raising a local defence of ‘alarm’ 
antiproteases in order to contain and inhibit neutrophil-mediated inflammation 
(Sallenave, 2000a). Cardiovascular tissues do not express elafin or other neutrophil 
elastase inhibitors, and are therefore more vulnerable to neutrophil-mediated injury. 
Augmentation of human elafin has consistently demonstrated impressive protective 
effects in rodent models of ischemic and inflammatory elastase-mediated vascular 
injury. Elafin infusion reduced muscular injury and neutrophil recruitment in the rat 
ischemic hind-limb and myocardial ischemia–reperfusion injury models (Crinnion et 
al., 1994, Tiefenbacher et al., 1997). Transgenic mice overexpressing human elafin 
under the control of the vascular pre-proendothelin promoter have relatively 
preserved left ventricular size and function following myocardial infarction (Ohta et 
al., 2004a). Compared to wild-type littermates, these animals are also protected from 
viral myocarditis and hypoxia-induced pulmonary hypertension, and exhibit less 
restenosis following wire induced carotid artery denudation (Zaidi et al., 1999, Zaidi 
et al., 2002a, Zaidi et al., 2000a). Elafin augmentation therefore protects the 
cardiovascular system from a range of conditions characterized by neutrophil 
elastase-mediated inflammation and injury.  
The purpose of the Elafin Myocardial Protection from Ischemia Reperfusion 
(EMPIRE) randomized controlled clinical trial was to provide proof-of-concept that 
Elafin treatment could reduce myocardial ischemia-reperfusion inflammation and 
injury in patients undergoing CABG surgery. 
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4.3 RESULTS 
4.3.1 PATIENT CHARACTERISTICS AND INTRA-OPERATIVE DETAILS 
A total of 189 patients were screened for recruitment of whom 29 were excluded, 79 
declined to participate, 88 patients gave informed consent and 1 died before surgery 
leaving 87 patients to undergo randomisation (Figure 4.1). In 85 of the 87 patients, 
the trial infusion was administered as planned. Patient characteristics and intra-
operative details are shown in Table 4-1. Full data to calculate area under the curve 
for cTnI (primary outcome) was obtained in 83 patients (95%).  Data quality was 
similarly good for all secondary end-points with missing data evenly balanced across 
the treatment arms. 
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Figure 4.1 Patient flow chart 
 
  
Chapter 4: Peri-Operative Elafin for Ischaemic Reperfusion Injury during CABG 
Detection, assessment and modulation of myocardial inflammation 124 
Table 4-1 Baseline characteristics and intra-operative details by treatment 
group.  Data are number of patients (%) or mean ± SD 
 Placebo Elafin 
Baseline characteristics 
Age 63.6 ± 8.4 63.9 ± 7.7 
2-vessel coronary disease 12  (27.9) 11 (25.0) 
3-vessel coronary disease 31 (72.1) 33 (75.0) 
Creatinine (mg/dl) 0.92 ± 0.18 0.94 ± 0.23 
Diabetes Mellitus 9 (20.9) 11 (25.0) 
Surgeon A 16 (37.2) 18 (40.9) 
Surgeon B 27 (62.8) 26 (59.1) 
Male Gender 36 (83.7) 38 (86.4) 
EuroSCORE 2.21 ± 1.73 2.64 ± 2.06 
Intra-operative details 
Number of bypass grafts 
One 1 2 
Two 19 14 
Three 14 22 
Four 9 5 
Five 0 1 
Cardiopulmonary bypass time 
(min) 
77 ± 26 78 ± 26 
Cross clamp time (min) 45 ± 15 47 ± 16 
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4.3.2 ELAFIN AND ELASTASE ACTIVITY 
Elafin infusion resulted >3000-fold higher plasma concentrations (31.1±9.6 versus 
0.01±0.07 μg/mL for placebo). This increase in plasma Elafin concentration was 
reflected in a marked reduction in plasma elastase activity (4.28±5.13 versus 
9.66±9.21units/mL; Figure 4.2). 
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Figure 4.2 Perioperative plasma Elafin concentration (A) and plasma elastase 
activity (B) between groups.  
Data are median plus interquartile range from the first skin incision (time 0 hours) to 
24 hours. Placebo group n = 41; Elafin group, n = 43. 
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4.3.3 TROPONIN I 
There was no significant change in troponin I concentrations over the first 48 hours 
in Elafin treated patients (adjusted ratio of geometric means (Elafin/placebo) 0.74, 
95% CI 0.47 to 1.15, P = 0.18). There remained no evidence of a difference in a pre-
specified secondary analysis where 3 patients who sustained a clinical myocardial 
infarction or had a cardiac arrest were excluded from analysis (adjusted ratio of 
geometric means 0.76, 95% CI 0.50 to 1.14, P = 0.17). Post-hoc analysis using the 
high-sensitivity assay demonstrated significant reduction of plasma cTnI 
concentrations in Elafin-treated patients at 6 hours (median 2.4 versus placebo 4.1 
μg/L, P = 0.035; Figure 4.3, Table 4-2). 
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Figure 4.3 Myocardial injury.  
Cardiac troponin I (cTnI) release following coronary artery bypass graft surgery 
between treatment groups from first skin incision (time 0 hours) to 48 hours. Data are 
median plus interquartile range. Placebo group, n= 42; Elafin group, n = 44. 
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Table 4-2 Post-hoc analysis of plasma cardiac troponin I (cTnI) concentration to 
48 hours.  
(μg/L, median and interquartile range, high-sensitive assay) 
Time 
(hours) 
Placebo  
(n = 43) 
Elafin 
(n = 44) 
P 
Wilcoxon 
0 0.00 (0.0, 0.0) 0.00 (0.0, 0.0) 0.861 
2 0.08 (0.0, 0.2) 0.07 (0.0, 0.1) 0.228 
6 4.07 (2.0, 6.4) 2.41 (1.0, 4.6) 0.035 
24 1.02 (0.6, 3.9) 1.08 (0.5, 2.3) 0.421 
48 0.53 (0.2, 1.9) 0.47 (0.2, 1.2) 0.648 
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4.3.4 CMR 
Data from pre and post-operative scans were available for 34 (77.3%) Elafin and 35 
(81.4%) placebo treated patients (Table 4-3). There was no difference in post-
operative left ventricular mass or left ventricular ejection fraction. The intra-class 
correlation coefficient for late gadolinium enhancement was 0.99 and the coefficient 
of repeatability 1.78 mL (1.87 g) giving a threshold of 1.8 mL (1.9 g) for an increase 
in late gadolinium enhancement. The incidence of increased myocardial infarction 
volume was similar between treatment groups.  
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Table 4-3 Magnetic resonance imaging analysis of postoperative ejection 
fraction, left ventricular mass and infarct volume. 
 Placebo (n =35) Elafin(n =34) 
Change in ejection fraction 
(percentage points) 
-0.62±6.2 -2.4± 6.3 
Change in LV mass (g) 1.2±3.8 2.0±3.8 
Change in infarct volume (%) 
Reduced volume  2.9 0 
No Change  82.9 79.4 
Increased volume  14.3 20.6 
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4.3.5 HUMORAL INFLAMMATORY MARKERS 
There was no effect on peak myeloperoxidase concentrations (mean difference 54.73 
ng/L, 95% CI -60.0 to 169.5, p = 0.35) but peak elastase concentration was reduced 
(mean difference -168.4 ng/mL, 95% CI; -323.4 to -13.47ng/mL, P = 0.03; Figure 
4.2). In contrast, there was no effect on the 48-hour AUC for plasma elastase 
concentration (mean difference -524.0 ng/mL/48-h, 95% CI -1239 to 
191.3ng/mL/48-h,P = 0.15). Although all inflammatory markers rose following 
CABG surgery (P < 0.001 for all), there was no treatment effect of Elafin (p > 0.05 
for all; Figure 4.4).  
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Figure 4.4 Perioperative hsCRP (A) and inflammatory cytokines IL-6 (B) and 
IL-8 (C) release between groups.  
Data are median plus interquartile range. Placebo group, n= 42; Elafin group, n = 44 
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4.3.6 CLINICAL OUTCOMES 
Median duration of stay in the intensive care unit was 24 and 23 h for patients treated 
with Elafin and placebo respectively (HR 1.25, 95% CI; 0.81 to 1.94 P = 0.32). 
Clinical outcomes and the incidence of perioperative complications in the first 48 
hours were also similar (in Figure 4.4).  
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Table 4-4 Post-operative complications and outcomes by treatment.  
Data are number of patients (%) or mean ± SD. 
 
 Placebo Elafin 
Post-operative complications and outcomes (48 hours) 
Death 0 (0) 0 (0) 
Stroke 0 (0) 0 (0) 
Myocardial infarction 0 (0) 1 (2.3) 
Inotrope or balloon pump 
support for > 24h 
10 (27.3) 12 (23.3) 
Red cell transfusion post-op 12 (27.9) 12 (27.3) 
Re-operation for bleeding 2 (4.7) 1 (2.3) 
Respiratory complications 3 (7.0) 5 (11.4) 
Antibiotic administration 2 (4.7) 4 (9.1) 
Atrial fibrillation 4 (9.3) 3 (6.8) 
Serum creatinine (mg/dl) 
24 hours 0.90 ± 0.32 0.87 ± 0.32 
48 hours 0.96 ± 0.48 0.88 ± 0.42 
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4.4 DISCUSSION 
This is the first Phase 2 clinical trial investigating the effect of Elafin, an endogenous 
neutrophil elastase inhibitor, on myocardial ischemia-reperfusion injury in patients 
undergoing CABG surgery. Despite achieving >3000-fold increase in plasma 
concentrations sufficient to more than halve plasma elastase activity, it was not 
possible to demonstrate a clear evidence of beneficial effect of human recombinant 
Elafin. Specifically, it was not possible to attenuate the systemic inflammatory 
response nor conclusively detect a reduction in two very sensitive, complementary 
and gold-standard measures of myocardial injury: AUC for plasma cTnI 
concentrations and late gadolinium enhancement on magnetic resonance imaging. 
However, Elafin was safe and well tolerated in this high-risk clinical population and 
post-hoc analysis indicated reduced myocardial injury at 6 hours raising the 
possibility that more extensive treatment effect would have been seen with multiple 
doses or bolus and infusion.  
All patients in this trial exhibited evidence of myocardial injury demonstrated by 
cTnI release. This was associated with a marginal reduction in left ventricular 
ejection fraction detected on post-operative MRI imaging.  Small increases in 
delayed gadolinium enhancement indicative of new myocardial infarction were 
detected in a fifth of patients in keeping with sub-clinical myocardial injury and 
infarction that follows circulatory arrest and ischemia-reperfusion during CABG 
surgery. The current MRI results contrast with an earlier study reporting increased 
infarct volume in 78% of patients undergoing planned CABG (Steuer et al., 2004b). 
A key difference that may explain this discrepancy is the detailed patient 
characterization in our study with availability of pre-operative MRI scans allowing 
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identification of small areas of pre-existing infarct that would be missed by using 
clinical history, echocardiography or ECGs to screen for pre-existing infarction.  
The data indicate that with single bolus administration, Elafin does not confer 
clinically meaningful myocardial protection in the context of CABG surgery.  This 
result was not changed in a secondary analysis excluding patients that had sustained 
clinical events thought to be unrelated to study drug that would have contributed to 
large additional cTnI elevations.  
cTnI by high sensitivity assay may have provided more accurate data given its’ limit 
of detection of 4.1 pg/mL, and  analysis of  all samples was performed as a batch at 
the same time. The reason it was not used for the primary endpoint was that it was 
not available until the end of the study and was therefore not included in the 
secondary endpoint. Although post hoc analysis identified a reduction in plasma cTnI 
concentrations at 6 hours in Elafin treated patients, the overall absence of a 
convincing beneficial effect conflicts with pre-clinical ischemia-reperfusion studies 
where Elafin infusion was associated with a 27%-reduction in myocardial infarct size 
and improved left ventricular performance. Our clinical CABG model allows 
recapitulation of a key condition in pre-clinical models where Elafin is administered 
up front or expressed in tissues prior to the onset of cardiopulmonary bypass and 
ischemic tissue injury. However, despite this, we were unable to demonstrate clear 
efficacy despite using two complementary and highly sensitive measures of 
myocardial injury. 
Elafin is one of several agents targeting inflammatory pathways that have been 
investigated in ischemia-reperfusion injury during cardiac surgery without success. 
Pexelizumab, a recombinant, single-chain anti-C5 monoclonal antibody, was studied 
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in 2 multi-center, randomised clinical trials of patients undergoing CABG surgery 
with or without valve surgery on cardiopulmonary bypass. There was no difference 
in the primary outcome of death or myocardial infarction between the Pexelizumab 
and placebo treatment groups (Verrier et al., 2004). Failure of treatment effect with 
Elafin and Pexelizumab may reflect different mechanisms responsible for myocardial 
injury during CABG. Myocardial ischemia and necrosis undoubtedly occur during 
CABG surgery and the magnitude of cTnI release is correlated with subsequent 
morbidity and mortality (Croal et al., 2006). Mechanism of ischemia in preclinical 
models commonly involves complete interruption of coronary blood flow with a 
ligature to the beating heart. In CABG surgery the heart is in a dormant state of 
circulatory arrest with protective cardioplegia and the impact of blood flow 
interruption is less severe. Despite evidence of neutrophil mediated inflammatory 
injury post-CABG, it may be activation of cellular survival pathways within 
cardiomyocytes that determines the outcome of ischemia-reperfusion in this setting. 
Pharmacological manipulation of the Na+-H+ exchanger with cariporide reduces 
lethal intracellular calcium accumulation following ischemia reperfusion and was 
associated with reduced perioperative myocardial infarction in two large studies 
(Boyce et al., 2003, Mentzer et al., 2008). Further development of this treatment was 
limited by an excess mortality from stroke but these studies do illustrate the 
therapeutic potential of blocking cell death pathways. Elafin treatment was 
associated with substantial (> 50%) inhibition of circulating elastase activity 
following CABG surgery and the data therefore indicate that neutrophil-derived 
elastase injury is not a prominent cause of myocardial injury in this setting.  
The patients did have evidence of neutrophil activation and degranulation with 
increased plasma concentrations of the primary granule contents, elastase and 
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myeloperoxidase. This is in keeping with other studies that have demonstrated 
increased expression of neutrophil cell surface adhesion molecules (CD18 and CD 
11b) and elevated elastase concentrations peaking at the end of cardiopulmonary 
bypass (Hill et al., 1995, Ninomiya et al., 2003). Peak elastase concentrations were 
reduced in Elafin-treated patients although there was no demonstrable effect on peak 
myeloperoxidase concentrations. This discrepancy is explained by differences in the 
origin of these two neutrophil primary granule proteins. Circulating human 
neutrophil elastase is derived largely from acute neutrophil degranulation. A pool of 
neutrophil-derived myeloperoxidase is transcytosed and bound to the subendothelial 
matrix (Baldus et al., 2001). This contributes to the circulating pool and is released 
following heparin administration during cardiopulmonary bypass (Rudolph et al., 
2013). 
Elafin mediated reductions in elastolytic activity and myeloperoxidase staining (as a 
marker of neutrophil infiltration) have been consistent findings in pre-clinical 
models. Elafin infusion produced impressive reductions in myocardial inflammation 
and necrosis in rabbits undergoing heterotopic cardiac transplantation (Cowan et al., 
1996). This was associated with a marked attenuation of myocardial elastolytic 
activity in transplanted hearts. Transgenic mice over-expressing full-length human 
elafin under the control of the vascular pre-proendothelin promoter exhibit complete 
inhibition of tissue elastolytic activity following acute myocardial infarction and 
carotid arterial wire denudation (Ohta et al., 2004a, Zaidi et al., 2000a). These 
favorable treatment effects consistently occurred with reduced tissue 
myeloperoxidase content in keeping with less neutrophil recruitment. It was not 
possible to access myocardial tissue for assessment of neutrophil infiltration and 
elastolytic activity but the significant reduction in peak elastase concentration leaves 
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open the possibility of an Elafin effect on neutrophil activation and degranulation 
which if present was not large enough to translate into a reduction in AUC elastase at 
6 hours.  
The EMPIRE patients exhibited increased IL-8 and IL-6 production and increased 
levels of circulating hs-CRP in keeping with a post-ischemic inflammatory response 
following CABG. A systemic inflammatory response follows CABG surgery driven 
both by major surgical insult and contact activation of blood with artificial surfaces 
of the extracorporeal circuit (Day and Taylor, 2005). Belief that magnitude of this 
response may drive clinical outcome has led to trials examining interventions to 
reduce post-operative inflammation. Peak and AUC hs-CRP, IL-6 and IL-8 release 
were similar between treatment groups. This result for Elafin contrasts with previous 
work indicating broad ranging anti-inflammatory activity in human endothelial cells 
and monocyte-derived macrophages. It has been demonstrated that overexpression of 
elafin reduced production of IL-8 and TNF-α by cultured human endothelial cells 
and monocyte derived macrophages respectively in response to inflammatory stimuli 
(Henriksen et al., 2004b). Elafin effect was mediated by reduced NF-κΒ regulated 
gene transcription through inhibition of degradation of the inhibitory IκΒα subunit. 
This work has been replicated by others using a human myelomonocytic cell line 
with the same recombinant Elafin used in the EMPIRE study (Butler et al., 2006). 
These in vitro findings suggested the potential of Elafin to work beyond 
neutralisation of elastase in suppressing inflammatory cytokine pathways. The failure 
of Elafin to suppress IL-8 production during CABG surgery may indicate that 
additional inflammatory pathways are active or that despite impacting on circulating 
elastase activity, Elafin is not reaching or is not active in the subcellular space 
between neutrophils and their target tissue. Large quantities of oxidants and 
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proteases released by neutrophils recruited to the site of inflammation can 
overwhelm and inactivate protease inhibitors. Adhesion of neutrophils to the 
extracellular matrix and release of elastase in association with neutrophil 
extracellular traps may compartmentalize the protease between the neutrophil and 
matrix and this microenvironment excludes larger circulating protease inhibitors such 
as α1-PI (Owen et al., 1995). 
ONO-6818 and Sivelestat are synthetic inhibitors of elastase that reduced IL-8 
production in models of a cardiopulmonary bypass circuit using human blood 
(Yoshimura et al., 2003, Matsuzaki et al., 2005) Aprotinin a serine protease inhibitor 
with broad ranging inhibitory activity provided proof of principle that 
pharmacological intervention can reduce inflammatory cytokine production in 
CABG patients. Aprotinin infusion led to a 5-fold fall in peak IL-8 release at the end 
of cardiopulmonary bypass and 4-fold reduction in IL-6 at 4 h in CABG patients 
(Isbir et al., 2001, Tassani et al., 2000). Clinical use of this drug was halted following 
evidence of serious renal, cardiac and cerebral events in a large observational study 
of 4374 patients (Mangano et al., 2006). Elafin infusion was safe. There were no 
drug related adverse events in this high-risk surgical group and no evidence of 
excessive bleeding, cardiovascular complications or renal dysfunction. Given lack of 
a conclusive therapeutic effect on myocardial injury and post-ischemic inflammation 
it is not surprising that the exploratory clinical endpoint of post-operative ITU stay 
was no different between treatment groups. 
In conclusion, despite the body of work indicating therapeutic potential from several 
groups using different models, species and modes of augmentation, Elafins’ promise 
as a therapeutic agent to attenuate myocardial ischemia-reperfusion injury and 
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inflammation was not translated in this first phase II study. Post-hoc analysis 
identified reduced cTnI concentrations at 6 h in Elafin treated patients and it is 
possible that a bigger dose would have conferred protection out to 48 hours.  Elafin 
was safe and lack of treatment effect was seen despite achieving high plasma Elafin 
concentrations and halving of circulating elastase activity.   
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Chapter 5: ASSESSMENT OF CELLULAR INFLAMMATION 
POST CORONARY BYPASS GRAFTING SURGERY – EMPIRE 
SUB-STUDY 
 
5.1 SUMMARY 
Very little is known about myocardial inflammation following CABG surgery. In 
Chapter 3: (page 89) it was established that CMR enhanced USPIO can identify 
cellular inflammation in the infarct zone post ST-elevation infarction. The work in 
this chapter investigated if this technique could be used in the post CABG surgery 
setting, and whether Elafin reduced cellular inflammation as assessed by USPIO 
enhanced scanning.  
 
The work presented in this chapter pertains to a sub-study of EMPIRE, the 
randomised double blind placebo controlled parallel group clinical trial described in 
Chapter 6:. 54 patients undergoing CABG surgery were randomized 1:1 to 
intravenous Elafin 200 mg or saline placebo after induction of anesthesia and prior to 
sternotomy and underwent USPIO infusion and CMR scanning within 14 days of 
surgery. Quantitative analysis of USPIO accumulation was achieved by calculation 
of T2* relaxation times before and after administration of USPIO. A variety of 
analysis techniques were explored. Plasma inflammatory biomarkers and hs-cTnI 
was tested in all patients. 
 
USPIO-defined cellular myocardial inflammation following coronary artery bypass 
surgery ranged from levels seen in healthy volunteers to those associated with type 1 
myocardial infarction (median 80.2 [IQR 67.4 to 104.8] /s). Although there was an 
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increased pan-myocardial uptake of USPIO, focal inflammation was best detected by 
taking the average of the top 3 R2* values in a 17-segment model. Macrophage 
recruitment into the myocardium correlated weakly with hsCRP, but there was no 
correlation with hs-cTnI or CPB time. There was no treatment effect of Elafin 
detected by USPIO enhanced CMR. 
 
Inflammatory markers rise post CABG surgery, and cellular inflammation can be 
detected by USPIO CMR. Humoral and cellular inflammation was co-ordinated, 
however the magnitude of myocardial inflammation was not dependent on degree of 
myocardial injury (hs-cTnI) or ischemia time. Elafin did not attenuate cellular 
inflammation as assessed by USPIO. 
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5.2  INTRODUCTION 
During coronary artery bypass graft surgery, the myocardium receives an immediate 
ischaemic insult that is exacerbated by post-ischaemic reperfusion inflammatory 
responses leading to increased myocardial injury. Inflammation within the infarcted 
myocardium is associated with induction of endothelial adhesion molecules and 
enhanced permeability of the microvasculature. Up regulation of chemokines 
including interleukin IL-8 and monocyte chemoattractant protein (MCP)-1 attracts 
neutrophils and monocytes to the site of injury. Early reperfusion therapy amplifies 
this inflammatory cell influx and accelerates the healing response through 
proliferative and maturation phases. Neutrophil adhesion to the endothelium of 
infarcted myocardium occurs within minutes of reperfusion. Ischaemic 
cardiomyocytes are further injured by adherent neutrophils that release reactive 
oxygen species and destructive proteases including HNE and proteinase 3. HNE has 
a wide range of substrates including matrix components elastin, fibronectin, and 
collagen types III and IV. Activated neutrophils also occlude microvessels and 
increase endothelial permeability contributing to myocardial oedema. Capillary 
plugging and obstruction by activated neutrophils contributes to failure of 
microvascular perfusion and increased infarct size within the ‘no-reflow’ zone.  
Non-invasive techniques to assess inflammation in the myocardium are limited. 
Inflammatory cells have high glycolytic activity, and the glucose component of 18F-
fluorodeoxyglucose (18F-FDG) can cross cell membranes to become phosphorylated 
and trapped. This can then be imaged using positron emission tomography (PET). 
This has been utilised to assess myocardial inflammation associated with sarcoidosis 
(Skali et al., 2013). Although this technique is sensitive, it relies on suppression of 
glucose uptake in normal myocardium. This is both difficult and unreliable in clinical 
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practice. Clinical CMR has been utilised by using water sensitive T2 sequences to 
identify oedema, but will only identify this consequence of inflammation rather than 
the cellular infiltration (Friedrich and Marcotte, 2013). Pre-clinical studies have 
utilised direct labelling of white cells, but have not yet been developed for clinical 
practice (Riou et al., 2002). Non-invasive imaging of cellular infiltration would allow 
early identification and quantification of the pathological process and identify 
patients suitable for modulation of inflammation. The efficacy of therapeutic 
interventions could also be monitored with such a technique and potentially provide 
prognostic information. 
In preclinical studies Elafin delivery and gene overexpression is associated with 
reduced myocardial injury and preserved left ventricular function following 
ischaemia and infarction. This effect is associated with reduced neutrophil infiltration 
and elastase activity at the site of injury. Activated neutrophils facilitate monocyte 
recruitment. Granule contents including LL-37, azurocidin and human neutrophil 
peptides 1-3 have direct chemotactic activity on monocytes. Neutrophil-derived 
proteases induce chemokine, MCP-1 and IL-8 production from endothelial cells and 
their effects on matrix components produce degradation products with chemotactic 
activity for monocytes (Richardson et al., 1976, Postlethwaite and Kang, 1976, 
Norris et al., 1982). 
As discussed in Chapter 3:(page 89), USPIO have the capacity to extravasate through 
capillaries and be taken up by tissue inflammatory cells of the reticuloendothelial 
system (Ruehm et al., 2001a). These cells are predominately macrophages, but 
neutrophils have also been shown to take up USPIOs (Dousset et al., 1999, Gellissen 
et al., 1999b). This model of USPIO-enhanced MRI can highlight areas of 
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inflammation in models of vertebral osteomyelitis, aortic atherosclerosis, arthritis-
induced hyperperfusion, autoimmune encephalomyelitis, nephritis and nephropathy, 
cerebral ischaemia, renal ischaemia (Bierry et al., 2008, Dousset et al., 1999, Ruehm 
et al., 2001a, Hauger et al., 2000, Rausch et al., 2001b, Lutz et al., 2006, Jo et al., 
2003b). USPIOs can be used to assess cellular vascular inflammation in patients with 
abdominal aortic aneurysms (Richards et al., 2011b). Histological examination of 
aneurysm tissue confirmed co-localization and uptake of USPIOs in areas with 
macrophage infiltration and this was associated with a 3-fold increase in the rate of 
abdominal aortic aneurysm expansion.  
The data presented in Chapter 4: established proof-of-concept that USPIOs can be 
used to image the myocardium in patients having sustained a recent acute myocardial 
infarction. The data demonstrates that there is a marked and clear uptake of USPIOs 
in the week following acute myocardial infarction and there is a 2-3 fold increase in 
the R2* value in the infarct and peri-infarct area. As a negative control, little or no 
change in the R2* value was observed in the myocardium remote from the site of 
ischaemia or skeletal muscle.   
In this chapter, USPIO enhanced CMR scanning was used to demonstrate cellular 
inflammation in the myocardium post CABG surgery, and to investigate if Elafin 
reduce neutrophil mediated post-ischaemic myocardial injury. We investigated four 
different protocols for analysing R2* signal change in the myocardium.  
In post hoc analysis, we investigated USPIO uptake in other tissues. We recorded 
R2* signal change in the kidney, skeletal muscle and organs of the reticuloenothelial 
system and examined variation in R2* with Elafin treatment in these organs. 
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5.3 METHODS 
See Chapter 2: (page 62). 
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5.4 RESULTS 
5.4.1 COMPLETION OF SCANNING PROTOCOL 
In total, 54 patients underwent USPIO infusion and CMR scanning within 14 days of 
surgery. USPIO infusion was well tolerated, with only 1 patient reporting muscle 
cramps after administration. 2 patients had ECG evidence of acute graft or coronary 
artery occlusion post surgery, and were excluded. Therefore 52 patients had available 
data for USPIO analysis, and these were compared with 10 contemporaneous healthy 
volunteers (Chapter 3, mean age 26±5 years, 5 male and 5 female) for reference. The 
data from Chapter 3:(page 89) analysing the infarct zone of patients who had 
experienced type 1 myocardial infarction are also provided for comparison (Alam et 
al., 2012d).  
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5.4.2 USPIO UPTAKE: ELAFIN VS PLACEBO 
5.4.2.1 MYOCARDIUM 
As described in chapter 2 (page 84), three methods of data analysis were employed 
(Table 5-1, Table 5-2, Figure 5.1).  
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Table 5-1 USPIO uptake from all myocardial segments 
 
Mean pan-myocardial 
R2* Value (s-1)  
Mean R2* increase for 
highest 3 segments (s-1)  
Sum of 3 segments with 
highest R2* increase (s-1) 
 
PLACEBO ELAFIN  
 
PLACEBO ELAFIN  
 
PLACEBO ELAFIN  
Number of 
values 24 28 
 
24 28 
 
24 28 
25% Percentile 38.2 38.9 
 
55.3 53.6 
 
166.0 160.8 
Median 47.4 53.1 
 
64.5 73.5 
 
193.4 220.4 
75% Percentile 58.6 67.7 
 
76.9 92.6 
 
230.6 277.9 
Mean 49.3 56.0 
 
66.9 76.3 
 
200.7 228.9 
Std. Deviation 18.4 20.6 
 
20.5 28.2 
 
61.4 84.5 
Std. Error of 
Mean 3.8 3.9 
 
4.2 5.3 
 
12.5 16.0 
Lower 95% CI 
of mean 41.6 48.0 
 
58.3 65.4 
 
174.8 196.1 
Upper 95% CI 
of mean 57.1 64.0 
 
76.0 87.2 
 
227 261.6 
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Table 5-2 USPIO uptake from all myocardial segments excluding the apex 
 
Mean pan-myocardial 
R2* Value (s-1)  
Mean R2* increase for 
highest 3 segments (s-1)  
Sum of 3 segments with 
highest R2* increase (s-1) 
 
PLACEBO ELAFIN  
 
PLACEBO ELAFIN  
 
PLACEBO ELAFIN  
Number of values 24 28 
 
24 28 
 
24 28 
25% Percentile 38.2 38.9 
 
55.3 53.6 
 
166.0 160.8 
Median 47.4 53.1 
 
64.5 73.5 
 
193.4 220.4 
75% Percentile 58.6 67.7 
 
76.9 92.6 
 
230.6 277.9 
Mean 49.3 56.0 
 
66.9 76.3 
 
200.7 228.9 
Std. Deviation 18.4 20.6 
 
20.5 28.2 
 
61.4 84.5 
Std. Error of 
Mean 3.8 3.9 
 
4.2 5.3 
 
12.5 16.0 
Lower 95% CI of 
mean 41.6 48.0 
 
58.3 65.4 
 
174.8 196.1 
Upper 95% CI of 
mean 57.1 64.0 
 
75.5 87.2 
 
226.6 261.6 
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Figure 5.1 Myocardial USPIO uptake 
Box-and-whisker plots of USPIO uptake as an average of all segments (left), average 
of the 3 segments with the highest uptake (centre) and the sum of the 3 highest 
segments. The upper panel includes data from all 17 segments, the bottom panel 
excludes data from the apex. 
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Patients receiving placebo had a median pan-myocardial R2* signal of 52.0 
[interquartile range 41.5 to 60.4] s-1. This was not significantly different to patients 
receiving Elafin: 57.8 [interquartile range 49.3 to 71.1] s-1 (p=0.20). There was no 
difference between placebo and Elafin groups if only scans performed within 7 days 
of surgery were analysed; placebo 78.5  [interquartile range  65.6 to 101.0 ] s-1, 
Elafin  86.8 [73.5 interquartile range  to 102.7] s-1 (p=0.44). Similarly, there was no 
significant difference when excluding the cardiac apex; placebo median R2* increase 
47.4 [interquartile range 38.2 to 58.6] s-1, Elafin 53.1 [interquartile range 38.9 to 
67.7] s-1 (p=0.27). 
Using the average for the three segments with the highest R2* increase, there was no 
difference between placebo and Elafin groups; placebo median 74.4 [interquartile 
range 65.8 to 87.4] s-1, Elafin 87.5 [interquartile range 74.0 to 113.8] s-1  (p=0.10). 
There was no difference between placebo and Elafin groups if only scans performed 
within 7 days of surgery were analysed; placebo 84.1  [interquartile range 70.1 to 
113.2 ] s-1, Elafin  88.3 [81.9 interquartile range  to 109.7] s-1 (p=0.51). There was 
also no difference when excluding the apex; placebo median 64.5 [interquartile range 
55.3 to 76.9] s-1, Elafin 73.5 [interquartile range 53.6 to 92.6] s-1 (p=0.10). 
Using the sum for the three segments with the highest R2* increase, there was no 
difference between placebo and Elafin groups; placebo median 221.8 [interquartile 
range 191.9 to 260.4] s-1, Elafin 262.6 [interquartile range 222.1 to 341.4] s-1 
(p=0.07). There was also no difference when excluding the apex; placebo median 
193.4 [interquartile range 166.0 to 230.6] s-1, Elafin 220.4 [interquartile range 160.8 
to 277.9] s-1  (p=0.24). 
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The mean number of “segments with significant USPIO uptake” was 9.1 (95% CI -
7.0 to 11.1) in the placebo group. This was not significantly different to the Elafin 
group; 8.9 (95% CI 6.8 to 10.9), p= 0.94.  
 
5.4.2.2 SKELETAL MUSCLE AND RETICULOENDOTHELIAL SYSTEM  UPTAKE 
There was no significant difference in R2* increase in skeletal muscle between elafin 
and placebo groups (p=0.22)  (Table 5-3).  Similarly, there was no significant 
difference in tissues of the reticuloendothelial system (Table 5-4). 
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Table 5-3 R2* increase in skeletal muscle post CABG (Elafin vs Placebo).  
The data was normally distributed. 
 Elafin Placebo 
 
p value 
   
 
Mean (s-1) 15.1 20.9 
 
0.22 
Std. Deviation 20.2 18.0 
 
Std. Error of 
Mean 3.5 3.2 
 
   
 
Lower 95% CI 
of mean 8.4 14.4 
 
Upper 95% CI 
of mean 22.2 27.4 
 
 
 
 
Table 5-4 Increase in R2* in the reticuloendothelial system (Elafin vs Placebo). 
The data was not normally distributed. 
 Elafin Placebo 
 
Elafin Placebo 
 
Elafin Placebo  
 
Liver Liver 
p 
value Spleen Spleen 
p 
value 
Bone 
marrow 
Bone 
marrow 
p 
value 
   
  
 
   
 25% 
Percentile 193 194 
 
243 273 
 
75.5 47.2 
 Median (s-1) 236 228 0.81 298 309 0.48 178 176 0.61 
75% 
Percentile 270 268 
 
362 369 
 
265 238 
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5.4.2.3 KIDNEYS 
Post-hoc analysis of renal USPIO uptake showed that in the Elafin group, R2* 
increased non-significantly from 79.9±19.7 s-1 to 95.10±36.6 s-1 (p=0.07). When only 
scans performed within a week of surgery were analysed, the R2* increase in the 
placebo group was significantly higher than the elafin group; 99.9±35.6 s-1 versus 
77.6±19.3s-1 respectively (p=0.03)  
 
The renal R2* increase in healthy volunteers was 64±15.8 s-1. Compared to the study 
population there was no significant difference compared to the Elafin group (p>0.1), 
but the placebo group had a larger R2* increase (p<0.001) (Figure 5.2). This was true 
for scans performed both with 7 days or 14 days of surgery.  
There was no significant difference in the absolute post-operative creatinine 
clearance, nor in the change in creatinine clearance from pre to post surgery between 
Elafin and placebo groups; p=0.98 and p=0.73 respectively (Table 5-5, Table 5-6).  
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Table 5-5 Change in creatinine levels and creatinine clearance pre and post 
CABG surgery in Elafin group. 
 
Baseline 
creatinine 
(μmol/L) 
24 hour 
post-
surgery 
creatinine 
(μmol/L) 
48 hour 
post-
surgery 
creatinine 
(μmol/L)  
Pre-
surgery 
creatinine 
clearance 
(ml/min) 
Post-
surgery 
peak 
creatinine 
(μmol/L) 
Post-
surgery 
creatinine 
clearance 
(ml/min) 
Change in 
creatinine 
clearance 
(ml/min) 
25% 
Percentile 61.5 60.0 60.0 94.0 64.5 78.5 0.0 
Median 72.0 69.0 68.0 126.1 76.0 109.6 -11.7 
75% 
Percentile 84.0 85.0 87.5 149.8 96.5 129.5 -23.8 
Mean 74.4 76.5 78.1 125.8 89.9 109.3 -16.5 
Std. 
Deviation 16.0 28.5 37.9 37.3 46.1 32.5 -32.3 
Std. Error 
of Mean 2.4 4.3 5.7 6.3 7.6 5.5 -5.5 
 
 
 
Table 5-6 Change in creatinine levels and creatinine clearance pre and post 
CABG surgery in Placebo group. 
 
Baseline 
creatinine 
(μmol/L) 
24 hour 
post-
surgery 
creatinine 
(μmol/L) 
48 hour 
post-
surgery 
creatinine 
(μmol/L)  
Pre-
surgery 
creatinine 
clearance 
(ml/min) 
Post-
surgery 
peak 
creatinine 
(μmol/L) 
Post-
surgery 
creatinine 
clearance 
(ml/min) 
Change in 
creatinine 
clearance 
(ml/min) 
25% 
Percentile 66.0 61.8 63.0 90.8 73.0 80.0 -0.6 
Median 74.5 71.5 72.0 104 85.0 89.4 12.3 
75% 
Percentile 86.3 81.5 89.0 124 99.5 112 21.9 
Mean 76.7 76.8 82.8 109 92.0 93.4 15.7 
Std. 
Deviation 14.9 24.7 34.3 30.8 32.4 26.0 26.3 
Std. Error 
of Mean 2.3 3.8 5.3 5.2 5.3 4.4 4.4 
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Figure 5.2 Increase in R2* values in renal tissue  
Mean and 95% confidence intervals. Blue – CABG patients receiving placebo. Red – 
CABG patients receiving Elafin. Green – Healthy volunteers. 
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5.4.3 USPIO UPTAKE: POOLED RESULTS 
5.4.3.1 MYOCARDIAL UPTAKE POST CABG SURGERY 
Since there was no demonstrable treatment effect of Elafin, data from both arms of 
the study were combined to assess post-CABG surgery inflammation. Patients 
undergoing CABG had increased pan-myocardial R2* (median 54.8 [interquartile 
range 43.8 to 68.4] s-1 versus 41.2 [32.6 to 50.4] s-1 in healthy volunteers, p<0.05) 
(Figure 5.3). It was also increased in the highest 3 of the 17 segments (median 80.2 
[67.4 to 104.8] s-1 versus 58.7 [48.8 to 68.6] s-1 in healthy volunteers, p<0.0001) and 
was similar to patients who had sustained type 1 myocardial infarction (109.5 [87.5 
to 128.3] s-1, p=0.41). Figure 5.4 provides comparison of the R2* increase compared 
to infarcted myocardium, healthy myocardium and to skeletal muscle. 
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Figure 5.3 Left – Pan-myocardium R2* increase in healthy volunteers (n=10) 
and post-coronary artery bypass graft (CABG) surgery.  
Median and inter-quartile range. 
Right - Tukey box plot comparing R2* increase in the myocardium of (a) patients 
with acute myocardial infarction (remote from the site of infarction), (b) healthy 
volunteers, (c) patients post-CABG surgery (pan-myocardial average), (d) patients 
post-CABG surgery (average of 3 highest values from 17 segment model), and (e) 
patients with acute myocardial infarction (site of infarction). 
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Figure 5.4 R2* increase in the myocadium of patients suffering MI, undergoing 
CABG surgery and healthy volunteers compared to skeletal muscle uptake. 
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Using data from the healthy volunteers, a significant increase in the myocardial 
segments with USPIO uptake could be defined by the upper 95% confidence interval 
(>49 s-1 increase in R2*), or by the 75% percentile (>51s-1 increase in R2*). The 
median number of segments with significant USPIO uptake was higher in the post 
surgical group (9.5 [interquartile range 5 to 13]) compared to healthy volunteers (3.5 
[interquartile range 0 to 6.75], p=0.005)  (Figure 5.5) regardless of the definition 
used. 
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Figure 5.5 Number of myocardial segments with significant USPIO uptake.  
Left – CABG patients (red). Right – Healthy volunteers (green). 
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R2* increase correlated with plasma hsCRP concentrations in CABG surgery 
patients (Figure 5.6; r=0.3, p=0.03) but not with cTnI release (r=0.15, p=0.15) or 
CPB time (r=0.00, p=0.49). 
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Figure 5.6 hsCRP vs R2* increase in the myocardium. 
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5.4.3.2 SKELETAL MUSCLE AND RETICULOENDOTHELIAL SYSTEM. 
In patients undergoing CABG surgery, there was a small increase in skeletal muscle 
R2* from median 60.1 [interquartile range 52.3 to 70.1.] s-1 to 76.2 [interquartile 
range 67.0 to 87.9] s-1 (Table 5-7). The absolute blood pool R2* value rose from 
29.9±14.0 s-1 to 126.9±49.6 s-1.  
 
Increase in R2* in the reticuloendothelial system is shown in Table 5-8. The spleen 
R2* value rose greatly from 63.7 [interquartile range 45.5 to 84.7] s-1 to 367.7 
[interquartile range 317.3 to 422.9] s-1. Bone marrow R2* also rose from 314.0 
[interquartile range 276.4 to 348.2] s-1 to 515.5 [interquartile range 440.2 to 561.9] s-
1.  
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Table 5-7 Increase in R2* from pre to post surgery in skeletal muscle. 
 
 
  
 CABG 
 
Healthy Volunteers 
 
 
Skeletal Muscle Skeletal Muscle p value 
Mean (s-1) 18.1 19.7 0.81 
Std. Deviation 18.7 17.9  
Std. Error of Mean 2.4 5.7  
  
  
Lower 95% CI of mean 13.3 6.9  
Upper 95% CI of mean 22.9 32.4  
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Table 5-8 Increase in R2*in the reticuloendothelial system in CABG patients 
compared to healthy  
P values have been given for parametric or non-parametric tests as appropriate. 
CABG – Coronary Artery Bypass Grafting, HV – Healthy Volunteers. 
 
 
 
 
 CABG 
 
HV 
 
CABG 
 
HV 
 
CABG 
 
HV 
 
 Liver 
 
 
 
Liver 
 
 
p 
value 
Spleen 
 
Spleen 
 
 
p 
value Bone  
Marrow 
 
Bone  
Marrow 
 
 
p 
value 
25% 
Percentile 193 215 
 
259 265 
 
63.8 233 
 
Median 
R2* (s-1) 232 221 
 
0.88 306 290 
 
175 275 
 
0.01 
75% 
Percentile 269 252 
 
371 415 
 
240 301 
 
Mean R2* 
(s-1) 228 229 
 
304 311 
 
0.84 177 272 
 
Std. 
Deviation 51.9 25.2 
 
90.2 93.0 
 
139 83.8 
 
Lower 
95% CI of 
mean 215 210 
 
281 244 
 
142 212 
 
Upper 95% 
CI of mean 241 247 
 
328 377 
 
213 331 
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There was no significant increase in the splenic R2* values of cardiac patients 
compared to healthy volunteers (290.0 [interquartile range 265.4 to 414.5] s-1, 
p=0.83). However the bone marrow rise in healthy volunteers was significantly 
higher (275.0 [interquartile range 232.8 to 301.0] s-1, p=0.01). 
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5.5 DISCUSSION 
In this chapter, USPIO contrast was used for the first time to assess in vivo 
myocardial inflammation following CABG surgery in a randomised controlled trial 
examining myocardial protection and anti-inflammatory effects of Elafin. We found 
no significant difference in cellular inflammatory cell infiltration between patients 
treated with Elafin and those receiving placebo. Even when only scans performed 
within 7 days of surgery were analysed to mitigate the effects of resolving 
inflammation, no difference was detected. This was consistent with systemic 
biomarker results reported in Chapter 4:.  
The average pan-myocardial USPIO uptake was higher in patients following CABG 
surgery than that of healthy myocardium from controls. However it would be 
expected that inflammation would not be uniform throughout the heart following 
CABG surgery given variation in the distribution and severity of coronary disease 
and surgical factors. Using the average USPIO uptake in the three segments with the 
highest uptake, a 2-fold increase was identified compared to the pan-myocardial 
values. Macrophage recruitment into the myocardium correlated weakly with hsCRP 
suggesting an association with humoral and cellular inflammation. However there 
was no correlation with hs-cTnI or CPB time indicating that the magnitude of 
myocardial inflammation was not dependent on degree of myocardial injury or 
ischemia time. The determinants and the sequelae of higher levels of cellular 
inflammation post-CABG surgery require further study. 
Four separate methods for USPIO analysis were examined. A pan-myocardial R2* 
increase was demonstrated post CABG surgery. This approach would be expected to 
miss focal areas of inflammation. Consequently the average USPIO uptake from the 
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three highest segments was preferred. This method is more sensitive for detecting 
focal inflammation, and averaging three segments diminishes the possibility of false 
positives resulting from artefact or blood pooling. Summing the three highest 
segments did not appear to provide any further advantage.  The number of segments 
with significantly increased USPIO uptake was greater in the post CABG population 
compared to healthy volunteer myocardium. This approach holds promise and could 
be used to better describe regional variations in myocardial inflammation. In this 
study the R2* value determining a significant increase was taken arbitrarily, as > 75th 
percentile from a population of 10 healthy volunteers. A larger study form matched 
controls could be used to determine a more robust value before instituting this 
method.  
Skeletal muscle was used as a marker of blood perfusion since it can be assumed that 
perfusion at rest would be relatively constant. Indeed, R2* increase was 19.7±17.9 s-1 
in healthy volunteers compared to 17.0±20.5 s-1 in CABG patients. There was a 
correlation between skeletal muscle and cardiac R2* increase in the healthy 
volunteers, confirming he contribution of USPIO blood perfusion. However there 
was no such correlation in CABG patients. This combined with the significantly 
larger increase in R2* values, in both patients undergoing CABG surgery or 
suffering myocardial infarction, indicated that USPIO accumulation in the 
myocardium of CABG patients was more than simply perfusion (Figure 5.4). 
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We found no difference in the Elafin and placebo groups in terms of USPIO uptake 
in skeletal muscle. The inflammatory insult does prime and release neutrophils 
systemically, followed by a decrease in circulation suggesting sequestration (Botha et 
al., 1995). Furthermore, endothelial induction of ICAM-1 and VCAM-1 during CPB 
initiates extravascular movement of neutrophils and monocytes (Patel et al., 2002). 
However there is complex kinetics of inflammatory cells following surgery that is 
reflected in different cell phenotypes and dynamic cytokine release (Pillay et al., 
2007). Differing amounts of neutrophil infiltration is seen in various organs 
following systemic inflammation caused by trauma (Nuytinck et al., 1988). It is 
likely that inflammatory cell infiltration occurs predominately at sites of tissue 
injury, ischaemia-reperfusion and infarction caused by emboli or thrombosis. 
Therefore skeletal muscle is unlikely to be significantly infiltrated by monocytes 
following systemic inflammatory response of surgery. There was also no difference 
in hepatic uptake, and this may reflect avid uptake by Kupffer cells regardless of 
inflammatory status. There was also no difference in the spleen or bone marrow 
despite the role these tissues play in systemic inflammation. The spleen has been 
identified as a reservoir of monocytes following myocardial infarction (Swirski et al., 
2009a). Pre-clinical models have shown pro-inflammatory monocytes are released by 
the spleen to take up residence with the infarcted myocardial infarction and 
potentially develop into macrophages (Nahrendorf et al., 2007b).  However we did 
not demonstrate a significant difference in USPIO uptake in the spleen post cardiac 
surgery compared to healthy volunteers. Patients were scanned at least five days 
following surgery and key changes in inflammatory cell activity may have subsided 
by then. The healthy volunteers provide a reference but were not matched for age or 
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other co-morbidity and these factors may contribute to the USPIO signal in the 
spleen. Although there was a lower R2* increase in the spleens of patients with 
myocardial infarction studied in chapter 3 (259.0 ± 145 s-1) suggesting monocyte 
release, this was not significant. This may have been due to the varied times from 
infarction to scanning (7330 hours). Nahrendorf et al demonstrated a change in the 
prevailing subsets of monocytes at day five following infarction, from cells 
responsible for inflammation to those having attenuated inflammatory and pro-
angiogenic properties. When pooling data for all patients undergoing surgery, even 
though the bone marrow of CABG patients demonstrated lower USPIO uptake 
overall, there was a large overlap with values from healthy volunteers. Cardiac 
surgery has been shown to release bone marrow resident progenitor cells (Dotsenko 
et al., 2010). CD14++ monocyte leave the bone marrow and differentiate into 
different subsets in cardiovascular disease (Zawada et al., 2012, Dutta and 
Nahrendorf, 2015). The overall reduction in bone marrow USPIO uptake 
demonstrated may reflect depletion of these progenitor cells. 
Acute kidney injury (AKI) complicates up to 30 % of patients following cardiac 
surgery (Parolari et al., 2012). The 30-day mortality of patients who develop a 0 to 
44.2 μmol/L or >44.2 μmol/L rise in serum creatinine is 2.77 or 18.64-fold higher, 
respectively, than patients without a change in serum creatinine (Lassnigg et al., 
2004). However, creatinine is an insensitive marker of renal injury since it will not 
be higher than the normal range until 50% of the renal function is lost (Najafi, 2014, 
Bagshaw and Gibney, 2008). As such the lack of correlation between creatinine and 
renal inflammation detected by USPIO may have been due to lack of an adequate 
biomarker. AKI associated with cardiac surgery is caused by a combination of 
factors including sympathetic nervous system induced vasoconstriction, 
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hypoperfusion, atheroembolism, formation of reactive oxygen species and systemic 
inflammation. All these processes lead to leucocyte recruitment and renal infiltration 
by neutrophils, macrophages and lymphocytes (O'Neal et al., 2016). During cardiac 
surgery in particular, there are macro and micro emboli generated by aortic 
cannulation and cross-clamping that can lead to kidney injury (Sreeram et al., 2004). 
Although maintaining that mean arterial pressures on CPB >70 mmHg leads to 
higher intraoperative creatinine clearances, this does not seem to change 
postoperative renal function as compared with pressures between 50 and 60 
mmHg (Urzua et al., 1992). 
Elevated inflammatory biomarkers are associated with post cardiac surgery acute 
renal injury and mortality (Zhang et al., 2015). Elafin is produced from epithelial 
surfaces including the kidney.  For this reason we examined renal USPIO signal post 
hoc in CABG surgery patients. Serum creatinine increased post CABG surgery and 
there was no difference in renal function between Elafin and placebo treated groups.  
There was decreased renal USPIO uptake in patients treated with Elafin compared to 
placebo. This was evident in patients who had CMR scanning within 7 days of 
surgery, with a non-significant decrease when patients with later scan dates were 
included in the analysis. This finding is consistent with renal infiltration with 
monocytes, with inflammation decreasing with time. Compared to healthy 
volunteers, renal R2* values were increased in placebo but not Elafin treated when 
including all patients scanned within 14 days of surgery. Neutrophils are central to 
renal ischaemia-reperfusion injury (Welbourn et al., 1991, Okusa, 2002), and there is 
massive infiltration in the cortex and outer medulla (Willinger et al., 1992). 
Neurophil elastase is a potent enzyme involved in inflammation and damage of renal 
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tissue (Oda et al., 1997). Sivelestat, a synthetic neutrophil elastase inhibitor, 
attenuates sepsis related kidney injury in rats (Li et al., 2016). Neutrophil activation 
and infiltration leads to monocyte recruitment (Soehnlein et al., 2009). Reducing 
monocyte/macrophage accumulation in the renal parenchyma reduces ischaemia-
reperfusion injury (Nagata et al., 2016). The post-hoc analysis was consistent with 
the possibility that Elafin inhibition of neutrophil elastase reduced the inflammatory 
cascade in kidneys, ultimately reducing monocyte/macrophage tissue residence. This 
was not reflected in changes in creatinine levels, the only available measure of 
glomerular filtration rate between placebo and Elafin groups. As previously stated, 
creatinine is an inadequate measure of acute kidney injury. Neutrophil gelatinase-
associated lipocalin (NGAL), cystatin C, KIM-1, and IL-18 rise within 6 hours of 
cardiac surgery and correlate with AKI and precede elevation in creatinine levels 
(Boldt and Wolf, 2008, Cruz et al., 2010, Haase et al., 2009, Ristikankare et al., 
2010). Blood NGAL levels can be detected in response to ischemic injury and its’ 
early appearance is independent of glomerular filtration rate, and so would have been 
a superior biomarker to detect subtle AKI associated with renal inflammation. 
Plasma volume, fluid administration, nephrotoxic drugs and blood pressure affect 
creatinine levels and renal function separately. Since these factors were not 
controlled, a correlation between renal inflammation and AKI may have been missed 
in this study. We were not able to obtain tissue for histological confirmation of 
monocyte or macrophage infiltration, and so the significance of the increased USPIO 
uptake remains uncertain. However we did perform a separate pre-clinical study in a 
allograft model of transplant rejection and renal inflammation (Appendix G: ). This 
study confirmed USPIO localisation within macrophages within the kidneys that can 
be detected by MRI. 
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One significant limitation is that USPIO-enhanced scans were carried out at later 
time points (5 to 14 days post-surgery), this may have hindered our ability to identify 
some of the correlations with our early (first 48 hours) biomarker assessments. 
In conclusion, for the first time we identified differing levels of inflammatory cell 
infiltrate into the myocardium post CABG. This varied from none to levels similar to 
infarcted myocardial tissues, and the cause and consequences of this requires further 
study. Elafin did not attenuate the cellular infiltration into the myocardium post 
CABG surgery, but did appear to reduce inflammation in renal tissue. There was also 
evidence of a reduction in cell population in the bone marrow post surgery, which 
was possible evidence of monocyte progenitor cell egress. USPIO enhanced CMR 
holds major promise in the non-invasive assessment of myocardial inflammation post 
surgery. 
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Chapter 6: MYOCARDIAL INFLAMMATION, INJURY AND 
INFARCTION DURING ON-PUMP CORONARY ARTERY 
BYPASS GRAFT SURGERY 
 
6.1 SUMMARY 
Myocardial inflammation and injury occur during CABG surgery. We aimed to 
characterise these processes during routine CABG surgery, and to inform the 
diagnosis of type 5 myocardial infarction.  
We pooled data from the EMPIRE study (Chapter 4: page 118) to assess 85 patients 
with stable coronary artery disease who underwent elective CABG surgery. 
Myocardial inflammation, injury and infarction were assessed using plasma 
inflammatory biomarkers, high-sensitivity cardiac troponin I (hs-cTnI) and CMR 
using late gadolinium enhancement LGE.  
Systemic humoral inflammatory biomarkers (myeloperoxidase, interleukin-6, 
interleukin-8 and c-reactive protein) increased in the post-operative period with C-
reactive protein concentrations plateauing by 48 h (median area under the curve 
(AUC) 7,530 [interquartile range (IQR) 6,088 to 9,027] mg/L/48h). Plasma hs-cTnI 
concentrations rose by ≥50-fold from baseline and exceeded 10-fold the upper limit 
of normal in all patients. Two distinct patterns of peak cTnI release were observed at 
6 and 24 h. After CABG surgery, new LGE was seen in 20% (n=18) of patients 
although clinical peri-operative type 5 myocardial infarction was diagnosed in only 
9% (n=8). LGE was associated with the delayed 24-h peak in hs-cTnI and its 
magnitude correlated with AUC plasma hs-cTnI concentrations (r=0.33, p<0.01) but 
not systemic inflammation, myocardial inflammation or bypass time. Patients 
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undergoing CABG surgery invariably have plasma hs-cTnI concentrations >10-fold 
the 99th centile upper limit of normal that is not attributable to inflammatory or 
ischemic injury alone. Peri-operative type 5 myocardial infarction is often 
unrecognised and is associated with a delayed 24-h peak in plasma hs-cTnI 
concentrations. Inflammatory markers rise post CABG surgery and this model can be 
used to assess the effect of anti-inflammatory agents such as Elafin. 
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6.2 INTRODUCTION 
Over 300,000 coronary artery bypass graft (CABG) operations are performed each 
year in the United States of America (Diodato and Chedrawy, 2014). 
Cardiopulmonary bypass (CPB) during these procedures is known to induce systemic 
and myocardial inflammation (Zahler et al., 1999, Paparella et al., 2002). 
Inflammatory cytokines such a tumour necrosis factor alpha (TNF-α) depress cardiac 
function after CPB (te Velthuis et al., 1995), whereas elevations of IL-6 and IL-8 are 
proportional to levels of myocardial injury and apoptosis (Wan et al., 2002). Elevated 
cardiac troponin concentrations have been identified in up to 100% of patients 
undergoing CABG (van Gaal et al., 2011). However, corresponding CMR evidence 
of myocardial necrosis is evident in only 28% of patients, suggesting that troponin 
release may reflect reversible injury resulting from other processes such as 
inflammation or ischemia-reperfusion injury rather than infarction (Noora et al., 
2005). The identification of clinically relevant peri-operative myocardial injury and 
infarction can be challenging but is important because it predicts short, medium and 
long-term mortality (Onorati et al., 2005, Croal et al., 2006).  
 
The universal definition of myocardial infarction defines procedural (type 5) MI as a 
>10-fold elevation above the 99th centile of cardiac troponin within 48 hours of 
CABG surgery accompanied by new pathological Q waves or left bundle branch 
block, angiographically documented new graft or new native coronary artery 
occlusion, or imaging evidence of new loss of viable myocardium or new regional 
wall motion abnormality (Thygesen et al., 2012a). Elevation of plasma cardiac 
troponin concentration is required but in the absence of these other clinical features, 
is insufficient to make the diagnosis of type 5 MI. 
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The latest generation of high-sensitivity cardiac troponin I (cTnI) assays have been 
widely adopted since the introduction of the third universal definition of MI. These 
assays have defined normal plasma concentrations in healthy populations and can 
identify at-risk patients presenting with chest pain and very small elevations in cTnI 
concentration that would pass undetected by older contemporary assays (Shah et al., 
2015b).  This increased sensitivity may have consequences for the identification and 
diagnosis of myocardial infarction in patients undergoing CABG surgery. 
Using a comprehensive panel of blood and imaging biomarkers, we explored the 
relationship between perioperative myocardial inflammation and infarction in order 
to characterise this injury  
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6.3 RESULTS 
6.3.1 RECRUITMENT AND BASELINE CHARACTERISTICS 
Consecutive patients were assessed for eligibility and 53% consented to participate. 
A total of 189 patients were screened for recruitment of whom 29 were excluded, 79 
declined to participate, 88 patients gave informed consent and 1 died before surgery 
leaving 87 patients to undergo randomisation (Figure 6.1 Study flow diagram). In 85 
of the 87 patients, the trial infusion was administered as planned. Patient 
characteristics and intra-operative details are shown in Table 6-1. Pre-existing 
(previously unidentified) myocardial infarction was common with 27% (21/79) of 
patients having pre-operative LGE. Two patients died in the early post-operative 
period from graft failure and cardiac arrest and a further 6 patients were diagnosed 
with a MI by the clinical team based on ECG changes and troponin release giving a 
total of 8 (9%) patients who were clinically diagnosed with type 5 myocardial 
infarction. Unrecognised type 5 myocardial infarction was identified in a further 10 
patients (total of 18; 21%) with new LGE on CMR. 
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Figure 6.1 Study flow diagram 
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Table 6-1 Baseline patient characteristics.  
Mean±SD or n (%) 
 
 
 
  
Age (years) 63±8 
2-vessel coronary disease 23  (26%) 
3-vessel coronary disease 64 (74%) 
Creatinine (mg/dL) 0.90±0.21 
Creatinine Clearance (mL/min) 117±35 
Diabetes Mellitus 20 (23%) 
Surgeon A 34 (39%) 
Surgeon B 53 (61%) 
Male Gender 74 (85%) 
EuroSCORE 2.4±190 
Clinically diagnosed previous MI 32/87 (37%) 
Clinical diagnosis of previous MI 
without LGE 
7/79 (9%) 
LGE without previous clinically 
recognized MI 
21/79 (27%) 
Intra-operative details 
Number of bypass grafts 
One 3 
Two 33 
Three 36 
Four 14 
Five 1 
Cardiopulmonary bypass time (min) 78±24 
Cross clamp time (min) 46±15 
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Overall 25.3% of patients required intra-aortic balloon pump counterpulsation, 
inotropes or vasoactive support in the first 48 hours, 33% required red cell 
transfusion, and 31% developed atrial fibrillation prior to discharge (Table 6-2). 
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Table 6-2 Clinical outcomes.  
Mean±SD or n (%) 
 
  
 <48 h In-hospital 
Post-operative complications and outcomes 
Death 0 (0) 2 (0) 
Stroke 0 (0) 0 (0) 
Clinically diagnosed 
Myocardial infarction 
1 (2.3) 8 (9) 
Inotrope or balloon pump 
support for > 24h 
22 (25.3) 22 (25.3) 
Red cell transfusion post-op 24 (27.6) 29 (33.3) 
Re-operation for bleeding 3 (3.4) 3 (3.4) 
Antibiotic administration 6 (6.9) 33 (37.9) 
Atrial fibrillation 7 (8) 27 (31) 
Peak serum creatinine (mg/dL) 1.00±0.41 1.03±0.45 
Peak creatinine clearance 
(mL/min) 
101.9±33.2 101.4±30.3 
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6.3.2 HUMORAL INFLAMMATION 
Systemic inflammatory markers rose following surgery (Table 6-3, Figure 6.2 
Perioperative cytokine, high-sensitivity c-reactive protein (hsCRP) concentrations 
and circulating white blood cell (WBC) count.with IL-6 and MPO peaking at 2 h, 
and IL-8 and TNF-α continuing to rise at 6 hours. Plasma hsCRP concentrations rose 
steeply at 6 h and continued to rise at 48 hours. There was no correlation between 
cytokines and LGE on CMR.  There was weak correlation between AUC hsCRP 
release and hs-TnI (r=-0.27, p=0.01). 
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Table 6-3 Cardiac troponin and cytokine concentrations.  
Median (inter-quartile range). hs-TnI – Troponin I by high sensitivity assay. hs-CRP 
– C-reactive protein by high sensitivity assay. AUC – area under the curve 
 
0 h 2 h 6 h 24 h 48 h AUC 
hs-TnI 
(ng/l or 
ng/l/48h) 
3.5 (2, 
9.6) 
76.5 
(35.6, 
163.6) 
3222 
(1413, 
5607) 
1043 
(5344, 
2948) 
5210 
(2302, 
1342) 
74480 
(35100, 
164100) 
hs-CRP protein 
(mg/L) 
2.00 
(0.5, 
3.00) 
1.00 
(0.50, 
2.00) 
2.00 
(1.00, 
3.00) 
121 
(96.0, 
148) 
236 
(182, 
279) 
7530 
(6088, 
9027) 
Interleukin-6 
(pg/mL) 
1.80 
(1.10, 
2.60) 
10.0 
(5.75, 
15.6) 
10.5 
(8.15, 
17.7) 
  55.8 
(43.3, 
80.5) 
Interleukin-8 
(pg/mL) 
8.90 
(6.28, 
11.7) 
7.60 
(4.95, 
16.9) 
93.8 
(45.9, 
148) 
  240 
(121, 
411) 
Tumour necrosis 
factor-α (pg/mL) 
4.50 
(4.50, 
7.30) 
4.50 
(4.50, 
11.5) 
7.10 
(4.50, 
14.25) 
  37.3 
(27.0, 
66.7) 
Myeloperoxidase 
(ng/mL) 
75.6 
(45.6, 
150) 
532 
(383, 
743) 
194 
(112, 
350) 
  2175 
(1588, 
2889) 
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Figure 6.2 Perioperative cytokine, high-sensitivity c-reactive protein (hsCRP) 
concentrations and circulating white blood cell (WBC) count.  
Mean ± SEM.  
IL-6 - Interleukin-6. IL-8 - Interleukin-8. TNF-α – Tumour necrosis factor alpha. 
MPO - Myeloperoxidase 
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6.3.3 MYOCARDIAL INJURY 
Complete cTnI profiles over 48 h were available in 84 patients. Plasma cTnI 
concentrations peaked at 6 h (median 3,220 [1,410 to 5,610] ng/L; Figure 6.3) with 
almost all patients demonstrating >100-fold (median 760 [151 to 1623] fold) increase 
from baseline to 6 h and all patients exhibiting >10-fold (median 102 [55 to 206] 
fold) elevation above the 99th centile URL. Patients without new LGE had lower 
increases (median 83 [11 to 161] fold) compared to patients with new LGE (median 
174 [91 to 248] fold, p=0.04; Figure 6.3). 
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Figure 6.3 Perioperative high-sensitivity cardiac troponin.  
Mean ± SD and fold increase from baseline (top left). Hs-cTnI concentration fold 
increase above 99th centile upper reference limit (URL) according to the presence of 
new late-gadolinium enhancement (top right). Perioperative hs-cTnI profiles of all 
patients (bottom)
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Two patterns of cTnI release were noted in the post-operative period with peak 
concentrations at 6 (n= 67) or 24 h (n=18; Figure 6.3). Median AUC for hs-cTnI 
release was 74,478 [35,100 to 164,100] ng/L/48 h. There was no correlation between 
cTnI AUC and cardiopulmonary bypass (r=0.14, p=0.11) or cross clamp time (r=0.02 
p=0.43). 
 
6.3.4 MYOCARDIAL INFARCTION 
6.3.4.1 ELECTROCARDIOGRAM 
Eleven (13 %) patients developed new ST-change/new bundle branch block/new Q-
waves consistent with myocardial infarction (Figure 6.4). The majority of patients 
had no ECG changes (n=41, 48%) or non-specific pericarditic change (n=19, 22%) 
and T wave inversion (n=14, 16%). Patients with ECG evidence of infarction 
exhibited a cTnI peak at 24 h: 6 hour mean, 6,124 ng/L (95% CI 1,758 to 10,490) 
and 24 hour mean 23,410 ng/L (95% CI 8,530 to 38,300). Patients without specific 
ECG changes of infarction (n=74) had peak cTnI concentrations at 6 h: 6 hour mean 
5,186 (95% confidence intervals 3,635, 6,738) ng/L and 24 hour mean 1,905 (95% 
confidence intervals 1,353, 2,458) ng/L. 
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Figure 6.4 Troponin versus CMR & ECG changes. 
Perioperative high-sensitivity cardiac troponin concentration (mean ± SEM) 
according to new late gadolinium enhancement (left) and ECG changes (right). Post-
operative evidence of infarction on ECG (bottom). 
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Overall, 7/11 (64%) of patients with an ECG suggesting infarction had a rise in cTnI 
concentration between 6 and 24 h. In patients with no evidence of infarction on ECG, 
only 11/74 (15%) had a rise in cTnI concentration between 6 and 24 h. Thus ECG 
analysis provided a positive predictive value of a late troponin peak of 64% (95% 
confidence intervals 31% to 89%) and a negative predictive value of 85% (95% 
confidence intervals 75% to 92%). An ECG demonstrating infarction was 23% 
sensitive and 98% specific for the formation of LGE. 
 
6.3.4.2 CARDIAC MAGNETIC RESONANCE 
Assessment of late gadolinium enhancement was available in 66 of 68 patients who 
underwent both pre- and post-operative CMR. Thirteen patients developed new LGE 
distributed by ECG category as follows; 3/4 (75%) with ST-change/new bundle 
branch block/new Q-waves, 7/35 (20%) with no ECG changes, 3/17 (18%) with 
pericarditic changes and 0/10 (0%) with T wave inversion (Figure 6.4). Infarct 
volume by LGE correlated with AUC for cTnI (r=0.33, p<0.01). For left ventricular 
function, 8/68 (12%) of patients had at least 5% increase in ejection fraction, 20/68 
(29%) had a decrease and 40/68 (59%) had no change (Figure 6.5).  
There was a correlation between hsTnI release and LGE (p<0.01, r=0.33), and 
between hsTnI and maximum hsCRP levels (p=0.01, r=0.26) (Figure 6.6) 
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Figure 6.5 Change in ejection fraction  
(Median and IQR) 
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Figure 6.6 Associations between area under the curve high-sensitivity cardiac 
troponin I and LGE & maximum hs-CRP  
(line of best fit and 95% confidence intervals) 
LGE – left 
hs-CRP - right 
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Peak plasma cTnI concentration occurred at 24 hours in patients with new LGE: 6-
hour mean 3,655 (95% confidence intervals 2,228 to 5,081) ng/L and 24-hour mean 
9,073 (95% confidence intervals 5106 to 18,660) ng/L. By contrast, patients without 
new LGE had a peak cTnI concentration at 6 hours of 5,487 (95% confidence 
intervals 3,390 to 7,585) ng/L compared to a mean of 1,545 (95% confidence 
intervals 1,060 to 2,031) ng/L at 24 hours. Overall 6/13 (46%) of patients with new 
LGE had a rise in cTnI concentration between 6 and 24 hours compared to 5/52 
(10%) in patients without LGE (p<0.01).  A rise in troponin release after 6 hours was 
46% sensitive (95% CI 19 to 75) and 90% specific (95% confidence intervals 79 to 
97) for detecting new LGE. The positive predictive value was 55% (95% confidence 
intervals 23.38 to 83.25) and the negative predictive value 87% (95% confidence 
intervals 75.10 to 94.63) respectively. 
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6.4 DISCUSSION 
This study was performed on a highly characterised and phenotyped population using 
the current gold standard techniques to detect myocardial injury and infarction (Shah 
et al., 2015b). Patients undergoing CABG surgery invariably have plasma hs-cTnI 
concentrations >10-fold the 99th centile that is not attributable to inflammatory or 
ischemic injury alone. Peri-operative type 5 myocardial infarction is often 
unrecognised and is associated with a delayed 24-hour peak in plasma hs-cTnI 
concentrations.  
Using the latest generation high-sensitivity assay, cTnI release was found to be >10-
fold the upper limit of normal (99th centile) in all patients following CABG surgery. 
Importantly, two patterns of release were identified with an early 6 hour peak and a 
more delayed 24 hour peak. These peaks reflect perioperative myocardial injury and 
infarction respectively as demonstrated by late gadolinium enhancement on cardiac 
magnetic resonance imaging. There appears to be no single discriminatory threshold 
for troponin concentration that could reliably discriminate clinically overt myocardial 
infarction. The data indicate that the profile, rather than peak, of troponin release 
may be more important when attempting to distinguish between myocardial injury 
and type 5 MI. 
 
All patients in the study exhibited at least 50-fold rise from baseline troponin and all 
but 4 had at least 100-fold increase. Many factors contribute to myocardial injury in 
the perioperative period including manipulation of the heart during on-pump surgery, 
cardioplegia, ischemia and patients specific factors including severity of underlying 
coronary artery disease and myocardial function. The average increase in cTnI 
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concentration from baseline was nearly 2,000. The third universal definition for type 
5 myocardial infarction occurring during CABG surgery stipulates a cardiac marker 
elevation of ≥10-fold the upper limit of normal (99th centile). In this study, all 
patients undergoing on-pump surgery fulfil this criterion and this threshold is 
therefore unhelpful and has no value. This leads to the questions of whether a higher 
single threshold should be employed or whether alternative criteria looking at the 
profile of cTnI release may be more discriminatory.  
The data do not support the approach of increasing troponin threshold to provide 
greater discrimination. For example, increasing the threshold to >100-fold 99th 
centile would have excluded 64% of patients with LGE proven macro-infarction and 
included 43% of patients without. The data support the findings by other groups that 
multiple time-point sampling to detect a late rise in troponin concentration is more 
discriminatory for type 5 myocardial infarction (Selvanayagam et al., 2005, Pegg et 
al., 2011, Lim et al., 2011). Selvanayagam et al demonstrated a late peak in troponin 
levels in patients with new LGE compared to those without (20.3±11.9 versus 
11.3±11.0 hours) (Selvanayagam et al., 2005). Both Pegg et al and Lim et al 
demonstrated that subjects with new LGE showed a trend for continuous increase of 
troponin up to 24 hours whereas those without new LGE showed peaks at 6 to 12 
hours (Lim et al., 2011, Pegg et al., 2011). In this study there were also two distinct 
cTnI concentration peaks at 6 and 24 hours. Patients with ECG or LGE evidence of 
infarction were much more likely to have a peak cTnI at 24 hours compared to those 
without. An ECG demonstrating infarction was highly specific (98%) for detecting 
the formation of LGE. However both ECG and cTnI profile in isolation had 
relatively low sensitivity for such detection. This may be because greater volume of 
infarction must occur in order to cause a change in the electrical or biochemical 
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profile. The data from this study suggest that the most effective and practical method 
for diagnosing type 5 myocardial infarction involves cTnI testing at 6 and 24 hours 
combined with ECG evidence of infarction.  
A previous study reported new LGE in up to 78% of patients undergoing CABG 
surgery, but the investigators did not perform pre-operative CMR (Steuer et al., 
2004a). In this study, LGE was identified in 27% of pre-operative MRI scans in 
patients with no prior clinical history of myocardial infarction suggesting the 
presence of sub-clinical infarction is common even in stable patients. Consistent with 
the work in this chapter, Pegg and colleagues also reported pre-existing LGE from 
preoperative scans in 8/40 (20%) of patients participating in a study of a novel hybrid 
method of on-pump beating heart CABG surgery (Pegg et al., 2011).  
Although it might have been anticipated that the magnitude of myocardial injury 
would correlate with CPB time, there was no association with AUC cTnI release. 
Furthermore there was no correlation with inflammatory cytokine release or 
myocardial inflammation. This suggests that injury is not mediated by inflammation 
alone. Other processes influence the cTnI injury such as microemboli, surgical 
manipulation of the heart and patient specific factors. The data also confirm that 
substantial cTnI release occurs in the perioperative period without imaging evidence 
of infarction and new scar formation consistent with reversible myocardial injury. 
The study has some limitations. Some patients had difficulty lying flat and breath-
holding in the MRI scanner for post-operative scans. This sometimes resulted in 
reduced scan quality.  Since the CMR scans were carried out at later time points (5 to 
14 days post-surgery), this may have hindered the ability to identify some of the 
correlations with our early (first 48 hours) biomarker assessments.  
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In conclusion, all patients undergoing CABG surgery demonstrate >10-fold elevation 
above the 99th centile of cardiac troponin indicating the current universal definition 
of type 5 myocardial infarction lacks specificity. A peak hs-cTnI at 6 hours following 
CABG appears to be related to the surgical process and non-specific myocardial 
injury whilst a continuing increase at 24 hours suggesting myocardial infarction. We 
would suggest cTnI sampling at 6 and 24 hours post CABG surgery together with 
ECG assessment for the routine detection and diagnosis of type 5 MI.  
Differing levels of humoral markers of inflammation post CABG surgery occurred 
and did not correlate directly with the length of CPB or hs-cTnI release, except for a 
weak correlation between hsCRP and hs-cTnI. 
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Chapter 7: CONCLUSIONS AND FUTURE DIRECTIONS 
 
7.1 BACKGROUND 
7.1.1 MYOCARDIAL INFARCTION 
Cardiovascular disease is the commonest cause of premature death in the United 
Kingdom and accounts for 30% of all deaths among men and 22% among women. 
The single largest cause of death is acute myocardial infarction 
(http://www.bts.org.uk/transplantation/heart/, 2015). 
 
Coronary atherosclerosis is responsible for the initiation of acute myocardial 
infarction with plaque rupture leading to acute coronary thrombosis and myocardial 
infarction. Current treatment in the acute phase involves re-establishing vessel 
patency by percutaneous coronary intervention supported by anti-thrombotic therapy. 
Thereafter, statins, angiotensin-converting enzyme inhibitors and beta-blockade all 
have prognostic benefit but no treatments have been successfully developed to target 
post-infarction inflammatory pathways.  
 
Necrotic cardiac muscle elicits an inflammatory cascade that serves to clear the 
infarct of dead cells and matrix debris. Human cardiac muscle has negligible 
regenerative capacity and ultimately inflammation leads to replacement of damaged 
tissue with a fibrotic scar. Enhancing reparative mechanisms following the 
inflammatory reaction to myocardial infarction may reduce cardiomyocyte injury, 
attenuate adverse remodelling and improve clinical outcome. A better understanding 
of the early post-infarct healing phase will also facilitate cell therapy strategies that 
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engraft stem cells or stimulate regeneration. In order to achieve this goal, we must 
better characterise the inflammatory processes that follow infarction and myocardial 
necrosis in humans.  
 
7.1.2 MYOCARDIAL INFLAMMATION FOLLOWING ISCHAEMIA AND INFARCTION 
 (i) Neutrophils and Human Neutrophil Elastase 
Inflammation within the infarcted myocardium is associated with induction of 
endothelial adhesion molecules and enhanced permeability of the microvasculature. 
Up regulation of chemokines, including IL-8 and MCP-1, attracts neutrophils and 
monocytes to the site of injury. Early reperfusion therapy amplifies this 
inflammatory cell influx and accelerates the healing response through proliferative 
and maturation phases. Neutrophil adhesion to endothelium of infarcted myocardium 
occurs within minutes of reperfusion. Ischaemic cardiomyocytes are further injured 
by adherent neutrophils that release reactive oxygen species and destructive 
proteases including HNE and proteinase 3. HNE has a wide range of substrates 
including matrix components elastin, fibronectin, and collagen types III and IV. 
Activated neutrophils also occlude microvessels and increase endothelial 
permeability contributing to myocardial oedema. Preclinical studies have 
demonstrated that neutrophil depletion or inhibition of neutrophil elastase attenuates 
post-ischemic inflammatory reperfusion injury within the myocardium (Romson et 
al., 1983a, Tiefenbacher et al., 1997).   
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(ii) Monocyte-derived Macrophages 
Recruitment of monocytes into the infarcted myocardium is followed by maturation 
and differentiation into macrophages. Macrophages have multiple roles within the 
infarct including (i) phagocytic clearance of dead cells and debris, (ii) production of 
growth factors and cytokines that stimulate fibroblast growth and angioneogenesis, 
and (iii) matrix turnover through the production of matrix metalloproteases and their 
inhibitors. Macrophages are resident within 24 hours of infarction and persist for up 
to 4 weeks. During this period, macrophages regulate infarct healing with the initial 
development of granulation tissue and subsequent scar formation. Monocytes 
arriving within the first 3 days mature into macrophages that scavenge necrotic 
debris through inflammatory mediator expression, proteolysis and phagocytosis 
while monocytes arriving later on give rise to macrophages which promote reparative 
processes such as angioneogenesis and extracellular matrix deposition (Nahrendorf et 
al., 2007a). 
MCP-1 expression is increased in ischaemic myocardium following reperfusion and 
this accounts for a substantial proportion of the monocyte chemotactic activity 
(Kumar et al., 1997). Macrophage activity outside the infarct zone may contribute to 
adverse myocardial remodelling following myocardial infarction. The role of the 
macrophage differs depending on differentiation and location within the 
myocardium. Therapeutic manipulation of this healing process will only come from 
understanding mechanisms and targeting reparative pathways. Indiscriminate 
immunosuppressive therapy in this setting may result in harm as observed in trials 
with methylprednisolone in acute myocardial infarction. 
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7.1.3 MAGNETIC RESONANCE IMAGING IN TRACKING CELLULAR INFLAMMATION 
Iron oxide particles can be used as a contrast medium in magnetic resonance imaging 
since they can alter the magnetic properties and relaxation of tissues after application 
of radiofrequency pulses. Such contrast media consist of an iron oxide core within a 
dextran coat. They can be classified as “ultrasmall superparamagnetic iron oxide 
particles” (USPIOs) which are under 30 nm in diameter (Lawaczeck et al., 2004). 
USPIOs are taken up by cells of the liver, spleen, bone marrow and lymph nodes. 
They have the capacity to extravasate through capillaries and be phagocytosed by 
tissue inflammatory cells of the reticuloendothelial system (Ruehm et al., 2001a). 
These cells are predominately macrophages, but neutrophils have also been shown to 
take up USPIOs (Dousset et al., 1999, Gellissen et al., 1999b). This model of 
USPIO-enhanced MRI can highlight areas of inflammation in models of vertebral 
osteomyelitis, aortic atherosclerosis, arthritis-induced hyperperfusion, autoimmune 
encephalomyelitis, nephritis and nephropathy, cerebral ischaemia and renal 
ischaemia (Bierry et al., 2008, Dousset et al., 1999, Ruehm et al., 2001a, Hauger et 
al., 2000, Rausch et al., 2001b, Lutz et al., 2006, Jo et al., 2003b). Therefore we 
hypothesised that USPIO enhanced CMR could identify and assess cellular 
inflammation of the myocardium. 
 
 
7.1.4 CORONARY ARTERY BYPASS SURGERY  
During coronary artery bypass graft surgery, the myocardium receives an immediate 
ischaemic insult that is exacerbated by post-ischaemic reperfusion inflammatory 
responses leading to increased myocardial injury. Coronary artery bypass graft 
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surgery can therefore be used as a clinical model of myocardial infarction and 
inflammation (Steuer et al., 2004c, Anselmi et al., 2004). 
 
7.1.5 ELAFIN 
Elafin inhibits destructive and inflammatory neutrophil derived proteases. Beyond 
this elafin inhibits inflammatory cytokines and modulates the innate and adaptive 
immune systems. Elafin is expressed within epithelial tissues that have evolved 
mechanisms to adapt and repair from neutrophil mediated injury.  In preclinical 
studies elafin delivery and gene overexpression is associated with reduced 
myocardial injury and preserved left ventricular function following ischaemia and 
infarction. This effect is associated with reduced neutrophil infiltration and elastase 
activity at the site of injury. Activated neutrophils facilitate monocyte recruitment. 
Granule contents including LL-37, azurocidin and human neutrophil peptides 1-3 
have direct chemotactic activity on monocytes. Neutrophil-derived proteases induce 
chemokine, MCP-1 and IL-8 production from endothelial cells and their effects on 
matrix components produce degradation products with chemotactic activity for 
monocytes (Richardson et al., 1976, Postlethwaite and Kang, 1976, Norris et al., 
1982). As such, elafin has a marked potential for the treatment of cardiovascular 
disease including acute myocardial infarction. Therefore, we hypothesised that elafin 
will reduce perioperative ischaemic myocardial injury and inflammation in patients 
undergoing elective coronary artery bypass graft surgery.  
 
  
Chapter 7: Conclusions and Future Directions 
Detection, assessment and modulation of myocardial inflammation 207 
7.2 SUMMARY OF THESIS FINDINGS 
7.2.1 CHANGES IN R2* IN USPIO ENHANCED MRI SCANS DETECT CELLULAR 
INFLAMMATION POST MYOCARDIAL INFARCTION 
We demonstrated for the first time that USPIOs are taken up by the infarct tissue in 
patients with recent myocardial infarction and by the peri-infarct myocardium to a 
lesser degree. Given previous pre-clinical and clinical studies, this is likely to 
correspond to cellular inflammation. This represents a novel non-invasive method to 
further study cardiac inflammation and therapeutic interventions. It may also provide 
prognostic information or provide a diagnostic tool for the investigation of 
inflammatory cardiac conditions such as myocarditis and transplant rejection, as well 
as a potential biomarker for therapeutic interventions targeted at improving left 
ventricular remodelling following infarction. 
 
7.2.2 MYOCARDIAL INJURY POST CORONARY ARTERY BYPASS SURGERY CAN BE ASSESSED 
WITH BLOOD MARKERS OF INFLAMMATION AND INFARCTION. 
All patients undergoing CABG surgery demonstrated >10-fold elevation above the 
99th centile of cardiac troponin indicating the current universal definition of type 5 
myocardial infarction lacks specificity. A peak hs-TnI at 6 hours following CABG 
surgery appears to be related to the surgical process and non-specific myocardial 
injury whilst a continuing increase at 24 hours suggesting myocardial infarction. We 
would suggest troponin sampling at 6 and 24 hours post CABG surgery together with 
ECG assessment for the routine detection and diagnosis of type 5 MI.  
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Differing levels of humoral makers inflammation post CABG surgery occurred, and 
did not correlate directly with the length of CPB or hs-TnI release. However the 
marked elevation of IL-6, IL-8, TNF-alpha, MPO and hsCRP following surgery 
indicated that CABG surgery can be used as a model of programmed cardiac injury 
and inflammation. 
 
7.2.3 ELAFIN, THE NEUTROPHIL ELASTASE INHIBITOR, DID NOT MODIFY POST CORONARY 
ARTERY BYPASS SURGERY MYOCARDIAL INJURY AND INFLAMMATION 
Despite the body of work indicating therapeutic potential from several groups using 
different models, species and modes of augmentation, Elafin’s promise as a 
therapeutic agent to attenuate myocardial ischemia-reperfusion injury and 
inflammation was not translated in this first phase II study. Post-hoc analysis 
identified reduced cTnI concentrations at 6 hours in Elafin treated patients and it is 
possible that repeated dosing would have conferred protection out to 48 hours.  
Elafin was safe and lack of treatment effect was seen despite achieving high plasma 
Elafin concentrations and halving of circulating elastase activity.  
 
7.2.4 CELLULAR INFLAMMATION POST CORONARY ARTERY BYPASS SURGERY CAN BE 
DETECTED AND ASSESSED USING USPIO ENHANCED MRI SCANNING. 
For the first time we identified differing levels of inflammatory cell infiltrate into the 
myocardium post CABG. This varied from none to levels similar to infarcted 
myocardial tissues, and the cause and consequences of this requires further study. 
Elafin did not attenuate the cellular infiltration into the myocardium post CABG 
surgery, but did appear to reduce inflammation in renal tissue. There was also 
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evidence of a reduction in cell population in the bone marrow post surgery, which 
was possible evidence of monocyte progenitor cell egress. USPIO enhanced CMR 
holds major promise in the non-invasive assessment of myocardial inflammation post 
surgery. 
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7.3 FUTURE DIRECTIONS 
7.3.1 PROPOSED CONTINUATION OF RESEARCH FROM CHAPTER 3 
7.3.1.1 IRON NANOPARTICLE ENHANCED MRI IN THE ASSESSMENT OF MYOCARDIAL 
INFARCTION (IRNMAN) TRIAL 
We have established uptake of USPIOs in the penumbra and infarct zone of the 
myocardium in patients with a recent myocardial infarction. In an investigation 
already underway, we aim to establish the time course and determinants of cellular 
tissue inflammation. This is the first clinical study to examine the ability of USPIOs 
to image myocardial inflammation following acute myocardial infarction. 
Using ferumoxytol (Rienso) as a USPIO contrast agent for magnetic resonance 
imaging at 3 tesla, we aim to conduct a clinical study to examine the utility of this 
novel contrast agent to image myocardial inflammation after myocardial infarction. 
 
7.3.1.1.1 HYPOTHESIS 
We hypothesise that the myocardial accumulation of ultrasmall superparamagnetic 
particles of iron oxide within phagocytic inflammatory cells will: 
i. Occur within and adjacent to areas of acute myocardial infarction. 
ii. Occur early and be proportional to the extent of infarction and the degree 
of systemic inflammation. 
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7.3.1.1.2 EXPECTED VALUE OF RESULTS 
We propose to describe, characterise and identify the determinants of USPIO uptake 
using the clinical model of acute myocardial infarction. This will be the first 
description of this ‘smart contrast agent’ in the setting of acute myocardial infarction 
and, if successful, this technique has many major potential benefits and 
ramifications. First, it may assist in risk stratifying patients who may have an adverse 
outcome. For example, intense and persistent USPIO uptake may be associated with 
adverse remodelling and progression to heart failure. Second, it will provide a 
method of assessing the inflammatory and reparative processes following infarction. 
This may be a useful biomarker to assess the impact of therapeutic interventions. 
 
For further details please refer to Appendix H: . 
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7.3.2 PROPOSED CONTINUATION OF RESEARCH FROM CHAPTER 4 
7.3.2.1 ELAFIN IN THE MODULATION OF CARDIOVASCULAR INFLAMMATION 
We showed that a single administration of Elafin prior to on-pump coronary artery 
bypass surgery did not result in attenuation of injury inflammation as measured 
troponin release or cytokine profiles. Inflammatory cascades are activated via 
multiple mechanisms, with overlap between substrates for different enzymes. Such 
redundancy in tissues inflammatory pathways may mean that inhibition of one 
pathway cannot modulate the overall acute response to injury. However, post hoc 
analysis did reveal that troponin levels were reduced at 6 hours albeit without 
statistical correction for multiple time-point analysis. As described in section 1.6 
(page 39) Elafin has anti-inflammatory effect through receptor interaction as well as 
enzyme activity. Elafin levels began to rise, with elastaste activity increasing at 2 
hours post skin incision. It is possible that more sustained HNE suppression and 
Elafin plasma levels may have resulted in significant attenuation of myocardial 
injury and inflammation.  
7.3.2.1.1 HYPOTHESIS 
Using the same model of cardiac inflammation and methods, repeated doses of Elafin 
to ensure sustained plasma levels and complete suppression of HNE will result in 
significant reduction in myocardial inflammation and injury. 
7.3.2.1.2 EXPECTED VALUE OF RESULTS 
If the anti-inflammatory effect of Elafin can be demonstrated in the above model of 
inflammation, it could be studied as a therapeutic intervention in more severe forms 
of cardiac inflammation. This would include type 1 myocardial infarction, valvular 
heart surgery and myocarditis.  
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7.3.3 PROPOSED CONTINUATION OF RESEARCH FROM CHAPTER 5 
We have established that USPIOs can be used to assess cellular inflammation in 
patients with acute myocardial infarction (Chapter 3:) and post CABG surgery 
(Chapter 5:, Figure 7.1). This technique can be utilised to detect inflammation in 
pathologies causing myocarditis. 
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Figure 7.1 Comparison of myocardial R2* values post surgery, infarction and in 
controls.  
Post cardiac surgery (green) compared to infarct (red) and non-infarct areas (blue) in 
patients with acute myocardial infarction. The myocardium of healthy volunteers is 
shown in yellow. 
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7.3.3.1 DETECTION OF CELLULAR INFLAMMATION WITH FERUMOXYTOL IN THE 
HEART: ‘DECIFER-HEART’ TRIAL 
7.3.3.1.1 CARDIAC TRANSPLANTATION 
Approximately 150 people per year receive a cardiac transplant in the United 
Kingdom (http://www.bts.org.uk/transplantation/heart/, 
2015)(http://www.bts.org.uk/transplantation/heart/, 2015) 
(http://www.bts.org.uk/transplantation/heart/, 2015). Up to 21 to 30 per cent of 
recipients are treated for rejection during the first year after transplantation (Hertz et 
al., 2009).  All patients therefore require lifetime immunosuppression and careful 
follow-up to assess for rejection. However no reliable non-invasive method of 
assessment exists for its detection or surveillance of at-risk patients (Christen et al., 
2010). During cardiac transplant rejection, antigen presenting cells stimulate 
lymphocytes to release cytokines which recruit and activate macrophages that are the 
main effector cells (Suzuki et al., 2010). In clinical specimens, macrophages and 
monocytes have been recognised as a correlate of humoral rejection in cardiac 
transplant recipients (Lones et al., 1995).  
Iron oxide particles have been used to assess heart transplant rejection in pre-clinical 
models (Kanno et al., 2001, Johansson et al., 2002, Penno et al., 2007). In a rodent 
model, Kanno and colleagues showed that T2 signal intensity decreased 24 hours 
after iron oxide particle administration in untreated allografts compared to isografts. 
Moreover, signal intensity in rejecting allografts returned to baseline after treatment 
with cyclosporin for seven days. Immunohistochemistry confirmed accumulation of 
iron oxide containing macrophages in areas of graft rejection. Thus there is great 
potential in the translational use of iron oxide particles in the clinical assessment of 
cardiac transplant recipients. 
Chapter 7: Conclusions and Future Directions 
Detection, assessment and modulation of myocardial inflammation 216 
7.3.3.1.2 MYOCARDITIS 
Acute myocarditis comprises a wide clinical spectrum from sub-clinical disease to 
severe heart failure. Its causes include infectious, toxic iatrogenic (often by 
chemotherapeutic agents) and autoimmune conditions although often no cause can be 
identified (Meybohm et al., 2009, Marchant et al., 2012). Currently biopsy is often 
considered the gold standard in diagnosis, although it is prone to sample error and 
clinically indicated in only a few scenarios (Cooper et al., 2007). Although in some 
cases cardiac MRI can reveal a ‘typical’ pattern of myocarditis based on T2 oedema 
imaging, the sensitivity and specificity is unclear and not yet established. The 
diagnostic yield is therefore limited.   
Monocytes and macrophages are intimately involved in myocarditis (Sagar et al., 
2012).  In pre-clinical models of myocarditis, monocytes differentiate into 
macrophages at sites of inflammation and exhibit a T-helper 1 (Th1)-type 
cytokine/chemokine profile suggesting they play an important role in the 
pathogenesis of myocarditis (Baba et al., 2006). Thus, iron oxide particles are ideally 
suited to target cellular inflammation in the myocardium and diagnose the condition 
with greater sensitivity then current techniques. 
7.3.3.1.3 CARDIAC SARCOIDOSIS 
The incidence of sarcoidosis varies: 3 to 20 per 100 000 for white and 35 to 80 per 
100 000 for black individuals (Rybicki and Iannuzzi, 2007). There is cardiac 
involvement in up to 27% of sarcoid cases (Silverman et al., 1978) and complications 
include atrial and ventricular arrhythmias, congestive cardiac failure and sudden 
cardiac death (Silverman et al., 1978, Roberts et al., 1977, Kandolin et al., 2011, 
Banba et al., 2007, Yazaki et al., 2001). The diagnosis is challenging and, although 
histology is the gold standard method, obtaining a tissue biopsy is invasive and 
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subject to sampling error. The role of imaging techniques such as magnetic 
resonance imaging remains ill defined, and there is a need for improved accuracy 
with greater sensitivity and specificity to diagnose the condition and guide 
therapeutic intervention.  
The core inflammatory cells of sarcoid granulomas include monocytes and 
macrophages (Mitchell et al., 1977) and an imaging technique targeting these cells 
would be ideally placed to establish the diagnosis and to assess disease activity. 
 
7.3.3.1.4 HYPOTHESIS 
USPIO-enhanced magnetic resonance imaging can be utilised for the diagnosis and 
characterisation of cardiac conditions associated with myocardial inflammation.  
Primary Objective: To non-invasively image myocardial accumulation of 
ultrasmall superparamagnetic particles of iron oxide (USPIOs) by an increase in R2* 
values (compared to controls) within the myocardium of patients with: 
i. Cardiac transplantation 
ii. Acute myocarditis 
iii. Active cardiac sarcoidosis 
Secondary Objectives:  
i. Does treatment or recovery from these inflammatory myocardial conditions 
reduce or halt uptake of USPIOs as assessed by reduction in R2* values. 
ii. Do systemic inflammatory markers correlate with R2* values  
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iii. Do patients with higher R2* values have worse outcomes assessed by 
deterioration in ejection fraction, increase in medications or increase in late 
gadolinium enhancement. 
7.3.3.1.5 EXPECTED VALUE OF RESULTS 
USPIO enhanced MRI could be used an a diagnostic and/or monitoring tool is the 
clinical care of conditions associated with inflammation of the myocardium. 
 
For further details please refer to 5.1.1.1.1.1.1.1Appendix H:  
 
 
7.3.3.2 DETECTION & MODULATION OF INFLAMMATION IN RENAL TISSUE 
We established that USPIO accumulation occurs in renal tissue post CABG surgery 
and can be assessed with R2* CMR imaging. In the context of pre-clinical studies, it 
can be assumed this represents concentration within macrophages. We also 
confirmed this using transplantation as a model of renal inflammation in Appendix 
G: (page 505). Furthermore, there was reduced USPIO accumulation in patients 
treated with Elafin compared to placebo or healthy volunteers suggesting an anti-
inflammatory treatment effect. However, this was post hoc analysis in a subset of 
patients. Therefore, this finding could be confirmed with clinical studies. 
We have established that on-pump cardiac surgery is associated with a systemic 
inflammatory response. Acute kidney injury (AKI) complicates up to 30 % of 
patients following cardiac surgery (Parolari et al., 2012). AKI associated with cardiac 
surgery is caused by a combination of factors including sympathetic nervous system 
induced vasoconstriction, hypoperfusion, atheroembolism, formation of reactive 
oxygen species and systemic inflammation. All these processes lead to leucocyte 
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recruitment and renal infiltration by neutrophils, macrophages and lymphocytes 
(O'Neal et al., 2016). 
The role of monocytes and macrophages in chronic renal allograft damage has been 
well established (Magil, 2009). Monocytes and macrophages are known to play a 
role in chronic renal allograft damage (Dang et al., 2012), and are key promotors of 
fibrosis in other organs, such as the liver (Duffield et al., 2005, Ramachandran et al., 
2012). 
7.3.3.2.1 HYPOTHESIS 
Using USPIO enhanced MRI, renal inflammation can be; 
A.  i) Assessed post cardiac surgery and correlated to markers of renal injury such 
as plasm and urinary NGAL. 
ii) Modulated by Elafin administration with complete HNE inhibition in the first 
24 hours post cardiac surgery 
B. Assessed in chronic renal allograft rejection and correlated to biopsy specimens. 
7.3.3.2.2 EXPECTED VALUE OF RESULTS 
USPIO enhanced MRI could be used an a diagnostic and/or monitoring tool is the 
clinical care of conditions associated with inflammation of renal tissues. 
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7.3.4 PROPOSED CONTINUATION OF RESEARCH IN CHAPTER 6 
We established that there are 2 peaks of troponin release post cardiac surgery at 6 
hours and 24 hours post skin incision. Using late gadolinium enhancement and ECG 
assessment, we showed a troponin peak at 24 hour indicated myocardial infarction. A 
peak at 6 hours was due to cardiac injury associated with cardiac surgery. This 
finding needs to be confirmed in a larger registry of patients undergoing cardiac 
surgery. 
7.3.4.1 HYPOTHESIS 
A rising troponin at 24 hours post cardiac troponin is caused my myocardial 
infarction independent of cardiac injury associated with cardiac surgery and confers 
an adverse prognosis. Such myocardial infarction can be treated with dual anti-
platelet therapy. 
Primary Objective: To measure plasma troponin concentrations at 6 hours and 24 
hours post cardiac surgery. Patients will be divided into 2 cohorts: 
i) Troponin peak within 24 hours from cardiac surgery 
ii) Troponin peak after 24 hours from cardiac surgery 
The cohorts will be followed up long-term for the incidence of fatal and non-fatal 
myocardial infarction, stroke, hospital admission for heart failure and all cause death.  
Secondary Objectives: If there are adverse outcomes for patients with a late 
troponin peak, a study can be set-up in which patients are randomised to dual anti-
platelet therapy or standard care. The primary end-point would be the incidence of 
fatal and non-fatal myocardial infarction, stroke, hospital admission for heart failure 
Chapter 7: Conclusions and Future Directions 
Detection, assessment and modulation of myocardial inflammation 221 
and all cause death. Gastro-intestinal haemorrhage and haemorrhagic stroke would 
be safety end-points. 
 
7.3.4.2 EXPECTED VALUE OF RESULTS 
By using troponin to identifying patients with an adverse prognosis post cardiac 
surgery, the diagnostic methodology of a type 5 myocardial infarction could be 
established. Such patients can then be better treated to improve clinical outcomes. 
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ABSTRACT 
Neutrophils and neutrophil-derived elastases play a major role in the regulation of 
vascular injury and inflammation, such as ischemia-reperfusion injury. Elafin is an 
endogenous inhibitor of neutrophil-derived elastases with numerous anti-
inflammatory functions that include modulation of inflammatory cytokine release as 
well as innate and adaptive immunity. It is produced by epithelial tissues including 
the skin and respiratory system that have adapted to respond to the microbial and 
chemical insults that lead to inflammation. The production of peptides like elafin 
with multi-faceted anti-inflammatory activity is an important part of this adaptation. 
Although not directly expressed within the cardiovascular system itself, pre-clinical 
studies have suggested therapeutic benefit of elafin in cardiovascular disease. 
The aim of this review is to highlight the role of neutrophil-derived elastases in 
vascular inflammation and injury. We will discuss the beneficial effects of elafin 
inhibition of neutrophil elastase and its extended anti-inflammatory activity in pre-
clinical models of inflammatory vascular injury.  
 
1. INTRODUCTION 
1.1 Neutrophil-derived elastases and vascular inflammation 
Extracellular matrix turnover  
Neutrophils lead the early phase of the inflammatory response gathering at sites of 
inflammation, and transmigrating through the endothelium to release granule 
contents and generate oxygen-derived free radicals that serve the host defence by 
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providing microbicidal activity. Human neutrophil elastase (HNE) and proteinase-3 
are amongst the contents of neutrophil azurophilc granules (Borregaard and 
Cowland, 1997). These enzymes degrade components of the extracellular matrix and 
the list of substrates for HNE is extensive  (Lee and Downey, 2001) including fibrin, 
fibronectin, collagen, the glycoprotein IIb/IIIa receptor (Si-Tahar et al., 1997), elastin 
and cadherins (Carden et al., 1998).  Figure 1 illustrates the effects of HNE and 
proteinase 3 within the vasculature. 
HNE’s action on extracellular matrix components exposes recognition sites that bind 
cellular integrin and tyrosine kinase receptors. These signals direct the cellular 
response to injury. Recognition of elastin-derived fragments by the elastin receptor 
results in migration and chemotaxis of monocytes and vascular smooth muscle cells 
(Robert et al., 1998, Houghton et al., 2006).  
Endothelial cells are susceptible to detachment when cultured with activated 
neutrophils or HNE (Westlin and Gimbrone Jr, 1993). Anchorage of cells to the 
extracellular matrix is necessary for survival and cleavage of matrix components and 
cadherins responsible for adhesion results in apoptosis (Frisch and Francis, 1994, 
Mtairag et al., 2002). HNE is joined by the matrix metalloproteinase (MMP) and the 
cathepsin family of proteases in modulating endothelial extracellular matrix 
degradation during acute inflammation (Garcia-Touchard et al., 2005). There is 
considerable overlap of substrates between these protease families leading to 
apparent redundancy. HNE is distinct in having both a broad range of substrates and 
the ability to be released rapidly and in high concentration from neutrophil granules 
at sites of inflammation. By contrast, many of the extracellular MMP and cathepsin 
proteases are regulated by gene expression and MMPs are activated in a cascade of 
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proteolytic steps (Chakraborti et al., 2003). HNE also modulates the activity of 
vascular extracellular proteases. It directly activates MMPs and inactivates their 
inhibitors (tissue inhibitors of metalloproteases: TIMPs) (Okada and Nakanishi, 
1989, Okada et al., 1988). A complex interplay between extracellular proteases that 
share common substrates occurs during inflammatory endothelial injury. HNE’s 
broad ranging activity and modulating activity over other proteolytic pathways 
suggest a central role at the onset of the proteolytic cascade in pathologies where 
neurophil degranulation is present. HNE has a central role alongside MMPs and 
cysteine proteases in atherosclerotic aneurysm development. Thrombus is present 
over the surface of larger aneurysms providing an active interface for neutrophil 
recruitment and activation. The thrombus from abdominal aortic aneurysms is rich in 
HNE particularly within the luminal compartment This contributes to aneurysm 
growth by preventing in-growth of smooth muscle cells and re-colonisation by 
circulating progenitors (Fontaine et al., 2004). Thrombus is continuously turning 
over and together with neutrophil recruitment provides a supply of HNE, plasmin 
and activated MMPs. These proteases permeate to the abluminal side of the thrombus 
to contribute to expansive arterial wall modelling 
 
1.2 Modulation of thrombosis and fibrinolysis 
The capacity of HNE to degrade components of the coagulation and fibrinolytic 
pathways has been demonstrated in vitro. Cleavage of plasminogen activator 
inhibitor type -1 (PAI-1) shortens clot lysis time in vitro (Wu et al., 1995). 
Plasminogen is degraded to miniplasminogen by HNE. This plasminogen fragment is 
more readily activated and the resulting miniplasmin retains fibrinolytic activity but 
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may be relatively resistant to inhibition by -2 antiplasmin (Duboscq et al., 1997). 
More recently, the role of neutrophil-derived elastases in thrombus formation has 
been demonstrated in knockout mice (Massberg et al., 2010). Compared to wild type 
mice the animals deficient in neutrophil elastase had markedly reduced fibrin 
formation in response to chemical injury on intravital videomicroscopy. The 
mechanism involved proteolytic inactivation of an endogenous anticoagulant, tissue 
factor pathway inhibitor (TFPI). TFPI and neutophil elastase were observed to co-
localise on the external surface of neutrophils in nucleosomes facilitating TFPI 
degradation. The formation and externalisation of nucleosomes is increased by 
neutrophil interaction with activated platelets. The combination of human neutrophils 
and platelets generates pro-coagulant activity measured by the production of active 
factor X and this was markedly reduced in the presence of HNE inhibitors (Massberg 
et al., 2010). These observations point to a hitherto unappreciated role for neutrophils 
and HNE in triggering coagulation and stabilising thrombus formation. Massberg et 
al suggested an innate immunity role for neutrophil elastase generated thrombosis 
promoting retention of invading pathogens within liver microvessels (Massberg et 
al., 2010). This work demonstrated the capability of neutrophils to promote thrombus 
formation in larger vessels in the absence of infection. The circulating neutrophil 
count is associated with clinical events including myocardial infarction (Madjid et 
al., 2004). Neutrophils from patients with acute coronary syndromes exhibit evidence 
of activation and degranulation (Buffon et al., 2002).  Together these finding suggest 
a more direct pro-thrombotic role for neutrophils in coronary disease. 
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1.3 Regulation of inflammatory signalling  
HNE and proteinase-3 modulate cytokine signaling. HNE and Proteinase-3 can 
proteolytically activate or process the inflammatory cytokines TNF-, IL-1, IL-8 
and IL-18 (Carroll et al., 2005, Coeshott et al., 1999, Padrines et al., 1994, Sugawara 
et al., 2001).  HNE is capable of degrading IL-1 and TNF- possibly acting as a 
negative regulator of inflammation. Chemerin is a chemoattractant protein that 
promotes recruitment of antigen presenting cells such as macrophages and dendritic 
cells (Wittamer et al., 2003). HNE activates chemerin from prochemerin by 
proteolytically cleaving its C-terminal peptide. This provides one mechanism 
whereby initial infiltration of neutrophils may orchestrate subsequent antigen 
presenting cell recruitment at inflammatory sites (Wittamer et al., 2005).  
HNE mediated cleavage of the CD14 receptor on monocytes and fibroblasts reduces 
responsiveness and TNF- production in response to LPS (Nemoto et al., 2000) as 
well as impairing recognition and clearance of apoptotic cells by phagocytosis 
(Vandivier et al., 2002). HNE mediated cleavage of the complement receptor 1 from 
the surface of erythrocytes generates a fragment that acts as an inhibitor of 
complement (Sadallah et al., 1999).  These findings indicate divergent effects on 
inflammatory signalling and may reflect changing roles for neutrophil derived 
elastases depending on variables such as local concentration, stage of inflammation 
and signalling context. 
HNE stimulates production of the neutrophil chemokine IL-8 and augments 
endothelial cell production of IL-8 in response to other stimuli such as 
lipopolysaccharide (Henriksen et al., 2004b). The observation that HNE stimulates 
cytokine production from a variety of cell types has raised the possibility of receptor 
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interaction.  Devaney et al demonstrated that HNE up-regulation of IL-8 mRNA and 
protein was dependent on expression of the toll-like receptor 4 in a kidney cell line 
(Devaney et al., 2003). HNE and proteinase-3 also activate the protease activated 
receptors (PAR) (Uehara et al., 2003, Uehara et al., 2002) that influence a wide range 
of physiological responses including platelet activation, intimal hyperplasia and the 
maintenance of vascular tone and barrier function (Leger et al., 2006). Activation of 
PAR-1, PAR-2 and PAR-4 stimulates IL-6, IL-8 and prostaglandin E2 release 
(Asokananthan et al., 2002). Selective activation of PAR-1 and PAR-2 by HNE 
results in increased epithelial permeability and transepithelial migration of 
neutrophils. This effect is blocked by PAR antagonists and is not related to cleavage 
of gap junctions (Chin et al., 2008). Recently, HNE has been shown to activate PAR-
2 through cleavage of the N-terminus (Ramachandran et al., 2011). This results in 
selective activation of downstream MAP kinase signaling pathways, and PAR-2 
dependent calcium signaling is silenced. This recent observation of interaction with 
specific cell surface receptors indicates the potential for discriminate signaling by 
HNE. 
 
1.4 Antimicrobial actions of HNE 
Neutrophil elastase deficient mice are susceptible to bacterial and fungal infection.  
(Belaaouaj et al., 2000a, Tkalcevic et al., 2000). HNE has direct antimicrobial action 
against gram-negative bacteria such as Escherichia coli by degrading the bacterium’s 
outer membrane protein A (Belaaouaj et al., 2000a).  Flagella are bacterial 
components with strong pro-inflammatory activity on epithelial and inflammatory 
cells. Degradation of flagellin the structural component of flagella in Pseudomonas 
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aeruginosa by HNE results in loss of this virulence factor’s stimulatory activity 
(Belaaouaj et al., 2000b, Belaaouaj et al., 1998, Hirche et al., 2008). HNE cleaves 
other virulence factors of enterobacteria and has direct antifungal activity against 
Candida albicans and Aspergillus fumigatus  (Reeves et al., 2002, Tkalcevic et al., 
2000). Antimicrobial activity of HNE and proteinase-3 against gram-positive 
bacteria was recently demonstrated with direct in vitro killing activity on 
Streptococcus pneumoniae  (Standish and Weiser, 2009).  
Cathelicidins are antimicrobial peptides that are stored and released from the 
lysosomes of neutrophils.  HNE and proteinase 3 regulate the activity of cathelicidins 
by proteolytic release of the antimicrobial C-terminal fragment (Lehrer and Ganz, 
2002).  Neutrophil derived elastases can therefore affect microbial killing by direct 
and indirect mechanisms. 
 
 
1.5 Neutrophil elastase activity is regulated by endogenous inhibitors 
Neutrophil derived elastases have wide ranging inflammatory effects on a broad 
range of substrates. Endogenous serine protease inhibitors (serpins) block activity by 
complexing with the elastase molecule. α1-antitrypsin (α1-PI) is the major 
circulating serpin produced in the liver with inhibitory activity against HNE. α1-PI is 
present at saturating levels within the circulation providing systemic inhibitory 
activity against HNE. Elafin and secretory leucocyte protease inhibitor (SLPI) are 
serpins produced locally at sites of inflammation by epithelial cells in response to 
inflammatory stimuli such as TNF-α and HNE. The ability to raise this local defence 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 254 
of ‘alarm’ antiproteases illustrates the extent to which epithelial tissues have evolved 
mechanisms to respond to, and contain, neutrophil-mediated inflammation 
(Sallenave, 2000b).  Cardiovascular tissues do not express these alarm antiproteases 
and are more vulnerable to HNE mediated injury as a result. 
 
HNE can evade high local concentrations of inhibitors through a series of 
mechanisms. Large quantities of oxidants and proteases released by leukocytes 
recruited to the site of inflammation can overwhelm and inactivate protease 
inhibitors. Adhesion of neutrophils to the extracellular matrix leads to the 
compartmentalisation of the released proteases between the neutrophil and matrix, 
and this microenvironment excludes the large circulating protease inhibitors such as 
α1-PI (Korkmaz et al., 2005). A large proportion of the serine proteases released 
from azurophil granules bind to the plasma membrane with catalytic activity 
preserved. Owen and colleagues suggested that this tight binding of extracellular 
neutrophil serine proteases to the cell membrane makes them inaccessible, and 
therefore resistant, to circulating, high-molecular-weight, endogenous inhibitors such 
as α1-PI (Owen et al., 1995). Surface bound HNE is inhibited by small molecule 
inhibitors including SLPI suggesting a specific locale for alarm antiproteases to 
control HNE (Owen et al., 1995). This local antiprotease shield is not present within 
the cardiovascular system and strategies to introduce or mimic it will reduce HNE 
mediated tissue injury and inflammation. Sections 2, 3 & 4 will examine the 
therapeutic potential of elafin in diseases characterised by neutrophil mediated 
vascular injury.  
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1.6 Clinical application of biological and synthetic inhibitors of HNE  
Endogenous and synthetic small molecule inhibitors have been developed to combat 
the pro-inflammatory activity of HNE. Clinical studies with elastase inhibitors have 
focussed on inflammatory lung disease. 
SLPI belongs to the same family of four disulphide core proteins as elafin. It shares  
many properties including inhibition of HNE and interference with 
lipopolysaccharide signalling, transcription factor NF-κB activation and TNF-α 
production. Delivery of recombinant SLPI was protective in rat and murine models 
of ischaemia reperfusion injury (Lentsch et al., 1999). A clinical study examining the 
effect of aerosolised SLPI in cystic fibrosis patients demonstrated reduced elastase 
activity, IL-8 and neutrophil levels in treated patients (McElvaney et al., 1992). α1-PI 
is regarded as the major inhibitor of HNE in the lung and intravenous formulations 
derived from human plasma (Prolastin; Talecris Corporation, Aralast; Alpha 
Therapeutic Corporation and Zemaira; CSL Behring) have been trialled in patients 
with α1-antitrypsin deficiency with minimal impact on disease progression 
(Silverman and Sandhaus, 2009). DX-890 (Depelstat; Dyax 
Corporation/Debiopharm) is a potent HNE inhibitor derived from human inter-α-
inhibitor. It may have application as an aerosol elastase inhibitor in the treatment of 
cystic fibrosis.  
Several synthetic neutrophil elastase inhibitors have been developed. Preclinical 
studies have shown promise in demonstrating reduced neutrophil elastase injury and 
inflammation but clinical translation has been frustrated by lack of efficacy and 
concerns over toxicity. Sivelestat (Ono Pharmaceutical) is a low molecular weight 
reversible competitive inhibitor of HNE. In observational studies, administration was  
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associated with reduced mortality in critically ill patients and attenuated pulmonary 
dysfunction in patients with acute respiratory distress syndrome (Hoshi et al., 2005, 
Okayama et al., 2006). In prospective double-blinded controlled trials, it has been 
shown to reduce IL-8 production and reduce acute lung injury after cardiopulmonary 
bypass, and reduce duration of ventilation in intensive care (Ryugo et al., 2006, 
Tamakuma et al., 2004). The only multi-centre double-blind placebo-controlled trial 
of sivelestat failed to show a decrease in mortality or reduced ventilator requirement 
in critically ill patients (Zeiher et al., 2004). ONO-6818 (Ono Pharmaceutical) is a 
non-peptide selective neutrophil elastase inhibitor that reduced IL-8 production and 
complement activation in a simulated cardiac bypass circuit (Yoshimura et al., 2003). 
Clinical studies in patients with lung disease were halted because of liver injury 
associated with the drug. Mr889 is a less potent, reversible and slow-binding 
competitive inhibitor of HNE developed by Medea Research. Clinical evaluation 
demonstrated the drug to be safe but ineffective in modifying biochemical markers of 
lung destruction (Luisetti et al., 1996).                                                                                        
 
 
2.  ELAFIN 
2.1 Elafin is a potent endogenous inhibitor of neutrophil elastase 
Elafin is an endogenous inhibitor of human neutrophil elastase (HNE) and 
proteinase-3 that was first isolated from psoriatic skin and human bronchial 
secretions.(Wiedow et al., 1990, Sallenave and Ryle, 1991b). Cloning of elafin 
cDNA indicates that initial transcription produces a protein of 117 amino acid 
residues, which undergoes intracellular cleavage of an N-terminal hydrophobic 
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signal sequence to produce pro-elafin (Molhuizen et al., 1993, Sallenave and Silva, 
1993, Schalkwijk et al., 1999). The pro-elafin protein is composed of 2 domains: a 
C-terminus consisting of 57 amino acids and an N-terminus consisting of 60 amino 
acids also known as the cementoin domain (Francart et al., 1997, Nara et al., 1994). 
The N-terminus contains VKGQ sequences that provide the substrate for 
transglutaminase, with glutamine and lysine acting as acyl donors and acceptors in 
formation of isopeptide inter-protein cross-links (Nara et al., 1994). 
Transglutaminisation allows elafin to be cross-linked to the extracellular matrix 
where it may persist as a tissue bound inhibitor of HNE. Sumi et al demonstrated 
elafin immunoreactivity within the intima of human coronary arteries in association 
with transglutaminase (Sumi et al., 2002). The C-terminus is responsible for the 
elastase inhibition. It has a four-disulphide core and shows structural similarity with 
the whey acidic protein (WAP) family (Nara et al., 1994, Tsunemi et al., 1996). This 
combination of a transglutaminase substrate area and a WAP/four-disulphide core 
has similarities with other proteins that have been named “trappins” (Schalkwijk et 
al., 1999). Elafin has 40% sequence homology with SLPI and is more specific in its 
spectrum of activity exhibiting potent inhibition of HNE and proteinase-3. It has 
equilibrium dissociation constants for these enzymes of 0.8 x 10-10 M and 1.2 x 10-10 
M respectively (Zani et al., 2004).  
 
2.2  Tissue distribution and regulation of elafin  
Elafin is secreted constitutively by the squamous epithelium of the skin, with 
expression raised in inflammatory skin conditions such as psoriasis (Wiedow et al., 
1990, Nara et al., 1994). It has also been isolated in other epithelia such as sweat 
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glands, hair follicles, tongue, tonsils, gingiva, epiglottis, esophageal lining, the 
vagina, the pharynx (Pfundt et al., 2000), submandibular glands (Lee et al., 2002), 
trachea, stomach, intestine (Nara et al., 1994), and mammaries (Zhang et al., 1995). 
More recently leucocyte expression has been identified within human endometrial 
neutrophils and alveolar macrophages of the respiratory system (King et al., 2003, 
Sallenave et al., 1993). The detection of elafin within human coronary arteries in 
association with atherosclerosis raises the question over whether it has originated 
from infiltrating inflammatory cells or free protein entering from the circulation. 
IL-1 and TNF- together with HNE are major inducers of elafin expression in 
human airway epithelial cells and keratinocytes (Sallenave et al., 1994, Pfundt et al., 
2000). Regulation by these inflammatory cytokines highlights the role elafin may 
play in the early orchestration of the inflammatory response as an ‘alarm’ 
antiprotease secreted by local cells.  
 
3  Extended anti-inflammatory roles of elafin 
3.3 Inhibition of inflammatory cytokine production 
Our group demonstrated attenuated inflammatory cytokine production by human 
endothelial cells and macrophages following elafin overexpression using adenoviral 
vectors (Henriksen et al., 2004b). Endothelial cell IL-8 production was reduced in 
response to bacterial lipopolysaccharide (LPS), TNF-α and oxidised low-density 
lipoprotein, a key inflammatory stimulus and driver of atherosclerotic plaque 
development. Overexpression in monocyte-differentiated human macrophages 
reduced TNF-α production in response to low concentrations of LPS (Henriksen et 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 259 
al., 2004b). SLPI has similar properties reducing TNF-α and matrix metalloprotease 
production in response to LPS (Jin et al., 1997, Zhu et al., 1999).  An intracellular 
mechanism was suggested by the finding that transfection of a non-secreted form of 
SLPI but not addition of recombinant SLPI to cultured macrophages suppresses the 
response to LPS (Zhu et al., 1999). In search of an intracellular target, we and others 
have identified the transcription factor NF-κB. NF-κB upregulates many 
inflammatory genes associated with the inflammatory response including IL-8 and 
TNF-α. Overexpression or incubation of elafin and SLPI with monocytes reduces 
LPS responsiveness (Butler et al., 2006, Henriksen et al., 2004b). This effect is seen 
in association with reduced proteolytic degradation of NF-κB’s inhibitory subunits 
IκBα and IκBα suggesting an action by elafin and SLPI on the unbiquitin-
proteosome pathway. 
 
3.4 Innate and adaptive immunity functions 
Elafin forms part of the complex antimicrobial defence screen on mucosal and 
epithelial surfaces. Elafin has direct antimicrobial activity against Staphlylococcus 
aureus and Pseudomonas aeruginosa (Simpson et al., 1999). It is possible the 
positive charge of elafin allows it to disrupt the anionic membrane of bacteria 
directly and this mechanism has been proposed for other cationic antimicrobial 
peptides. The interaction of elafin with LPS is complex. When preincubated together, 
the elafin-LPS complex increases cytokine production from inflammatory cells 
suggesting that elafin is priming the innate immune response (McMichael et al., 
2005). This facilitates recognition of bacterial invasion on epithelial surfaces where 
concentrations of elafin are high allowing complexes to form prior to signalling. This 
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contrasts with the inhibitory effects of elafin on LPS signalling described above and 
the reduced production of TNF-α in response to systemic LPS administration 
observed in elafin expressing mice (Sallenave et al., 2003). Cleavage of the surface 
receptor CD14 by HNE impedes apoptotic cell recognition and tethering by 
macrophages. Our group demonstrated that adenoviral overexpression of elafin in 
human macrophages prevents CD14 cleavage and preserved apoptotic cell tethering 
(Henriksen et al., 2004a). This rescues these cells from an HNE induced pro-
inflammatory to anti-inflammatory phenotype favouring apoptotic cell recognition 
and clearance (Savill et al., 2002). 
Elafin favours the development of a Th1-type immune response. Overexpression in 
transgenic mice or delivery using adenoviral vectors was associated with increased 
numbers and activation of antigen presenting dendritic cells (Roghanian et al., 2006). 
Cytokine and antibody analysis from pulmonary cells, serum and bronchial washings 
suggested that immunity was biased toward a type 1 response with production of IL-
12, IFN-γ and IgG2a antibody. Clinically, this finding is supported by high 
concentrations of elafin in bronchoalveolar lavage from farmer’s lung and psoriatic 
skin (Tremblay et al., 1996, Schalkwijk et al., 1993).  Both conditions are 
characterised by a vigorous type-1 immune response. 
 
4. NEUTROPHIL MEDIATED CARDIOVASCULAR INJURY: THE 
ROLE OF HNE AND THERAPEUTIC POTENTIAL OF ELAFIN 
The earlier sections outlined the pro-inflammatory actions of HNE that serve to 
initiate and sustain inflammatory tissue injury. Elafin is a potent endogenous 
inhibitor of HNE with multifaceted anti-inflammatory roles. Production of elafin in 
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response to inflammatory injury represents a mechanism whereby epithelial tissues 
have evolved to contain and repair neutrophil-mediated injury. The following 
sections will outline the prominent role of neutrophils and HNE in cardiovascular 
pathologies including myocardial infarction and arterial inflammation. We will 
discuss the substantial evidence from pre-clinical studies (summarised in table 1) 
indicating a therapeutic role for elafin in models of vascular injury.  
 
4.1 Neutrophil-mediated ischemia-reperfusion injury 
The role of the neutrophil in myocardial-reperfusion injury following myocardial 
infarction has been reviewed by Hansen and Jordan et al (Jordan et al., 1999, 
Hansen, 1995). Cardiomyocyte injury is exacerbated following reperfusion and 
neutrophils are pivotal mediators determining post-ischemic inflammatory 
reperfusion injury. Neutrophils accumulate within the reperfused myocardium 
releasing HNE and reactive oxygen species that further effect microvascular and 
myocardial injury. Preclinical studies have demonstrated that neutrophil depletion or 
inhibition of neutrophil elastase attenuates post-ischemic inflammatory reperfusion 
injury within the myocardium (Romson et al., 1983a, Tiefenbacher et al., 1997).   
 
Plasma HNE and myeloperoxidase concentrations increase following myocardial 
infarction providing evidence of neutrophil activation (Dinerman and Mehta, 1990, 
Mocatta et al., 2007). Neutrophils are activated by a vast array of mediators released 
from endothelial cells, mast cells and myocytes within the myocardium following 
ischemia. The complement fragment C5a, IL-8 and platelet activating factor act as 
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chemoattractants and stimulate adherence to the endothelium. TNF-α released from 
mast cells and IL-6 from ischemic cardiomyocytes further stimulate neutrophil 
superoxide production, transendothelial migration and degranulation (Richter et al., 
1990).  
 
Coronary occlusion without reperfusion is associated with ischemia and restricted 
infiltration of neutrophils into the border area of the infarcted zone over 24 hours 
(Reimer et al., 1989). The goal of therapy in acute myocardial infarction is timely 
restoration of perfusion and whereas this reduces infarct size, it is associated with 
accelerated accumulation of neutrophils within the reperfused myocardium (Dreyer 
et al., 1991, Zhao et al., 2001). Neutrophil adhesion to the endothelium occurs within 
minutes of reperfusion (Sheridan et al., 1996, Murohara et al., 1994). Release of 
proteases and reactive oxygen species cause cardiomyocyte necrosis. Neutrophils 
also occlude microvessels and cause changes in endothelial permeability that 
contribute to myocardial edema (Engler et al., 1983). Capillary plugging and 
obstruction by activated neutrophils contributes to failure of microvascular perfusion 
and increased infarct size within the “no-reflow” zone. Neutrophil depletion reduced 
this phenomenon and infarct size in a pre-clinical model (Litt et al., 1989). 
Neutrophil mediated inflammation generates production of further chemokines and 
adhesion molecule expression that amplify inflammatory cell recruitment. The goal 
of therapy is both to reduce neutrophil-mediated injury and to break the vicious cycle 
of further neutrophil recruitment. 
Administration or over-expression of elafin was associated with reduced infarct size 
and neutrophil infiltration in several models of ischemia-reperfusion injury. 
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Tiefenbacher et al investigated cardiac reperfusion injury in a rat model inducing 
repeated ischemia and reperfusion with ligation of the left coronary artery 
(Tiefenbacher et al., 1997). The animal received a bolus of recombinant elafin by tail 
vein injection prior to ischemia. Myocardial function measured by systolic fractional 
thickening was better in animals receiving elafin or a synthetic elastase inhibitor. 
Systolic fractional thickening of the myocardium measured by pulsed Doppler was 
reduced by 50% in the controls compared to 22% in elafin treated animals. Mice 
expressing human elafin under the control of the preproendothelin promoter exhibit 
better cardiac function compared to littermates following myocardial infarction. Left 
ventricular dimensions in diastole were significantly increased in the wild-type mice 
(mean 4.75 mm) compared to sham operated mice (mean 3.95 mm).  Elafin 
expressing mice had some increase in cavity size (mean 4.30 mm) which was not 
significantly different from sham operated mice. Elafin expressing mice had reduced 
infarct expansion and less scar thinning. The increases in myocardial tissue elastase 
and matrix metalloprotease activity following infarction were effectively suppressed 
in elafin transgenic animals compared to wild type littermates (Ohta et al., 2004b). 
Tissue myeloperoxidase content can be used as a measure of neutrophil infiltration. 
In the rat myocardial infarction model myeloperoxidase levels increased 14-fold in 
control animals compared to only a 3-fold rise in elafin treated animals 
(Tiefenbacher et al., 1997). Similar reductions in neutrophil infiltration were 
observed in the elafin transgenic mice and following elafin administration prior to 
arterial ligation in a rodent limb ischemia model (Crinnion et al., 1994). In the latter 
study, elafin attenuated the acceleration in neutrophil infiltration (myeloperoxidase 
content) following reperfusion and was associated with reduced myocyte necrosis.  
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Elafin administration or overexpression was consistently associated with reduced 
myocyte death and preserved function following ischemia and reperfusion across 
different models.  The reduction in neutrophil infiltration suggests that elafin 
interrupts the positive feedback loop signaling further neutrophil recruitment during 
reperfusion. This may be through combined direct inhibitory action on HNE and 
proteinase 3 mediated tissue injury and suppression of the potent neutrophil 
chemokine IL-8. 
 
4.2 Neutrophil elastase-mediated inflammation of the vessel wall  
Endothelial function is compromised by neutrophil-mediated injury. Loss of 
permeability barrier leads to edema and hemorrhage and loss of antithrombotic 
activity is conducive to platelet adhesion and fibrin deposition. These effects 
manifest in diverse diseases that share neutrophil-mediated injury including the adult 
respiratory distress syndrome, vasculitides and disseminated intravascular 
coagulation. Activated endothelial cells release platelet activating factor and IL-8 
facilitating paracrine activation and degranulation of neutrophils. HNE stimulates IL-
8 production directly and augments endothelial cell production in response to other 
stimuli such as lipopolysaccharide (Henriksen et al., 2004b). HNE activation of 
endothelial PAR receptors (described above) may signal thrombus formation and 
neutrophil adhesion through mobilisation and secretion of Weibel-Palade bodies, 
which harbor vWF multimers and the P-selectin adhesion molecule (Hattori et al., 
1989).  
The neutrophil is not a prevalent cell type within atherosclerotic plaque. Nevertheless 
an expanding body of evidence implicates neutrophils and HNE in the development 
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of arterial wall inflammation. Macrophage and endothelial cell localisation of HNE 
mRNA was identified by in situ hybridisation within human atheroma (Dollery et al., 
2003). HNE colocalised with macrophages at the plaque shoulder. This region is 
characterised by a paucity of smooth muscle cells and is prone to rupture through 
mechanisms involving excess proteolytic activity. This work demonstrated HNE 
production by human endothelial cells and peripheral blood-derived monocytes 
suggesting the intriguing possibility that these cell types may contribute directly to 
elastase activity within the arterial wall. Neutrophils are activated in patients the 
acute coronary syndromes (Buffon et al., 2002) and are observed infiltrating ruptured 
plaques and areas of endothelial erosion responsible for thrombosis in human 
coronary specimens (Naruko et al., 2002).  It is possible that HNE is assimilated into 
the plaque from degranulating neutrophils. The phenomenon of neutrophil-derived 
proteins accumulating in the subendothelial space of atheromatous vessels has been 
demonstrated for myeloperoxidase which is taken up by endothelial cells through 
transcytosis (Baldus et al., 2003, Daugherty et al., 1994). 
Rabinovitch’s group have demonstrated that augmentation of elafin by delivery of 
recombinant protein or overexpression using transgenic mice or vectors has 
therapeutic benefit in models of inflammatory vessel wall injury(Zaidi et al., 2000b). 
Neutrophil recruitment and elastase activity increase within the arterial wall 
following balloon angioplasty (Barolet et al., 2001, Okamoto et al., 2001). Two 
episodes of balloon angioplasty 3 weeks apart were used in a double injury model in 
rabbit carotid arteries (Barolet et al., 2001). There was an 8-fold increase in elastase 
activity peaking 1 week after the second balloon injury. The elastase activity was 
associated with a 25 kDa protein that was inhibited by elafin suggesting neutrophil 
elastase. Using a liposome vector, human elafin cDNA was transfected into the 
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carotid arteries following the second balloon injury. Elafin transgene expression was 
evident at 48 hours and suppressed the rise in elastase activity by 90% compared with 
controls. This was associated with reduced restenosis and a 43% reduction in intimal 
cross-sectional area in elafin-transfected arteries. Wire induced carotid injury in 
transgenic mice expressing elafin produced similar findings (Zaidi et al., 2000b). 
Elafin transgenic animals exhibited almost complete suppression of elastase activity 
in response to wire injury. Wild-type mice had a doubling in the cross sectional 
arterial medial area at 10 days. This was taken as a measure of restenosis and reflects 
matrix deposition, cellular migration and proliferation. There was no significant 
difference in the medial area between non-injured wild-type and injured elafin 
transgenic mice. These changes were seen in association with reduced neutrophil 
infiltration and lower deposition of the matrix protein tenascin-C. Tenascin-C signals 
vascular smooth muscle cell proliferation (Jones et al., 1997), a key feature of arterial 
restenosis following angioplasty. Venous grafts are used as conduits in coronary 
bypass surgery. They are susceptible to rapid atherosclerotic degeneration and this 
was modelled in the rabbit with an interposition jugular venous graft inserted into the 
carotid artery (O'Blenes et al., 2000). Liposomal transfection of elafin cDNA resulted 
in reduced elastase activity, neutrophil infiltration within the graft and a 50% 
reduction in neointimal formation compared to mock transfected control grafts. This 
model was used to study the effects of elafin on chronic atherosclerotic plaque 
development. Following 3 months of high cholesterol feed, the rabbit interposition 
venous grafts developed marked intimal plaque with high lipid and macrophage 
content. The plaque size was reduced in elafin-transfected grafts by 40% and lipid 
content was reduced by 50%. 
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These findings indicate a prominent role for neutrophil elastase in acute arterial 
inflammation.  Overexpression of human elafin cDNA in the arterial wall (rodents do 
not produce elafin) was associated with a reduction in elastase activity, neutrophil 
infiltration and injury response in the form of restenosis in response to mechanical 
injury. The observation that elafin overexpression reduced atherosclerotic plaque 
development in a chronic model of hyperlipidemic rabbits raises the possibility that 
additional anti-inflammatory actions of elafin may be at work reducing inflammatory 
cytokine production. 
 
 
 
5. THERAPEUTIC APPLICATION OF ELAFIN IN CARDIOVASCULAR 
DISEASE 
Elafin augmentation protects the cardiovascular system from a range of diseases 
characterized by neutrophil-mediated inflammation (Figure 2). Elafin provides the 
endothelium and myocardium with protection against the damaging effects of 
neutrophil-derived elastases. This suggests that intravenous elafin administration or 
gene overexpression can provide inhibition by reaching elastase enzyme that is not 
suppressed by the high circulating concentrations of larger molecular weight elastase 
inhibitors. Elafin attenuates disease progression in chronic injury models including 
atherosclerosis and pulmonary hypertension (Zaidi et al., 2002b) and provides 
survival benefit in a murine model of viral myocarditis (Zaidi et al., 1999). The 
neutrophil does not have a prominent role in these pathologies indicating alternative 
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mechanisms for elafin’s effect beyond inhibition of elastase through suppressing NF-
κB activation or modulating the adaptive immune response. Recombinant elafin has 
very low toxicity with short plasma and activity half-lives. It is possible to maintain 
circulating activity with intravenous infusion and this approach is used routinely with 
antithrombotic drugs in acute coronary syndrome patients. Translating the efficacy of 
elafin in pre-clinical models to diseases, such as acute myocardial infarction, will 
depend on achieving adequate concentrations of active protein at the site of tissue 
injury. In most pre-clinical models, elafin is delivered before or at the point of 
vascular injury. This advantageous position is not generally feasible in the clinic. The 
complexities of human disease over animal models have seen many promising 
therapies for ischemia reperfusion fail at translation (Bolli et al., 2004). The EMPIRE 
study (Elafin Myocardial Protection from Ischaemia Reperfusion: EudraCT no. 
2010-019527-58) will recapitulate some of the conditions of pre-clinical studies to 
demonstrate whether elafin can attenuate myocardial ischemia-reperfusion injury and 
inflammation in patients undergoing coronary bypass surgery. Patients will receive 
an elafin infusion prior to going onto cardiopulmonary bypass and the effects on 
myocardial injury will be quantified by troponin release within the first 48 h after 
surgery and infarct volume measured with cardiac magnetic resonance scanning. 
Post-operative inflammatory cytokine response will also be examined. This study 
aims to provide proof-of-principle for elafin’s therapeutic potential in cardiovascular 
disease. 
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Elafin inhibits destructive and inflammatory neutrophil derived proteases. Beyond 
this elafin inhibits inflammatory cytokines and modulates the innate and adaptive 
immune systems. Elafin is expressed within epithelial tissues that have evolved 
mechanisms to adapt and repair from neutrophil mediated injury.  Elafin 
administration in preclinical studies of inflammatory vascular injury limits tissue 
destruction and preserves organ function. As such it may provide a therapeutic option 
in the clinical setting. The EMPIRE trial is currently underway to investigate this. 
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LEGEND 
 
Graphical Abstract: Pre-clinical studies indicate the therapeutic potential of the 
human neutrophil elastase inhibitor “elafin” in inflammatory cardiovascular 
pathology 
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Figure 1: Actions of neutrophil-derived elastases: Human neutrophil elastase 
and proteinase 3 
Activated neutrophils release HNE and proteinase 3 leading to endothelial disruption 
and extracellular matrix degradation. These processes contribute to aneurysm 
development and disruption of vulnerable atherosclerotic plaques. HNE and 
proteinase-3 modulate the activity of TNF-, IL-1, IL-8 and IL-18 by proteolytic 
cleavage. HNE activation of protease activated receptors (PAR) activation may 
contribute to changes in endothelial permeability and migration of neutrophils. HNE 
stimulates production of IL-8 production from endothelial cells and induces IL-6 
release from necrotic myocardium. HNE cleavage of the CD14 receptor on 
macrophages impedes resolution of inflammation by preventing recognition and 
clearance of apoptotic cells. HNE also promotes thrombosis by inactivating tissue 
factor pathway inhibitor. 
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Figure 2: Cardiovascular effects of Elafin 
Elafin administration or gene overexpression has demonstrated beneficial effects in a 
series of vascular injury models. Clockwise from top-right these are arterial injury 
and balloon angioplasty, myocarditis, myocardial ischaemia and infarction, 
pulmonary hypertension and vein graft degeneration.  Elafin treatment is associated 
with consistent findings of reduced elastase activity, tissue injury and inflammatory 
cell infiltration in these models. 
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Abstract 
Magnetic Resonance Imaging (MRI) has become a primary tool for non-invasive 
assessment of cardiovascular anatomy, pathology and function. Existing contrast 
agents have been utilised for the identification of infarction, fibrosis, perfusion 
deficits and for angiography. Novel USPIO contrast agents that are taken up by 
inflammatory cells can detect cellular inflammation non-invasively using MRI, 
potentially aiding the diagnosis of inflammatory medical conditions, guiding their 
treatment and giving insight into their pathophysiology. In this review we describe 
the utilization of ultrasmall superparamagnetic particles of iron oxide as a novel 
contrast agent in vascular disease. 
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Introduction 
Inflammation is central to many cardiovascular pathophysiological processes 
including atherosclerosis, myocardial infarction and heart failure. Macrophages are 
key mediators of these inflammatory pathways, initiating both destructive and 
reparative processes (Nahrendorf et al., 2010). Quantification and characterization of 
tissue macrophage activity may therefore assist in our understanding of the 
pathogenesis of cardiovascular disease and help determine disease severity and 
prognosis, as well as providing a biomarker to assess the efficacy of established or 
novel therapeutic interventions. 
Magnetic resonance imaging (MRI) is a well-established clinical imaging modality 
offering excellent soft tissue contrast and spatial resolution, whilst avoiding ionizing 
radiation. Standard gadolinium-based contrast agents are paramagnetic and are 
infused into the blood pool with variable organ extraction rates, although subsequent 
extravasation and redistribution can be used to identify the interstitial and 
extracellular spaces. Gadolinium is commonly used as an MRI contrast agent after 
acute myocardial infarction (MI) to identify areas of tissue infarction and fibrosis 
(Lima et al., 1995, Schelbert et al., 2010). Tissue oedema and rupture of cell 
membranes with consequent diffusion of gadolinium into the inter- and intra-cellular 
spaces (Lima et al., 1995) results in a “delayed gadolinium enhancement” effect in 
infarcted regions. Recent interest has turned to novel agents that provide additional 
structural and functional cellular information. Such ‘smart’ contrast agents include 
iron oxide nanoparticles. 
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Iron Oxide Nano-Particles 
 
Particles of iron oxide are divided into classes based on their size (Table 1). In this 
review, we will focus on ultrasmall superparamagnetic particles of iron oxide 
(USPIOs) that consist of nanoparticles with a diameter of <50 nm and include 
ferumoxtran-10 (Sinerem, Guerbet) and ferumoxytol (Rienso, Takeda; Feraheme, 
AMAG Pharmaceuticals). Although Rienso had been authorised for use in European 
Union, Takeda since has withdrawn it. However Feraheme is clinically available in 
the United States for the treatment of iron deficiency anemia in adult patients with 
chronic kidney disease (CKD). 
Ferumoxytol is well tolerated by patients with chronic kidney disease and iron 
deficiency anaemia, and had a similar overall treatment-related adverse event rate to 
oral iron (Spinowitz et al., 2008). This safety data is further supported by additional 
retrospective observational data from three large haemodialysis clinics in the United 
States involving more than 8,600 patients and more than 33,300 administered doses 
of ferumoxytol (Schiller et al., 2011, Sharma et al., 2011). The only contraindications 
to use are known hypersensitivity or iron overload. Therefore there is little to limit 
widespread clinical use as an imaging agent. 
USPIOs can be used as a blood pool contrast agent but it is their ability to be taken 
up by inflammatory cells that has distinguished them (Christen et al., 2013). Cellular 
uptake of USPIOs occurs through a variety of mechanisms. Phagocytosis and 
receptor-mediated endocytosis are important for uptake of larger particles, whilst 
smaller particles are internalized by pinocytosis. Although the avidity of macrophage 
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uptake is strongly influenced by particle size and charge, the surface coating is 
particularly important (Saito et al., 2012, Tsuchiya et al., 2013). As a result of their 
smaller size, USPIOs are less readily recognized by phagocytic cells and persist in 
the circulation for longer than other iron particles (plasma half-life 14-30 h in 
humans) (Landry et al., 2005, Hunt et al., 2005). They are capable of passing through 
capillary walls, to be taken up by tissue-resident macrophages and neutrophils 
(Figure 1) (Ruehm et al., 2001b, Dousset et al., 1999, Gellissen et al., 1999a). These 
characteristics allow USPIOs to detect and highlight cellular inflammation within 
tissues using MRI. 
 
Imaging Methodology 
USPIOs induce local magnetic field inhomogeneities that shorten T2 and T2* 
relaxations times resulting in a signal deficit on magnetic resonance images. USPIOs 
also have a T1 shortening effect, particularly at low concentrations, and appear bright 
on T1 weighted images.  The T1 shortening effect mainly depends on the strength of 
the magnetic field, and is higher in lower field strength. 
A range of approaches have been used to evaluate USPIO accumulation in tissues. 
Most simply, images may be qualitatively assessed for signal deficits. However this 
approach is subjective, and signal deficits due to calcification or other artefacts may 
be misinterpreted.  Manually drawn regions of interest have been used to allow 
comparison of signal intensity of the target tissue with that of control tissue although 
discrete focal areas of USPIO accumulation, and thus focal inflammation, may be 
missed. 
Tissue properties, such as the presence of oedema or haemorrhage, can alter image 
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intensities on T2* sequences, and so pre- and post-contrast images need to be 
compared to delineate the impact of USPIO accumulation. This requires accurate co-
registration of these paired scans and adjustments for differences in baseline 
intensity. A specific region of interest (ROI) map can be drawn and subsequently 
transferred to each subsequent co-registered image, thus ensuring the signal intensity 
can be compared for identical sample regions in different scans from the same 
patient. 
 
Rather than assessing focal image brightness at a single echo time, the T2* time 
constant can be calculated from the exponential decay curve using multiple echo 
times (Figure 2). This method provides greater reproducibility, broad applicability 
throughout the field of view, and independence from T1 effects and a range of 
imaging variables. In the presence of USPIO, the T2* relaxation rate is increased 
thus giving a lower T2* value, or higher R2* value (R2* is the inverse of T2*, R2* = 
1/T2*). Calculation of these values permits the generation of T2* or R2* maps 
indicative of USPIO accumulation (Figure 3).  
 
Various authors have used different techniques to calculate USPIO uptake in tissues, 
and have reported results using T2, T2* or R2*. This can cause confusion since 
higher values infer diminished USPIO uptake in T2/T2* weighted images, but higher 
uptake in R2* maps. For the purposes of this paper, imaging techniques will be 
described but results reported in terms of “increased USPIO uptake.” In order to 
account for native R2* values, various authors have used the delta increase in R2* 
value from successive scans, or factor increase. When pre-USPIO scans have not 
been performed, it must be assumed that non-inflamed tissue has similar R2* values 
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to pre-USPIO native R2* values.  
Finally, it must be noted that USPIO imaging can be affected by artefact. USPIO also 
shorten T1, and so cause signal enhancement of T1 weighted imaging (Small et al., 
1993). However, at high concentration USPIO can cause signal loss with such 
imaging limiting its use with T1 weighted sequences (Fananapazir et al., 2014). The 
superparamagnetic nature of the particles means that they generate strong local 
magnetic field inhomogeneities, and it is this magnetic susceptibility that is being 
imaged by MRI. However this can cause loss of distinction of anatomical borders 
and distort normal tissues (“blooming artefact”). USPIO will accumulate in the 
reticulo-endothelial system including the liver and spleen. This accumulation can 
affect neighbouring structures, and care must be taken not mistake blooming artefact 
for USPIO uptake. 
 
Cardiovascular Applications 
Atherosclerotic Plaque 
Given the central role of macrophage biology in the pathogenesis of atherosclerosis, 
USPIOs have an obvious application in the investigation of atherosclerotic disease. 
In pre-clinical studies, uptake of USPIOs is demonstrable within numerous 
atherosclerotic models including aortic plaques of hyperlipidemic rabbits (Schmitz et 
al., 2000, Schmitz et al., 2002) and mice (Sigovan et al., 2010) as well as the 
neointimal hyperplasia following balloon injury (Ruehm et al., 2001b, Hyafil et al., 
2006), and is proportional to plaque macrophage content. 
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Modulation of inflammation within atherosclerotic plaques can be assessed by 
USPIO imaging (Morris et al., 2008). P38 Mitogen-activated protein kinase (MAPK) 
is an inflammatory signalling pathway activated by angiotensin II in various vascular 
cell types (Herlaar and Brown, 1999, Ju et al., 2002). Angiotensin II infusion leads to 
macrophage accumulation and UPSIO uptake in atherosclerotic plaques of mice 
(Morris et al., 2008, Brasier et al., 2002) that can be inhibited by co-administration of 
a p38 MAPK pathway inhibitor. Interestingly, this effect was predominantly 
manifested by a reduction in USPIO uptake by macrophages rather than a reduction 
in macrophage numbers, suggesting an effect on macrophage activity rather than 
recruitment. In contrast, the angiotensin II type 1 receptor antagonist, irbesartan, 
decreased both USPIO uptake and macrophage content in the apolipoprotein E 
deficient mouse model (Sigovan et al., 2012).  
USPIO uptake occurs in human carotid atherosclerotic plaques and appears to 
correlate with the number of iron-laden macrophages on histology (Trivedi et al., 
2006a). Consistent with the inflammatory cell infiltrate associated with vulnerable 
plaques, 75% of ruptured or rupture-prone lesions show USPIO uptake compared to 
only 7% of apparently stable lesions. Determining the overall macrophage burden is 
challenging because of  a number of factors. There is a curvilinear relationship 
between area of signal intensity reduction and USPIO concentration.  Signal intensity 
is also dependent on density of particle accumulation, and a heterogeneous 
population of macrophages would be expected to have differing degrees of USPIO 
uptake. The amount of USPIO infused, and by extrapolation perfusion of target 
tissue, will also determine the magnitude of MRI changes (Lutz et al., 2005). 
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USPIO uptake and inflammation does not correlate with plaque volume or the degree 
of luminal stenosis (Tang et al., 2008b), and as already stated USPIO maybe useful 
in investigating USPIO activity in contrast to concentration (Brasier et al., 2002). 
This raises the possibility of using USPIO uptake to monitor disease activity in 
carotid stenosis rather than using conventional anatomical measurements. For 
instance, statins reduce inflammation within atherosclerotic plaques as well as 
systemic markers of inflammation (Ridker et al., 2001, Tahara et al., 2006) and this 
has been assessed using USPIO uptake. The ATHEROMA study (Atorvastatin 
THerapy: Effects on Reduction Of Macrophage Activity) compared the effect of 
high-dose (80 mg daily) versus low-dose (10 mg daily) atorvastatin on plaque 
inflammation (Tang et al., 2009). Patients underwent UPSIO-enhanced MRI at 
baseline, 6 weeks and 12 weeks of therapy. Although there were no differences in 
USPIO uptake over the course of the study in the low-dose group, there was a 
reduction in USPIO uptake in the high-dose group at both 6 and 12 weeks. This 
correlated with a reduction in LDL cholesterol and a reduction in micro-emboli count 
on trans-cranial Doppler (Patterson et al., 2011).  
 
Abdominal Aortic Aneurysms 
Macrophages are intimately involved in the development, expansion and ultimately 
rupture of abdominal aortic aneurysms. Preliminary evidence of USPIO uptake in 
human abdominal aortic aneurysms (AAA) has been described (Sadat et al., 2011, 
Howarth et al., 2007). In a pilot study, we demonstrated that just under half of 
patients with AAA had focal mural uptake of USPIOs. The aneurysm expansion rate 
was three-fold higher in patients with USPIO uptake in the aneurysm wall (0.66 
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versus 0.22 cm/year) (Richards et al., 2011a). Histology of tissue excised at the time 
of elective surgical repair confirmed co-localization of USPIOs with CD68 
immunostaining for macrophages. Thus USPIO-enhanced MRI appears to identify 
those patients with more rapid disease progression requiring earlier preventative 
surgical or endovascular intervention to prevent rupture. 
 
 
Cerebrovascular Disease 
Stroke results from an acute disruption to the cerebral blood supply leading to tissue 
ischemia and eventually necrosis. Inflammatory cells are recruited to the infarct 
zone, but may extend the injury by interacting with “at risk” cells in the penumbra of 
the infarct (Braun et al., 1996, del Zoppo et al., 2000). In a murine model of middle 
cerebral artery occlusion, USPIO uptake is detected in this penumbra region of 
infarction (Rausch et al., 2001a, Wiart et al., 2007). By 7 days the USPIO is confined 
to the infarct itself, and histology confirms a large population of iron-containing 
macrophages in the infarcted tissue consistent with migration of macrophages from 
the penumbra. Further work has indicated that in the setting of established stroke, 
USPIO leaks through the injured blood-brain barrier accounting for the initial 
accumulation at the periphery of the infarct and intravascular trapping rather than 
macrophage uptake (Desestret et al., 2009). In addition there is widespread uptake 
resulting from leakage of USPIO into the cerebro-spinal fluid with delivery of 
nanoparticals to more remote areas. Thus the application of USPIO in such settings is 
limited although it is possible to track focal USPIO uptake associated with 
macrophage/microglial infiltration 6 days after cerebral ischaemia, identifying a 
subacute pathological process (Yang et al., 2014, Yang et al., 2013). 
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Clinical studies have utilized ferumoxtran-10 in patients 4-5 days after stroke, with 
imaging at 24-36 hours and repeated 48-72 hours later (Saleh et al., 2004). T1- and 
T2/T2*-weighted imaging reveals parenchymal enhancement that increases between 
the 2 scans, corresponding to the expected macrophage distribution. These USPIO 
induced changes do not correspond to conventional gadolinium-enhanced changes, 
suggesting they occurred independently of blood-brain-barrier breakdown. It could 
be speculated that these changes may have been due to differences in blood pooling 
effects due to perfusion changes rather than USPIO inflammatory cell uptake. It 
would be expected that ischemic volume would correlate with inflammatory burden 
and MRI changes if USPIOs were being taken up by inflammatory cells. 
Nighoghossian et al found no such correlation six days after stroke (Nighoghossian 
et al., 2007) although the study had a number of limitations including imperfect 
timing of the scans and the completion of only 5 patients using the more sensitive 
T2* imaging protocol. 
Despite these limitations, a pre-clinical model of the investigation of anti-
inflammatory medication in the treatment of stroke has major potential (Marinescu et 
al., 2013). Using a murine model, the anti-inflammatory agent minocycline can be 
evaluated after middle cerebral artery occlusion (Marinescu et al., 2013). 
Minocycline treatment reduced USPIO uptake within the infarct, and was associated 
with reductions in infarct size, blood-brain barrier permeability and 
microglia/macrophage counts. 
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Future Applications 
The application of USPIOs to study myocardial inflammation has translational 
application where the pathology involves substantial monocyte influx into the plaque 
or tissue (Alam et al., 2012c) (Table 2).  
 
Targeted Iron Oxide Particles 
Conjugating iron oxide particles with antibodies allows targeted imaging. Pre-
clinical imaging to date has employed 9.4 Tesla MRI. This would be more sensitive 
in detecting USPIO than clinical MRI systems (1.5 or 3-tesla). In addition, injected 
unconjugated USPIOs injected directly into the blood stream concentrate within 
macrophages resulting in high local distribution. It remains to be seen if antibody-
labelled USPIOs will be sufficiently concentrated at their target site to allow 
detection in clinical MRI systems. Specific subsets of monocytes or other cell types 
could be tracked with successful application of this method. This would allow 
delineation of the temporal dynamics of cellular and immunological processes by 
repeated scanning. This has been demonstrated in a pre-clinical model of cerebral 
ischaemia using USPIOs grafted with a specific peptide targeting vascular cellular 
adhesion molecule-1 (VCAM-1) . This study indicated the potential of VCAM-1 to 
assess vascular injury. 
 E-selectin is an adhesion molecule between the endothelium and leukocytes that 
plays a critical role in the pathogenesis of inflammation (Kansas, 1996).  An E-
selectin monoclonal antibody-USPIO conjugate has been used to track vascular 
inflammation in a murine model of contact hypersensitivity (Reynolds et al., 2006). 
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More recently, USPIOs have been conjugated with a scavenger receptor to identify 
inflammation in atherosclerotic plaques (Segers et al., 2013). 
Another potential confounding factor is that macrophages of different subsets or with 
different activation status take up USPIO at different rates.  This could result in false 
positive or negative MRI enhancement. Direct labeling of cells with USPIO would 
avoid this error but published data are limited. Although directly labeling of 
macrophages with USPIO and delivery through the carotid artery has been successful 
in producing T2* hypo-enhancement after transient ischaemia, it is associated with 
increased mortality in a rat model (Riou et al., 2013). 
 
USPIO cell labelling and monitoring cell trafficking  
The ability to track cells non-invasively in vivo would be a valuable technique with a 
number of potential applications that include inflammatory cell tracking and 
evaluation of engraftment of cells administered as part of cell-based therapies. 
USPIOs can be used to label cells in vitro for subsequent in vivo tracking. Smooth 
muscle cells labelled with iron nanoparticles can be imaged when directly injected 
into either healthy or infarcted myocardium in a pre-clinical model (Riviere et al., 
2005).  This technique can be utilized to label human aortic smooth muscle cells 
incorporated into tissue engineered vascular grafts and implanted into mice (Nelson 
et al., 2008). We have also demonstrated that cell tracking can be achieved in vivo in 
humans using similar approaches with the larger SPIOs (Richards et al., 2012b) 
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Summary 
USPIOs are taken up by macrophages, and can be identified in vivo by MRI 
scanning. T2 and T2*-weighted scanning provide a sensitive method of assessing 
USPIO accumulation.  
USPIO-enhanced magnetic resonance imaging is a promising method for assessing 
inflammatory processes associated with a range of cardiovascular diseases including 
those affecting the atherosclerotic plaque and large arteries. Potential clinical 
applications are under evaluation and include assessing the effects of novel 
pharmacological agents and in vivo cell tracking to determine the fate of cells 
administered as part of cell therapy. 
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ABBREVIATIONS 
 
CABG  - Coronary Artery Bypass Grafting 
FDG-PET - Fluorodeoxyglucose-Positron Emission Tomography 
MAPK  - Mitogen-activated protein kinase 
MCP-1 - Monocyte Chemotactic Protein-1  
MI  - Myocardial Infarction 
MRI  - Magnetic Resonance Imaging 
RAS  - Renin-Angiotensin System  
ROI  - Region of Interest 
SPIO   -  Super-paramagnetic Iron Oxide  
TNF-  -  Tumour Necrosis Factor Alpha 
USPIO  - Ultrasmall Super-paramagnetic Iron Oxide 
VCAM-1 - Vascular cell adhesion molecule 1 
  
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 301 
Acknowledgements 
The authors are supported by grants from the British Heart Foundation (RE/08/001 
and FS/12/83), Medical Research Council (G1001339), National Institute for Health 
Research (EME 11/20/03), Chest Heart and Stroke Scotland (R11/A135) and Chief 
Scientist Office (ETM/266). DEN is supported by the British Heart Foundation 
(CH/09/002). PAH is supported by NHS Research Scotland Fellowship. 
 
Conflict of Interest Disclosures 
None. 
 
Contributions 
 
SA conceived and wrote the review paper. GT provided figure 1, SS provided figure 
2. CA, JR, SM,PH and DN reviewed and edited the paper. All authors read and 
approved the manuscript. 
 
  
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 302 
References 
 
1. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct 
inflammation and repair after myocardial infarction. Circulation. 2010; 121(22): 
2437. 
2. Lima JA, Judd RM, Bazille A, Schulman SP, Atalar E, Zerhouni EA. 
Regional heterogeneity of human myocardial infarcts demonstrated by contrast-
enhanced MRI. Potential mechanisms. Circulation. 1995; 92(5): 1117-25. 
3. Schelbert EB, Hsu LY, Anderson SA, Mohanty BD, Karim SM, Kellman P, 
et al. Late gadolinium-enhancement cardiac magnetic resonance identifies 
postinfarction myocardial fibrosis and the border zone at the near cellular level in ex 
vivo rat heart. Circ Cardiovasc Imaging. 2010; 3(6): 743-52. 
4. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo 
MV, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc 
Nephrol. 2008; 19(8): 1599-605. 
5. Schiller B, Bhat P, Sharma A, Li Z, Fortin G, McLaughlin J, et al. Safety of 
Feraheme¬Æ(Ferumoxytol) in hemodialysis patients at 3 dialysis chains over a 1-
year period. J Am Soc Nephrol. 2011; 22: 477A-8A. 
6. Sharma A, Bhat P, Schiller B, Fortin G, McLaughlin J, Li Z, et al. Efficacy of 
Feraheme¬Æ(Ferumoxytol) administration on target hemoglobin levels and other 
iron parameters across 3 dialysis chains. J Am Soc Nephrol. 2011; 22: 485A. 
7. Christen T, Ni W, Qiu D, Schmiedeskamp H, Bammer R, Moseley M, et al. 
High-resolution cerebral blood volume imaging in humans using the blood pool 
contrast agent ferumoxytol. Magnetic Resonance in Medicine. 2013; 70(3): 705-10. 
8. Saito S, Tsugeno M, Koto D, Mori Y, Yoshioka Y, Nohara S, et al. Impact of 
surface coating and particle size on the uptake of small and ultrasmall 
superparamagnetic iron oxide nanoparticles by macrophages. Int J Nanomedicine. 
2012; 7: 5415-21. 
9. Tsuchiya K, Nitta N, Sonoda A, Otani H, Takahashi M, Murata K, et al. 
Atherosclerotic imaging using 4 types of superparamagnetic iron oxides: new 
possibilities for mannan-coated particles. Eur J Radiol. 2013; 82(11): 1919-25. 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 303 
10. Landry R, Jacobs PM, Davis R, Shenouda M, Bolton WK. Pharmacokinetic 
study of ferumoxytol: a new iron replacement therapy in normal subjects and 
hemodialysis patients. Am J Nephrol. 2005; 25(4): 400-10. 
11. Hunt MA, Bago AG, Neuwelt EA. Single-dose contrast agent for 
intraoperative MR imaging of intrinsic brain tumors by using ferumoxtran-10. AJNR 
Am J Neuroradiol. 2005; 26(5): 1084-8. 
12. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance 
imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron 
oxide in hyperlipidemic rabbits. Circulation. 2001; 103(3): 415-22. 
13. Dousset V, Delalande C, Ballarino L, Quesson B, Seilhan D, Coussemacq M, 
et al. In vivo macrophage activity imaging in the central nervous system detected by 
magnetic resonance. Magnetic resonance in medicine. 1999; 41(2): 329-33. 
14. Gellissen J, Axmann C, Prescher A, Bohndorf K, Lodemann KP. Extra- and 
intracellular accumulation of ultrasmall superparamagnetic iron oxides (USPIO) in 
experimentally induced abscesses of the peripheral soft tissues and their effects on 
magnetic resonance imaging. Magn Reson Imaging. 1999; 17(4): 557-67. 
15. Small WC, Nelson RC, Bernardino ME. Dual contrast enhancement of both 
T1- and T2-weighted sequences using ultrasmall superparamagnetic iron oxide. 
Magn Reson Imaging. 1993; 11(5): 645-54. 
16. Fananapazir G, Marin D, Suhocki PV, Kim CY, Bashir MR. Vascular artifact 
mimicking thrombosis on MR imaging using ferumoxytol as a contrast agent in 
abdominal vascular assessment. J Vasc Interv Radiol. 2014; 25(6): 969-76. 
17. Schmitz SA, Coupland SE, Gust R, Winterhalter S, Wagner S, Kresse M, et 
al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in 
Watanabe hereditable hyperlipidemic rabbits. Invest Radiol. 2000; 35(8): 460-71. 
18. Schmitz SA, Taupitz M, Wagner S, Coupland SE, Gust R, Nikolova A, et al. 
Iron-oxide-enhanced magnetic resonance imaging of atherosclerotic plaques: 
postmortem analysis of accuracy, inter-observer agreement, and pitfalls. Invest 
Radiol. 2002; 37(7): 405-11. 
19. Sigovan M, Bessaad A, Alsaid H, Lancelot E, Corot C, Neyran B, et al. 
Assessment of age modulated vascular inflammation in ApoE-/- mice by USPIO-
enhanced magnetic resonance imaging. Invest Radiol. 2010; 45(11): 702-7. 
20. Hyafil F, Laissy JP, Mazighi M, Tchetche D, Louedec L, Adle-Biassette H, et 
al. Ferumoxtran-10-enhanced MRI of the hypercholesterolemic rabbit aorta: 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 304 
relationship between signal loss and macrophage infiltration. Arterioscler Thromb 
Vasc Biol. 2006; 26(1): 176-81. 
21. Morris JB, Olzinski AR, Bernard RE, Aravindhan K, Mirabile RC, Boyce R, 
et al. p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide 
uptake in a mouse model of atherosclerosis: MRI assessment. Arterioscler Thromb 
Vasc Biol. 2008; 28(2): 265-71. 
22. Herlaar E, Brown Z. p38 MAPK signalling cascades in inflammatory disease. 
Mol Med Today. 1999; 5(10): 439-47. 
23. Ju H, Nerurkar S, Sauermelch CF, Olzinski AR, Mirabile R, Zimmerman D, 
et al. Sustained activation of p38 mitogen-activated protein kinase contributes to the 
vascular response to injury. J Pharmacol Exp Ther. 2002; 301(1): 15-20. 
24. Brasier AR, Recinos A, 3rd, Eledrisi MS. Vascular inflammation and the 
renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002; 22(8): 1257-66. 
25. Sigovan M, Kaye E, Lancelot E, Corot C, Provost N, Majd Z, et al. Anti-
Inflammatory Drug Evaluation in ApoE-/- Mice by Ultrasmall Superparamagnetic 
Iron Oxide-Enhanced Magnetic Resonance Imaging. Invest Radiol. 2012; 47(9): 546-
52. 
26. Trivedi RA, Mallawarachi C, JM UK-I, Graves MJ, Horsley J, Goddard MJ, 
et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR 
imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol. 2006; 26(7): 
1601-6. 
27. Lutz AM, Weishaupt D, Persohn E, Goepfert K, Froehlich J, Sasse B, et al. 
Imaging of macrophages in soft-tissue infection in rats: relationship between 
ultrasmall superparamagnetic iron oxide dose and MR signal characteristics. 
Radiology. 2005; 234(3): 765-75. 
28. Tang TY, Howarth SP, Miller SR, Graves MJ, JM UK-I, Li ZY, et al. 
Correlation of carotid atheromatous plaque inflammation using USPIO-enhanced 
MR imaging with degree of luminal stenosis. Stroke. 2008; 39(7): 2144-7. 
29. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. 
Measurement of C-reactive protein for the targeting of statin therapy in the primary 
prevention of acute coronary events. N Engl J Med. 2001; 344(26): 1959-65. 
30. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. 
Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose 
positron emission tomography. J Am Coll Cardiol. 2006; 48(9): 1825-31. 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 305 
31. Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, JM UK-I, et al. 
The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage 
Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced 
magnetic resonance imaging in carotid disease. J Am Coll Cardiol. 2009; 53(22): 
2039-50. 
32. Patterson AJ, Tang TY, Graves MJ, Muller KH, Gillard JH. In vivo carotid 
plaque MRI using quantitative T2* measurements with ultrasmall superparamagnetic 
iron oxide particles: a dose-response study to statin therapy. NMR Biomed. 2011; 
24(1): 89-95. 
33. Sadat U, Taviani V, Patterson AJ, Young VE, Graves MJ, Teng Z, et al. 
Ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging of 
abdominal aortic aneurysms--a feasibility study. Eur J Vasc Endovasc Surg. 2011; 
41(2): 167-74. 
34. Howarth SP, Tang TY, Graves MJ, JM UK-I, Li ZY, Walsh SR, et al. Non-
invasive MR imaging of inflammation in a patient with both asymptomatic carotid 
atheroma and an abdominal aortic aneurysm: a case report. Ann Surg Innov Res. 
2007; 1: 4. 
35. Richards JM, Semple SI, MacGillivray TJ, Gray C, Langrish JP, Williams M, 
et al. Abdominal aortic aneurysm growth predicted by uptake of ultrasmall 
superparamagnetic particles of iron oxide: a pilot study. Circ Cardiovasc Imaging. 
2011; 4(3): 274-81. 
36. Braun JS, Jander S, Schroeter M, Witte OW, Stoll G. Spatiotemporal 
relationship of apoptotic cell death to lymphomonocytic infiltration in 
photochemically induced focal ischemia of the rat cerebral cortex. Acta Neuropathol. 
1996; 92(3): 255-63. 
37. del Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X, Feuerstein GZ. 
Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS 
in brain response to ischemia. Brain Pathol. 2000; 10(1): 95-112. 
38. Rausch M, Sauter A, Frohlich J, Neubacher U, Radu EW, Rudin M. Dynamic 
patterns of USPIO enhancement can be observed in macrophages after ischemic 
brain damage. Magn Reson Med. 2001; 46(5): 1018-22. 
39. Wiart M, Davoust N, Pialat JB, Desestret V, Moucharrafie S, Cho TH, et al. 
MRI monitoring of neuroinflammation in mouse focal ischemia. Stroke. 2007; 38(1): 
131-7. 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 306 
40. Desestret V, Brisset JC, Moucharrafie S, Devillard E, Nataf S, Honnorat J, et 
al. Early-stage investigations of ultrasmall superparamagnetic iron oxide-induced 
signal change after permanent middle cerebral artery occlusion in mice. Stroke. 
2009; 40(5): 1834-41. 
41. Yang YM, Feng X, Yin le K, Li CC, Jia J, Du ZG. Comparison of USPIO-
enhanced MRI and Gd-DTPA enhancement during the subacute stage of focal 
cerebral ischemia in rats. Acta radiologica. 2014; 55(7): 864-73. 
42. Yang YM, Feng XY, Yin le K, Li CC, Li AN, Jia J, et al. In vivo USPIO-
enhanced MR signal characteristics of secondary degeneration in the ipsilateral 
substantia nigra after middle cerebral artery occlusion at 3T. J Neuroradiol. 2013; 
40(3): 198-203. 
43. Saleh A, Schroeter M, Jonkmanns C, Hartung HP, Modder U, Jander S. In 
vivo MRI of brain inflammation in human ischaemic stroke. Brain. 2004; 127(Pt 7): 
1670-7. 
44. Nighoghossian N, Wiart M, Cakmak S, Berthezene Y, Derex L, Cho TH, et 
al. Inflammatory response after ischemic stroke: a USPIO-enhanced MRI study in 
patients. Stroke. 2007; 38(2): 303-7. 
45. Marinescu M, Chauveau F, Durand A, Riou A, Cho TH, Dencausse A, et al. 
Monitoring therapeutic effects in experimental stroke by serial USPIO-enhanced 
MRI. European Radiology. 2013; 23(1): 37-47. 
46. Alam SR, Shah AS, Richards J, Lang NN, Barnes G, Joshi N, et al. 
Ultrasmall superparamagnetic particles of iron oxide in patients with acute 
myocardial infarction: early clinical experience. Circ Cardiovasc Imaging. 2012; 
5(5): 559-65. 
47. Kansas GS. Selectins and their ligands: current concepts and controversies. 
Blood. 1996; 88(9): 3259-87. 
48. Reynolds PR, Larkman DJ, Haskard DO, Hajnal JV, Kennea NL, George AJ, 
et al. Detection of vascular expression of E-selectin in vivo with MR imaging. 
Radiology. 2006; 241(2): 469-76. 
49. Segers FM, den Adel B, Bot I, van der Graaf LM, van der Veer EP, Gonzalez 
W, et al. Scavenger receptor-AI-targeted iron oxide nanoparticles for in vivo MRI 
detection of atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2013; 33(8): 
1812-9. 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 307 
50. Riou A, Chauveau F, Cho TH, Marinescu M, Nataf S, Nighoghossian N, et 
al. MRI assessment of the intra-carotid route for macrophage delivery after transient 
cerebral ischemia. NMR in biomedicine. 2013; 26(2): 115-23. 
51. Riviere C, Boudghene FP, Gazeau F, Roger J, Pons JN, Laissy JP, et al. Iron 
oxide nanoparticle-labeled rat smooth muscle cells: cardiac MR imaging for cell 
graft monitoring and quantitation. Radiology. 2005; 235(3): 959-67. 
52. Nelson GN, Roh JD, Mirensky TL, Wang Y, Yi T, Tellides G, et al. Initial 
evaluation of the use of USPIO cell labeling and noninvasive MR monitoring of 
human tissue-engineered vascular grafts in vivo. FASEB J. 2008; 22(11): 3888-95. 
53. Richards JM, Shaw CA, Lang NN, Williams MC, Semple SI, MacGillivray 
TJ, et al. In vivo mononuclear cell tracking using superparamagnetic particles of iron 
oxide: feasibility and safety in humans. Circ Cardiovasc Imaging. 2012; 5(4): 509-
17. 
54. Shapiro EM, Skrtic S, Koretsky AP. Sizing it up: cellular MRI using micron-
sized iron oxide particles. Magnetic Resonance in Medicine. 2005; 53(2): 329-38. 
55. McAteer MA, von Zur Muhlen C, Anthony DC, Sibson NR, Choudhury RP. 
Magnetic resonance imaging of brain inflammation using microparticles of iron 
oxide. Methods Mol Biol. 2011; 680: 103-15. 
56. Yang Y, Yanasak N, Schumacher A, Hu TC. Temporal and noninvasive 
monitoring of inflammatory-cell infiltration to myocardial infarction sites using 
micrometer-sized iron oxide particles. Magn Reson Med. 2010; 63(1): 33-40. 
57. Boutry S, Brunin S, Mahieu I, Laurent S, Vander Elst L, Muller RN. 
Magnetic labeling of non-phagocytic adherent cells with iron oxide nanoparticles: a 
comprehensive study. Contrast media & molecular imaging. 2008; 3(6): 223-32. 
58. Margolis DJ, Hoffman JM, Herfkens RJ, Jeffrey RB, Quon A, Gambhir SS. 
Molecular imaging techniques in body imaging. Radiology. 2007; 245(2): 333-56. 
59. Richards JM, Shaw CA, Lang NN, Williams MC, Semple SI, MacGillivray 
TJ, et al. In Vivo Mononuclear Cell Tracking Using Superparamagnetic Particles of 
Iron OxideClinical Perspective Feasibility and Safety in Humans. Circulation: 
Cardiovascular Imaging. 2012; 5(4): 509-17. 
60. Di Marco M, Sadun C, Port M, Guilbert I, Couvreur P, Dubernet C. 
Physicochemical characterization of ultrasmall superparamagnetic iron oxide 
particles (USPIO) for biomedical application as MRI contrast agents. International 
journal of nanomedicine. 2007; 2(4): 609-22. 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 308 
61. Taupitz M, Wagner S, Schnorr J, Kravec I, Pilgrimm H, Bergmann-Fritsch H, 
et al. Phase I clinical evaluation of citrate-coated monocrystalline very small 
superparamagnetic iron oxide particles as a new contrast medium for magnetic 
resonance imaging. Investigative Radiology. 2004; 39(7): 394-405. 
62. Schnorr J, Taupitz M, Schellenberger EA, Warmuth C, Fahlenkamp UL, 
Wagner S, et al. Cardiac magnetic resonance angiography using blood-pool contrast 
agents: comparison of citrate-coated very small superparamagnetic iron oxide 
particles with gadofosveset trisodium in pigs. Rofo. 2012; 184(2): 105-12. 
63. Wagner M, Wagner S, Schnorr J, Schellenberger E, Kivelitz D, Krug L, et al. 
Coronary MR angiography using citrate-coated very small superparamagnetic iron 
oxide particles as blood-pool contrast agent: initial experience in humans. J Magn 
Reson Imaging. 2011; 34(4): 816-23. 
64. Ludwig A, Poller WC, Westphal K, Minkwitz S, Lattig-Tunnemann G, 
Metzkow S, et al. Rapid binding of electrostatically stabilized iron oxide 
nanoparticles to THP-1 monocytic cells via interaction with glycosaminoglycans. 
Basic Res Cardiol. 2013; 108(2): 328. 
65. Herborn CU, Vogt FM, Lauenstein TC, Dirsch O, Corot C, Robert P, et al. 
Magnetic resonance imaging of experimental atherosclerotic plaque: comparison of 
two ultrasmall superparamagnetic particles of iron oxide. J Magn Reson Imaging. 
2006; 24(2): 388-93. 
66. Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers 
M, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in 
human atherosclerotic plaques can be detected by in vivo magnetic resonance 
imaging. Circulation. 2003; 107(19): 2453-8. 
67. Tang TY, Howarth SP, Miller SR, Graves MJ, JM UK-I, Trivedi RA, et al. 
Comparison of the inflammatory burden of truly asymptomatic carotid atheroma 
with atherosclerotic plaques contralateral to symptomatic carotid stenosis: an ultra 
small superparamagnetic iron oxide enhanced magnetic resonance study. J Neurol 
Neurosurg Psychiatry. 2007; 78(12): 1337-43. 
68. Tang TY, Howarth SP, Miller SR, Graves MJ, JM UK-I, Li ZY, et al. 
Comparison of the inflammatory burden of truly asymptomatic carotid atheroma 
with atherosclerotic plaques in patients with asymptomatic carotid stenosis 
undergoing coronary artery bypass grafting: an ultrasmall superparamagnetic iron 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 309 
oxide enhanced magnetic resonance study. Eur J Vasc Endovasc Surg. 2008; 35(4): 
392-8. 
69. Rausch M, Baumann D, Neubacher U, Rudin M. In-vivo visualization of 
phagocytotic cells in rat brains after transient ischemia by USPIO. NMR Biomed. 
2002; 15(4): 278-83. 
70. Marinescu M, Chauveau F, Durand A, Riou A, Cho TH, Dencausse A, et al. 
Monitoring therapeutic effects in experimental stroke by serial USPIO-enhanced 
MRI. Eur Radiol. 2012. 
71. Krombach GA, Wendland MF, Higgins CB, Saeed M. MR imaging of spatial 
extent of microvascular injury in reperfused ischemically injured rat myocardium: 
value of blood pool ultrasmall superparamagnetic particles of iron oxide. Radiology. 
2002; 225(2): 479-86. 
72. Montet-Abou K, Daire JL, Hyacinthe JN, Jorge-Costa M, Grosdemange K, 
Mach F, et al. In vivo labelling of resting monocytes in the reticuloendothelial 
system with fluorescent iron oxide nanoparticles prior to injury reveals that they are 
mobilized to infarcted myocardium. Eur Heart J. 2010; 31(11): 1410-20. 
73. Kanno S, Wu YJ, Lee PC, Dodd SJ, Williams M, Griffith BP, et al. 
Macrophage accumulation associated with rat cardiac allograft rejection detected by 
magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. 
Circulation. 2001; 104(8): 934-8. 
 
 
  
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 310 
Figures 
Figure 1: Murine blood monocyte in peripheral circulation 48 hours after 
infusion of USPIO. Inlay (bottom right – magnified form black box) 
demonstrates USPIO within lysosome. 
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Figure 2: Theoretical T2* exponential decay curves. The T2* curve can be 
plotted using signal intensities from a region of interest (green crosses) for 
specific echo times (TEs). In this case, a line of best fit is plotted using the 
known equation for T2* decay. A T2* map is created from these derived T2* 
values giving pixel-by-pixel measurements of T2* reported in units of 
milliseconds, rather than signal intensity of raw images. The red curve describes 
the decay from pre-USPIO tissue, and the green curved indicated a faster decay 
due to presence of USPIO. The blue line describes the time constant, T2*.  
 
  
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 312 
Figure 3: Cardiac T2* Imaging. Multiple images obtained from increasing echo 
time points (3 time points shown from the left) can be combined to create a T2* 
map (final image on the right). This map includes the spleen and liver (yellow 
arrows) and the myocardium (white arrow). These tissues are dark indicating 
low T2* values consistent with higher USPIO uptake. 
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Table 1: Iron oxide nanoparticle preparations  
 
Particle Size 
(Diameter) 
Plasma 
Half-life 
(h) 
Application 
Microparticles of 
iron oxide (MPIOs) 
1-6 µm (Shapiro 
et al., 2005a) 
 1-2 min Readily endocytosed and detected with 
MRI.(Shapiro et al., 2005a) Need immediate 
scan following infusion.  
Can be combined with ligands for cellular 
targets allowing molecular imaging 
(McAteer et al., 2011).  
Large size means they remain in the blood 
pool and are suitable for endovascular 
imaging t (Yang et al., 2010).   
Superparamagnetic 
particles of iron 
oxide (SPIOs) 
65-150 nm 
(Boutry et al., 
2008) 
2-3 h Ferumoxide (Endorem, Guerbet, France) 
and ferucarbotran (Resovist, Bayer-
Schering Pharma, Germany).  
Recognised by cells of the 
reticuloendothelial system. Have been used 
for oncological imaging including liver 
studies where they are taken up by Kuppfer 
cells in normal tumour-free liver .(Margolis 
et al., 2007) 
Mesenchymal stem cell, 
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monocyte/macrophage labelling  (Richards 
et al., 2012a).  
Ultrasmall SPIO 
(USPIOs) 
<50 nm (Di 
Marco et al., 
2007) 
Ferumoxytol
: 9-15 h 
Ferumoxtran
-10: 25-30 h 
Ferumoxtran-10 (Sinerem, Guerbet, France) 
and ferumoxytol (Rienso, Takeda, United 
Kingdom).  
Very small 
superparamagnetic 
iron oxide particles 
(VSOPs) 
<10 nm (Taupitz 
et al., 2004) 
 1 h Alternative blood pool agents with longer 
circulating half-life than gadolinium based 
agents (Schnorr et al., 2012, Wagner et al., 
2011).  
Potential as cell tracking agents (Ludwig et 
al., 2013). 
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Table 2: USPIO in cardiovascular disease. 
Target Model & USPIO 
Preparation 
Imaging Findings 
Atherosclerotic 
Plaques 
Ferumoxtran-10 imaging of 
rabbit aorta (Ruehm et al., 
2001b). 
UPSIOs identified within aortic atherosclerotic 
plaques. They are taken up by macrophages. 
Ferumoxtran-10 & 
ferumoxytol in rabbit aorta 
(Herborn et al., 2006).  
Both USPIO preparations could lidentified within 
atherosclerotic inflammation. The peak signal for 
imaging was 2-3 days after ferumoxytol injection, 
compared to 4-5 days with ferumoxtran-10.  
ApoE-/- mice infused with 
angiotensin II, or 
angiotensin II and a p38 
MAPK inhibitor with 
ferumoxtran-10 imaging 
(Morris et al., 2008).   
The angiotensin II treated animals had the greatest 
USPIO uptake corresponding with macrophage 
infiltration. The angiotensin II/p38 MAPK inhibitor 
group had lower USPIO uptake, which was no different 
to untreated controls. Modulation of inflammatory cell 
activity within atherosclerotic plaque could be 
monitored with USPIO contrast. 
ApoE-/- mice treated with 
irbesartan were compared to 
non-treated mice using P904 
USPIO (Sigovan et al., 
2012). in vivo USPIO 
labelled macrophages 
compared to in vitro USPIO 
labelling macrophages.  
Irbesartan treatment resulted in decreased USPIO 
uptake compared to controls, which was associated 
with a significant reduction in macrophage-covered 
area. The use of in vitro labelled macrophages did not 
produce a significant difference in T2* values despite a 
difference in macrophage accumulation at histology. 
Carotid 
Atherosclerosis 
Human carotid plaques 
using ferumoxtran-10 (Kooi 
USPIOs taken up by macrophages could be identified 
in human atherosclerotic plaques. High risk plaques 
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et al., 2003a). took up USPIO more avidly. 
Ferumoxtran-10 uptake 
within carotid plaques of 
patients with symptomatic 
and asymptomatic disease. 
(Tang et al., 2007).  
There was more USPIO signal in “contralateral 
asymptomatic plaques” compared to “truly 
asymptomatic” patients. Patients with stroke disease 
have a higher inflammatory burden within non-culprit 
carotid artery plaques compared with the plaques from 
asymptomatic patients. 
Comparison of carotid 
plaques of patients awaiting 
CABG to asymptomatic 
patients using ferumoxtran-
10 (Tang et al., 2008a).  
Higher USPIO uptake within the CABG group. The 
plaques of the CABG patients exhibited a USPIO 
related signal of  i 16.4% compared to 8.4% in 
asymptomatic patients. Patients awaiting CABG had  
higher inflammatory plaque burden.  
The ATHEROMA study 
(Atorvastatin THerapy: 
Effects on Reduction Of 
Macrophage Activity) to 
investigate the effects of 
high-dose versus low-dose 
statin with ferumoxtran-10 
imaging (Tang et al., 2009, 
Patterson et al., 2011). 
Significant reduction in USPIO uptake in the high-dose 
atorvastatin group at 6 and 12 weeks. This correlated 
with favourable reductions in LDL cholesterol and 
micro-emboli count.  Quantitative T2* values showed a 
highly significant reduction in USPIO-related signal 
over the course of follow-up. Modulation of plaque 
inflammation by statins can be monitored by USPIO 
imaging. 
Stroke Murine model of middle 
cerebral artery occlusion 
using ferumoxtran-10 
(Rausch et al., 2001a).  
48 hours after stroke, USPIO signal identified within 
peri-infarct zone. Histology confirmed a large 
population of iron containing macrophages in the 
infarcted tissue. 
Murine model with 
ferumoxtran-10 and T2-
Disruption of the blood brain barrier leads to leakage of 
USPIO into the CSF, limiting the specificity of 
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weighted imaging with 
multiple scanning points in 
the first 72 hours after stroke 
(Wiart et al., 2007). 
inflammatory cell imaging. 
Spatio-temporal distribution 
of ferumoxtran-10 was 
monitored in a rat model of 
transient cerebral infarction 
using T1- and T2-weighted 
MRI sequences(Rausch et 
al., 2002).  
Maximum USPIO related signal occurred on day 2. 
The technique was successful in achieving non-
invasive imaging of inflammation associated with 
transient ischaemia, but was not sensitive enough to 
identify increased macrophage infiltration at later time 
points.  
Murine model to investigate 
the effects of anti-
inflammatory minocycline 
after middle cerebral artery 
occlusion using P904 
(Marinescu et al., 2012).  
Treatment reduced infarct size, blood-brain barrier 
permeability and microglia/macrophage counts. This 
correlated with decreased R2* value (and USPIO 
uptake) on imaging as well as tissue iron content. 
Ferumoxtran-10 
administered to patients 4-5 
days after suffering a stroke 
with imaging performed 24-
36 hours and 48-72 hours 
later (Saleh et al., 2004). 
T1 weighted imaging revealed parenchymal 
enhancement that increased between the 2 scans, 
corresponding to the expected macrophage distribution. 
T2/T2* weighted imaging revealed increased USPIO 
enhancement between scans, which the authors 
interpreted as blood pool effect. These USPIO induced 
changes did not correspond to conventional gadolinium 
enhanced changes, suggesting they occurred 
independent of blood-brain-barrier breakdown.  
Myocardial 
Infarction 
USPIO agent NC100150 as 
a blood pool agent in a 
Hyperenhancement of the myocardium by UPSIO was 
compared to infarct size. USPIO T1-weighted hyper-
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rodent model of reperfusion 
after MI (Krombach et al., 
2002).  
enhancement was larger than infarction area after 
reperfusion, but smaller than area at risk. UPSIO 
corresponded with micro vascular injury and was 
associated with leakage into the extravascular space. 
Montet-Abou et al studied  
fluorescent iron oxide 
nanoparticles (5-20nm) in a 
rodent MI model (Montet-
Abou et al., 2010).  
 
Rats with a sham operation and those with MI but not 
given USPIO did not have significant change in USPIO 
uptake. The MI group given USPIO had a significant 
increase in USPIO uptake over the 3 days, with 
excellent correlation of monocytes/macrophages on 
histology. CD-68 immuno-staining confirmed co-
localisation of fluorescent USPIO particles within 
macrophages. Rats treated with anti-inflammatory 
medication showed reduced USPIO signal. This 
corresponded with less monocyte/macrophage 
infiltration confirming that USPIO can track 
inflammation and response to therapeutic intervention 
within infarcted myocardium. 
Ferumoxytol in human 
myocardial infarction (Alam 
et al., 2012c).  
USPIO uptake increased significantly in the infarct 
zone and also in the peri-infarct and remote 
myocardium to lesser extents.  
Cardiac 
Transplant 
Synthesised dextran coated 
USPIO to investigate 
macrophage accumulation in 
a rodent cardiac allograft 
rejection model 72,
 
(Kanno et 
al., 2001).  
Control rodents did not have significant USPIO uptake 
at baseline. Allograft rodents exhibited large USPIO 
uptake which was reduced by immunosuppression.. 
Corresponding macrophage counts were greatest in the 
allograft group and reduced by immunosuppressive 
treatment indicating that USPIOs can be used to 
monitor transplant rejection. 
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Appendix C:  USPIO TO DETECT CELLULAR 
INFLAMMATION IN PATIENTS WITH ACUTE 
MYOCARDIAL INFARCTION 
 
CONSENT FORM FOR ACTIVE GROUP (FIGURE 1) 
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Figure 1:  Consent form - Active Group 
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GP INFORMATION  - ACTIVE GROUP (FIGURE 2) 
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Figure 2: GP Letter - Active Group 
  
Ferumoxytol for Magnetic Resonance Imaging of Myocardial Infarction 
GP/Consultant Letter; Version 1.0; 2nd September 2010 
 
  
 
  
 
 
 
 Cardiovascular Research 
 Chancellor’s Building 
 Royal Infirmary of Edinburgh 
 EDINBURGH 
 EH16 4SU 
       
Dr. Name  
Address 
Address 
Post code 
 
Dear Dr 
 
Re:  Patient Name, Address (DOB):  
 
The above named patient has agreed to participate in a clinical research study entitled 
“Ferumoxytol for Magnetic Resonance Imaging of Myocardial Infarction”. I enclose 
a copy of the information sheet. This study is being conducted by Dr Ninian Lang 
(Clinical Lecturer in Cardiology, University of Edinburgh) and Professor David 
Newby (British Heart Foundation Professor in Cardiology, University of Edinburgh). 
 
The inclusion criteria for the study comprise: Presentation with myocardial infarction 
(either ‘ST-elevation’ myocardial infarction or ‘non-ST-elevation’ myocardial 
infarction, troponin I ≥ 10 IU/mL at 12 hours after the onset of chest pain and age 18 
– 80 years inclusive. Exclusion criteria include known critical (≤95%) left main stem 
coronary artery disease, continued symptoms of angina at rest or minimal exertion, 
atrial fibrillation, symptomatic heart failure; Killip Class ≥2, hepatic failure (Childs-
Pugh grade B or C) or renal failure (estimated glomerular filtration rate <25 mL/min). 
Patients with a contraindication to magnetic resonance imaging, a past history of 
systemic iron overload/haemochromatosis and those with known allergy to dextran- 
or iron-containing compounds will also be excluded. 
 
We will notify you of any clinically significant information arising from your 
patient’s participation in this study. Should you require any further information please 
do not hesitate to contact myself or Dr Ninian Lang on telephone number 0131 536 
1000, e-mail ninianlang@gmail.com. 
 
Yours sincerely, 
 
 
Dr Shirjel Alam 
Research Fellow in Cardiology 
Enc. 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 324 
PATIENT INFORMATION – ACTIVE GROUP 
 
 
 
 
FERUMOXYTOL FOR MAGNETIC RESONANCE IMAGING OF MYOCARDIAL 
INFARCTION  
Participant Information Sheet 
 
You are being invited to participate in a clinical research study. Before you decide it 
is important for you to understand why the research is being done and what it will 
involve. Please feel free to discuss it with friends, relatives and your GP if you wish. 
You are welcome to ask us any questions you may have. You may also contact the 
independent advisor for the study, Dr Cruden, who is a doctor in the Cardiology 
Department who is not directly involved in the study. Dr Cruden’s contact details can 
be found at the bottom of this information sheet. Take time to decide whether or not 
you wish to take part. 
This study is being conducted at the Royal Infirmary of Edinburgh by Dr S Alam 
(Research Fellow in Cardiology), Dr. N Lang (Clinical Lecturer in Cardiology) and 
Professor D Newby (Professor of Cardiology). 
Thank you for taking the time to read this information sheet. 
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What is the purpose of the study? 
This study will make use of new heart scanning techniques to look at inflammation 
in the heart after a heart attack. An approved treatment for people with anaemia is to 
give an infusion of microscopic particles of iron called ferumoxytol. However, there 
is also evidence that the tiny particles of iron are taken up by cells involved with 
inflammation and can be seen using magnetic resonance imaging (MRI). We aim to 
perform MRI scans of the heart before and after administering ferumoxytol to assess 
whether this a useful technique to assess the amount of inflammation after a heart 
attack. Using blood tests, we will also examine the amount of inflammation in the 
body as a whole. Another group of patients will undergo MRI scanning of the heart 
after heart attack but will not receive ferumoxytol. This will allow us to compare 
non-specific MRI changes after a heart attack with the changes that are specifically 
highlighted by ferumoxytol. 
 
Why have I been chosen? 
You have been chosen because you have had a heart attack and are recovering well. 
Twelve participants will be recruited for this part of the study. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. You 
are still free to withdraw at any time and without giving a reason. You will not 
benefit directly from this study. However, the information we get from this study 
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may help us to understand and develop new treatments for conditions such as heart 
attacks, heart failure and strokes. 
 
What will happen to me if I take part? 
One to three days after your admission to hospital we will perform an MRI scan of 
your heart. We will also scan the upper part of your abdomen to look for changes in 
the liver and spleen that normally contain a lot of cells involved in inflammation and 
may also take up the ferumoxytol. The MRI scan involves lying on a flat bed and 
passing through the tube-shaped scanner. This scanner does not use x-rays. In order 
for us to look in more detail at the part of the heart that has been affected by the heart 
attack, we will administer an agent called ‘gadolinium’ through a vein before the 
scan. Gadolinium is in routine clinical use. The scan should take about forty-five 
minutes in total. 
Shortly after the scan we will administer the microscopic iron particles, known as 
ferumoxytol (the trade name is Feraheme). Ferumoxytol is approved for use in the 
treatment of anaemia and is safely used at the same dose that we propose to give. It 
has also been used in MRI scanning at this dose but has not been used after heart 
attack in this way. It will be given through a vein in your arm. Your blood pressure, 
heart rhythm, temperature and oxygen levels will be monitored during, and for at 
least one hour after, the infusion. The infusion itself will take less than a minute.  
Twenty-four hours and forty-eight hours after the infusion, you will undergo another 
MRI scan of the heart and upper abdomen. You will also be invited to return for 
another scan at 4 days, 1 week and 1 month after the infusion. However, if you were 
not keen to undergo these further scans (for example due to travel constraints) then 
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we would still be able to include you as a participant to undergo the scans in the first 
48 hours. 
Immediately after each MRI scan and immediately after the infusion of ferumoxytol 
we will take a blood test (25 mL; approx. 2 tablespoonsful). This will be used to 
measure components in the blood that indicate levels of inflammation throughout the 
body. Therefore, over the course of the study we will take a maximum of 
approximately 175 mL blood (less than half the volume that would be given in a 
routine blood donation) and we will perform a maximum of six MRI scans. 
All of the procedures will take place either in the Coronary Care Unit, Cardiology 
Ward, Clinical Research Facility or the Clinical Research Imaging centre at the 
Royal Infirmary of Edinburgh. None of the procedures should interfere with your 
routine care after a heart attack and your date of discharge from the hospital should 
not be affected. 
Any expenses you incur (for example travel expenses) will be reimbursed. 
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Figure 1. Chain of events. There would also be 3 optional MRI scans 96 hours, 1 
week and 1 month after the first can if your are willing to participate 
 
 
 
 
 
 
Figure 2. Line diagram showing process of events during scans 1, 3, 4, 5 and 6. 
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Figure 3. Line diagram showing process of events during scan 2 (ferumoxytol 
infusion) 
 
 
What are the side effects of any treatment received when taking part? 
Taking the amount of blood that we plan should not harm you in any way. Taking 
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pacemakers or a history of eye injury involving metal (such as from shrapnel or 
welding) will not be able to take part. Patients who have had brain surgery with the 
implantation of metalwork will also have to be excluded. MRI scanners do not use x-
rays and therefore are not associated with the risks of radiation associated with other 
imaging methods including CT scans. Other than the risk associated with MRI in 
people with metal implants, there are no known risks from MRI scanning. The MRI 
scanner is noisy, so you will wear special headphones to reduce the noise. 
It is unlikely that this study should cause you any side effects. If you are concerned 
about the way you are feeling at any stage during course of the study you should 
contact Dr Lang or Professor Newby. Dr Lang’s contact details can be found at the 
bottom of this information sheet. Professor Newby can be contacted by telephoning 
the Royal Infirmary of Edinburgh (0131 242 1000). 
 
What are the possible benefits of taking part? 
Taking part in this study will not affect your normal medical care. This study is not 
intended to benefit you personally. It may help us to discover new treatments for 
people who have had a heart attack, stroke or have impaired heart pumping action. 
However, this is just one step in a long series of experiments. 
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What if something abnormal is found in my scans?  
As part of your study we will obtain pictures of your heart. We expect to be able to 
see the area of the heart attack and are interested to see whether the ferumoxytol can 
also be seen there. Our research studies are designed to improve our knowledge of 
the heart after a heart attack.  They are not designed for other purposes.  After your 
scan, a specialist will examine these pictures (this will not be done on the day of your 
study). Other changes either related or unrelated to your heart attack may be seen but 
you should be aware that because our pictures are taken for a specific research 
purpose, not all abnormalities that might be detected by other MRI scans are 
necessarily seen.  On rare occasions, we might find an abnormality that is significant 
and which should be investigated further.  If we find such a significant abnormality 
in your heart, we will contact the Consultant Cardiologist directly involved in your 
ongoing clinical care. Although a significant abnormality is unlikely, you should be 
aware that if such an abnormality is detected and you are informed, then this may 
have consequences for your treatment.  
 
Is there anything else that I may be asked to do? 
If, following you heart attack, you undergo a heart bypass operation we would seek 
your permission to obtain a small biopsy specimen (about 1 mm x 2 mm in size) 
from the heart muscle at the region of the previous heart attack. We would use this to 
compare what the cells and/or ferumoxytol look like under the microscope in 
comparison to the MRI pictures. A Consultant Cardiac Surgeon involved with the 
study would perform this procedure. This procedure has been safely performed 
around the world many times before and is associated with only a small risk of 
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bleeding from the heart muscle but this would be carefully monitored and treated at 
the time of the operation if felt to be necessary. Consent to providing this biopsy 
specimen is not required for participation in the study and you can complete the rest 
of the study in the normal fashion if you do not wish a biopsy to be taken.   
 
 
Will my GP be informed? 
We would like to inform your General Practitioner of your participation in this study. 
We will notify your General Practitioner, and also the Consultant Cardiologist in 
charge of your ongoing care, should any clinically relevant material come to light 
during the study. 
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the treatment being studied. If this happens, your research doctor will 
tell you about it and discuss with you whether you want to continue in the study. If 
you decide to continue in the study you will be asked to sign an updated consent 
form. 
Also, on receiving new information your research doctor might consider it to be in 
your best interests to withdraw you from the study. This will be explained to you. 
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What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, then 
you may have grounds for legal action but you may have to pay for it. 
 
Will my taking part in this study be kept confidential? 
All the information collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital will have 
your name and address removed so that you cannot be recognised from it. 
 
What will happen to the results of the research study? 
We aim to complete this research by 2012. Once we have analysed all of the results, 
we will write a paper that will be submitted for publication in one of the medical 
research journals. You will not be personally identified in any report/publication. If 
you would like a copy of the paper, please contact Dr. Lang at the address below. 
 
Who is organising and funding the research? 
The research is being performed by doctors employed by The University of 
Edinburgh. Your doctors will not be paid for including you in this study. 
Who has reviewed the study? 
The study has been reviewed by the South East Scotland Research Ethics Committee. 
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Where can I obtain further information about the study? 
Further information about the study can be obtained from Dr. Ninian Lang who will 
arrange to meet you. In addition you can discuss the study with Dr. Nicholas Cruden. 
He is another doctor who works in the hospital but is not involved with the study and 
acts an independent advisor. 
 
Thank you once again for taking the time to read this information sheet. 
Contact for further information 
Dr Ninian Lang     Dr Nicholas Cruden 
(Principal Investigator)    (Independent Advisor) 
Lecturer in Cardiology    Consultant Cardiologist 
Cardiovascular Research Unit               Royal Infirmary of Edinburgh 
University of Edinburgh    49  Little France Crescent 
Chancellor’s Building         EDINBURGH  
49 Little France Crescent    EH16 4SU 
EDINBURGH      Tel 0131 242 1000 
EH16 4SB                                      
Tel: 0131 242 1000 
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CONSENT FORM FOR CONTROL GROUP (FIGURE 3) 
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7.4 GP INFORMATION FOR CONTROL GROUP ( FIGURE 4) 
  
Ferumoxytol for Magnetic Resonance Imaging of Myocardial Infarction 
GP/Consultant Letter; Version 1.0; 2nd September 2010 
 
  
 
  
 
 
 
 Cardiovascular Research 
 Chancellor’s Building 
 Royal Infirmary of Edinburgh 
 EDINBURGH 
 EH16 4SU 
Dr. Name  
Address 
Address 
Post code 
 
Dear Dr 
 
Re:  Patient Name, Address (DOB):  
 
The above named patient has agreed to participate in a clinical research study entitled 
“Ferumoxytol for Magnetic Resonance Imaging of Myocardial Infarction”. I enclose 
a copy of the information sheet. This study is being conducted by Dr Ninian Lang 
(Clinical Lecturer in Cardiology, University of Edinburgh) and Professor David 
Newby (British Heart Foundation Professor in Cardiology, University of Edinburgh). 
 
The inclusion criteria for the study comprise: Presentation with myocardial infarction 
(either ‘ST-elevation’ myocardial infarction or ‘non-ST-elevation’ myocardial 
infarction, troponin I ≥ 10 IU/mL at 12 hours after the onset of chest pain and age 18 
– 80 years inclusive. Exclusion criteria include known critical (≤95%) left main stem 
coronary artery disease, continued symptoms of angina at rest or minimal exertion, 
atrial fibrillation, symptomatic heart failure; Killip Class ≥2, hepatic failure (Childs-
Pugh grade B or C) or renal failure (estimated glomerular filtration rate <25 mL/min). 
Patients with a contraindication to magnetic resonance imaging, a past history of 
systemic iron overload/haemochromatosis and those with known allergy to dextran- 
or iron-containing compounds will also be excluded. 
 
We will notify you of any clinically significant information arising from your 
patient’s participation in this study. Should you require any further information please 
do not hesitate to contact myself or Dr Ninian Lang on telephone number 0131 536 
1000, e-mail ninianlang@gmail.com. 
 
Yours sincerely, 
 
 
Dr Shirjel Alam 
Research Fellow in Cardiology 
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PATIENT INFORMATION – CONTROL GROUP 
 
 
 
FERUMOXYTOL FOR MAGNETIC RESONANCE IMAGING OF MYOCARDIAL 
INFARCTION  
Participant Information Sheet 
 
You are being invited to participate in a clinical research study. Before you decide it 
is important for you to understand why the research is being done and what it will 
involve. Please feel free to discuss it with friends, relatives and your GP if you wish. 
You are welcome to ask us any questions you may have. You may also contact the 
independent advisor for the study, Dr Cruden, who is a doctor in the Cardiology 
Department who is not directly involved in the study. Dr Cruden’s contact details can 
be found at the bottom of this information sheet. Take time to decide whether or not 
you wish to take part. 
This study is being conducted at the Royal Infirmary of Edinburgh by Dr S Alam 
(Research Fellow in Cardiology), Dr. N Lang (Clinical Lecturer in Cardiology) and 
Professor D Newby (Professor of Cardiology). 
Thank you for taking the time to read this information sheet. 
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What is the purpose of the study? 
We are conducting a study giving a preparation of microscopic iron particles (called 
ferumoxytol) to patients after a heart attack. We aim to assess whether this will help 
to highlight the inflammation in the heart seen using magnetic resonance imaging 
(MRI).  
 
However, to understand what are specific effects of ferumoxytol and not just the 
effects of the heart attack itself we need to conduct similar scans of patients who 
have had a heart attack but have not been administered ferumoxytol. We will 
compare the scans of patients in the two groups.  
 
Participants in this part of the study will act as a ‘control’ group and will not 
receive ferumoxytol. 
 
Why have I been chosen? 
You have been chosen because you have had a heart attack and are recovering well. 
Six participants will be recruited for this part of the study. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. You 
are still free to withdraw at any time and without giving a reason. You will not 
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benefit directly from this study. However, the information we get from this study 
may help us to understand and develop new treatments for conditions such as heart 
attacks, heart failure and strokes. 
 
 
What will happen to me if I take part? 
One to three days after your admission to hospital we will perform an MRI scan of 
your heart. We will also scan the upper part of your abdomen to look at the liver and 
spleen that normally contain a lot of cells involved in inflammation. The MRI scan 
involves lying on a flat bed and passing through the tube-shaped scanner. This 
scanner does not use x-rays. In order for us to look in more detail at the part of the 
heart that has been affected by the heart attack, we will administer an agent called 
‘gadolinium’ through a vein before the scan. Gadolinium is in routine clinical use. 
The scan should take about forty-five minutes in total. 
Twenty-four hours and forty-eight hours after the first scan, you will undergo another 
MRI scan of the heart and upper abdomen. You will also be invited to return for 
another scan at 4 days, 1 week and 1 month after the first scan. However, if you were 
not keen to undergo these further scans (for example due to travel constraints) then 
we would still be able to include you as a participant to undergo the scans in the first 
48 hours. 
Immediately after each MRI scan we will take a blood test (25 mL; approx. 2 
tablespoonsful). This will be used to measure components in the blood that indicate 
levels of inflammation throughout the body. Therefore, over the course of the study 
we will take a maximum of approximately 150 mL blood (less than half the volume 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 340 
that would be given in a routine blood donation) and we will perform a maximum of 
six MRI scans. 
All of the procedures will take place either in the Coronary Care Unit, Cardiology 
Ward, Clinical Research Facility or the Clinical Research Imaging centre at the 
Royal Infirmary of Edinburgh. None of the procedures should interfere with your 
routine care after a heart attack and your date of discharge from the hospital should 
not be affected. 
Any expenses you incur (for example travel expenses) will be reimbursed. 
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Figure 1. Flow diagram showing chain of events. There would also be 3 optional 
MRI scans 96 hours, 1 week and 1 month after the first can if your are willing to 
participate 
 
 
 
 
 
 
 
 
Figure 2. Line diagram showing process of events during all MRI 
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What are the side effects of any treatment received when taking part? 
Taking the amount of blood that we plan should not harm you in any way. Taking 
blood should not be associated with any more than mild discomfort at the needle site.  
Because MRI scanners use strong magnets, we will complete a detailed safety 
questionnaire before you enroll in the study to check that there is no reason why it 
would be unsafe for you to have a scan. People with metal joint replacements, 
pacemakers or a history of eye injury involving metal (such as from shrapnel or 
welding) will not be able to take part. Patients who have had brain surgery with the 
implantation of metalwork will also have to be excluded. MRI scanners do not use x-
rays and therefore are not associated with the risks of radiation associated with other 
imaging methods including CT scans. Other than the risk associated with MRI in 
people with metal implants, there are no known risks from MRI scanning. The MRI 
scanner is noisy, so you will wear special headphones to reduce the noise. 
People with a history of any condition associated with abnormally high levels of iron 
in the body will not be eligible to take part. 
It is unlikely that this study should cause you any side effects. If you are concerned 
about the way you are feeling at any stage during course of the study you should 
contact Dr Lang or Professor Newby. Dr Lang’s contact details can be found at the 
bottom of this information sheet. Professor Newby can be contacted by telephoning 
the Royal Infirmary of Edinburgh (0131 242 1000). 
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What are the possible benefits of taking part? 
Taking part in this study will not affect your normal medical care. This study is not 
intended to benefit you personally. It may help us to discover new treatments for 
people who have had a heart attack, stroke or have impaired heart pumping action. 
However, this is just one step in a long series of experiments. 
 
What if something abnormal is found in my scans?  
As part of your study we will obtain pictures of your heart, liver and spleen. Our 
research studies are designed to improve our knowledge of the heart after a heart 
attack.  They are not designed for other purposes.  After your scan, a specialist will 
examine these pictures (this will not be done on the day of your study). Other 
changes either related or unrelated to your heart attack may be seen but you should 
be aware that because our pictures are taken for a specific research purpose, not all 
abnormalities that might be detected by other MRI scans are necessarily seen.  On 
rare occasions, we might find an abnormality that is significant and which should be 
investigated further.  If we find such a significant abnormality in your heart, we will 
contact the Consultant Cardiologist directly involved in your ongoing clinical care. 
Although a significant abnormality is unlikely, you should be aware that if such an 
abnormality is detected and you are informed, then this may have consequences for 
your treatment.  
 
Will my GP be informed? 
We would like to inform your General Practitioner of your participation in this study. 
We will notify your General Practitioner, and also the Consultant Cardiologist in 
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charge of your ongoing care, should any clinically relevant material come to light 
during the study. 
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the treatment being studied. If this happens, your research doctor will 
tell you about it and discuss with you whether you want to continue in the study. If 
you decide to continue in the study you will be asked to sign an updated consent 
form. 
Also, on receiving new information your research doctor might consider it to be in 
your best interests to withdraw you from the study. This will be explained to you. 
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, then 
you may have grounds for legal action but you may have to pay for it. 
 
Will my taking part in this study be kept confidential? 
All the information collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital will have 
your name and address removed so that you cannot be recognised from it. 
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What will happen to the results of the research study? 
We aim to complete this research by 2012. Once we have analysed all of the results, 
we will write a paper that will be submitted for publication in one of the medical 
research journals. You will not be personally identified in any report/publication. If 
you would like a copy of the paper, please contact Dr. Lang at the address below. 
Who is organising and funding the research? 
The research is being performed by doctors employed by The University of 
Edinburgh. Your doctors will not be paid for including you in this study. 
 
Who has reviewed the study? 
The study has been reviewed by the South East Scotland Research Ethics Committee. 
 
Where can I obtain further information about the study? 
Further information about the study can be obtained from Dr. Ninian Lang who will 
arrange to meet you. In addition you can discuss the study with Dr. Nicholas Cruden. 
He is another doctor who works in the hospital but is not involved with the study and 
acts an independent advisor. 
Thank you once again for taking the time to read this information sheet. 
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Contact for further information 
Dr Ninian Lang     Dr Nicholas Cruden 
(Principal Investigator)    (Independent Advisor) 
Lecturer in Cardiology    Consultant Cardiologist 
Cardiovascular Research Unit               Royal Infirmary of Edinburgh 
University of Edinburgh    49  Little France Crescent 
Chancellor’s Building         EDINBURGH  
49 Little France Crescent    EH16 4SU 
EDINBURGH      Tel 0131 242 1000 
EH16 4SB                                      
Tel: 0131 242 1000 
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STUDY PROTOCOL 
RESEARCH PROTOCOL 
ASSESSMENT OF FERUMOXYTOL AS A NOVEL CONTRAST AGENT 
FOR MAGNETIC RESONANCE IMAGING OF MYOCARDIAL 
INFARCTION 
 
Cardiovascular disease is the commonest cause of premature death in the United 
Kingdom and accounts for thirty percent of all deaths among men and twenty two 
percent among women. The single largest cause of death is acute myocardial 
infarction.(2004) 
In the context of myocardial infarction, activation of inflammatory cascades is 
maximal and seen as a ripe target for novel therapeutic strategies currently in clinical 
development. The development of a robust, non-invasive imaging method to 
highlight active myocardial inflammation is overdue. Such a technique would not 
only provide valuable clinical information would also be a valuable tool with which 
to assess the therapeutic utility of novel anti-inflammatory cardiac therapies. 
 
The Role of Inflammatory Cells in Myocardial Infarction 
After myocardial infarction, the myocardium subtended by the critically stenotic or 
occluded coronary artery consists of heterogeneous tissue that may recover 
immediately, be stunned or be apoptotic/necrotic. Indeed recruitment of 
inflammatory cells, including mononuclear leucocytes, into the myocardium from 
circulating blood may initiate and maintain processes of inflammation, wound 
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healing and the clearance of cellular debris.(Frantz et al., 2009) These interactions 
are complex and incompletely understood. However, a fine balance appears to exist 
between the benefits afforded by inflammatory mechanisms in wound healing and 
ventricular remodelling versus the potential deleterious effects of uncontrolled 
inflammation including infarct expansion.  
  
Magnetic Resonance Imaging of Myocardial Inflammation 
Magnetic resonance imaging is ideally suited for the serial examination of disease 
progression as it is non-invasive, does not require ionizing radiation and has 
excellent spatial resolution. 
Ferumoxytol (Feraheme, Advanced Magnetics, Inc., Cambridge, MA) was originally 
developed for the treatment of iron-deficiency anaemia in patients with chronic 
kidney disease but it has also gained data supporting its use as a magnetic resonance 
imaging contrast agent. It consists of a suspension of ultrasmall superparamagnetic 
particles of iron oxide (USPIO) with an ultrasmall core (~7 nm) and a semi-synthetic 
carbohydrate coating giving an overall particle size of 30 nm. The size of the particle 
prevents any early redistribution outside the vascular space and therefore it has 
received specific assessment for blood pool imaging where its plasma elimination 
half-life is approximately 10-14 hours in humans. During this period it allows first-
pass and equilibrium phase imaging of the vasculature and causes a marked increase 
in signal-to-noise ratio in T1-weighted MR images. Indeed, it allows a greater 
window of time for imaging than provided by conventional gadolinium-chelates 
which rapidly distribute into the extra-vascular space (Prince et al., 2003). 
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Although their small size allows USPIOs to escape immediate recognition by 
phagocytic cells, clearance of the particles is via phagocytosis by macrophages and, 
therefore, after the initial blood-pool effects have peaked, signal changes 
(particularly on T2- and T2*-weighted imaging) may be observed in the reticulo-
endothelial system. Capitalising on these effects, USPIOs have been used in the 
diagnosis of diseases of the liver, spleen and lymph nodes.  
Ferumoxytol has been proposed for use in the imaging of active atherosclerosis. 
Other USPIOs, such as ferumoxtran-10 (Sinerem, Guerbet Laboratories, France), 
have been demonstrated to be useful for the detection of carotid atheroma. In clinical 
studies with ferumoxtran-10, T2*-weighted MRI signal decrease has been 
demonstrated within the carotid plaques of patients prior to endarterectomy. 
Furthermore, USPIO signal effect correlates with the propensity for plaque rupture. 
Indeed, histology post surgery confirmed the presence of intracellular USPIO in 
plaque macrophages (Kooi et al., 2003b, Trivedi et al., 2006b). These magnetic 
resonance and histologic observations are consistent with findings in the aortae of 
hyperlipidaemic rabbits administered ferumoxtran-10 (Schmitz et al., 2001, Ruehm 
et al., 2001b). 
Herborn and colleagues examined the utility of ferumoxytol (Feraheme) for imaging 
atheroma in the aortae of hyperlipidaemic rabbits using a 1.5T MR scanner.(Herborn 
et al., 2006) Susceptibility artefacts were detectable in the aortic wall at day 2 to 3 
post administration of contrast. Signal voids were observed as a result of T2/T2* 
effects and were more homogenous than seen in similar animals administered 
ferumoxtran-10. Histology revealed the accumulation of iron particles under the 
endothelium and into the medial layer of diseased vessels (Herborn et al., 2006). 
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Ferumoxytol has been administered safely as a bolus dose of 4 mgFe/kg for use as an 
MRI contrast agent in man (Ersoy et al., 2004, Li et al., 2007, Li et al., 2005, Prince 
et al., 2003, Neuwelt et al., 2007). Most of these studies have examined and 
confirmed its utility as a blood-pool contrast agent. However, it has also been 
assessed for its use in lymph node imaging for cancer staging. In a study of patients 
with prostate cancer, ferumoxytol was administered at 4 mgFe/kg and imaging 
performed at baseline, 5, 8 and 24 hours post dose using a 1.5 T scanner. Maximum 
signal to noise ratio was observed in lymph nodes at 24 hours on T2*-weighted MR 
imaging (Harisinghani et al., 2007). 
The utility of USPIOs, including ferumoxytol, for imaging myocardial infarction and 
inflammation has not been assessed but, given the effects seen in atheroma imaging, 
more marked effects would be expected given the potentially larger area and more 
aggressive inflammation associated with myocardial infarction. Furthermore, clinical 
studies examining USPIO magnetic resonance effects have primarily been in 
scanners limited to a magnetic field strength of 1.5 Tesla and susceptibility effects 
would be expected to be greater in newer, more powerful clinical scanners with a 
field strength of 3 Tesla. 
 
 
AIMS AND HYPOTHESES 
 
Using ferumoxtran (Feraheme) as a USPIO contrast agent for magnetic resonance 
imaging at 3 Tesla, we aim to conduct the first clinical study to examine the utility of 
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this novel contrast agent to image myocardial inflammation after myocardial 
infarction.  
 
We will test the following hypotheses in patients who have suffered recent acute 
myocardial infarction.  
 
1) Intravenous injection of ferumoxytol accumulates at the site of myocardial 
infarction and this can be visualised by magnetic resonance imaging. 
   
2) The spatial extent of the MRI signal change evoked by ferumoxytol in the 
myocardium is proportional to the volume of infarcted myocardium (as 
assessed by a gadolinium late-enhancement study). 
 
3) Myocardial MRI signal change evoked by ferumoxytol is positively correlated 
with blood markers of systemic inflammation. 
 
 
METHODS 
 
Study Population 
This study will be open-label and non-randomised. We will perform this pilot, proof-
of-concept study in 18 patients who have suffered a myocardial infarction.  
 
Stable patients who are eligible for inclusion will be approached up to 48 hours after 
admission and asked to consider participation.  
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Inclusion Criteria:  
• Presentation with myocardial infarction (either ‘ST-elevation’ 
myocardial infarction or ‘non-ST-elevation’ myocardial infarction 
• Troponin I ≥ 10 IU/mL at 12 hours after the onset of chest pain 
• Age 18 – 80 years inclusive 
 
Exclusion Criteria: 
• Known critical (≥95%) left main stem coronary artery disease 
• Continued symptoms of angina at rest or minimal exertion 
• Atrial fibrillation 
• Symptomatic heart failure; Killip Class ≥2. 
• Hepatic failure (Childs-Pugh grade B or C) or renal failure (estimated 
glomerular filtration rate <25 mL/min) 
• Contraindication to magnetic resonance imaging  
• Past history of systemic iron overload/haemochromatosis 
• Patients with known allergy to dextran- or iron-containing 
compounds 
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Study Groups 
Group 1 – Ferumoxytol 
Twelve subjects will be recruited to receive ferumoxytol and to undergo imaging and 
assessments outlined below. 
 
Group 2 – Control 
Six subjects will be recruited to undergo the same study procedures as those in Group 
1 but will not receive ferumoxytol. This group will allow us to control for any non-
specific effects of myocardial infarction upon the MRI signal parameters assessed. For 
example, it will allow us to control for the potential confounding effect of intra-
myocardial micro-haemorrhage associated with myocardial infarction.  
 
 
Administration  
Ferumoxytol will be supplied by Advanced Magnetics, Inc., Cambridge, MA. As 
supplied, each vial contains 510 mg of elemental iron in 17 mL (30 mg/mL). It will 
be administered via a peripheral venous cannula at a dose of 4 mgFe/kg body weight 
at a rate of up to 1 mL/sec. This dose has been safely administered before and 
equates to 8% of total body iron for males and 9.5% for females, or about the same 
amount of iron as is contained in 1-2 units of blood.  
Administration of ferumoxytol will be immediately after the first ‘baseline’ cardiac 
MR scan (see below). Administration will be performed by a member of the research 
team or a qualified research nurse, either in the Clinical Research Facility, Coronary 
Care Unit or Cardiology ward at the Royal Infirmary of Edinburgh.  
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 354 
Non-invasive physiological monitoring (continuous ECG monitoring, oxygen 
saturation probe, non-invasive blood pressure, temperature and nurse observation) will 
be performed during ferumoxytol administration. If, on clinical grounds, the patient is 
due for discharge the same day, they will be observed for at least one hour following 
the administration of ferumoxytol prior to discharge. 
 
Magnetic Resonance Imaging 
Magnetic resonance imaging will be performed using a dedicated clinical research 
Siemens 3T Verio MRI scanner at the Clinical Research Imaging Centre at the 
Queen’s Medical Research Institute, University of Edinburgh. Data will be acquired 
using a body matrix coil.  
Standard cardiac imaging breath-held ECG-gated sequences will be used to acquire 2-
chamber, 4-chamber, long axis and short axis views of the heart.  USPIO imaging will 
be performed using established T2*-weighted multi-echo gradient-echo sequences, 
breath-held and cardiac gated. Scan parameters (such as echo time to dictate degree of 
T2*-weighting) will require a degree of optimisation for USPIO imaging of the 
myocardium at 3T (high concentrations of USPIO will require reduction in echo 
times).  The use of multi-echo sequence allows a quantitative analysis of USPIO 
accumulation through calculation of T2* relaxation times before and after 
administration of USPIO.  Therefore, it is anticipated that scanning of the first few 
patients will constitute a scanning protocol optimisation phase. In order to optimise 
image analysis of T2*-weighted images (and prevent analysis degradation due to “T2*-
blooming” artefacts, USPIO images will be quantitatively analysed using a 
susceptibility gradient mapping post-processing technique previously used in SPIO 
imaging to quantitate USPIO accumulation using changes in calculated T2* relaxation 
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times.(Liu et al., 2008) We have recently employed this technique to quantify T2*-
weighted signal change post-ferumoxytol-10 administration in patients with 
abdominal aortic aneurysm.(Richards et al., 2010) 
Imaging will be performed at baseline (24 – 72 hours after admission) prior to 
administration of ferumoxytol. Subsequent imaging will be performed 24 and 48 
hours after the administration of ferumoxytol. Volunteers will also be invited to return 
for scanning at 96 hours, 96 hours, one week and one month post ferumoxytol, but this 
will not be a mandatory feature of the protocol.  
Immediately prior to the baseline T2*-weighted scan, a breath-held inversion recovery 
sequence will be used to acquire delayed enhancement images after a delay of 10-15 
minutes following an intravenous administration of 0.2 mmol/kg of MR gadolinium 
contrast agent.  Standard cardiac MR acquisition parameters will be used for these 
acquisitions. Delayed enhancement analysis will be performed using QMass software 
(Medis medical imaging systems, Netherlands), allowing quantification of infarct size 
and location for correlation with SPIO-related signal changes. 
An additional T2*-weighted acquisition will be acquired axially through the liver for 
each time point to allow quantification of non-specific ferumoxytol uptake within the 
reticulo-endothelial system via changes in hepatic and splenic tissue T2*. 
The investigator performing image analysis will be blinded to the subject’s study 
group. 
Systemic Markers of Inflammation 
Prior to each MRI scan, approximately 25 mL peripheral venous blood will be 
obtained from each volunteer for the measurement of systemic markers of 
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inflammation. These will include high sensitivity C-reactive protein (hsCRP), 
interleukin-6 (IL-6), interleukin-8 (IL-8), tumour necrosis factor alpha (TNF) and 
full blood count for differential leucocyte count. Platelet function assays will also be 
performed. This will allow the evaluation of any correlation of myocardial signal 
change, putatively reflecting local myocardial inflammation, with markers of systemic 
inflammation.  
 
Myocardial Tissue Collection 
Patients who undergo coronary artery bypass grafting will be asked whether they 
consent to left ventricular ‘Tru-Cut’ core biopsy of a small area of infarcted 
myocardium at the time of surgery. This tissue sample would allow the direct 
histological assessment of the presence of intra-myocardial iron/mononuclear cells.  
 
 
 
 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 357 
Figure 5: Timing for cardiac magnetic resonance scanning and ferumoxytol 
administration. 
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Appendix D:  EMPIRE TRIAL 
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CONSENT FORM (FIGURE 1) 
Figure 1: EMPIRE Study - Consent Form 
 
The effect of elafin in coronary artery bypass surgery 
Consent Form Version 2: 23
rd
 November 2010 
 
 
 
 
 
The effect of elafin in coronary artery bypass surgery 
Consent Form 
 
 
1.  I confirm that I have read the information sheet dated 23
rd
 November 
2010   for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and I am free to 
withdraw at any time without giving any reason, without my medical 
treatment or legal rights being affected. 
 
3.  I agree to have blood taken for the study at 6 extra sampling points 
from routine clinical care (approximately 175 mL). 
 
4.  I agree to undergo 3 cardiac MRI scans. 
 
5.  I understand that my medical notes and data collected during the 
study may be looked at by the individuals carrying out the research, 
regulatory authorities or NHS Lothian Trust, where it is relevant to my 
taking part in this research. I give permission for these individuals to 
have access to my medical records for the purpose of research. 
 
6. If I withdraw from the study, I agree any data already collected may 
be used as part of the results of the trial.      
 
 
7.  I agree to my GP being informed about my participation in the 
study. 
 
 
6.  I agree to take part in the study. 
 
 
Name of patient   date    signature 
 
 
 
 
Name of person taking consent date    signature 
 
 
Patient’s 
initials 
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GP LETTER (FIGURE 2) 
Figure 2 EMPIRE Study - GP Letter 
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 Cardiovascular Research 
 Chancellor’s Building 
 Royal Infirmary of Edinburgh 
 EDINBURGH 
 EH16 4SU 
     
 Date 
Dr. Name  
Address 
Address 
Post code 
 
Dear Dr 
 
Re:  Patient Name, Address (DOB):  
 
The above named patient has agreed to participate in a clinical research study entitled 
“The effect of elafin in coronary artery bypass surgery”. I enclose a copy of the 
information sheet. This study is being conducted by Dr Shirjel Alam (Reseach Fellow 
in Cardiology, University of Edinburgh) and Dr Peter Henriksen (Consultant in 
Cardiology, NHS Lothian & University of Edinburgh). 
 
 
 
We will notify you of any clinically significant information arising from your 
patient’s participation in this study. Should you require any further information please 
do not hesitate to contact myself or Dr Nicholas Crudenon telephone number 0131 
242 1843. 
 
Yours sincerely, 
 
 
Dr Shirjel Alam 
Research Fellow in Cardiology 
 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 365 
EMPRIRE STUDY – PATIENT INFORMATION 
Participant Information Sheet 
The effect of elafin in coronary artery bypass surgery 
You are being invited to take part in a research study.  Before you decide whether or 
not to take part, it is important for you to understand why the research is being done 
and what it will involve.  Please take time to read the following information 
carefully. Talk to others about the study if you wish.  Contact us if there is anything 
that is not clear or if you would like more information.  Take time to decide whether 
or not you wish to take part. 
 
What is the purpose of the study? 
 
Heart muscle cells are susceptible to injury and death following interruption of blood 
flow e.g. after a heart attack.  One of the treatments for this is coronary heart bypass 
surgery although this treatment can cause a very mild form of heart injury.  We can 
assess this injury by taking blood samples and measuring for a specific marker, 
troponin and this provides a helpful model to study drugs that may reduce heart 
injury 
 
Neutrophils are blood cells that contribute to heart injury by releasing destructive 
enzymes (elastases). Humans produce a protein called elafin that reduces neutrophil 
elastase injury. Extensive research from different international centres indicates that 
elafin has a therapeutic role in diseases of the arteries and heart muscle. We believe 
that administering elafin to patients undergoing bypass surgery will reduce 
neutrophil mediated heart injury and therefore help patients recover more quickly 
from surgery 
We intend to study heart injury and inflammation using blood tests and cardiac 
magnetic resonance imaging (CMRI): a detailed heart scan.  We are aiming to recruit 
80 patients into the study. 
 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 366 
Why have I been asked to take part? 
 
You have been asked to take part as you have been referred for coronary artery 
bypass surgery at the Edinburgh Heart Centre. 
 
 
Do I have to take part? 
 
No, it is up to you to decide whether or not to take part.  If you do decide to take part 
you will be given this information sheet to keep and be asked to sign a consent form.  
If you decide to take part you are still free to withdraw at any time and without 
giving a reason. Deciding not to take part, or withdrawing from the study, will not 
affect the healthcare that you receive. 
What is the drug being tested? 
 
Elafin is a protein that is naturally produced within the body. The drug is produced 
using molecular biology techniques from yeast. Elafin has been given to healthy 
volunteers and patients undergoing surgery. No significant toxicity or side effects 
have been identified. 
 
What will happen if I take part? 
If you agree to take part you will be asked to sign a consent form recognising that 
you have read this information leaflet and have agreed to participate in the trial. 
If you consent to participating in the trial you will receive the following additional 
tests over and above your routine clinical care. 
 
CMRI heart scan  
 
You will attend for 3 CMRI heart scans on separate days. The first will be 
conducted around 7 days before your operation. The second and third scans will be 
conducted on consecutive days between day 5 and day 9 after the operation. These 
scans are performed in the MRI scanner in the Clinical Research Imaging Centre 
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(CRIC) within the University of Edinburgh’s Queen’s Medical Research Institute on 
the Little France site  
The MRI scan involves lying on a flat bed and passing through the tube-shaped 
scanner. This scanner does not use x-rays. In order for us to look in more detail at the 
heart we will administer an agent called ‘gadolinium’ through a vein in your arm 
before the scan. Gadolinium is in routine clinical use. The scan should take about 
forty-five minutes in total. 
After the second scan, we will administer microscopic iron particles, known as 
ferumoxytol (the trade name is Feraheme). Ferumoxytol is approved for use in the 
treatment of anaemia and is safely used at the same dose that we propose to give. It 
has also been used in MRI scanning at this dose but has not been used after bypass 
surgery in this way. It will be given through a vein in your arm. Your blood pressure, 
heart rhythm, temperature and oxygen levels will be monitored during, and for at 
least one hour after, the infusion. The infusion itself will take less than a minute.  
 
Twenty-four hours after the ferumoxytol infusion, you will undergo the final MRI 
scan of the heart  
 
The research team will arrange these scans, keep you informed and offer 
reimbursement for travel and food. 
 
All of the procedures will take place either in the cardiothoracic surgery units, 
Clinical Research Facility or the Clinical Research Imaging centre at the Royal 
Infirmary of Edinburgh. None of the procedures should interfere with your routine 
care after a heart attack and your date of discharge from the hospital should not be 
affected. 
 
Blood tests and drug administration 
 
On the day of surgery you will be allocated at random to receive either the study 
drug (Elafin) or placebo (saline) during the operation. The research team, surgical 
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team and you will not know which of these treatments is given. This is standard 
process for clinical trials and means that you will not know whether you received the 
drug or placebo. 
During and after surgery blood tests will be taken from a plastic cannula that has 
inserted as part of your routine care during the operation. These blood tests will be 
used to measure heart muscle injury and inflammation. If you participate in the study 
a small amount of extra blood will be taken for analysis (around 40 mls in total).  
The blood will not be stored after the study is finished. 
 
 
 
What are the possible benefits of taking part? 
 
You may not get a direct benefit from taking part in this study. The CMRI heart scan 
will assess your heart function very closely and it is possible that findings from this 
may help the surgical and medical teams looking after you. 
We expect that Elafin will assist with healing and recovery after the operation, 
although it may not. We believe that elafin’s action may translate into a more rapid 
post-operative recovery and we will be measuring this in the clinical trial. 
 
 
What are the possible disadvantages and risks of taking part? 
 
It is not thought that there are many disadvantages. Previous studies with elafin in 
humans including healthy volunteers and surgical patients have suggested that it is a 
drug with no specific toxicity or side effects. With any drug there is a possible low 
risk of allergic reaction and you will be monitored for this as part of the trial. 
 
There is a similar low risk of reactions to the contrast agents given for the MRI 
study. The injection of ferumoxytol should not be painful and has not been 
associated with any significant side effects. However, we will monitor carefully for 
these at the time of the administration of ferumoxytol and afterwards and would treat 
you as necessary. People who have a past history of allergies to iron-containing 
compounds or ‘dextran’ (a component of ferumoxytol) would be excluded from 
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participation. The iron particles will be degraded by your body and removed by your 
liver. Because we will be giving extra iron, people with a history of conditions 
associated with abnormally high quantities of iron in the body will be excluded from 
taking part. 
 
Because MRI scanners use strong magnets, we will complete a detailed safety 
questionnaire before you enroll in the study to check that there is no reason why it 
would be unsafe for you to have a scan. People with metal joint replacements, 
pacemakers or a history of eye injury involving metal (such as from shrapnel or 
welding) will not be able to take part. Patients who have had brain surgery with the 
implantation of metalwork will also have to be excluded. MRI scanners do not use x-
rays and therefore are not associated with the risks of radiation associated with other 
imaging methods including CT scans. Other than the risk associated with MRI in 
people with metal implants, there are no known risks from MRI scanning. The MRI 
scanner is noisy, so you will wear special headphones to reduce the noise. 
 
What if something abnormal is found in my scans?  
 
As part of your study we will obtain pictures of your heart. We expect to be able to 
see areas of mild heart injury and are interested to see whether the ferumoxytol can 
also be seen in these areas. Our research studies are designed to improve our 
knowledge of the heart after heart muscle injury following bypass surgery.  They are 
not designed for other purposes.  After your scan, a specialist will examine these 
pictures (this will not be done on the day of your study). Other changes either related 
or unrelated to your heart may be seen but you should be aware that because our 
pictures are taken for a specific research purpose, not all abnormalities that might be 
detected by other MRI scans are necessarily seen.  On rare occasions, we might find 
an abnormality that is significant and which should be investigated further.  If we 
find such a significant abnormality in your heart, we will contact the Consultant 
Surgeon directly involved in your ongoing clinical care. Although a significant 
abnormality is unlikely, you should be aware that if such an abnormality is detected 
and you are informed, then this may have consequences for your treatment.  
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What happens when the study is finished? 
 
Your involvement will finish following the final post-operative MRI scan. You will 
continue with routine care including follow-up clinics with your surgeon and 
cardiologist. We can provide a summary of the trial results to patients who 
participate on request. If you would like this please let the person taking your consent 
know. 
 
 
Will my taking part in the study be kept confidential? 
 
All the information we collect during the course of the research will be kept 
confidential and there are strict laws which safeguard your privacy at every stage. 
Your name will be removed from the data so that you cannot be recognised from it.   
 
Will my GP be informed? 
We would like to inform your General Practitioner of your participation in this study. 
We will notify your General Practitioner, and also the Consultant Surgeon in charge 
of your ongoing care, should any clinically relevant material come to light during the 
study. 
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the treatment being studied. If this happens, your research doctor will 
tell you about it and discuss with you whether you want to continue in the study. If 
you decide to continue in the study you will be asked to sign an updated consent 
form. 
Also, on receiving new information your research doctor might consider it to be in 
your best interests to withdraw you from the study. This will be explained to you. 
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What will happen to the results of the study? 
 
At the end of the research we will complete analysis of the information collected 
from the blood tests and CMRI scans. We will publish this data in peer-reviewed 
international journals. A positive result in this trial will pave the way to further 
clinical studies examining the therapeutic benefit of elafin in coronary bypass 
surgery and other diseases including heart attack and organ transplantation. 
 
 
Who is organising the research and why? 
 
The study is being led by Dr Peter Henriksen a Consultant Cardiologist at Edinburgh 
Heart Centre. Dr Henriksen has been researching the protective effects of elafin on 
the heart and blood vessels. The value and importance of this study has been 
recognised by the Medical Research Council who have agreed to fund it after 
rigorous peer-review. 
 
 
Who has reviewed the study? 
 
The study proposal has been reviewed by 7 independent clinical trial experts in the 
field and a dedicated research board within the Medical Research Council. The study 
has been reviewed by the South East Scotland Research Ethics Committee.  NHS 
management approval has also been obtained 
 
 
If you have any further questions about the study please contact:  
 
Dr Shirjel Alam  Mobile: 07813955996  
    Email: s.r.alam@sms.ed.ac.uk 
Dr Peter Henriksen  Mobile 07747603492                 
    Email: peter.henriksen@luht.scot.nhs.uk 
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If you would like to discuss this study with someone independent of the study 
please contact: 
 
Dr Nicholas Cruden 
Consultant Cardiologist 
Edinburgh Heart Centre 
Royal Infirmary of Edinburgh 
Little France 
EH16 4SA 
Phone: 0131-242-1843 
 
If you wish to make a complaint at any stage please contact NHS Lothian: 
NHS Lothian Complaints Team 
2nd Floor 
Waverley Gate 
2-4 Waterloo Place 
Edinburgh 
EH1 3EG 
Tel: 0131 465 5708 
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TRIAL PROTOCOL 
 
Study Protocol 
EMPIRE  
Elafin Myocardial Protection from Ischaemia RepErfusion injury 
A randomised trial to investigate the effect of Elafin on myocardial injury and 
inflammation in coronary artery bypass surgery 
Sponsor University of Edinburgh and NHS Lothian Health 
Board 
Funder Medical Research Council and Chest Heart and Stroke, 
Scotland 
Funding Reference  G1001339 (MRC) and R11/A135 (CHSS) 
 Chief Investigator Dr Peter Henriksen 
EudraCT Number 2010-019527-58 
CTA Number 27586/0015/001-0001 
MREC Number 11/MRE00/5 
ISRCTN Number ISRCTN82061264 
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Protocol Approval 
Insert study title:  Elafin Myocardial Protection from Ischaemia RepErfusion injury 
 
 
EudraCT number: 2010-019527-58  
 
 
Signatures 
 
    
Chief Investigator Signature  Date 
    
 
 
 
   
    
    
Trial Statistician Signature  Date 
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List Of Abbreviations 
 
Coronary artery bypass surgery CABG 
Edinburgh Clinical Trials Unit ECTU 
Cardiac magnetic resonance imaging CMRI 
Ultra-small superparamagnetic particles of iron oxide  USPIO 
highly sensitive C-reactive protein hsCRP   
Estimated glomerular filtration rate eGFR  
Electrocardiogram  ECG 
Medicines and Healthcare products Regulatory 
Agency  
MHRA 
Interleukin 8 IL-8 
Tumour necrosis factor α TNF-α  
Interleukin 6 IL-6 
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SUMMARY 
Professional: During coronary artery bypass graft surgery, the myocardium receives 
an immediate ischaemic insult, exacerbated by post-ischaemic inflammatory 
responses following reperfusion that lead to increased myocardial injury. Elafin is a 
potent endogenous anti-elastase with wide ranging anti-inflammatory properties that 
inhibit destructive post-ischaemic inflammatory pathways. We hypothesise that 
elafin will reduce perioperative ischaemic myocardial injury and systemic 
inflammation in elective coronary artery bypass graft surgery. Myocardial injury will 
be quantified over the first 48 hours using serial measurements of plasma troponin I 
concentrations. Subsequent myocardial infarct volume will be quantified by cardiac 
magnetic resonance imaging (CMRI). CMRI will also be used to detect 
inflammatory macrophage activity within the infarcted myocardium.  This proof-of-
concept study will establish whether elafin has cardioprotective effects in a clinical 
model of predictable myocardial injury. It has implications for the treatment of 
ischaemic heart disease, myocardial infarction and other diseases of ischaemic 
origin. 
 
Lay: Heart muscle cells are susceptible to injury and death following interruption of 
blood flow. A mild form of injury occurs during coronary artery bypass surgery. 
Certain white blood cells contribute to this heart injury by releasing enzymes that 
break down the tissues. Elafin is a naturally occurring protein that can potentially 
reduce heart injury by blocking these harmful enzymes. We believe that 
administering elafin to patients undergoing coronary artery bypass surgery will 
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reduce heart injury and potentially improve patient outcome. This study sets out to 
determine whether elafin can indeed benefit patients in this setting. 
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INTRODUCTION 
 
BACKGROUND 
Post-ischaemic inflammatory myocardial injury: the role of neutrophil elastase 
Myocardial injury characterised by myocardial troponin release occurs in all patients 
undergoing coronary artery bypass graft surgery.1;2 Elevated postoperative plasma 
troponin concentrations are closely correlated with worse clinical outcomes and 
mortality. Ischaemic myocardial injury is an immediate result of coronary blood flow 
interruption during cardiopulmonary bypass. Cardiomyocyte injury is exacerbated 
following reperfusion and neutrophils are pivotal mediators determining post-
ischaemic inflammatory reperfusion injury.3 Neutrophils accumulate within the 
reperfused myocardium and release cytotoxic elastases and reactive oxygen species 
that further affect microvascular and myocardial injury. Preclinical studies have 
demonstrated that neutrophil depletion or inhibition of neutrophil elastase attenuates 
post-ischaemic inflammatory reperfusion injury within the myocardium.4-6  
Interaction between neutrophil mediated injury and macrophage infiltration 
Inflammation is characterised by initial recruitment of neutrophils preceding a 
second wave of monocytes to the site of injury or infection. Leucocytosis including 
neutrophilia and monocytosis predicts prognosis following acute myocardial 
infarction.7 Neutrophil mediated injury facilitates monocyte infiltration.8;9 Neutrophil 
derived granule proteins including cathelicidin LL-37 and defensins exhibit 
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chemotactic activity for monocytes and neutrophil depletion reduces monocyte 
recruitment following inflammatory injury.10;11 Data from murine models indicate 
that monocytes infiltrate the infarcted myocardium and persist as tissue differentiated 
macrophages where they orchestrate the reparatory response through processes such 
as extracellular matrix turn over and removal of apoptotic cardiomyocytes.12 
Following myocardial infarction, patients with monocytosis display more left 
ventricular dilatation and are more likely to develop post-infarct aneurysms.13 
Clinical and experimental evidence from the lung and kidney indicate a central role 
for macrophages in coordinating the reparatory response to inflammatory tissue 
injury.  Relatively little is known about the role of macrophages following 
myocardial infarction in humans. 
Systemic inflammatory response following CABG  
Plasma myeloperoxidase and elastase concentrations can be used as circulating 
markers of neutrophil activation following coronary bypass graft surgery.14 A 
systemic inflammatory response follows surgical trauma, tissue ischaemia and 
exposure of circulating blood to the cardiopulmonary bypass circuit.15 This can be 
measured with plasma markers including highly sensitive C-reactive protein (hsCRP) 
and inflammatory cytokines (IL-6, IL-8 and TNF-α).16 Higher plasma IL-6 and IL-8 
concentrations are associated with a complicated postoperative course including 
weight gain, greater oxygen requirement and trends toward worsening renal function. 
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RATIONALE FOR STUDY 
Vascular injury is reduced by administration of elafin 
Elafin is a multifaceted anti-inflammatory molecule directly inhibiting destructive 
neutrophil elastases and reducing inflammatory cytokine production.17 We have 
demonstrated a reduction in cytotoxicity and IL-8 production from human 
endothelial cells incubated with neutrophil elastase when elafin is added to the 
culture medium.18 Elafin overexpression reduces inflammatory IL-8 and TNF-α 
production in human endothelial cells and macrophages exposed to bacterial 
lipopolysaccharide. This effect is mediated through a mechanism involving 
diminished activation of the NF-κB transcription pathway possibly through a direct 
action of elafin on the ubiquitin-proteosome degradation pathway.18;19 Elafin has 
protective effects in a range of acute vascular injury models. Elafin infusion reduced 
skeletal muscle infarction and neutrophil recruitment quantified by muscle 
myeloperoxidase content in a rat ischaemic hind limb model.20 Elafin delivery was 
associated with a 27 % reduction in myocardial infarct size (% area at risk) compared 
to placebo in rats.5 The same study demonstrated better myocardial function 
following repetitive ischaemia reperfusion with a 22% reduction in 
echocardiographic fractional thickening in elafin treated animals compared to 50% 
drop in controls. Elafin gene overexpression led to preserved left ventricular function 
in a murine model of myocardial infarction.6 Work within our own institution on the 
same elafin transgenic mice has further characterised the phenotype and 
demonstrated diminished post-infarct failure with reduced pulmonary oedema and 
markedly reduced plasma atrial natriuretic peptide concentrations. Elafin is therefore 
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well suited to addressing the neutrophil mediated inflammatory tissue injury 
occurring post cardiac surgery. 
 
Coronary bypass surgery provides a controlled vascular injury model 
Elective coronary artery bypass graft surgery provides a clinical model of predictable 
and programmed ischaemic myocardial injury and systemic inflammatory activation. 
It is suited to the study of interventions targeted at reducing ischaemic myocardial 
and tissue injury.2;21;22 
Therefore in this study, CABG surgery will provide an ideal vehicle for the 
assessment of elafin as an anti-inflammatory cardioprotective agent in humans for 
the first time. 
 
STUDY OBJECTIVES 
OBJECTIVES 
Primary Objective 
To demonstrate that perioperative Elafin administration reduces post-ischaemic 
inflammatory myocardial injury following coronary artery bypass graft surgery.  
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Secondary Objectives 
To examine the infiltration of macrophages into the myocardium following 
ischaemic myocardial injury using advanced CMRI techniques 
 
ENDPOINTS AND OUTCOMES 
Primary Endpoint 
The primary endpoint will be area under the curve for plasma troponin I 
concentration profile over the first 48 h. 
Secondary Endpoints 
The effect of Elafin on myocardial injury and inflammation will be further quantified 
by comparing infarct volume and macrophage infiltration before and after surgery.  
Infarct volume and macrophage infiltration will be quantified using MRI together 
with late gadolinium enhancement and accumulation of ultra-small 
superparamagnetic particles of iron oxide (USPIO) respectively. USPIO contrast acts 
as a cellular marker through the detection of macrophage-mediated inflammation 
within tissues.23;24 
Elafin’s effect on inflammatory activation will be assessed by comparing peak and 
area under the curve of plasma hsCRP and cytokine (IL-6, TNF-α and IL-8) 
concentrations.  
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Neutrophil activation will be assessed by measuring the white cell and neutrophil 
differential counts and measuring peak and area under the curve of plasma 
myeloperoxidase and elastase concentrations.  
Postoperative intensive therapy unit (ITU) stay will be recorded from the end of the 
operation (as documented on the anaesthetic chart) until the ITU team consider the 
patient fit for ‘step down’ either to cardiothoracic high dependency unit (HDU) or 
general surgical ward. It will be measured hours. 
 
Additional outcomes 
The following data will be collected as expected events in the care of patients post 
coronary bypass surgery, but NOT reported as adverse events related to the study. 
They will not be included in the primary or secondary end point analysis. 
• Serum Elafin concentration and plasma elastase activity (0 to 24 h) 
• Postoperative complications related to coronary artery bypass surgery 
between 0 (time of first skin incision) and 48 h including; 
• Wound infection; sternotomy and vein harvest sites 
• Respiratory complications; chest infection, pleural effusion requiring 
drainage 
• Administration of antibiotics for any infection 
• Atrial fibrillation (sustained for more than 5 minutes) 
• Stroke 
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• Renal function measured by creatinine/GFR 
• Low cardiac output syndrome and inotrope requirement 
• Red blood cell transfusion 
• Re-operation for bleeding 
 
 
STUDY DESIGN 
This is a single centre randomised placebo-controlled trial.  The use of matched 
placebo treatment that is identical in appearance to the active treatment means that 
patients, administering clinicians, surgeons and theatre staff, and those collecting 
data and assessing endpoints will all be blinded to the allocated treatment. Patients 
will be given information about the trial to take away and the research team will 
contact them by telephone to find out if they are willing to participate. Consent and 
recruitment will occur on the day of the preoperative MRI scan. The study will run 
for 3 years with the intention of recruiting 80 patients within 2.5 years. 
Patients will be randomised to either Elafin or matched placebo control the day 
before surgery. Randomisation will include a minimisation technique that will 
incorporate age, sex, extent of coronary artery disease, presence of left ventricular 
dysfunction, presence of diabetes mellitus, surgeon and estimated glomerular 
filtration rate. This will be performed by Edinburgh Clinical Trials Unit (ECTU) to 
ensure allocation concealment. 
 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 385 
Coronary artery bypass surgery and anaesthesia 
All patients will have general anaesthesia. Routine monitoring will include arterial 
line, central venous line, urinary catheter and electrocardiogram (ECG). Surgical 
approach will be via a median sternotomy and, where possible, use the left internal 
mammary artery. All patients will be put on a cardiopulmonary bypass circuit and 
the surgical protocol will be no different to patients not in the trial. Other conduits 
will be chosen from saphenous vein, radial artery or the right internal mammary 
artery (depending on coronary anatomy and surgeon preference). Patients will 
receive usual postoperative care within the intensive care unit. Patients in both 
treatment arms will receive standard medications during anaesthesia, surgery and 
during the postoperative period. No drug interactions have been identified with 
Elafin and no specific rescue treatment is available. 
 
Elafin and placebo administration 
A 200 mg dose of Elafin in 250 mL of normal saline or normal saline placebo will be 
prepared in the hospital and delivered to the theatre suite by the clinical research 
nurse or pharmacist. The drug will be administered to the patient through a central 
venous cannula over a period of 30 min. Investigators and theatre staff will be 
blinded to the study drug. The intravenous infusion will begin at time 0 h: the time of 
the first skin incision. Administration will therefore be complete by 20 min before 
cardiopulmonary bypass commences.  The period of just over 48h between the start 
of Elafin or placebo infusion will be considered the treatment phase. 
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Cardiac MRI scanning 
Each patient will require 3 visits for MRI scanning- preoperative (visit 1), day 7±2 
(visit 2- prior to USPIO administration) then 24 h post-USPIO administration (visit 
3). Patients will have visit 1 within a period of 6 weeks prior to coronary artery 
bypass surgery. Visit 2 will be conducted no sooner than 5 days after surgery to 
examine for delayed enhancement and myocardial infarction using gadolinium 
contrast. In the event of clinical circumstance dictating a delay in the patient 
receiving the post-operative scans, these will be performed as close to this timeframe 
as possible. Reasons and the extent of any delay will be recorded. After the 2nd MRI 
scan patients will receive an infusion of Feraheme. The infusion will take less than 1 
minute and patients will have their blood pressure recorded prior and 1 hr post 
infusion. Patients will be imaged using a dedicated research 3T Siemens Verio 
scanner using the phased array body matrix.  ECG-gating will be obtained using the 
Siemens on-line ECG gating system, with a MEDRAD VERIS monitor for gating 
backup. Total imaging time per cardiac scan per patient will be approximately 40 
minutes. Analysis of late gadolinium enhancement infarct size and 
USPIO/inflammation assessment will be determined using established departmental 
protocols and dedicated cardiac analysis software by two independent blinded 
observers trained in cardiac MRI analysis. Discrepancies will be discussed so that a 
single value can be entered into the study database. The follow up phase will 
continue up until completion of the third postoperative MRI. All MRI images 
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obtained for the study will have a clinical report supervised by Dr Graham McKillop, 
Consultant Radiologist, Royal Infirmary of Edinburgh. 
 
Blood sampling 
Blood samples will be taken at baseline (defined as up to 4 hours before the first skin 
incision, time 0 h) and at 2, 6, 24 and 48 h after this time. The baseline and 2-h intra-
operative samples will be taken by the theatre staff and collected by the clinical 
research nurse. The 6, 24 and 48-h samples will be taken on the ward by either the 
nursing staff or clinical research nurse. Samples taken at baseline, 2 and 6 hours will 
represent additional blood sampling to the routine care of the patient if they were not 
in the research study. Troponin I will be measured by the Abbot Architect assay. 
This Troponin I assay has been chosen because it has the greatest accuracy and 
precision of all Troponin assays at low concentrations, Using this assay will also 
enable samples to be handled by the clinical laboratories at the Royal Infirmary of 
Edinburgh ensuring robust analysis. Blood sampling will be conducted through an 
arterial line. Plasma concentrations of TNF-α, interleukins (IL-6, IL-8), 
myeloperoxidase and elastase will be quantified at each time point out to 6 h using 
enzyme-linked immunosorbant assays (ELISA; R&D Systems). Serum hsCRP 
concentrations will be quantified at each time point out to 48 hours. Plasma elastase 
activity and serum Elafin concentrations will be measured from baseline to 24 by the 
University Kiel (Department of Dermatologie, Laboratory of Prof. Wiedow). The 
intended measurement techniques have been used for analysis of Elafin and Elastase 
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in the past two Elafin studies. The methods have been tested repeatedly and reliably 
over years, but they are however, research assays and no formally validated methods. 
 
 
STUDY POPULATION 
NUMBER OF PARTICIPANTS 
We will recruit 80 patients referred for coronary artery bypass surgery into this 
study, 40 into each treatment group. 
The only site involved will be the Royal Infirmary of Edinburgh, with a 12-30 month 
recruitment period. 
 
INCLUSION CRITERIA  
Patients 18 years or older, who are referred for coronary artery bypass graft surgery 
requiring 2 or more grafts will be approached for consent to enter the study during 
visits to the cardiothoracic surgery outpatient clinic. 
 
EXCLUSION CRITERIA 
The following exclusion criteria will apply: Recent myocardial infarction (a recorded 
troponin elevation within 1 month of surgery), emergency surgery, concomitant 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 389 
valve or aortic surgery, re-intervention or re-do surgery, chronic renal failure 
(estimated glomerular filtration rate <40 mL/min), severe respiratory disease 
(maintenance corticosteroid therapy or forced expiratory volume in one second 
(FEV1) < 50% predicted), severe left ventricular dysfunction (ejection fraction less 
than 30%), contraindication to MRI scanning or a history of chronic inflammatory 
illness requiring immunosuppressive treatment such as inflammatory joint disease, 
connective tissue disorder. Woman with child-bearing potential will not be enrolled 
into the trial (woman who have experienced menarche, are pre-menopausal, have not 
been sterilised or who are currently pregnant). Patients unable to give informed 
consent will not be approached. 
People with a contraindication to feraheme will be excluded from having the final 
MRI scan but will not be excluded from the study. 
 
PARTICIPANT SELECTION AND ENROLMENT 
SCREENING FOR ELIGIBILITY 
Initial screening will be performed using information from the detailed clinic referral 
letter.  
 
IDENTIFYING PARTICIPANTS 
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Patients referred for coronary artery bypass grafting to clinics at the Royal Infirmary 
of Edinburgh will be given information about the research study and invited to 
participate. The cardiothoracic surgeons involved in the patients’ care and the 
research nurse will identify potentially suitable patients from the surgical referrals. 
The cardiothoracic surgical team will invite suitable patients to participate at surgical 
clinic. Suitable patients awaiting coronary bypass surgery on the ward will be 
identified by the research nurse and physicians on the research team. 
 
CONSENTING PARTICIPANTS 
The research study will be explained by the cardiothoracic surgeon or research nurse 
at the cardiothoracic surgical clinic and the patient will be invited to participate. 
Patients will be given information on the research study to take away after the initial 
visit. They will be contacted by telephone within 24 hours and if they agree to take 
part they will be booked in for a preoperative MRI visit during which full written 
consent will be obtained by physicians on the research team, the research nurse or a 
deputy. 
 
INELIGIBLE AND NON-RECRUITED PARTICIPANTS 
There are no particular arrangements for follow up or assessment of ineligible 
patients or patients that decline to participate. 
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RANDOMISATION 
After enrolment in the study and the baseline MRI scan, patients will be randomised 
(1:1) to receive an infusion of Elafin or matched placebo. Elafin or placebo will be 
prepared and dispensed by the pharmacy department or Clinical Research Facility, 
who will have received randomisation instructions, on the day of surgery. No 
member of the clinical team or research team will have randomisation information. 
Subsequent clinical management and trial protocol investigation will be identical.   
Randomisation will be performed by the Edinburgh Clinical Trials Unit (ECTU) to 
ensure allocation concealment, and by minimisation technique that will incorporate 
the following binary criteria: 
• Age; ≥ 65 or < 65 years 
• Sex; male or female 
• Diabetes Mellitus; present or absent 
• Extent of coronary artery disease; 2 or 3 vessel coronary disease 
• Presence of significant left ventricular dysfunction (estimated ejection 
fraction less than 40% or echocardiographic evidence of left ventricular 
impairment); present or absent 
• Estimated glomerular filtration rate (eGFR mL/min); 40- 59 or ≥60  
• Surgeon; Mr Renzo Pessotto or Mr Vipin Zamvar 
• Communication of randomisation to the pharmacy department will be web-
based. 
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Treatment Allocation 
A 200 mg dose of Elafin in 250 mL of normal saline or matched saline placebo will 
be prepared and infused through a central venous cannula. The infusion will start at 
the time of skin incision (time 0), and last 30 minutes. The infusion will be complete 
at least 20 minutes prior to commencement of cardio-pulmonary bypass circulation. 
 
Emergency Unblinding Procedures 
In case of a medical emergency, when the study drug assignment is needed to make 
treatment decisions for the patient, the clinical team may unblind the patient's drug 
assignment by contacting the study investigators (Dr Alam, Dr Henriksen or 
Professor Newby). If unblinding is deemed necessary, the study investigators will 
contact the pharmacy department, Clinical Research Facility or the pharmacist on 
call who will keep details of the randomisation and will be able to unblind the 
allocation if necessary. 
The Academic and Clinical Central Office of Research and Development 
(ACCORD) will be notified immediately of adverse events and the need to unblind 
study allocation. The circumstances leading to the breaking of the code will be fully 
documented, in the investigator’s study files, in the study database and in the 
patient’s source documentation.  
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Premature Withdrawal 
Patients are free to withdraw from the study at any point, but where possible we will 
try to obtain a complete set of blood samples from each time point to enable a full 
intention-to-treat analysis on the primary end-point. Consent will include the option 
for data already collected prior to withdrawal (i.e. results of blood tests or MRI 
scans) to be included in the study. Where patients withdraw from the study prior to 
coronary bypass surgery the reason for withdrawal will be noted and a further patient 
will be recruited. 
Some patients may be unable to comply with MRI scanning. The reason for this will 
be recorded (e.g. claustrophobia, booking error, unable to travel etc). Patients 
without scans will continue to be followed up as per protocol and will remain in the 
primary analysis. 
 
Emergency stopping criteria and rescue treatments  
The Elafin infusion is delivered over a short window of 30 mins when the patient is 
anaesthetised prior to going onto cardiopulmonary bypass. No specific toxicity is 
expected. In the unlikely event that the cardiothoracic surgical team feel that a 
significant change in the patient’s condition may be related to the study they will 
make a clinical decision to stop the study drug infusion. No specific rescue treatment 
is available for Elafin. 
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INVESTIGATIONAL MEDICINAL PRODUCT AND PLACEBO 
STUDY DRUG 
Study Drug Identification 
Elafin CAS number: 820211-82-3. “Recombinant human Elafin” is produced in yeast 
with a structure identical to the 57 amino acid human form and with 95% purity. It 
will be prepared and infused as aqueous solution in 0.9% saline.  
Amino acid sequence (SwissProt accession number: P19957): 
Ala-Gln-Glu-Pro-Val-Lys-Gly-Pro-Val-Ser-Thr-Lys-Pro-Gly-Ser-Cys-Pro-Ile-Ile-
Leu-Ile-Arg-Cys-Ala-Met-Leu-Asn-Pro-Pro-Asn-Arg-Cys-Leu-Lys-Asp-Thr-Asp-
Cys-Pro-Gly-Ile-Lys-Lys-Cys-Cys-Glu-Gly-Ser-Cys-Gly-Met-Ala-Cys-Phe-Val-
Pro-Gln 
 
Study Drug Manufacturer 
Elafin, the investigational medicinal product, is manufactured, packaged and labelled 
by Eurogentac S.A. (Biologics, Liege Science Park, 4102 Seraing, Belgium) as a 
subcontractor of Proteo Biotech AG in accordance with current Good Manufacturing 
Practice (GMP) guidelines. 
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Marketing Authorisation Holder 
Elafin is an Investigational Medicinal Phase II product without Marketing 
Authorisation 
 
Labelling and Packaging 
Vial labelling: 
Recombinant human Elafin 
Vol: 5ml, conc. 10 mg/mL in 0,9% sodium chloride 
Concentrate for solution for infusion 
Route of administration: i.v. infusion 0.9% sodium chloride 
Ch.B. M-HPI-P02/50 
Sponsor: Proteo Biotech AG, Am Kiel-Kanal 44, D-24106 Kiel 
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Box Labelling 
Proteo Biotech rec. human ELAFIN, 50 mg/vial 
Content: ... vials 
Ch.B. M-HPI-P02/50 
Retest date: 08/27/2012 
Concentrate for solution for infusion 
Route of administration: i.v. infusion 0.9% sodium chloride 
Dosage according to leaflet enclosed 
Storage: -20°C 
Medicine for clinical trial use only 
Keep out of reach of children 
SPONSOR: Proteo Biotech AG 
Am Kiel-Kanal 44 
D-24106 Kiel 
phone +49 431 8888 462 
The pharmacy department at the Royal Infirmary of Edinburgh and the research 
nurses within the Welcome Trust Clinical Research Facility will share the 
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responsibility for the preparation of 200 mg of Elafin in 250 mL of 0.9% saline or 
matched placebo 0.9% saline solution, as well as labelling the infusion for blinding 
the study to investigators and participants. 
 
Storage 
The study drug will be kept in the pharmacy department as per product label. 
 
Summary of Product Characteristics 
Elafin is an unlicensed trial medication and so no “summary of product 
characteristic” is available. There are no contra-indications or side-effects expected. 
 
PLACEBO 
Placebo will consist of 250 mL of 0.9% saline to be infused via a peripheral intra-
venous cannula. 
 
DOSING REGIME 
Elafin 200 mg in 250 mL 0.9% saline will be administered. The infusion will last 30 
min with administration starting at the time of skin incision and ending prior to onset 
of cardio-pulmonary bypass circulation. 
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DOSE CHANGES 
No dose changes envisioned. 
 
PARTICIPANT COMPLIANCE 
Responsibility for infusion will be with the anaesthetic team, with timing and dose 
noted on anaesthetic chart as per usual clinical practice. This information will be 
entered into the study database. 
 
OVERDOSE 
From previous studies, a dose of 400 mg was not associated with any relevant safety 
concerns. The only side effects of nausea and headache were attributed to the 
investigational procedure. The study drug infusion will be prepared with no other 
source of Elafin being available for clinicians or the research team to administer 
additional amounts. Therefore each patient will not receive more than 200 mg of 
Elafin. 
 
OTHER MEDICATIONS 
Permitted Medications 
Any other medication necessary for clinical care can be taken, with no specific 
restrictions placed due to the study. 
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Prohibited Medications 
Any other medication necessary for clinical care can be taken, with no specific 
restrictions placed due to the study. 
 
STUDY ASSESSMENTS 
The patient will undergo standard monitoring during cardiac surgery and the 
subsequent cardiac intensive care unit stay. No additional safety assessment will be 
required due to the intensity of monitoring during this time. 
 
The study assessments are outlined below, and will also include measurement of 
length of stay in cardiac intensive care. The beginning of this period will be the end 
of surgery as noted on the anaesthetic chart, until the time the responsible consultant 
deems the patient fit for discharge to the HDU or general ward. 
 
DATA COLLECTION 
Figure 1.1 & Figure 1.2 provides an outline of data collection from blood sampling 
and CMRI. Each patient will undergo blood sampling at 5 time points to measure 
Troponin I. hsCRP will be measured at each time point out to 48 h. IL-6, IL-8, TNF-
α, myeloperoxidase and elastase concentrations will be measured at each time point 
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out to 6 h. Serum Elafin concentration and plasma elastase activity will be measured 
out to 24 h. Each patient will attend for 1 preoperative and 2 postoperative CMRIs. 
Myocardial infarct volume and USPIO signal will be analysed and recorded by the 
Wellcome Trust Clinical Research Facility Imaging Core. Blood samples will be 
collected by nursing staff employed in the cardiothoracic unit. Quantification of 
troponin I will be made in a reference laboratory Abbot Architecture assay using the 
supplier’s commercial kits. Data collection will be performed by the research nurse 
and trial research fellow. 
 
Figure 1.1 Blood  Sampling and MRI Time points 
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Figure 1.2: Blood Sampling Time Points 
TIME POINTS 
(HOURS POST SKIN 
INCISION) 
 
TESTS 
6 week period pre-surgery Cardiac MRI scan 
Baseline (‘X’ = up to  4 
hours before skin incision) 
IL-6, 1L-8, TNF-α, elastase, elastase activity, Myeloperoxidase, 
hsCRP, Troponin I, Elafin 
0 (Skin incision)  
2 IL-6, 1L-8, TNF-α, elastase, elastase activity, Myeloperoxidase, 
hsCRP, Troponin I, Elafin 
6 IL-6, 1L-8, TNF-α, elastase, elastase activity, Myeloperoxidase, 
hsCRP, Troponin I, Elafin  
24 hsCRP, , Troponin I, elastase activity, Elafin 
48 hsCRP, Troponin I 
168 Cardiac MRI scan 
192 Cardiac MRI scan 
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STATISTICS AND DATA ANALYSIS 
SAMPLE SIZE CALCULATION  
We will recruit 80 patients into the study, 40 into each group. A recent study of 
patients in a U.K. centre undergoing coronary artery bypass surgery indicated a mean 
area under the troponin T release curve in control patients of36.12 µg/L (s.d. 26.08) 
and in treated patients the value was 20.58 (s.d. 9.58)2. No contemporary data are 
available on Troponin I release in this patient group but the measurements are 
equivalent in terms of quantifying myocardial injury. The troponin I assay used in 
the EMPIRE study has greater accuracy and precision than assays for troponin T. 
Our calculations (based on Troponin T release) assume a 90% power, a significance 
level of 5%, use a t-test with unequal variances and allow for 4 dropouts in each arm. 
Additional quantification of infarct size will be conducted with MRI. The expected 
mean infarct volume in control patients is 4.4g (s.d. 5.5] and in Elafin treated patients 
we estimate a mean of 1.4g (s.d. 1.7).25 With our proposed sample size of 80 patients 
we will have 85% power to detect this difference, at a significance level of 5% 
(allowing for drop out) 
In a double blind randomised controlled trial of high dose aprotinin in 20 patients 
undergoing cardiopulmonary bypass surgery, IL-6 production was reduced by 58% 
in the aprotinin treated group.22 This study suggests that the proposed study size is 
adequately powered to detect moderate changes in troponin I and inflammatory 
cytokine production.  
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PROPOSED ANALYSES 
The primary outcome variable is the area under the curve for plasma troponin I 
concentration from the end of the infusion to 48 hours post infusion. It will be 
analysed using a generalised linear model, including terms for the treatment 
allocation and the variables on which the randomisation minimised. Other secondary 
outcomes involving area under the curve will be analysed similarly.  
The volume of infarction from cardiac MRI on the first postoperative scan will be 
analysed using analysis of covariance, with terms for the volume identified on the 
preoperative MRI scan, treatment allocation and the variables on which the 
randomisation minimised. Other secondary outcomes that are measured at baseline 
and follow up will be analysed similarly. If any variable does not fulfil the 
distributional assumptions for the techniques described above, another suitable 
technique will be used. Every effort will be made to complete an intention-to-treat 
analysis. Patients will be analysed in the groups they were assigned at randomisation, 
regardless of the treatment actually received. Full follow-up data will be obtained 
wherever possible. Where data are missing the reason will be recorded to obtain 
information on the missingness mechanism. 
There are no pre-planned subgroup analyses. 
A full statistical analysis plan will be written separately. This will include a plan on 
how missing data will be dealt with, using the guidance available at 
http://missingdata.lshtm.ac.uk/. 
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ADVERSE EVENTS 
The Investigator is responsible for the detection and documentation of events 
meeting the criteria and definitions detailed below. All adverse events (AEs) that 
occur after intervention begins must be reported in detail. In the case of an AE, the 
investigator will initiate the appropriate treatment according to their medical 
judgment. Participants with AEs present at the last visit must be followed up until 
resolution of the event. 
Participants should be instructed to contact their Investigator at any time after 
consenting to join the trial if any symptoms develop. All adverse events (AEs) that 
occur after joining the trial must be reported in detail in the CRF. In the case of an 
AE, the Investigator should initiate the appropriate treatment according to their 
medical judgment. Participants with AEs present at the last visit must be followed 
up. 
 
ADVERSE EFFECTS ASSOCIATED WITH ELAFIN ADMINISTRATION  
The tolerability and safety of intravenous Elafin at 20-400 mg in humans was studied 
in a single-ascending-dose double-blind randomised placebo-controlled Phase I 
clinical trial performed on healthy male subjects. In this trial Elafin elicited no severe 
adverse events. Clinical adverse events were generally mild, showed no obvious 
correlation with a particular Elafin dose and resolved spontaneously without any 
sequelae. Elafin had no significant effect on vital signs, ECG, and safety laboratory 
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values. Headache and nausea reported in some patients was thought to be due to 
frequent blood sampling rather than Elafin administration. 
 
ADVERSE EFFECTS ASSOCIATED WITH CARDIAC MRI, GADOLINIUM 
AND USPIO CONTRAST ADMINISTRATION  
Ultra-small SPIOs (USPIOs), with particle sizes in the range 10-30 nm escape 
immediate recognition by the reticulo-endothelial system having a circulatory half-
life of approximately 16 hours. Current preparations are biodegradable, safe for 
clinical administration and used in routine clinical practice to treat iron deficiency 
anaemia in patients undergoing regular renal dialysis treatment. Feraheme will be the 
USPIO used in the study.24 Patients can feel nauseas, constipated, dizzy, suffer 
hypotension, pruritus, back pain or general gastrointestinal upset when taking 
Feraheme.  
 
MRI confers no use of ionising radiation, and is not associated with any adverse 
outcome. The only risk is in patients with magnetic internal or external magnetic 
material interacting with the magnetic field of the MRI machine. Patient will fill in a 
safety questionnaire, and be screened by research staff as well as the scanning 
radiographers prior to scanning. Any patients with possible magnetic material will be 
excluded from scanning. Patients can feel claustrophobic and anxious as well as 
suffer muscle aches from prolonged positioning in the MRI scanner.  
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Gadolinum is the contrast agent used in MRI scanning. It has been used for 15 years 
and has an incidence of less than 1 in 1000 of hypersensitivity or allergic reaction. 
Patients will be screened for previous reactions to gadolinium, and be excluded if 
present. Full resuscitation equipment will be available, and the scan will be 
supervised by trained medical staff. Gadolinium can increase the risk of nephrogenic 
system fibrosis in people with severe renal insufficiency, but only patients with an 
eGFR >40 will be included in the study. Gadovist will be the preparation of 
gadolinium used in the study. Patients can suffer from nausea, headache, dizziness or 
local injection site pain when gadovist is infused.  
 
ADVERSE EFFECTS AND COMPLICATIONS OF CABG SURGERY 
CABG surgery is associated with risks of perioperative morbidity and mortality. 
Patients would require careful titration of analgesia for discomfort relating to the 
sternotomy in the postoperative period. The following are common complications in 
the immediate postoperative period (0-48h) with mild to moderate severity, and will 
not be reported as adverse events but as additional outcomes: 
Atrial fibrillation 
Superficial infection of sternotomy wound and vein harvest site 
Respiratory tract infection 
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Administration of antibiotics for infection in the first 48 h. 
Renal function measured by Creatinine/GFR 
Pleural effusion requiring percutaneous drainage 
Requirement for red blood cell transfusion 
The following are serious complications of CABG surgery, which will not be 
reported as adverse events but as additional outcomes during the period of 0-48h post 
surgery: 
Stroke  
Myocardial infarction 
Inotrope support for low cardiac output state 
Repeat surgery for bleeding.  
The following is a serious complication of CABG surgery, which will reported as an 
adverse event. 
Death 
The patient is quoted an individualised risk of these complications within our unit 
using the Euroscore algorithm.26 
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DEFINITIONS 
An adverse event (AE) is any untoward medical occurrence in a clinical trial subject 
who is administered a medicinal product, which does not have a causal relationship 
with the treatment. 
An adverse reaction (AR) is any untoward or unintended response to an 
investigational medicinal product related to any dose administered.  
An unexpected adverse reaction (UAR) is an adverse reaction that is not consistent 
with the product information in the Elafin brochure. 
A serious adverse event (SAE), serious adverse reaction (SAR) or suspected 
unexpected serious adverse reaction (SUSAR) is any AE, AR or UAR that at any 
dose: 
results in death; 
is life threatening (i.e. the subject was at risk of death at the time of the event; it does 
not refer to an event which hypothetically might have caused death if it were more 
severe); 
requires hospitalisation or prolongation of existing hospitalisation; 
results in persistent or significant disability or incapacity; 
or is a congenital anomaly/birth defect 
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Note: Hospitalisations for treatment planned prior to randomisation and 
hospitalisation for elective treatment of a pre-existing condition will not be 
considered as an AE. Complications occurring during such hospitalisation will be 
AEs. 
 
DETECTING AEs AND SAEs 
All AEs and SAEs must be recorded from the time a participant undergoes the first 
MRI scan, until the last MRI visit ends (or discharge from hospital if the patient does 
not undergo MRI scanning after surgery). 
The Investigator will ask about the occurrence of AEs/SAEs at every visit during the 
study.  Open-ended and non-leading verbal questioning of the participant will be 
used to enquire about AE/SAE occurrence. Participants will also be asked if they 
have been admitted to hospital, had any accidents, used any new medicines or 
changed concomitant medication regimens.  If there is any doubt as to whether a 
clinical observation is an AE, the event should be recorded. 
 
RECORDING AEs AND SAEs 
When an AE/SAE occurs, it is the responsibility of the Investigator to review all 
documentation (e.g. hospital notes, laboratory and diagnostic reports) related to the 
event. The Investigator should then record all relevant information in the CRF and on 
the SAE form (if the AE meets the criteria of serious). 
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Information to be collected includes dose, type of event, onset date, Investigator 
assessment of severity and causality, date of resolution as well as treatment required, 
investigations needed and outcome. MedDRA will be used to code all AEs. 
 
EVALUATION OF AEs AND SAEs 
Seriousness, causality, severity and expectedness should be evaluated as though the 
participant is taking active drug. Where cases are considered serious plus possibly, 
probably or definitely related to drug and unexpected (i.e. SUSARs) the investigator 
team will make a decision regarding unblinding. 
 
Assessment of Seriousness 
The Investigator should make an assessment of seriousness as defined in Section 
10.1. 
 
Assessment of Causality 
The Investigator will make an assessment of whether the AE/SAE is likely to be 
related to treatment according to the following definitions. All AEs/SAEs judged as 
having a reasonable suspected causal relationship (e.g. possibly, probably, definitely) 
to the study drug will be considered as ARs/SARs. All AEs/SAEs judged as being 
related (e.g. possibly, probably, definitely) to an interaction between the study drug 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 411 
and concomitant or rescue/escape drugs, or any AE/SAE that cannot be attributed to 
only the study drug or the concomitant or rescue/escape drugs will also be considered 
to be ARs/SARs . 
Unrelated: where an event is not considered to be related to the study drug. 
Possibly: although a relationship to the study drug cannot be completely ruled out, 
the nature of the event, the underlying disease, concomitant medication or temporal 
relationship make other explanations possible. 
Probably: the temporal relationship and absence of a more likely explanation 
suggest the event could be related to the study drug. 
Definitely: The known effects of the study drug or its therapeutic class, or based on 
challenge testing, suggest that study drug is the most likely cause. 
Alternative causes such as natural history of the underlying disease, other risk factors 
and the temporal relationship of the event to the treatment should be considered and 
investigated. The blind should not be broken for the purpose of making this 
assessment.  
 
Assessment of Severity 
The Investigator will make an assessment of severity for each AE/SAE and record 
this on the CRF according to one of the following categories: 
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Mild: an event that is easily tolerated by the participant, causing minimal discomfort 
and not interfering with every day activities. 
Moderate: an event that is sufficiently discomforting to interfere with normal 
everyday activities. 
Severe: an event that prevents normal everyday activities. 
Note: the term ‘severe’, used to describe the intensity, should not be confused with 
‘serious’ which is a regulatory definition based on participant/event outcome or 
action criteria.  For example, a headache may be severe but not serious, while a 
minor stroke is serious but may not be severe. 
 
Assessment of Expectedness 
If an event is judged to be an AR/SAR, the evaluation of expectedness should be 
made based on knowledge of the reaction and the relevant product information 
documented in the product literature. 
 
REPORTING OF SAEs/SARs/SUSARs 
Once the Investigator becomes aware that an SAE has occurred in a study 
participant, they will report the information to the ACCORD office within 24 hours. 
The SAE form will be completed as thoroughly as possible with all available details 
of the event, signed by a member of the Investigator team. If the Investigator does 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 413 
not have all information regarding an SAE, they will not wait for this additional 
information before notifying ACCORD. The form will be updated when the 
additional information is received. 
The SAE report must provide an assessment of causality and expectedness at the 
time of the initial report to ACCORD according to Sections 10.4.2, Assessment of 
Causality and 10.4.4, Assessment of Expectedness. 
The SAE form should be transmitted by fax to the ACCORD central office on 0131 
242 9447 or may be transmitted by hand to the office. 
The SAE form will also be sent to Proteo Biotech AG on +49 (431) 8888463. 
Events listed in section 2.2.3 will not be reported as adverse events however, will be 
recorded. 
 
REGULATORY REPORTING REQUIREMENTS 
The University of Edinburgh is responsible for Pharmacovigilance reporting on 
behalf of the Co-Sponsors (University of Edinburgh and Lothian Health Board). 
The University of Edinburgh has a legal responsibility to notify the regulatory 
competent authority and the relevant ethics committee (main Research Ethics 
Committee (REC) that approved the trial).  Fatal or life threatening SUSARs will be 
reported no later than 7 calendar days and all other SUSARs will be reported no later 
than 15 calendar days after ACCORD is first aware of the reaction.   
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An Annual Safety Report will be submitted to the regulatory competent authority and 
the main REC listing all SARs and SUSARs.  
A copy of the annual safety report will also be sent to Proteo Biotech AG. 
 
FOLLOW UP PROCEDURES 
After initially recording an AE or recording and reporting an SAE, the Investigator 
will follow each participant‘s medical progress. Follow up information on an SAE 
should be reported to the ACCORD office. 
AEs still present in participants at the last study visit should be monitored until 
resolution of the event or until no longer medically indicated. 
 
PREGNANCY 
Woman of child bearing potential (including pregnant woman) will not be enrolled 
into the trial. 
 
TRIAL MANAGEMENT AND OVERSIGHT ARRANGEMENTS 
PROJECT MANAGEMENT GROUP 
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The trial will be coordinated by a Project Management Group, consisting of the Trial 
Investigators, Trial Research Fellow, Trial Research Nurse, Trial Manager and Data 
Manager. 
 
TRIAL MANAGEMENT 
A Trial Manager and Trial Research Fellow will oversee the study and will be 
accountable to the Chief Investigator. The Trial Manager will be responsible for 
checking the CRFs for completeness, plausibility and consistency. Any queries will 
be resolved by the Investigator or delegated member of the trial team.  
A Delegation Log will be prepared, detailing the responsibilities of each member of 
staff working on the trial.   
 
CENTRAL TRIAL OFFICE 
The Central Trial Office is based in the Edinburgh Clinical Trials Unit. The office 
will be responsible for randomisation, collection of data in collaboration with the 
research nurses, data processing and analysis. 
Publication and dissemination of the study results will be coordinated by “Trial 
Research Fellow,” in collaboration with the Chief Investigator and other 
Investigators. 
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TRIAL STEERING COMMITTEE 
A Trial Steering Committee (TSC) will consist of an independent cardiologist, 
cardiothoracic surgeon and clinical academic together with the trial management 
group Dr Peter Henriksen, Professor Newby, Dr Shirjel Alam, and the trial manager. 
Responsibility for calling and organising trial steering committee meetings will lie 
with the principal investigator, and at least one meeting will be convened midway 
through the trial. 
 
DATA MONITORING COMMITTEE 
An independent Data Monitoring Committee (DMC) will be established to oversee 
the safety of subjects in the trial.  This will include an independent statistician, 
cardiologist and clinical pharmacologist. At least one meeting will be convened, 
which will take place after 40 trial participants have completed. 
INSPECTION OF RECORDS 
Principal Investigators and institutions involved in the study will permit trial related 
monitoring, audits, REC review, and regulatory inspection(s). In the event of an 
audit, the Investigator agrees to allow the Sponsors, representatives of the Sponsors 
or regulatory authorities direct access to all study records and source documentation. 
 
STUDY MONITORING 
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The ACCORD (joint office for University of Edinburgh and Lothian Health Board) 
Clinical Trials Monitor or an appointed local monitor will visit the Edinburgh study 
site prior to the start of the study and during the course of the study.   
 
RISK ASSESSMENT 
This will be carried out by the ACCORD Clinical Trials Monitor to provide risk 
assessment analysis and will follow an agreed plan as agreed by the sponsor. An 
independent risk assessment will also be carried out by the ACCORD Quality 
Assurance to determine if an audit(s) should be performed before/during/after the 
study. 
 
Potential Risks 
There were no specific toxicities identified from a phase I trial. There is theoretical 
risk of anaphylaxis, and extravasations of the infusion via a central venous cannula. 
There are very low risks associated with MRI scanning and the use of Feraheme and 
gadolinium contrast (see section 10.2). 
Minimising Risk 
The patient will be invasively monitored by the anaesthetic, surgical and nursing 
staff during the operation (when Elafin/placebo is being infused) and in the 
subsequent cardiac intensive care stay. 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 418 
 
GOOD CLINICAL PRACTICE MODULE 
 
ETHICAL CONDUCT OF THE STUDY 
The study will be conducted in accordance with the principles of the International 
Conference on Harmonisation Tripartite Guideline for Good Clinical Practice (ICH 
GCP). 
A favourable ethical opinion will be obtained from the appropriate REC and local 
R&D approval will be obtained prior to commencement of the study. 
 
REGULATORY COMPLIANCE THE STUDY 
The study will not commence until a Clinical Trial Authorisation (CTA) is obtained 
from the MHRA. The protocol and study conduct will comply with the Medicines for 
Human Use (Clinical Trials) Regulations 2004, and any relevant amendments. 
 
INVESTIGATOR RESPONSIBILITIES 
The Investigator is responsible for the overall conduct of the study at the site and 
compliance with the protocol and any protocol amendments. In accordance with the 
principles of ICH GCP, the following areas listed in this section are also the 
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responsibility of the Investigator. Responsibilities may be delegated to an appropriate 
member of study site staff. Delegated tasks will be documented on a delegation log 
and signed by those named on the list. 
 
Informed Consent 
The Investigator is responsible for ensuring informed consent is obtained before any 
protocol specific procedures are carried out. The decision of a participant to 
participate in clinical research is voluntary and should be based on a clear 
understanding of what is involved.  
Participants will receive adequate oral and written information –participant 
information and informed consent forms will be provided. The oral explanation to 
the participant will be performed by the Investigator or designated person, and must 
cover all the elements specified in the participant information sheet/informed 
consent.  
The participant must be given every opportunity to clarify any points they do not 
understand and, if necessary, ask for more information. The participant will be given 
sufficient time to consider the information provided. It will be emphasised that the 
participant may withdraw their consent to participate at any time without loss of 
benefits to which they otherwise would be entitled. 
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The participant should be informed and agree to their medical records being 
inspected by regulatory authorities but understand that their name will not be 
disclosed outside the hospital. 
The Investigator or delegated member of the trial team and the participant will sign 
and date the informed consent form(s) to confirm that consent has been obtained.  
The participant should receive a copy of this document and a copy filed in the 
Investigator Site File (ISF).  
Study Site Staff 
The Investigator will be familiar with the IMP, protocol and the study requirements. 
It is the Investigator’s responsibility to ensure that all staff assisting with the study 
are adequately informed about the IMP, protocol and their trial related duties.  
 
Data Recording 
The Investigator is responsible for the quality of the data recorded in the CRF.   
 
Investigator Documentation 
Prior to beginning the study, each Investigator will provide the following documents 
to ECTU, including but not limited to: 
An original signed Investigator’s Declaration (as part of the Clinical Trial Agreement 
documents); 
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Curriculum vitae (CV), signed and dated by the Investigator indicating that it is 
accurate and current. 
ECTU will ensure all other documents required by ICH GCP are retained in a Trial 
Master File and that appropriate documentation is available in local ISFs. 
 
GCP Training 
All study staff will hold evidence of appropriate GCP training or undergo GCP 
training. This should be updated every two years throughout the trial. 
 
 
Confidentiality 
All laboratory specimens, evaluation forms, reports, and other records will be 
identified in a manner designed to maintain participant confidentiality. All records 
will be kept in a secure storage area with limited access. Clinical information will not 
be released without the written permission of the participant, except as necessary for 
monitoring and auditing by the Sponsor, its designee, Regulatory Authorities, or the 
REC. The Investigator and study site staff involved with this study may not disclose 
or use for any purpose other than performance of the study, any data, record, or other 
unpublished, confidential information disclosed to those individuals for the purpose 
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of the study. Prior written agreement from the Sponsor or its designee must be 
obtained for the disclosure of any said confidential information to other parties. 
 
Data Protection 
All Investigators and study site staff involved with this study will comply with the 
requirements of the Data Protection Act 1998 with regard to the collection, storage, 
processing and disclosure of personal information and will uphold the Act’s core 
principles. Access to collated participant data will be restricted to those clinicians 
treating the participants. 
Computers used to collate the data will have limited access measures via user names 
and passwords. 
Published results will not contain any personal data that could allow identification of 
individual participants. 
 
 
STUDY CONDUCT RESPONSIBILITIES 
 
PROTOCOL AMENDMENTS 
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Any changes in research activity, except those necessary to remove an apparent, 
immediate hazard to the participant, must be reviewed and approved by the Chief 
Investigator. Amendments to the protocol must be submitted in writing to the 
appropriate REC, Regulatory Authority and local R&D for approval prior to 
participants being enrolled into an amended protocol. 
 
PROTOCOL VIOLATIONS AND DEVIATIONS 
The Investigator should not implement any deviation from the protocol without 
agreement from the Chief Investigator and appropriate REC, Regulatory Authority 
and R&D approval except where necessary to eliminate an immediate hazard to trial 
participants. 
In the event that an Investigator needs to deviate from the protocol, the nature of and 
reasons for the deviation should be recorded in the CRF. If this necessitates a 
subsequent protocol amendment, this should be submitted to the REC, Regulatory 
Authority and local R&D for review and approval if appropriate. 
 
STUDY RECORD RETENTION 
All study documentation will be kept for 15 years. 
 
END OF STUDY 
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The end of study is defined as the last participant’s last visit. 
The Investigators and/or the trial steering committee have the right at any time to 
terminate the study for clinical or administrative reasons.  
The end of the study will be reported to the REC and Regulatory Authority within 90 
days, or 15 days if the study is terminated prematurely. The Investigators will inform 
participants and ensure that the appropriate follow up is arranged for all involved. 
A summary report of the study will be provided to the REC and Regulatory 
Authority within 1 year of the end of the study. 
 
 
CONTINUATION OF DRUG FOLLOWING THE END OF STUDY 
The study drug will not be continued at the end of the study. The efficacy of the 
medication surrounds its ability to attenuate cardiac injury and inflammation at the 
time of cardiac bypass.  
 
REPORTING, PUBLICATIONS AND NOTIFICATION OF RESULTS 
AUTHORSHIP POLICY 
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Ownership of the data arising from this study resides with the study team. On 
completion of the study, the study data will be analysed and tabulated, and a clinical 
study report will be prepared in accordance with ICH guidelines.  
 
PUBLICATION 
The clinical study report will be used for publication and presentation at scientific 
meetings. Investigators have the right to publish orally or in writing the results of the 
study. 
Summaries of results will also be made available to Investigators for dissemination 
within their clinics (where appropriate and according to their discretion). 
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Abstract 
 
Background: Inflammation following acute myocardial infarction has detrimental 
effects on reperfusion, myocardial remodelling and ventricular function. Magnetic 
resonance imaging using ultrasmall superparamagnetic particles of iron oxide 
(USPIO) can detect cellular inflammation in tissues, and we therefore explored its 
role in acute myocardial infarction in humans. 
Methods: Sixteen patients within five days of ST-segment elevation myocardial 
infarction underwent 3 sequential magnetic resonance scans at -1, 24 and 48 h 
following no infusion (controls; n=6) or intravenous infusion of USPIO (n=10; 4 
mg/kg). T2*-weighted multi-gradient-echo sequences were acquired and R2* values 
calculated for specific regions of interest.  
Results: In the control group, R2* remained constant in all tissues throughout all 
scans with excellent repeatability (bias of  -0.208, s-1, coefficient of repeatability of 
26.96, s-1; intra-class coefficient 0.989). Consistent with uptake by the 
reticuloendothelial system, R2* increased in the liver (84±49.5 to 319±70.0 s-1; 
p<0.001) but was unchanged in skeletal muscle (54±8.4 to 67.0±9.5 s-1; p>0.05) 24 
hours after USPIO administration. In the myocardial infarct, R2* increased from 
41.0±12.0 (baseline) to 155±45.0  (p<0.001) and 124±35.0 s-1 (p<0.05) at 24 and 48 
h respectively. A similar but lower magnitude response was seen in the remote 
myocardium from 39±3.2 to 80±14.9 (p<0.001) and 67.0±15.7 s-1 (p<0.05) 
respectively. 
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Conclusion: Following acute myocardial infarction, USPIO uptake occurs with the 
infarcted and remote myocardium. This technique holds major promise as a potential 
method of assessing cellular myocardial inflammation and left ventricular 
remodelling that may have a range of applications in patients with myocardial 
infarction and other inflammatory cardiac conditions. 
Clinical Trial Registration Information: 
http://clinicaltrials.gov/ct2/show/NCT01323296 
Unique Identifier - NCT01323296 
Other Study ID (NHS Research Ethic Committee) - 10/S1103/50 
 
Key Words:  Myocardial Infarction, Inflammation, Magnetic Resonance, USPIO 
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Introduction 
Inflammation occurs in the acutely infarcted myocardium in order to remove necrotic 
cellular debris and allow tissue remodelling. Excessive inflammation may follow 
reperfusion therapy, and can have detrimental effects on healing and left ventricular 
remodelling.(Nahrendorf et al., 2010) With the aim of improving outcomes following 
acute myocardial infarction, novel drugs are increasingly focusing on optimisation of 
myocardial repair and regeneration, and include anti-inflammatory 
interventions.(Bonvini et al., 2005, Frangogiannis, 2006, Gonzalez et al., 2011, 
Steffens et al., 2009) There is therefore a need for non-invasive methods to assess in 
vivo myocardial inflammation following myocardial infarction both to define the 
healing process and to measure the potential efficacy of novel therapeutic 
interventions. 
Magnetic resonance imaging is ideally suited for the serial examination of the heart 
as it is non-invasive, does not involve ionizing radiation and has excellent soft tissue 
contrast and spatial resolution. Cardiac magnetic resonance, using T2-weighted 
imaging, has previously been used to detect myocardial edema associated with 
myocardial infarction as it may help delineate the “area at risk” from the infarcted 
region.(Garcia-Dorado et al., 1993) However there are major differences in the 
diagnostic performance of edema imaging and there have been conflicting results 
regarding its utility as a prognostic marker or guide to therapeutic 
intervention.(Viallon et al., 2012) (Eitel et al., 2010, Larose et al., 2010) One 
explanation for this is that magnetic resonance imaging of edema does not directly 
assess the more dynamic cellular inflammatory processes.  
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Iron oxide particles can be used as a contrast medium in magnetic resonance imaging 
since they alter the T2* relaxation time of tissues in which they accumulate. 
Ultrasmall superparamagnetic particles of iron oxide (USPIO) are taken up by cells 
of the liver, spleen, bone marrow and lymph nodes. As a result of their small size 
(approximately 30 nm) they extravasate freely through capillaries and are 
phagocytosed by tissue-resident inflammatory cells of the reticuloendothelial 
system.(Ruehm et al., 2001b) These cells are predominately macrophages, but 
neutrophils may also take up USPIOs.(Dousset et al., 1999, Gellissen et al., 1999a) 
We have recently established that USPIOs can be used to assess vascular cellular 
inflammation in patients with abdominal aortic aneurysms.(Richards et al., 2011a) 
Histological examination of aneurysm tissue confirmed co-localization and uptake of 
USPIO in areas with macrophage infiltration and mural USPIO uptake was 
associated with a 3-fold increase in the rate of abdominal aortic aneurysm 
expansion.(Richards et al., 2011a) T2*-weighted MRI has been validated as a 
method of detecting hepatic and myocardial iron accumulation in patients with 
thalassemia and transfusion-related iron overload, and this method could be adapted 
for the detection of focal USPIO accumulation.(Anderson et al., 2001, Westwood et 
al., 2005) 
We hypothesised that we could use USPIO to track inflammatory cell infiltration 
within the myocardium of patients who had recently sustained an acute myocardial 
infarction. The aims of the study were therefore to investigate the proof-of-principle 
that USPIO could be used to assess cellular myocardial inflammation following acute 
myocardial infarction in humans.  
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Methods 
Subjects 
This study was an open-label pilot proof-of-concept study in 16 patients who 
suffered a recent myocardial infarction. Inclusion criteria were age 18-80 years, 
recent (within 48 h) myocardial infarction defined by the universal definition of 
myocardial infarction and plasma troponin I concentration in excess of 10 µg/L at 12 
h from the onset of chest pain (Thygesen et al., 2007a). Exclusion criteria were 
known critical stenosis (≥95%) of left main stem, ongoing symptoms of unstable 
angina, atrial fibrillation, heart failure (Killip class ≥II), hepatic failure (Childs-Pugh 
grade B or C) or renal failure (estimated glomerular filtration rate <25 mL/min), 
contraindication to magnetic resonance imaging, past history of systemic iron 
overload or hemochromatosis, and patients with known allergy to dextran- or iron-
containing compounds.  
All patients suffered an acute ST-elevation myocardial infarction. One patient in 
each group received thrombolytic therapy with tenecteplase, followed by 
percutaneous coronary angioplasty and stent placement. One patient in the control 
group re-perfused spontaneously followed by percutaneous coronary angioplasty and 
stent placement. All other patients were treated by primary percutaneous coronary 
intervention. 
All patients gave written informed consent and the study was conducted with the 
approval of the local research ethics committee. 
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Ultrasmall superparamagnetic particles of iron oxide 
Intravenous infusion of USPIO was performed immediately following the initial 
baseline magnetic resonance scan. USPIO (Ferumoxytol; Advanced Magnetics Inc, 
Cambridge, MA) was administered via a peripheral venous cannula at a dose of 4 
mg/kg at a rate of up to 1 mL/s. Hemodynamic and electrocardiographic monitoring 
was conducted throughout. 
Magnetic Resonance Imaging 
 
Sequential imaging was performed at baseline (24-72 h after admission), and 24 and 
48 h thereafter. In 10 patients, USPIO was administered immediately after the baseline 
scan. Six patients received no infusion and acted as control subjects. Magnetic 
resonance imaging was performed using a combination of body matrix and spine coil 
matrix coil elements of a 3-tesla Verio scanner (Siemens Medical, Germany). 
Standard cardiac breath-held ECG-gated true-FISP sequences were used to acquire 
vertical long axis, horizontal long axis and short axis views of the heart.  USPIO 
imaging was performed using established T2*-weighted multi-gradient-echo 
sequences, breath-held and cardiac-gated after a volumetric shim had been applied 
over the entire heart volume. Standard cardiac slice width (6 mm width with 4 mm 
gap) and echo times (2.1-17.1 ms range) with matrix size of 256x115. The in-plane 
resolution differed as required for larger or smaller objects, generally a field of view 
of 400x300 was used with an in-plane resolution of 2.6x1.6. Quantitative analysis of 
USPIO accumulation was achieved by calculation of T2* relaxation times before and 
after administration of USPIO.(Richards et al., 2011a) In order to optimise image 
analysis and prevent degradation due to “T2*-blooming” artefacts, USPIO images 
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were quantitatively analysed using a susceptibility gradient mapping post-processing 
technique previously used in SPIO imaging to quantitate USPIO accumulation using 
changes in calculated T2* relaxation times.(Dahnke et al., 2008) 
Immediately after the baseline T2*-weighted scan, breath-held inversion recovery 
sequences in the short-axis, and horizontal and vertical long-axis planes were used to 
acquire late enhancement images 10-15 min following an intravenous administration 
of gadolinium contrast agent (0.2 mmol/kg; Gadovist, Bayer Plc, Germany).  Optimal 
TI was determined on a slice-by-slice basis using standard late enhancement 
protocols.  The inversion recovery late enhancement short axis slices were acquired 
with the same slice position as the short axis T2*-weighted slices. The T2*-weighted 
short-axis acquisitions included views through the liver and spleen, and allowed 
quantification of USPIO uptake within the reticuloendothelial system via changes in 
these tissues’ R2* value. 
Image Analysis 
Late enhancement analysis was performed using QMass software (Medis medical 
imaging systems, Netherlands), allowing quantification of infarct size and location 
for correlation with USPIO-related signal changes.  
Baseline, and 24 and 48 h T2*-weighted multi-gradient-echo images for each patient 
were spatially co-registered using ANALYZE software (AnalyzeDirect Software, 
United States). The four echoes (TE = 2.13, 4.27, 6.41, 8.55 ms) in a multi-echo 
T2*-weighted sequence were combined to generate a T2* map, in which the data 
represented the T2* value (S(t) = S(0)exp- (t/T2*)) for each voxel. This was 
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achieved using in-house software developed in Matlab (Mathworks, US). The T2* 
value is the decay constant for the exponential decay of signal intensity with time. In 
the presence of USPIO, the signal decays more rapidly due to local field 
inhomogeneities and the T2* value is reduced. A 3x3 voxel Gaussian filter was 
applied to the individual echoes to reduce noise. By minimising the sum of the 
squares of errors between the data and an exponential function, the decay constant 
(i.e. T2*) was obtained. An experimentally determined threshold for the co-efficient 
of determination (r2>0.85) was used to exclude data that did not have an acceptable 
exponential decay when SI was plotted against echo time. The inverse of T2*, R2*, 
was then calculated to assess USPIO uptake. In our laboratory, we have previously 
assessed the repeatability of the measurement of the R2* value by comparing data 
from two T2*W sequences (run 1 versus run 2) performed in quick succession 
without moving the patient. This was performed on a voxel-by-voxel basis with a 
total of 32,936 data points, of which 1.2% were affected by artifact and discarded. 
Using the Bland and Altman method,18 there was no evidence of mean difference 
(0.99±21.9 s-1) with a coefficient of repeatability of 42.9 s-1.  
The transformation matrix of the co-registration was then applied to the subsequent 
T2*-weighted echoes and R2* was calculated on a voxel-by-voxel basis to generate 
co-registered R2* ‘maps’ at baseline, and 24 and 48 h. The late enhancement short-
axis images were also spatially co-registered with the R2* images for each visit in 
case of lack of reproducibility of patient breath-holding between scans. Regions of 
interests (ROIs) were selected on the late enhancement images and applied to the co-
registered R2* maps corresponding to: (i) micro-vascular obstruction if present, (ii) 
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infarct area (defined by late gadolinium enhancement), (iii) peri-infarct area 
(adjacent to late gadolinium enhancement), (iv) myocardium remote from the infarct 
zone (distant from late gadolinium enhancement), (v) skeletal muscle, (vi) blood 
pool, (vii) liver and (viii) spleen (Figure 1). The ROIs were mapped to the first T2* 
echo before being applied to R2* maps to ensure there was coherence to the 
corresponding areas on all 3 scans, and no overlap with the blood pool or extra-
cardiac structures. Two investigators created and quantified ROIs for all scans 
independently in order to assess reproducibility of the technique. 
 
Statistical Analysis 
All statistical analysis was performed with GraphPad Prism version 4.00 (GraphPad 
Software, San Diego California USA), except the Intraclass Correlation (ICC) which 
was performed with SPSS (IBM Version 20.0.0, USA) using a one-way random 
effects model. Repeatability was assessed by the method of Bland and Altman and 
coefficient of repeatability defined as twice the standard deviation of the mean of the 
differences.(Bland and Altman, 1986) Patient characteristics (Table 1) were 
compared using unpaired non-parametric Mann-Whitney test. R2* values at baseline, 
24 hours and 48 hours for each ROI were compared using repeated measure one-way 
ANOVA (Friedman test). If significant, Dunn’s multiple comparison post-test was 
performed comparing R2* value at baseline to 24 hours, and baseline to 48 hours. 
Statistical significance was defined as two-sided P<0.05. 
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Results 
 
All patients sustained an acute myocardial infarction with a substantial area of 
myocardial necrosis (Table 1). All patients underwent three scans (baseline, and 24 
and 48 h) including T2*-weighted multi-gradient-echo sequences and late 
gadolinium enhancement. Late enhancement reconfirmed myocardial infarction in all 
patients.  
Repeatability 
Data from patients who did not receive USPIO administration were used to assess 
any potential changes in R2* attributable to acute myocardial infarction alone. There 
were no changes in R2* value within the myocardium or the infarct zone itself 
(Figures 2 and 3; on-line data supplement Table S1; p>0.05). Similar findings were 
also observed in other organs such as the liver, spleen and skeletal muscle. 
Moreover, we were able to demonstrate excellent repeatability for the assessment of 
R2* value with a mean bias of -0.208,s-1, coefficient of repeatability of 26.96 s-1 and 
intra-class coefficient 0.989 (on-line data supplement Figure S1). 
Effect of USPIO Administration 
All patients tolerated the infusions well with no significant adverse events or 
arrhythmia. In the area of myocardial infarction, R2* increased from 41.0±12.0 s-1 at 
baseline to 155±45.0 (p<0.001) and 124±35.0 s-1 (p<0.05) at 24 and 48 h respectively 
following USPIO administration (Figures 2 and 3). Although more modest, the 
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remote non-infarcted myocardium also demonstrated an increase from a baseline of 
39.0±3.2 to 80.0±14.9 (p<0.001) and 67.0±15.7 s-1 (p<0.05) at 24 and 48 h 
respectively (Figures 2 and 3; online data supplement Table S2).   
To determine whether there was a non-specific effect of USPIO enhancing R2* 
values in muscle, we assessed regions of interest within skeletal muscle. We were 
able to confirm that there was no change in R2* value of skeletal muscle (Figures 2 
and 3; online data supplement Table S2). Given that USPIO are taken up by cells of 
the reticuloendothelial system, both the liver and spleen were expected to develop 
marked changes in R2* values and act as positive controls. In the liver, there was a 
large increase in R2* from 84.0±49.5 s-1 at baseline to 319±70.0 (p<0.001) and 
243.0±63.6 s-1 (p<0.001) at 24 and 48 h respectively following USPIO 
administration. A similar pattern was also seen in the spleen (online data supplement 
Table S2).
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Discussion 
For the first time, we have demonstrated that USPIO are taken up into the 
myocardium of patients with a recent myocardial infarction. The increase of R2* by 
USPIO was highest within infarcted tissue, although we did observe a more modest 
increase within myocardium remote from the site of infarction. This suggests early 
macrophage and inflammatory cell infiltration predominantly occurs within the 
infarcted myocardium but appears to be associated with a more global influx of these 
cells that extends beyond the area at risk. However no histological quantification of 
macrophage infiltration was performed, and so the degree of inflammation cannot be 
correlated to MRI changes. Our preliminary findings need further confirmation in 
larger cohorts but this technique does appear to hold major promise in the 
investigation of myocardial inflammation following myocardial infarction and could 
be applied to other inflammatory cardiac diseases such as cardiac sarcoidosis, 
myocarditis or transplant rejection. 
USPIO are actively taken up by inflammatory phagocytic cells, especially 
macrophages. They have been used to explore a number of inflammatory conditions 
including atherosclerotic plaques and abdominal aortic aneurysms.(Kooi et al., 
2003b, Trivedi et al., 2006b) (Richards et al., 2011a) Histological examination of 
excised clinical tissue has confirmed co-localisation of USPIO with 
macrophages.(Kooi et al., 2003b, Trivedi et al., 2006b, Schmitz et al., 2001, Ruehm 
et al., 2001b) More specifically, pre-clinical models have demonstrated the uptake of 
magnetic nanoparticles into macrophages of infarcted myocardium by both 
fluorescence microscopy and immunohistochemistry.(Sosnovik et al., 2007) We 
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were unable to obtain tissue confirmation of USPIO uptake into macrophages in our 
cohort of patients. It is possible that other cell types with phagocytic capacity such as 
neutrophils may contribute to the increase in R2* value.(Gellissen et al., 1999a) 
However, we have no reason to believe that uptake would differ from previous 
studies and, indeed, phagocytosis into macrophages is 4-6 times greater with 
ferumoxytol than with ferumoxtran-10, a previously used USPIO agent.(Yancy et al., 
2005) Moreover, we have demonstrated that organs of the reticuloendothelial system, 
such as the liver and spleen, demonstrate marked increases in R2* consistent with 
monocyte and macrophage uptake.  
Data have also demonstrated increased numbers of macrophages in the myocardium 
remote from the area of infarction both in murine models and autopsies of patients 
who have died from myocardial infarction.(Lee et al., 2012) Expression of cytokines 
is not confined to the infarct or peri-infarct zone, but is also expressed by 
myocardium remote from the infarct.(Irwin et al., 1999) Furthermore, when 
myocardial infarction is induced in an abdominal heterotopic transplanted rodent 
heart, the native heart demonstrates a decrease in left ventricular (LV) fractional 
shortening and increased in LV end-diastolic dimension accompanied by increased 
TNF-.(Nakamura et al., 2003) Thus the post-infarct inflammatory process may 
induce cytokine production and inflammatory cell infiltration in remote “normal 
myocardium”. We found an almost three-fold increase in R2* in remote 
myocardium. However, this may have been to USPIO within the blood pool altering 
R2* when perfusing the myocardium. This does seem to be the case when imaging 
24 hours post USPIO infusion (see Chapter 5: page 108). However, if imaging took 
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place after the blood pool of USPIO was cleared and the flux of monocytes in the 
myocardium had ceased, it would be possible to investigate the presence of tissue 
resident macrophages in the remote myocardium. Thus our technique has the 
potential, pending histo-pathological confirmation, to study macrophage infiltration 
and myocardial inflammation not just in the area of infarction but throughout the 
heart. This has potential applications as a method of assessing and monitoring left 
ventricular inflammation and remodelling following myocardial infarction. 
R2* was decreasing in myocardial, splenic and hepatic tissues by 48 h post-infusion. 
The decrease in R2* in the blood pool is to be expected given efficient USPIO 
phagocytosis by reticuloendothelial cells leading to rapid clearance.(Yancy et al., 
2005) However pre-clinical findings suggest that monocyte tissue residence in 
infarcted myocardium is brief despite high recruitment rates.(Leuschner et al., 2012)  
Consistent with this study, we found evidence of high extra-medullary activity in 
terms of high USPIO uptake in the liver and spleen in contrast with minimal uptake 
in the bone marrow (on-line data supplement Figure S2). The decrease in R2* value 
in the splenic tissues at 48 hours may represent mobilisation of the splenic reservoir 
of monocytes.(Swirski et al., 2009b, Nahrendorf et al., 2010)  In addition, the 
decrease in tissue R2* will reflect clearance of extravasated particles by phagocytic 
cells through efflux of USPIO laden inflammatory cells. The time course of 
monocyte and macrophage recruitment into the myocardium is unclear from our 
study and would require USPIO administration at differing time points following 
myocardial infarction. This would help define the peak influx and time course of 
macrophage trafficking into the myocardium.  
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We have applied this technique to patients who have recently sustained a myocardial 
infarction. However, this approach could be applied to other cardiac conditions that 
involve intense inflammatory processes. This could include viral myocarditis, giant 
cell myocarditis, anthracycline-induced cardiotoxicity and sarcoidosis. Indeed, it may 
also have a role in detecting cardiac transplant rejection in a non-invasive manner. 
However, this needs further careful validation in well phenotyped clinical subgroups.  
Limitations to our study included the lack of histo-pathological confirmation of 
macrophage uptake, the longer reperfusion time in the USPIO group potentially 
resulting in more inflammation and the injection of USPIOs at variable time points 
post MI. However, given the previous evidence that USPIO are taken up by 
macrophages, our study provides proof of principle that cellular inflammation may 
be tracked post myocardial infarction. 
In conclusion, we have demonstrated for the first time that USPIO is taken up by the 
infarct tissue in patients with recent myocardial infarction, and by the peri-infarct and 
remote myocardium to a lesser degree. Given previous pre-clinical and clinical 
studies, this is likely to correspond to cellular inflammation. This represents a novel 
non-invasive method to further study cardiac inflammation and therapeutic 
interventions. It may also provide prognostic information or provide a diagnostic tool 
for the investigation of inflammatory cardiac conditions such as myocarditis and 
transplant rejection, as well as a potential biomarker for therapeutic interventions 
targeted at improving left ventricular remodelling following infarction. 
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Table & Figure Legends 
Table 1 
Characteristics of trial participants. 
 
Figure 1: Object map creation - Following registration with late gadolinium 
enhancement (LGE) images, an “object map” (OM) was defined from regions of 
interest of specific tissues and subsections: skeletal muscle (light blue), spleen (dark 
blue), liver (yellow), blood pool (lilac) and heart subdivided into areas of infarction 
(red), peri-infarction (white) and remote myocardium (green). The object map was 
spatially co-registered with the R2* map (R2*) to measure specific R2* values 
(R2*+OM).  
Figure 2: Tissue R2* Values - R2* value in regions of interest from the different 
tissues in control patients (blue) and patients who received an infusion of ultrasmall 
supraparamagnetic particles of iron oxide (USPIO; red). Asterisk denotes a 
significant increase from baseline. 
Figure 3: Comparison of R2* colour maps in patients with myocardial infarction at 
(i) baseline and (ii) 24 hours after no infusion (3A, upper panels) or after an infusion 
of ultrasmall supraparamagnetic particles of iron oxide (USPIO; 3B, lower panels). 
R2* values did not change in the liver (blue) or myocardium (remote myocardium, 
green; infarct, red; microvascular obstruction, purple) of the control patient (3A iii) 
but did rise in the patient who received USPIOs (3B iii). 
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Table & Figure Legends for Supplementary Data 
Table S1: 
R2* value (s-1) in infarct region of interest (ROI) of control patients.  
Table S2:  
R2* value (s-1) in infarct region of interest (ROI) of patients receiving ultrasmall 
superparamagnetic particles of iron oxide (USPIO).  
 
 
Figure S1: Bland-Altman plot - Differences versus average of R2* values in all 
patients. 
Figure S2: Medullary and extramedullary R2* value post myocardial infarction - 
There is a significant increase in R2* value of hepatic and splenic tissues at 24 hours, 
that later fall. The R2* value of rib bone marrow does not increase significantly. 
*P<0.05 versus baseline. 
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Table 1 
 USPIO 
GROUP 
CONTRO
L GROUP 
 
p Value 
    
Number 10 6  
Age (yr (range)) 52 (38-65) 55 (48-65) 0.5622 
Male 10 5 0.1824  
WBC  (x109/L) 9.3±2.6 12.7±3.9 0.0934 
    
Risk Factors    
      Hypercholesterolemia 5 2 0.5153 
      Hypertension 4 0 0.7897 
      Family History of  6 3 0.6963 
      Diabetes Mellitus 0 0 1.0 
      Current Smoker (Ex-smoker) 4 (2) 3 (1) 0.6963 
    
Myocardial Infarction    
      Time from symptoms to reperfusion  
(min; meanSD) 
300218 18192 0.2198 
      Plasma Troponin I concentration  
(µg/L) 
33.0415.5 45.2710.6
3 
0.1120 
      Infarct Volume  
(mL (95% confidence intervals)) 
35.1  
(8.0, 62.2)  
43.2 
(14.9,71.7) 
0.1471 
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USPIO – Ultrasmall superparamagnetic particles of iron oxide; CAD – coronary 
artery disease; SD – standard deviation. 
 
  
    
Site of Infarction    
      Anterior Infarct 3 3 0.4237 
      Lateral Infarct 1 3 0.0736 
      Inferior Infarct 6 0 0.0164 
    
Left Ventricular Variables    
      Ejection Fraction (%, meanSD) 5415 48 11  0.5622 
      Myocardial Mass (g, meanSD) 7619 67 15 0.3676 
    
Timing of Scanning    
      Reperfusion to Baseline Scan  
(h (meanSD)) 
4930 4416 0.8749 
      Reperfusion to Scan 2 (h (meanSD)) 7330 6817 0.9578 
      Reperfusion to Scan 3 (h (meanSD)) 9530 9238 0.7925 
      USPIO Infusion to Scan 2 (h (meanSD)) 222 NA  
      USPIO Infusion to Scan 3 (h (meanSD)) 443 NA  
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Figure 1 
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Figure 2 
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Figure 3 
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Abstract 
 
Background. Elafin is a potent endogenous neutrophil elastase inhibitor that 
protects against myocardial inflammation and injury in pre-clinical models of 
ischemic-reperfusion injury. We investigated whether Elafin could inhibit 
myocardial ischemia-reperfusion injury induced during coronary artery bypass 
graft (CABG) surgery. 
 
Methods and Results. In a randomized double blind placebo controlled parallel 
group clinical trial, 87 patients undergoing CABG surgery were randomized 1:1 
to intravenous Elafin 200 mg or saline placebo administered after induction of 
anesthesia and prior to sternotomy. Myocardial injury was measured as cardiac 
troponin I release over 48 h (area under the curve, AUC) and myocardial 
infarction identified with magnetic resonance imaging. Post-ischemic 
inflammation was measured by plasma markers including AUC high-sensitive C-
reactive protein (hs-CRP), and myeloperoxidase (MPO). 
 
Elafin infusion was safe and resulted in >3000-fold increase in plasma Elafin 
concentrations and >50% inhibition of elastase activity in the first 24 hours. This 
did not reduce myocardial injury over 48 hours (ratio of geometric means 
(Elafin/placebo) of AUC troponin I 0.74 (95% CI 0.47 to 1.15, P=0.18) although 
post-hoc analysis of the high-sensitive assay revealed lower troponin I 
concentrations at 6 hours in Elafin treated patients (median 2.4 versus 4.1 μg/L, 
P=0.035). Elafin had no effect on myocardial infarction (Elafin, 7/34 versus 
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placebo, 5/35 patients) or on markers of inflammation: mean differences for 
AUC hs-CRP of 499 mg/L/48-h (95% CI -207 to 1205, P=0.16), and AUC MPO of 
238 ng/mL/48-h (95% CI -235 to 711, P=0.320).  
 
Conclusion. There was no strong evidence that neutrophil elastase inhibition with 
a single-dose Elafin treatment reduced myocardial injury and inflammation 
following CABG-induced ischemia-reperfusion injury. 
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What is already known about this subject? 
Ischaemia-reperfusion contributes to myocardial injury during cardiac surgery. 
Therapies to reduce injury remain elusive despite promise from pre-clinical studies. 
Elafin is an endogenous neutrophil elastase inhibitor with broad ranging anti-
inflammatory activity. Elafin reduces myocardial injury and infarct size and is 
associated with better myocardial function in pre-clinical models of ischaemia- 
reperfusion injury. 
What does this study add? 
We investigated Elafin in myocardial ischemia-reperfusion injury induced during 
coronary artery bypass graft surgery. A single dose of Elafin was safe and reduced 
circulating elastase activity but did not attenuate ischaemia-reperfusion injury or 
post-operative inflammation following coronary artery bypass surgery.  
How might this impact on clinical practice? 
Elafin’s promise as a therapeutic agent was not translated in this first phase 2 clinical 
trial.  Post-hoc analysis revealed reduced myocardial injury at an early timpeoint in 
Elafin treated patients.  Further studies with continuous infusion and alternative 
clinical models are needed to elucidate whether Elafin can confer protection form 
ischaemia-reperfusion injury. 
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Trial registration. EudraCT 2010-019527-58, ISRCTN82061264 
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Introduction 
 
Ischemia-reperfusion injury occurs when blood flow is restored to organs and 
tissues that have sustained a period of interrupted blood supply. This occurs 
following therapies for acute myocardial infarction and ischemic stroke, and is a 
necessary consequence of solid organ transplantation. Mechanisms of cell and 
tissue injury include a neutrophil-mediated post-ischemic inflammatory response 
and activation of cellular death pathways following reperfusion (Hansen, 1995). 
Protecting organs from ischemia-reperfusion injury to improve clinical outcome is 
a high priority. Despite intense research efforts and huge promise from pre-
clinical and early phase clinical trials, there are currently no effective therapies 
that can limit this injurious response.  
 
During coronary artery bypass graft (CABG) surgery and cardiopulmonary 
bypass, coronary blood flow is interrupted and the heart is put into circulatory 
arrest. This causes ischemia-reperfusion injury that is exacerbated by adverse 
neutrophil-mediated myocardial inflammation and injury (Vinten-Johansen, 
2004, Butler et al., 1993, Wakayama et al., 2007). CABG surgery therefore 
represents a programmed clinical model of ischemia-reperfusion injury that lends 
itself to testing the efficacy of potential therapeutic interventions (Hausenloy et 
al., 2007). 
 
Elafin is an endogenous anti-inflammatory protein that was first isolated in the 
search for inhibitors of neutrophil elastase activity in the lung and skin 
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(Sallenave and Ryle, 1991a, Wiedow et al., 1991). It has inhibitory activity 
against both human neutrophil elastase and proteinase-3 as well as suppressing 
production of inflammatory cytokines such as interleukin-8 (IL-8) and tumor 
necrosis factor alpha (TNF-α) (Henriksen et al., 2004b). Elafin is produced locally 
at sites of inflammation, raising a local defence of ‘alarm’ antiproteases in order 
to contain and inhibit neutrophil-mediated inflammation (Sallenave, 2000a). 
Cardiovascular tissues do not express elafin or other neutrophil elastase 
inhibitors, and are therefore more vulnerable to neutrophil-mediated injury. 
 
Augmentation of human elafin has consistently demonstrated impressive 
protective effects in rodent models of ischemic and inflammatory elastase-
mediated vascular injury. Elafin infusion reduced muscular injury and neutrophil 
recruitment in the rat ischemic hind-limb and myocardial ischemia–reperfusion 
injury models (Crinnion et al., 1994, Tiefenbacher et al., 1997). Transgenic mice 
overexpressing human elafin under the control of the vascular pre-proendothelin 
promoter have relatively preserved left ventricular size and function following 
myocardial infarction (Ohta et al., 2004a). Compared to wild-type littermates, 
these animals are also protected from viral myocarditis and hypoxia-induced 
pulmonary hypertension, and exhibit less restenosis following wire induced 
carotid artery denudation (Zaidi et al., 1999, Zaidi et al., 2002a, Zaidi et al., 
2000a). Elafin augmentation therefore protects the cardiovascular system from a 
range of conditions characterized by neutrophil elastase-mediated inflammation 
and injury.  
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The purpose of the Elafin Myocardial Protection from Ischemia Reperfusion 
(EMPIRE) randomized controlled clinical trial was to provide proof-of-concept 
that Elafin treatment could reduce myocardial ischemia-reperfusion inflammation 
and injury in patients undergoing CABG surgery.  
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Methods 
 
This single center clinical trial was performed with the approval of the national 
research ethics committee (11/MRE00/5), in accordance with the Declaration of 
Helsinki (2000), under a Clinical Trial Authorization (27586/0015/001-0001) 
from the Medicine and Healthcare products Regulatory Authority (MHRA, United 
Kingdom), and the written informed consent of all participants. 
 
Trial Population 
Between June 2011 and September 2013, consecutive patients referred for 
elective CABG surgery were recruited from two clinics at Edinburgh Heart Centre. 
Patients were 18 years or older, and were referred for isolated CABG surgery 
requiring 2 or more grafts. Exclusion criteria included patients with recent 
myocardial infarction (within 1 month of surgery), emergency or concomitant 
valve surgery, significant renal impairment (estimated glomerular filtration rate 
<40 mL/min), severe respiratory disease (maintenance corticosteroid therapy or 
forced expiratory volume in one second <50% predicted), severe left ventricular 
impairment (ejection fraction <40%), contraindication to magnetic resonance 
scanning, treatment for chronic inflammatory disease, women of child-bearing 
potential and inability to provide consent.  
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Study drug and randomization 
Intravenous recombinant human Elafin (Proteo Biotech AG, Germany) 200 mg or 
saline placebo was prepared and infused as aqueous solution of 250 mL 0.9% 
saline. Patients were randomized (1:1) to receive Elafin or matched placebo by 
Edinburgh Clinical Trials Unit to ensure allocation concealment. Randomization 
incorporated minimization for age, presence of diabetes mellitus, extent of 
coronary artery disease, renal function and surgeon A or B. To ensure blinding, 
study drugs were prepared by staff independent of the study investigators or 
clinical team responsible for the patients care.  
 
Intravenous Elafin 200 mg causes complete inhibition of plasma elastase activity 
for 2 h and >50% inhibition for 6 h. This dosage regime was selected to cover 
the increased elastase release following CABG surgery that peaks at the time of 
weaning from cardiopulmonary bypass and has returned to baseline by 6-7 h. 
The study drug was administered to the patient through a central venous 
cannula over a period of 30 min. The intravenous infusion was started at first 
skin incision and completed at least 20 min before cardiopulmonary bypass 
commenced. 
 
Anesthesia and coronary artery bypass surgery 
General anesthesia was maintained with isoflurane and propofol infusion during 
bypass. Surgical approach was via a median sternotomy and cardiopulmonary 
bypass was started after heparin administration with a non-pulsatile flow and a 
membrane oxygenator. Cardioprotection was provided by cold-blood cardioplegia 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 472 
(1:4), which was administered antegradely, after cross-clamping the aorta, into 
the coronary arteries or by cross clamp fibrillation.  
 
Blood samples 
Blood samples were taken at baseline (time 0, skin incision) and at 2, 6, 24 and 
48 h post-operatively. Plasma cardiac troponin I (cTnI) concentrations were 
measured with the ARCHITECTSTAT troponin I assay and ARCHITECTSTAT high-
sensitive troponin I assay (Abbott Laboratories, Abbott Park, IL) validated in our 
institution.(Mills et al., 2011, Mills et al., 2012). Plasma concentrations of high-
sensitive C-reactive protein (hsCRP), interleukin (IL)-6, IL-8, myeloperoxidase 
and elastase were quantified using enzyme-linked immunosorbant assays 
(ELISAs; R&D Systems, U.K.; Elastase ELISA, Cambridge Biosciences, U.K.). 
Plasma elastase activity and serum Elafin concentrations were measured by the 
Department of Dermatology, University of Kiel, Germany.  
 
Cardiac magnetic resonance imaging and analysis 
Each patient underwent cardiac magnetic resonance imaging twice: within 6 
weeks before surgery and from 5 days after surgery. Patients were scanned 
using a research-dedicated 3T Siemens Verio scanner (Siemens Medical, 
Germany). Quantification of left ventricular mass, ejection fraction and late 
gadolinium enhancement infarct size were determined using established 
protocols and dedicated cardiac analysis software by two trained independent 
blinded observers.   
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Statistical analysis 
The primary outcome variable was the 48-h area under the curve (AUC) for 
plasma cTnI concentration. It was analyzed using a generalized linear model, 
including terms for the treatment allocation and the variables on which the 
randomization was minimised. Log transformations were applied as the data 
were skewed, and the results have been unlogged and presented as geometric 
means. Secondary outcome measures involving area under the curve (hs-CRP, 
IL-6, IL-8, myeloperoxidase and elastase) were analyzed similarly, taking log 
transformation if the data were skewed. Left ventricular ejection fraction and 
mass were analyzed using QMass software (Medis medical imaging systems, 
Netherlands). The change in volume of infarction from preoperative and first 
postoperative magnetic resonance scans was categorized as increased, no 
change or reduced according to detection threshold based on inter-observer 
variability.  Post hoc analyses of individual time points used Wilcoxon tests. 
 
The primary analysis included all randomized patients on an intention-to-treat 
basis regardless of compliance with allocated treatment, and post randomization 
events. A secondary pre-specified exploratory analysis of AUC cTnI release 
excluded patients who had myocardial infarction or a cardiac arrest resulting in 
loss of cardiac output for >1 min. Type V myocardial infarction was defined 
according to the third universal definition (Thygesen et al., 2012b). Finally, post 
hoc, we examined treatment effect for each time point using the high-sensitive 
cTnI assay. 
 
Power calculations were based on a recent study of patients undergoing remote 
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ischemic preconditioning before coronary artery bypass surgery (Hausenloy et 
al., 2007). Mean cardiac troponin T release quantified as area under the curve 
was 36.12 µg/L (s.d. 26.08) and 20.58 µg/L (s.d. 9.58) in the control and 
treated patients respectively. No contemporary AUC data were available for cTnI 
release in this patient group but the measurements are equivalent in terms of 
quantifying myocardial injury. With a sample size of 80 patients we had 90% 
power to detect this 40 % difference in AUC cTnI with a significance level of 5%, 
using a t-test with unequal variances and allowing for 4 dropouts in each arm. 
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Results 
 
A participant flow diagram is shown in Figure 1. In 85 of the 87 patients, the trial 
infusion was administered as planned. Patient characteristics and intra-operative 
details are shown in Table 1. Full data to calculate area under the curve for cTnI 
(primary outcome) was obtained in 83 patients (95%).  Data quality was 
similarly good for all secondary end-points with missing data evenly balanced 
across the treatment arms. 
 
Elafin infusion resulted in >3000-fold higher plasma concentrations (mean AUC 
at 24 h; 31.1±9.6 versus 0.01±0.07 μg/mL for placebo) that was associated 
with a marked reduction in plasma elastase activity (mean AUC at 24 h; 
4.28±5.13 versus 9.66±9.21units/mL; Figure 2). 
 
There was no change in mean AUC troponin concentrations over the first 48 h in 
Elafin treated patients (adjusted ratio of geometric means (Elafin/placebo) 0.74, 
95% CI 0.47 to 1.15, P = 0.18; Figure 3). There remained no evidence of a 
difference in a pre-specified secondary analysis where 3 patients who sustained 
a clinical myocardial infarction or had a cardiac arrest were excluded from 
analysis. Post-hoc analysis using the high-sensitive assay demonstrated a 
reduction of plasma cTnI concentrations in Elafin-treated patients at 6 h (median 
2.4 versus placebo 4.1 μg/L, P = 0.035; Table 2). 
Data from pre and post-operative scans were available for 34 (77.3%) Elafin and 
35 (81.4%) placebo treated patients (Table 3). There was no difference in post-
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operative left ventricular mass, left ventricular ejection fraction. The intra-class 
correlation coefficient for late gadolinium enhancement was 0.99 and the 
coefficient of repeatability of 1.78 mL (1.87 g) giving a threshold of 1.8 mL (1.9 
g) for an increase in late gadolinium enhancement. Using this threshold the 
incidence of increased myocardial infarction volume was 20.3% in Elafin and 
14.3% in placebo treated patients.  
 
There was no effect on peak myeloperoxidase concentrations (mean difference 
54.73 ng/L, 95% CI -60.0 to 169.5, P = 0.35) but peak elastase concentration 
was reduced (mean difference -168.4 ng/mL, 95% CI; -323.4 to -13.47, P = 
0.03; Figure 4). In contrast, there was no effect on the 6-h AUC for plasma 
elastase concentration (mean difference -524.0 ng/mL/48-h, 95% CI -1239 to 
191.3,P = 0.15). Although hs-CRP, IL-6 and IL-8 concentrations rose following 
CABG surgery (P < 0.001 for all), there was no treatment effect of Elafin (mean 
differences for 48-h AUC hs-CRP of 499 mg/L/48-h, 95% CI -207 to 1205, 
P=0.16) and P > 0.05 for both IL-6 and IL-8; Figure 4).  
 
Median duration of stay in the intensive care unit was 24 and 23 h for patients 
treated with Elafin and placebo respectively (HR 1.25, 95% CI; 0.81 to 1.94 P = 
0.32). Clinical outcomes and the incidence of perioperative complications in the 
first 48 h were also similar (Table 4).  
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Discussion 
 
This is the first phase 2 clinical trial investigating the effect of Elafin, an 
endogenous neutrophil elastase inhibitor, on myocardial ischemia-reperfusion 
injury in patients undergoing CABG surgery. Despite achieving >3000-fold 
increase in plasma concentrations sufficient to more than halve plasma elastase 
activity, we did not demonstrate clear evidence of beneficial effect of human 
recombinant Elafin in our patients. Specifically, we were unable to attenuate the 
systemic inflammatory response despite evidence of anti-inflammatory activity in 
preclinical disease models (Alam et al., 2012a). Nor could we conclusively detect 
a reduction in two very sensitive, complementary and gold-standard measures of 
myocardial injury: AUC for plasma cTnI concentrations and late gadolinium 
enhancement on magnetic resonance imaging despite pre-clinical studies with 
Elafin reducing myocardial inflammation and injury after myocardial infarction 
(Ohta et al., 2004b, Tiefenbacher et al., 1997). Differences between pre-clinical 
studies and the clinical CABG surgery model may have been responsible for 
different results. Elafin has never been tested in large animal models or in the 
setting of cardiopulmonary bypass surgery. The surgical population was 
relatively low risk and the use of isoflurane anaesthesia may provide 
cardioprotection (Kersten et al., 1997). Nevertheless, ischaemia-reperfusion 
injury in CABG surgery produced conditions where Elafin would be expected to 
exert a treatment effect: neutrophil activation, elastase release and heightened 
circulating elastase activity together with activation of inflammatory cytokine 
pathways. 
Elafin was safe and well tolerated in this high-risk clinical setting and post-hoc 
analysis indicated reduced myocardial injury at 6 h raising the possibility that 
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more extensive treatment effect could have been seen with multiple doses or 
bolus and sustained infusions.  
 
All patients in our trial exhibited evidence of myocardial injury demonstrated by 
cTnI release. This was associated with a marginal reduction in left ventricular 
ejection fraction detected on post-operative MRI imaging.  Small increases in 
delayed gadolinium enhancement indicative of new myocardial infarction were 
detected in a fifth of patients in keeping with sub-clinical myocardial injury and 
infarction that follows circulatory arrest and ischemia-reperfusion during CABG 
surgery. The current MRI results contrast with an earlier study reporting 
increased infarct volume in 78% of patients undergoing planned CABG (Steuer et 
al., 2004b). A key difference that may explain this discrepancy is the detailed 
patient characterization in our study with availability of pre-operative MRI scans 
allowing identification of small areas of pre-existing infarct that would be missed 
by using clinical history, echocardiography or ECGs to screen for pre-existing 
infarction.  
 
Our data indicate that with single bolus administration, Elafin does not confer 
myocardial protection in the first 48 h following CABG surgery.  This result was 
unchanged in a secondary analysis excluding patients who had sustained clinical 
events thought to be unrelated to study drug that would have contributed to 
large additional cTnI elevations. The absence of a convincing beneficial effect 
conflicts with pre-clinical ischemia-reperfusion studies where Elafin infusion was 
associated with a 27% reduction in myocardial infarct size and improved left 
ventricular performance. Our clinical CABG model allows recapitulation of a key 
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condition in pre-clinical models where Elafin is administered up front or 
expressed in tissues prior to the onset of cardiopulmonary bypass and ischemic 
tissue injury. However, despite this, we were unable to demonstrate clear 
efficacy using two complementary and highly sensitive measures of myocardial 
injury. Post hoc analysis identified a reduction in plasma cTnI concentrations at 6 
h in Elafin treated patients. Preclinical studies utilized continuous Elafin delivery 
by infusion or gene expression and the reduced cTnI concentration at an early 
post-operative time point raises the question whether continuous Elafin infusion 
following the bolus may have extended the treatment effect to 48 h. 
 
Elafin is one of several agents targeting inflammatory pathways that have been 
investigated in ischemia-reperfusion injury during cardiac surgery without 
success. Pexelizumab, a recombinant, single-chain anti-C5 monoclonal antibody, 
was studied in 2 multicenter, randomized clinical trials of patients undergoing 
CABG surgery with or without valve surgery on cardiopulmonary bypass. There 
was no difference in the primary outcome of death or myocardial infarction 
between the Pexelizumab and placebo treatment groups (Verrier et al., 2004). 
Failure of treatment effect with Elafin and Pexelizumab may reflect different 
mechanisms responsible for myocardial injury during CABG. Myocardial ischemia 
and necrosis undoubtedly occur during CABG surgery and the magnitude of cTnI 
release is correlated with subsequent morbidity and mortality (Croal et al., 
2006). Mechanism of ischemia in preclinical models commonly involves complete 
interruption of coronary blood flow with a ligature to the beating heart. In CABG 
surgery the heart is in a state of circulatory arrest with protective cardioplegia 
and the impact of blood flow interruption is less severe. Despite evidence of 
neutrophil mediated inflammatory injury post-CABG, it may be activation of 
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cellular survival pathways within cardiomyocytes that determines the outcome of 
ischemia-reperfusion in this setting. Ischemic pre-conditioning refers to 
resistance to acute myocardial ischemia reperfusion conferred by the application 
of brief repeated episodes of ischemia. This approach has been used successfully 
in CABG surgery to limit cardiac marker release (Hausenloy et al., 2007). We 
demonstrated substantial (>50%) inhibition of circulating elastase activity by 
Elafin following CABG surgery and our data therefore indicate that neutrophil-
derived elastase injury is not a prominent cause of myocardial injury in this 
setting.  
 
The patients in our study did have evidence of neutrophil activation and 
degranulation with increased plasma concentrations of the primary granule 
contents, elastase and myeloperoxidase. Peak elastase concentrations were 
reduced in Elafin-treated patients although there was no demonstrable effect on 
peak myeloperoxidase concentrations. This discrepancy is explained by 
differences in the origin of these two neutrophil primary granule proteins. 
Circulating human neutrophil elastase is derived largely from acute neutrophil 
degranulation. A pool of neutrophil-derived myeloperoxidase is transcytosed and 
bound to the subendothelial matrix (Baldus et al., 2001). This contributes to the 
circulating pool and is released following heparin administration during 
cardiopulmonary bypass (Rudolph et al., 2013). 
 
Elafin mediated reductions in elastolytic activity and myeloperoxidase staining 
(as a marker of neutrophil infiltration) have been consistent findings in pre-
clinical models. Elafin infusion produced impressive reductions in myocardial 
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inflammation and necrosis in rabbits undergoing heterotopic cardiac 
transplantation (Cowan et al., 1996). This was associated with a marked 
attenuation of myocardial elastolytic activity in transplanted hearts. Transgenic 
mice over-expressing full-length human elafin under the control of the vascular 
pre-proendothelin promoter exhibit complete inhibition of tissue elastolytic 
activity following acute myocardial infarction and carotid arterial wire denudation 
(Ohta et al., 2004a, Zaidi et al., 2000a). These favorable treatment effects 
consistently occurred with reduced tissue myeloperoxidase content in keeping 
with less neutrophil recruitment. We were not able to access myocardial tissue 
for assessment of neutrophil infiltration and elastolytic activity but the significant 
reduction in peak elastase concentration leaves open the possibility of an Elafin 
effect on neutrophil activation and degranulation which if present was not large 
enough to translate into a reduction in AUC elastase at 6 h.  
 
The EMPIRE patients exhibited increased IL-8 and IL-6 production and increased 
levels of circulating hs-CRP in keeping with a post-ischemic inflammatory 
response following CABG surgery. A systemic inflammatory response follows 
CABG surgery driven both by major surgical insult and contact activation of 
blood with artificial surfaces of the extracorporeal circuit (Day and Taylor, 2005). 
Belief that the magnitude of this response may drive clinical outcome has led to 
trials examining interventions to reduce post-operative inflammation. Peak and 
AUC hs-CRP, IL-6 and IL-8 release were similar between treatment groups. This 
result for Elafin contrasts with previous work indicating broad ranging anti-
inflammatory activity in human endothelial cells and monocyte-derived 
macrophages (Henriksen et al., 2004b). The failure of Elafin to suppress IL-8 
production during CABG surgery may indicate that additional inflammatory 
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pathways are active or that despite impacting on circulating elastase activity, 
Elafin is not reaching or is not active in the subcellular space between 
neutrophils and their target tissue.  
 
Given lack of a conclusive therapeutic effect on myocardial injury and post-
ischemic inflammation it is not surprising that the exploratory clinical endpoint of 
post-operative ITU stay was no different between treatment groups. Elafin 
infusion was safe. There were no drug related adverse events in this high-risk 
surgical group and no evidence of excessive bleeding, cardiovascular 
complications or renal dysfunction. 
 
In conclusion, despite the body of work indicating therapeutic potential from 
several groups using different models, species and modes of augmentation, 
Elafin’s promise as a therapeutic agent to attenuate myocardial ischemia-
reperfusion injury and inflammation was not translated in this first phase 2 
clinical trial. Post-hoc analysis identified reduced cTnI concentrations at 6 h in 
Elafin treated patients and it is possible that a bigger dose could have conferred 
protection out to 48 h.  Elafin was safe and lack of treatment effect was seen 
despite achieving high plasma Elafin concentrations and halving of circulating 
elastase activity.  
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Figures 
 
 
 
Figure 1: Trial flow diagram. 
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Figure 2: Perioperative plasma Elafin concentration (Left) and plasma elastase 
activity (Right) between groups. Data are median plus interquartile range from 
the first skin incision (time 0 h) to 24 h. Placebo group n = 41;Elafin group, n 
=43. 
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Figure 3: Myocardial injury. Cardiac troponin I (cTnI) release following coronary 
artery bypass graft surgery between treatment groups from first skin incision 
(time 0 h) to 48 h. Data are median plus interquartile range. Placebo group, n= 
42; Elafin group, n = 44. 
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Figure 4: Perioperative circulating concentrations of neutrophil granule proteins 
elastase (top left), myeloperoxidase (top right), inflammatory cytokines IL-6 
(bottom left) and IL-8 (bottom right) between treatment groups out to 6 h. Data 
are median plus interquartile range. Placebo group, n= 42; Elafin group, n = 44 
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Tables 
 Placebo Elafin 
Baseline characteristics 
Age 63.6 ± 8.4 63.9 ± 7.7 
2-vessel coronary 
disease 
12  (27.9) 11 (25.0) 
3-vessel coronary 
disease 
31 (72.1) 33 (75.0) 
Creatinine (mg/dl) 0.92 ± 0.18 0.94 ± 0.23 
Diabetes Mellitus 9 (20.9) 11 (25.0) 
Surgeon A 16 (37.2) 18 (40.9) 
Surgeon B 27 (62.8) 26 (59.1) 
Male Gender 36 (83.7) 38 (86.4) 
EuroSCORE 2.21 ± 1.73 2.64 ± 2.06 
Intra-operative details 
Number of bypass grafts 
One 1 2 
Two 19 14 
Three 14 22 
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Four 9 5 
Five 0 1 
Cardiopulmonary 
bypass time (min) 
77 ± 26 78 ± 26 
Cross clamp time (min) 45 ± 15 47 ± 16 
 
Table 1: Baseline characteristics and intra-operative details by treatment group.  
Data are number of patients (%) or mean ± SD 
 
 
Time 
(h) 
Placebo  
(n = 43) 
Elafin 
(n = 44) 
P 
Wilcoxon 
0 0.00 (0.0, 0.0) 0.00 (0.0, 0.0) 0.861 
2 0.08 (0.0, 0.2) 0.07 (0.0, 0.1) 0.228 
6 4.07 (2.0, 6.4) 2.41 (1.0, 4.6) 0.035 
24 1.02 (0.6, 3.9) 1.08 (0.5, 2.3) 0.421 
48 0.53 (0.2, 1.9) 0.47 (0.2, 1.2) 0.648 
 
Table 2: Post-hoc analysis of plasma cardiac troponin I (cTnI) concentration 
(μg/L, median and interquartile range, high-sensitive assay) to 48 h. 
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 Placebo (n =35) Elafin(n =34) 
Change in ejection 
fraction (%) 
-0.62±6.2 -2.4± 6.3 
Change in LV mass (g) 1.2±3.8 2.0±3.8 
Change in infarct volume (%) 
Reduced volume  2.9 0 
No Change  82.9 79.4 
Increased volume  14.3 20.6 
 
Table 3: Magnetic resonance imaging analysis of postoperative ejection fraction, 
left ventricular mass and infarct volume. 
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 Placebo Elafin 
Post-operative complications and outcomes (48 h) 
Death 0 (0) 0 (0) 
Stroke 0 (0) 0 (0) 
Myocardial infarction 0 (0) 1 (2.3) 
Inotrope or balloon 
pump support for > 24h 
10 (27.3) 12 (23.3) 
Red cell transfusion 
post-op 
12 (27.9) 12 (27.3) 
Re-operation for 
bleeding 
2 (4.7) 1 (2.3) 
Respiratory 
complications 
3 (7.0) 5 (11.4) 
Antibiotic administration 2 (4.7) 4 (9.1) 
Atrial fibrillation 4 (9.3) 3 (6.8) 
Serum creatinine (mg/dl) 
24 hours 0.90 ± 0.32 0.87 ± 0.32 
48 hours 0.96 ± 0.48 0.88 ± 0.42 
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Table 4: Post-operative complications and outcomes by treatment. Data are 
number of patients (%) or mean ± SD.  
Figure Legends 
 
Figure 1 
Trial flow diagram. 
 
Figure 2 
Perioperative plasma Elafin concentration (A) and plasma elastase activity (B) 
between groups. Data are median plus interquartile range from the first skin 
incision (time 0 h) to 24 h. Placebo group n = 41;Elafin group, n =43. 
 
Figure 3 
Myocardial injury. Cardiac troponin I (cTnI) release following coronary artery 
bypass graft surgery between treatment groups from first skin incision (time 0 
h) to 48 h. Data are median plus interquartile range. Placebo group, n= 42; 
Elafin group, n = 44 
 
Figure 4 
Figure 4: Perioperative circulating concentrations of neutrophil granule proteins 
elastase (top left), myeloperoxidase (top right), inflammatory cytokines IL-6 
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(bottom left) and IL-8 (bottom right) between treatment groups out to 6 h. Data 
are median plus interquartile range. Placebo group, n= 42; Elafin group, n = 44 
Table Legends 
 
 
Table 1 
Baseline characteristics and intra-operative details by treatment group.  Data are 
number of patients (%) or mean ± SD 
 
 
Table 2 
Post-hoc analysis of plasma cardiac troponin I (cTnI) concentration (μg/L, 
median and interquartile range, high-sensitive assay) to 48 h. 
 
 
Table 3 
Magnetic resonance imaging analysis of postoperative ejection fraction, left 
ventricular mass and infarct volume. 
 
Table 4 
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 496 
Post-operative complications and outcomes by treatment. Data are number of 
patients (%) or mean ± SD.  
 
Appendix G:  ANIMAL STUDIES  
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USPIO ENHANCED CMR IN RODENT MODEL OF MYOCARDIAL 
INFARCTION 
BACKGROUND 
We have shown that USPIO uptake occurs in the infarcted region in myocardium of 
patients following MI. However histological confirmation of monocytes taking up 
the USPIO within this region is not available. Using a pre-clinical model of MI, we 
aimed to show that USPIO does indeed identify cellular inflammation. The animal 
work was carried out by Dr Gillian Gray (GG), and imaging by Maurits Jansen 
(MJ)(BHF/ University Centre for Cardiovascular Science, Queens Medical Research 
Institute, University of Edinburgh). 
 
METHODS 
Adult male Wistar rats (200-250 g; Charles River, Margate, UK) were used. All 
experiments were performed according to the guidelines of the Animals (Scientific 
Procedures) Act 1986 (U.K. Home Office) and the National Institutes of Health (NIH 
Publication No. 85-23, revised 1996) and were approved by the ethical review 
committee for animal research at the University of Edinburgh. 
 
It was attempted to induce myocardial infarction in 3 rats by ligation of the left 
anterior descending artery as described previously (Gray et al., 2000). Adult male 
Wistar rats, 250–300 g (Charles River), were anaesthetised (isofluorane) and 
intubated via the mouth for ventilation.  Buprenorphine analgesic was administered 
subcutaneously. The chest was opened by left thoracotomy and the heart exteriorised 
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for placement of a suture (5/0 silk suture (Ethicon Ltd, U.K.)) around the left anterior 
descending coronary artery. The heart will be placed back into the chest and the 
suture will be tightened around the artery for 30 minutes using a reversible snare then 
released for reperfusion.  
 
Ferumoxytol was supplied by Advanced Magnetics Inc (Cambridge, MA) with each 
vial containing 510 mg of elemental iron in 17 mL (30 mg/mL). It was administered 
via a a tail vein injection (MJ) at a dose of 4 mg Fe/kg body weight at a rate of up to 
1 mL/sec 24 hours prior to MRI scanning, so 4 days after MI. 
4 days after infarction/reperfusion, the study rats received 4mg/kg Ferumoxytol by 
tail injection. After 24 hours, MRI (T2* - 4 echos) were performed to image the 
myocardium (Figure 1).  
The rat were sacrificed by anaesthetic overdose immediately after imaging and the 
heart was rinsed in saline and placed into 10% phosphate buffered formalin for 24h, 
then into alcohol before processing and wax embedding. 5µm sections were cut for 
histological staining. Separate parallel sections will be stained using H&E for general 
visualisation of tissue structure, Prussian blue for detection of iron oxide and a 
general macrophage antibody (ED-1). 
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Figure 1: Flow chart of protocol. 
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Magnetic resonance imaging was performed using our pre-clinical research 7T 
magnetic resonance imaging scanner (Edinburgh Preclinical Imaging, BRF, 
Chancellors Building, University of Edinburgh).  
Standard cardiac imaging ECG-gated sequences were used. USPIO imaging was 
performed using T2*-weighted cardiac gated echo gradient-echo sequences. Each echo 
will be acquired individually. Scan parameters (such as echo time to dictate degree of 
T2*-weighting) required a degree of optimisation for USPIO imaging of the 
myocardium at 7T (high concentrations of USPIO will require reduction in echo 
times).  The use of multi-echo sequence allowed a quantitative analysis of USPIO 
accumulation through calculation of T2* relaxation times before and after 
administration of USPIO. In order to optimise image analysis of T2*-weighted images 
(and prevent analysis degradation due to “T2*-blooming” artefacts) USPIO images 
was quantitatively analysed using a susceptibility gradient mapping post-processing 
technique previously used in patients with myocardial infarction. 
Analysis was performed at the Clinical Research Imaging Centre. The first MRI scan 
acquired will be used as a baseline scan. The subsequent MRI scans will be registered 
and orientated to the baseline using ANALYZE software (AnalyzeDirect Software, 
United States). The myocardium will then be separated into infarct zone and remote 
myocardium. 
RESULTS 
Successful myocardial infarction was induced in 2 rats, and 1 rat survived 24 hours 
after the procedure. 4 mg/kg of USPIO was infused via rat tail injection. The rat then 
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underwent CMR with T2* sequences, and histological analysis of the myocardium 
(Figure 2). 
 
 
Figure 2:  There was USPIO uptake in the anterior myocardium corresponding 
to the infarct zone (left). There was a high level of ED-1 staining in the 
corresponding myocardium indicating monocyte infiltration (middle). This also 
corresponded to Prussian blue staining indicating iron accumulation (right). 
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There was evidence of high USPIO uptake in the anterior myocardium corresponding 
to the distribution of the left anterior descending artery. R2* values 420 s-1 in this 
region. The same region had a high level of ED-1 antibody staining indicating high 
monocyte infiltration. The corresponding area also stained for Prussian Blue, with 
co-localisation indicating USPIO uptake by monocytes in the infarcted myocardium 
(Figure 3).  
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Figure 3: Monocytes in the infarcted myocardium stained with Prussian Blue. 
 
 
. 
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CONCLUSION 
In this model of ischaemia-reperfusion in 1 rat, we demonstrated increased USPIO 
uptake by CMR that corresponded to monocyte infiltration. This provides further 
evidence of successful non-invasive detection of cellular inflammation in the post 
infarct myocardium in the clinical setting as performed in Chapter 3: Chapter 5: 
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NANOPARTICLE ENHANCED MRI SCANNING TO DETECT CELLULAR 
INFLAMMATION IN EXPERIMENTAL CHRONIC RENAL ALLOGRAFT 
REJECTION. 
 
 
ABSTRACT 
 
Objectves: We investigated whether ultrasmall paramagnetic particles of iron oxide 
(USPIO)-enhanced magnetic resonance imaging (MRI) can detect experimental 
chronic allograft damage in a murine renal allograft model.   
Materials and Methods: Two cohorts of mice underwent renal transplantation with 
either a syngeneic isograft or allograft kidney. MRI scanning was performed prior to 
and 48 hours after USPIO infusion using T2*-weighted protocols. R2* values were 
calculated to indicate the degree of USPIO uptake. Native kidneys and skeletal 
muscle were imaged as reference tissues and renal explants analysed by histology 
and electron-microscopy. 
Results: R2* values in the allograft group were higher compared to the isograft group 
when indexed to native kidney (median 1.24 (interquartile range: 1.12 to 1.36) versus 
0.96 (0.92 to 1.04) , P<0.01). R2* values were also higher in the allograft transplant 
when indexed to skeletal muscle (6.24 (5.63 to 13.51)) compared to native kidney 
(2.91 (1.11 to 6.46) P<0.05). Increased R2* signal in kidney allograft was associated 
with macrophage and iron staining on histology. Internalised USPIO were identified 
within tissue resident macrophages on electron microscopy.  
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Conclusion: USPIO-enhanced MRI identifies macrophage infiltration within chronic 
renal damage. This technique offers the potential for non-invasive detection and 
monitoring of renal allograft refection following transplantation.  
 
 
 
INTRODUCTION 
 
Chronic allograft damage (CAD), characterised by interstitial fibrosis and tubular 
atrophy (IFTA), is the commonest cause of transplant failure following surgery. 
(Paul, 1999) The demand for organ transplantation is expanding and waiting lists for 
a kidney are likely to increase in coming years (Webb et al., 2010). Early 
identification of chronic allograft damage remains challenging but is crucial to allow 
intervention with immunosuppressive therapy. Renal biopsy remains the gold-
standard for detecting allograft rejection but is associated with significant morbidity 
and mortality. The average complication rate is 7.4% with a life-threatening 
complication occurring in 1% (Korbet, 2002, Nankivell and Chapman, 2006). It 
would be advantageous to have a non-invasive imaging approach for the detection of 
acute rejection and IFTA. This would provide an alternative or adjunctive clinical 
assessment that may reduce the number of biopsies.  
Current imaging techniques for monitoring allograft function involve the use of 
ultrasound to exclude ureteric obstruction or vascular compromise in the failing 
kidney. Measurement of vascular resistive index or the use of contrast-enhanced 
ultrasonography have been advocated, but have not been clinically validated 
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(Radermacher et al., 2003, Schwenger et al., 2006, Naesens et al., 2013). There is no 
imaging modality available to measure the development of graft fibrosis and current 
practice involves a biopsy when renal function deteriorates (Nankivell and Kuypers, 
2011). The role of monocytes and macrophages in chronic renal allograft damage has 
been well established (Magil, 2009). Monocytes and macrophages are known to play 
a role in chronic renal allograft damage (Dang et al., 2012), and are key promotors of 
fibrosis in other organs, such as the liver (Duffield et al., 2005, Ramachandran et al., 
2012). Several animal models of allograft rejection exhibit monocyte and 
macrophage infiltration in allograft tissue (Diamond et al., 1992, Hancock et al., 
1993, Heemann et al., 1994, Azuma et al., 1994, Ziai et al., 2000), and these cells 
have a central role in human chronic allograft  damage (Regele et al., 2002, Fahim et 
al., 2007). We have developed a model of chronic allograft damage: characterised by 
a single class II mismatch a kidney from C57BL/6BM12 (H-2BBM12) donor is 
transplanted into a C57BL/6 (H-2B) recipient and leads to the progressive 
development of interstitial fibrosis and tubular atrophy (IFTA) over 4 to 8 weeks. 
The key role of macrophages in this model has been demonstrated when transplants 
were performed into galectin-3 knockout recipients on a C57Bl/6 background. This 
led to an alteration in macrophage phenotype with reduced numbers of YM1-
expressing macrophages in the knockout group, and protection from IFTA (Dang et 
al., 2012). 
Magnetic resonance imaging (MRI) offers detailed characterization of the kidney 
structure without using ionizing radiation and is suitable for monitoring renal 
allograft damage with repeated scanning. Iron oxide particles have been used as a 
contrast medium for MRI as they alter the T2* relaxation time of tissues in which 
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they accumulate (Alam et al., 2012b). Ultrasmall (approximately 30 nm), 
superparamagnetic particles of iron oxide (USPIO) extravasate freely through 
capillaries and are taken up by tissue-resident inflammatory cells of the 
reticuloendothelial system (Ruehm et al., 2001b). Available USPIOs include 
ferumoxytol (Rienso, Takeda; Feraheme, AMAG Pharmaceuticals), which is 
licensed for the treatment of anaemia caused by iron deficiency in patients with 
chronic kidney disease rather than as a contrast agent for MRI. Together with other 
groups, we have used USPIO as MRI conrast in clinical studies (Alam et al., 2012b, 
Sadat et al., 2012, Richards et al., 2011a, Tang et al., 2009). 
Monocytes, macrophages and to a lesser extent neutrophils take up USPIOs, and 
accumulation in allograft rejection can be identified (Dousset et al., 1999, Gellissen 
et al., 1999a). MRI detected USPIO accumulation within the outer renal medulla in a 
model of renal ischaemia and this correlated histologically with USPIO uptake by 
macrophages (Jo et al., 2003a). USPIO have been used to investigate acute renal 
transplant rejection in pre-clinical models, however these effects may have been due 
to ischaemia reperfusion injury (Zhang et al., 2000, Ye et al., 2002). We 
hypothesized that they could be used to identify inflammation and fibrosis in a model 
of chronic renal allograft damage. 
 
 
MATERIALS AND METHODS  
 
Murine Model of Renal Transplantation 
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Two cohorts of C57BL/6 mice underwent renal transplantation. Syngeneic renal 
transplants (n=8) were performed between litter mates and allograft renal transplants 
from C57BL/6BM12 donors  into C57Bl/6 recipients (n=10). Characterised by a single 
class II mHC mismatch, such kidneys develop chronic allograft damage over a 
progressive twelve-week period.  The model is not transplant-dependent as the 
contralateral kidney is left in situ. The isograft transplanted kidney and the native 
non-transplanted kidney were available as controls for comparison with the allograft 
kidney. Mice were bred in-house in the Biomedical Research Resources, University 
of Edinburgh or purchased from Charles River. All animal experiments were 
performed under a project licence and in accordance with legislation in the Home 
Office Animal (Scientific Procedures) Act of 1986. Baseline MRI scanning was 
performed 4 weeks post transplant followed immediately by an infusion of USPIO 
by tail vein injection (4 mg/kg ferumoxytol; Rienso, Takeda). Repeat MRI scanning 
was performed 48 hours post infusion.  
 
MR Imaging Protocols.  
All MRI experiments were performed using a 7 Tesla horizontal bore NMR 
spectrometer (Agilent Technologies, Yarnton, UK), equipped with a high-
performance gradient insert (60-mm inner diameter), maximum gradient strength 
1000 mT/m. Mice were anaesthetised with 1.5% isofluorane in oxygen/air (50/50, 
1 L/min) and placed in a cradle (Rapid Biomedical GmbH, Rimpar, Germany). The 
rectal temperature and respiration rate were monitored throughout the experiments, 
and body temperature was maintained at 37 °C with a heat fan. A 33-mm diameter 
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birdcage volume coil (Rapid Biomedical GmbH, Rimpar, Germany) was used for 
radio frequency transmission and signal reception. For anatomical assessment and to 
aid placement of the slice for the T2* mapping sequence, respiration-gated T2-
weighted fast spin echo images (echo train length of 8) of 1-mm slice thickness in a 
coronal orientation were collected with the following parameters: repetition time 
(TR) ≈ 3000 ms depending on the respiration rate; effective echo time = 36 ms; 16 
slices, field of view = 35 mm × 35 mm; matrix = 192 × 128, 2 signal averages. For 
T2* mapping and calculation of T2* relaxation times, image acquisition used a 
gradient echo, respiratory-gated pulse sequence (dummy pulses during respiratory 
movement) of 7 images weighted in T2* acquired consecutively; TE = 1.83, 3, 5, 7, 
10, 12, 15 ms and a TR of 60 ms. The field of view was 35 x 35 mm and the 
acquisition matrix 192 × 128  (in-plane resolution = 0.182 × 0.273 mm). Slice 
thickness was 1-mm with 2 signal averages. 
 
USPIO imaging was performed with T2*-weighted gradient-echo sequences using a 
7 T MRI scanner. Quantitative analysis of USPIO accumulation was achieved by 
calculation of T2* relaxation times before and after administration of USPIO.(Alam 
et al., 2012b) In order to optimise image analysis and prevent degradation due to 
“T2*-blooming”lartefacts, images were quantitatively analysed using a susceptibility 
gradient mapping post-processing technique previously used in SPIO imaging to 
quantitate USPIO accumulation using changes in calculated T2* relaxation 
times.(Dahnke et al., 2008)  
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Image Analysis 
The seven echoes in the multi-echo T2*-weighted sequence were combined to 
generate a T2* map, in which the data represented the T2* value (S(t) = S(0)exp- 
(t/T2*)) for each voxel. This was achieved using in-house software developed in 
Matlab (Mathworks, US). The T2* value is the decay constant for the exponential 
decay of signal intensity with time. In the presence of USPIO, the signal decays more 
rapidly due to local field inhomogeneities and the T2* value is reduced. By 
minimising the sum of the squares of errors between the data and an exponential 
function, the decay constant (i.e. T2* in ms) was obtained. An experimentally 
determined threshold for the co-efficient of determination (r2>0.85) was used to 
exclude data that did not have an acceptable exponential decay when SI was plotted 
against echo time. The inverse of T2*, R2*, was then calculated to assess USPIO 
uptake. The greater the accumulation of USPIO in tissues, the greater the R2* value.  
R2* values were obtained from baseline and 48-hour scans using ANALYZE 
software (AnalyzeDirect Software, United States). Regions of interest were drawn on 
parenchyma, and pre-USPIO scans compared to post-USPIO scans. A semi-
quantitative analysis was made from the increase in R2* value. To correct for 
differences in blood pool USPIO concentration, due to infusion errors or difference 
in blood volume, the transplanted kidney R2* increase was indexed to the native 
kidney R2* increase. To provide a value of translational value to clinical medicine, 
where a normal healthy native kidney will not be present, the renal R2* increase was 
also indexed to skeletal muscle R2* increase. 
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Allograft Injury - Histology 
Kidneys were divided and fixed fresh frozen or in methyl carnoy’s solution and 
embedded in paraffin.  Tissue sections were stained with haematoxylin-eosin to 
allow histological analysis, and reveal presence of inflammatory infiltrate.(Qi et al., 
2008, Jabs et al., 2003)  
 
Allograft Injury - Cellular Infiltrate 
Macrophage infiltration was identified by F4/80+ (Abcam, Cambridge, UK) staining 
by immunohistochemistry using paraffin embedded tissue sections.  Light 
microscopy was performed and images obtained and quantified by computer-assisted 
image analysis of 10 sequentially selected non-overlapping fields of renal cortex and 
medulla and expressed as the percentage of tissue surface area positive for staining.   
 
Electron microscopy  
For transmission electron microscopy, samples were fixed in 3% glutaraldehyde in 
0.1M sodium cacodylate buffer, pH 7.3, for 2 h then post-fixed in 1% osmium 
tetroxide in 0.1M sodium cacodylate for 45 min.  Samples were then dehydrated and 
embedded in araldite resin. Ultrathin 60-nm sections were cut from selected areas, 
stained in uranyl acetate and lead citrate then viewed in a Philips CM120 
transmission electron microscope, images obtained with a Gatan Orius CCD camera. 
 
Statistical Analysis 
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Statistical analysis was performed with GraphPad Prism version 4.00 (GraphPad 
Software, San Diego California USA). Grafts were compared with native kidneys 
using paired two-tailed non-parametric t-tests (Wilcoxon matched-pairs signed rank 
test). Isograft and allograft kidneys were compared using non-paired two-tailed non-
parametric t-tests (Mann Whitney test). Statistical significance was taken as a two-
sided P<0.05. 
 
 
RESULTS  
One allograft and 2 isograft recipients sustained infarction of the transplanted kidney. 
This left 9 allograft mice and 6 isograft mice for analysis. 
 
Change in R2* values in allograft and isograft kidneys 
Illustrative MRI scans with R2* signal derived colour maps of USPIO uptake in 
allograft and isograft kidneys are shown in Figures 6 & 7. Increased R2* signal and 
USPIO uptake is indicated by green and red colour. 
Baseline R2* values were similar in native (median (interquartile range), 42.8 ( 38.5 
to 50.5) ms-1)and allograft kidneys (44.2 (39.6 to 52.8) ms-1). USPIO administration 
increased R2* values in both isograft and allograft kidneys. The increase in R2* 
value at 48 h was greater in allograft kidneys (30.15 (14.0 to 68.0) ms-1) compared to 
native kidney (15.7 ( 4.5 to 26.8) ms-1, P < 0.01). In contrast, the increased R2* 
signal in isograft kidneys at 48h (23.24 ms-1 (7.53 to 71.2) ms-1) was no different to 
native kidney (26.4 ms-1 (3.71 to 86.9) ms-1), P = 0.58).  
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Figure 6: Transplanted kidney (white arrows) compared to native kidney 
(yellow arrows) for allograft. 
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Figure 7: Transplanted kidney (white arrows) compared to native kidney 
(yellow arrows) for isograft. 
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R2* value increases indexed for changes in native kidney and skeletal muscle are 
shown in Figure 8. Median increase (interquartile range), indexed for native kidney, 
was greater in allografts 1.24 (1.12 to 1.36) compared to isografts 0.96 (0.92 to 1.04), 
P < 0.01, Figure 2A. A similar result was obtained following indexing for skeletal 
muscle R2* increase (Figure 2B). The median increase in R2* value indexed to 
skeletal was greater in the allograft kidney 6.24 ( 5.63 to 13.51) compared to native 
kidney 2.91 (1.11 to 6.46), P < 0.05. The corresponding skeletal muscle indexed 
signals were similar in isograft 3.83 ( 0.78 to 6.24) and native kidneys 3.63 (1.00 to 
5.33) and significantly lower than the allograft signal, P < 0.05.  
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Figure 8: Increase in R2* value from baseline to 48 hours for transplanted 
kidney indexed to native kidney (A) and skeletal muscle (B). 
 
 
 
  
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 518 
Histology and Electron Microscopy 
F4/80 staining confirmed heavy macrophage resident cells in the allograft kidneys 
(2.70±0.84 percentage area staining) with very few cells in in the isograft kidneys 
(0.52±0.44 percentage area staining), (Figures 9 & 10). Iron staining with Prussian 
blue demonstrated deposition in allograft tissue with none in the isograft tissue. The 
reticulo-endothelial tissue of the spleen was also rich in monocyte and iron staining. 
Electron microscopy confirmed monocyte/macrophage USPIO uptake within the 
renal tissue (Figure 11). 
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Figure 9: F4/80 staining (top panel) for monocyte derived macrophages in the 
spleen and allograft and isograft (hollow arrows). Prussian blue staining 
(bottom panel) comparing iron deposition in the spleen, allograft tissue and 
isograft (sold black arrows). 
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Figure 10: Histological monocyte count in allograft, isograft and non-
transplanted native kidneys. 
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Figure 11:  Electron microscopy of macrophages in renal allograft tissue. The 
inlay (top right - magnification from black box) demonstrates USPIO within 
lysosomes. 
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DISCUSSION 
We have shown for the first time that USPIO-enhanced MRI can detect macrophage 
infiltration in a model of chronic inflammatory allograft damage. The prospect of 
non-invasive detection and monitoring of CAD, without resorting to renal biopsy, 
would be a significant advance in the management of renal transplant patients. 
 
In this study the allograft USPIO signal was significantly increased compared to the 
native kidney. This direct comparison would be not feasible in a clinical study where 
the native kidney would be diseased or absent. Additionally human pathological 
factors may impact on the USPIO related signal. USPIO has a circulating half life of 
18-30 hours and persistence of particles in the circulation will affect the tissue R2* 
value due to perfusion (Landry et al., 2005). In this study differences in blood 
volume and organ perfusion, due to surgical blood loss or physiological variation 
related to inflammation and rejection, may contribute to the blood pool related signal 
in each animal. To address this problem we indexed USPIO signal to skeletal muscle 
and native kidney. These findings on non-invasive imaging were associated with 
greatly increased macrophage infiltration and USPIO iron staining in allografts 
compared to isografts. We were able to further demonstrate macrophage USPIO 
uptake on scanning electron microscopy confirming that the USPIO signal on MRI 
was related to the macrophage infiltration in CAD. 
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It was not possible to be certain about the mechanism of cell labeling and distribution 
of USPIO within renal tissue. As a result of their smaller size, USPIOs are less 
readily recognized by phagocytic cells and persist in the circulation for longer than 
other iron particles (plasma half-life 14-30 h in humans) (Landry et al., 2005, Hunt et 
al., 2005). They are capable of passing through capillary walls, to be taken up 
through pinocytosis by tissue-resident macrophages and neutrophils (Ruehm et al., 
2001b, Dousset et al., 1999, Gellissen et al., 1999a). Extravasated USPIO may 
remain in the interstitial space or be taken up by resident macrophages. Circulating 
USPIO may also be taken up by monocytes that subsequently infiltrate the kidney.  
These processes (monocyte uptake, USPIO blood extravasation and resident 
macrophage uptake) may have different kinetics and could all contribute to the 
increased USPIO signal in allografts. The study aim was to provide proof of 
principle that allograft rejection can be detected non-invasively with contrast MRI 
but this approach could be used to further dissect out CAD mechanisms. 
 
 
Significant advances have been made in the management of acute rejection as 
modern immunosuppressive agents target primarily T lymphocytes. However, the 
rate of CAD characterized by interstitial fibrosis remains relatively constant, giving 
rise to the loss of 4% renal transplants per year. Work from our own group has 
demonstrated that modification of macrophage biology can protect against fibrosis in 
this model of CAD and the role of macrophages in renal and liver fibrosis has been 
well established (Dang et al., 2012, Henderson et al., 2008, Duffield et al., 2005, 
Ramachandran et al., 2012). Examination of macrophage phenotype was beyond the 
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remit of this study, which focused primarily on imaging, but would be of interest to 
determine whether the macrophages were predominantly YM1-expressing pro-
fibrotic phenotype.  
 
One limitation of the study is that imaging was performed at 4 weeks post-transplant, 
when there was already histological evidence of fibrosis and, as the model is not 
transplant dependent, it is not possible to ascertain whether deterioration in renal 
function had already occurred. However this is a proof of principle investigation to 
determine the feasibility of such an approach, and subsequent work will require 
imaging at earlier time points and correlating with renal function. 
 
Blooming artefact associated with T2*/R2* imaging with MRI is another potential 
limitation. These distortions can be erroneously included in the region of interest 
covering the renal tissue leading to falsely high R2* readings. In our study, this was 
particularly evident when the spleen laden with USPIO could distort the values in the 
neighbouring transplanted kidney. Care was taken to avoid drawing regions of 
interest over such areas. In addition, T2*/R2* imaging identifies areas or tissue 
edema or hemorrhage in other organs, and as such the differing R2* values of 
baseline scans may have been due to differing amounts of edema (Ghugre et al., 
2011). Finally, the relationship between R2* value and iron accumulation is non-
linear, and so absolute increase in R2* value may not be directly proportional to 
increased inflammation (Patterson et al., 2011). The technique is semi-quantitive and 
so increasing values do indicate an increase in the number of monocytes or 
macrophages in a tissue, or an increase in activity. There was a range of values in the 
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allograft group, suggesting a differing amount of inflammation in the different 
allografts. As the mechanism of rejection in this model of CAD is multifaceted a 
single measurement at 4 weeks is expected to have variation given that this model 
develops gradual histological injury up to 12 weeks and beyond (Tse et al., 2013). 
 
The USPIO agent Ferumoxytol is used as an intravenous iron supplementation agent 
for patients with end stage renal failure. It has an good safety profile and is an ideal 
agent for investigation of transplant rejection in patients (Schiller et al., 2014). 
Further translational studies are needed to identify if there is a R2* threshold value 
which would identify a level of excessive inflammation requiring alteration of 
therapy. 
 
In conclusion, we have developed an MRI technique for detecting inflammation in a 
model of chronic renal allograft damage. The protocol employs USPIO contrast that 
is compatible with patients who have renal dysfunction. This non-invasive approach 
for the detection of changes of CAD offers the possibility of avoiding renal biopsy in 
some patients. Translational studies are required to assess its applicability in clinical 
practice. 
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Appendix H:  FUTURE STUDIES 
 
IRON NANOPARTICLE ENHANCED MRI IN THE ASSESSMENT OF MYOCARDIAL INFARCTION 
(IRNMAN) TRIAL 
 
Study Population 
All patients will undergo intensive clinical phenotyping including demographics, 
cardiovascular risk factors, concomitant medication, past medical history, clinical 
examination and standard clinical haematological and biochemical analyses. All 
patients will be followed up out to at least 3 months through clinic visits and 12 
months by electronic patient record tracking. 
We will recruit 80 patients. 
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Table 1: Inclusion and exclusion criteria  
Inclusion Criteria:  Exclusion Criteria: 
>18 years Critical (≥95%) left main stem coronary artery 
stenosis 
Plasma troponin concentration >5 ng/mL; upper 
limit of normal 0.04 ng/mL)  
Continued symptoms of angina at rest or 
minimal exertion 
Acute myocardial infarction defined according to 
the Universal Definition of myocardial 
infarction.(Thygesen et al., 2007b) 
Past history of systemic iron overload or 
haemochromatosis 
 Renal failure (estimated glomerular filtration 
rate <25 mL/min) 
 Contraindication to magnetic resonance 
imaging 
 Significant heart failure (Killip class ≥2) 
 Known allergy to dextran- or iron-containing 
compounds 
 
  
APPENDICES 
Detection, assessment and modulation of myocardial inflammation 564 
Study Groups 
In the first 40 patients, subjects will receive USPIOs on a specific day after acute 
myocardial infarction; day 1-3, day 4-9, 10-20 or day 89±14 days (n=10 per group). 
All subjects will be scanned on days 2-4, 5-10, 11-21 and 74-104 as well as on the 
day of, and immediately prior to, USPIO administration. This will be subject to 
patient availability and scanner availability. This will provide an assessment of the 
time course of the uptake of USPIOs. Half of the recruited patients will receive a 
second infusion of USPIO at 3 months followed by repeat MRI scanning 24 hours 
later. This will provide information regarding any residual inflammation at this point, 
and if absent allow patients to acts as their own controls for scan comparison. 
Thus the patient schedule will follow one of the pathways in Figure 1. 
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Figure 1: Time course of USPIO infusion and MRI scans 
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Based on this data, we will select the optimum time to administer USPIOs and 
undertake this in the remaining 40 patients.  
 
Administration  
Ferumoxytol (Rienso) will be supplied by Takeda and each vial contains 510 mg of 
elemental iron in 17 mL (30 mg/mL). It will be administered via a peripheral venous 
cannula at a dose of 4 mg Fe/kg body weight at a rate of up to 1 mL/sec. We have 
administered this preparation in our pilot studies without adverse effect.  
 
Magnetic Resonance Imaging 
Magnetic resonance imaging will be performed using our British Heart Foundation-
funded clinical research 3T magnetic resonance imaging scanner (Siemens 3T Verio) 
at the Clinical Research Imaging Centre at the Queen’s Medical Research Institute, 
University of Edinburgh.  
 
Standard cardiac imaging breath-held ECG-gated sequences and USPIO imaging will 
be performed as per the pilot study and EMPIRE trial described in chapters 2 & 3. 
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Systemic Markers of Inflammation 
We will undertake detailed phenotyping of these patients including accurate 
recording of clinical characteristics, risk factor profile, systemic inflammatory 
markers (including MCP-1), infarct size and oedema as well as follow them up for 
clinical outcomes at 3, 6 and 12 months. Prior to each MRI scan, approximately 50 
mL peripheral venous blood will be obtained from each volunteer for the 
measurement of systemic markers of inflammation and inflammatory cell activity 
such as high sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), IL-8, 
TNF, MCP-1 and full blood count for differential leucocyte count.  
 
Data Analysis and Statistics 
Data will be compared using analysis of variance with repeated measures and 
unpaired and paired Student’s t-test as appropriate. For continuous variables, 
regression analysis will be performed to explore for associations. Statistical 
significance will be taken as a two-sided P<0.05.  
We will be undertaking a time-course assessment of USPIO uptake in 30 patients 
following acute myocardial infarction. Based on our preliminary pilot data, the mean 
R2* value for myocardium is 0.041 with a standard deviation of 0.016. Following 
USPIO administration we expect are a 4-fold increase in the R2* value 
(0.164±0.051). Given the different time points and gradation of uptake, we wish to 
be able to detect a 50% increase in R2* value. At 80% power and two-sided P<0.05, 
we will require 10 subjects per group. We will assess key clinical factors such as 
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infarct size to assess for determinants of USPIO uptake. For a sample size of 60 
patients, we will have 80% power at two-sided P<0.05 to detect a correlation of 
≤0.35 between the change in the R2* and clinical correlates. Allowing for drop out 
due to the multiple scanning regimen, we aim to recruit 80 patients. 
 
Expected Value of Results 
We propose to describe, characterise and identify the determinants of USPIO uptake 
using the clinical model of acute myocardial infarction. This will be the first 
description of this ‘smart contrast agent’ in the setting of acute myocardial infarction 
and, if successful, this technique has many major potential benefits and 
ramifications. First, it may assist in risk stratifying patients who may have an adverse 
outcome. For example, intense and persistent USPIO uptake may be associated with 
adverse remodelling and progression to heart failure. Second, it will provide a 
method of assessing the inflammatory and reparative processes following infarction. 
This may be a useful biomarker to assess the impact of therapeutic interventions. 
 
DETECTION OF CELLULAR INFLAMMATION WITH FERUMOXYTOL IN THE HEART: 
DECIFER-HEART TRIAL 
 
Study Design 
This is an open-label comparative investigational cohort study.  
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Patients from each of the 3 cohorts (see below) and 20 control subjects (with a wide 
and evenly distributed range of age and sex) will undergo a baseline MRI scan. They 
will then receive USPIOs immediately after this, with repeat scanning 24 hours later 
to assess USPIO uptake (Figure 2).  
In patient cohorts, MRI scans will be repeated after 3 months to assess response to 
treatment, or a change in clinical status. Prior to the MRI scans, approximately 100 
mL peripheral venous blood will be obtained from each volunteer for the 
measurement of systemic markers of inflammation and inflammatory cell activity 
such as high sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), IL-8, 
tumour necrosis factor alpha (TNF), monocyte chemotactic protein 1 (MCP-1) and 
full blood count for differential leucocyte count. To characterise the inflammatory 
cell phenotype, blood will also be taken for flow cytometry to assess the surface 
expression markers of peripheral blood mononuclear cells (Tsujioka et al., 2009). 
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Figure 2: Time course of USPIO infusion and CMR scans 
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Cohort 1: 20 patients under routine follow up after cardiac transplant. 
Patients will be recruited from the national advanced heart failure and cardiac transplantation 
unit at the Golden Jubilee National Hospital, Glasgow. Currently 121 patients are under 
regular surveillance and will include a clinical spectrum ranging from no rejection to those 
with clinical and histological signs of acute rejection. The results of CMR scanning will be 
compared when possible to biopsy samples in all patients using the International Society for 
Heart and Lung Transplantation (ISHLT) grading system (which was introduced in 1990 and 
revised in 2004) (Stewart et al., 2005). We will predominantly recruit patients who exhibit 
clinical features suggesting differing stages of rejection, although we will also recruit 
patients who appear well without clinical evidence of rejection. 
Cohort 2: 20 patients diagnosed with acute myocarditis.Patients will be recruited 
from all centres. The clinical diagnosis of acute myocarditis is not well defined and 
there are no internationally recognised diagnostic criteria. It is therefore a diagnosis 
of exclusion and maybe caused by infection, chemotherapy, auto-immune conditions 
or unknown aetiologies.  Occasionally patients may undergo myocardial biopsy 
when a more definitive diagnosis can be made although this is subject to sampling 
bias (Feldman and McNamara, 2000). Patients with acute myocarditis will be 
recruited if the diagnosis has been made by a cardiologist based on clinical, 
biochemical, electrocardiographic, echocardiographic or angiographic data. We will 
perform a post hoc analysis to define aetiologies. If subsequent to the initial scan, the 
clinical diagnosis changes from being one of myocarditis, this will exclude the 
patient from the cohort. 
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Cohort 3: 20 patients with cardiac sarcoidosis. 
Patients will be recruited from the national cardiac sarcoidosis service at the Royal 
Brompton Hospital with the assistance of Professor Athol Wells and Dr Elizabetta 
Renzoni. The diagnosis will be made by the internationally recognised guidelines of 
the “Japanese Society of Sarcoidosis and Other Granulomatous Disorders”.(Dubrey 
and Falk, 2010) Patients with new presentation of active sarcoidosis will be 
recruited. The Royal Brompton Hospital sees over 150 new cases of sarcoidosis each 
year with approximately a quarter having cardiac involvement. The total database 
includes over 1,000 patients with sarcoidosis, of whom approximately 300 have 
cardiac involvement. We will recruit patients who have been diagnosed clinically 
with acute cardiac sarcoid by the specialist team. If subsequent to the initial scan, the 
clinical diagnosis changes from being one of cardiac sarcoidosis, this will exclude 
the patient from the cohort. 
Cohort 4: 20 healthy volunteers. 
We will recruit healthy volunteers through advertising, with a wide and evenly 
distributed range of age and sex. Subjects will have no significant past medical 
history and be otherwise fit and well in order to act as a normal reference population 
and to define any non-specific myocardial USPIO uptake. 
Patients will be excluded if they have had a diagnosis of myocardial infarction within 
1 month, renal failure (estimated glomerular filtration rate <25 mL/min), 
contraindication to magnetic resonance imaging, past history of systemic iron 
overload or haemochromatosis, polycythaemia or known allergy to dextran- or iron-
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containing compounds. All patients will undergo intensive clinical phenotyping 
including demographics, cardiovascular risk factors, concomitant medication, past 
medical history, clinical examination and standard clinical haematological and 
biochemical analyses.  
The research team will track relevant or significant clinical outcomes for up to 5 
years after the study is completed, by examining local electronic health records at 
each centre. 
We will recruit 80 participants (over 24 months), 20 in each cohort.  Recruitment 
will take place in three centres; Royal Infirmary of Edinburgh, Golden Jubilee 
National Hospital in Glasgow and the Royal Brompton Hospital in London.  
Sample Size Calculation 
There will be tissue resident macrophages as well as possible continued influx of 
monocytes into the myocardium of the 3 patient cohorts. However the concentration 
of such inflammatory cells in each condition is unknown. In a pilot study however, 
we found that the change in myocardial R2* value in patients with myocardial 
infarction pre and post USPIO was 114+/-60s-1 compared to 41±15 s-1 in healthy 
controls.  That said, the R2* value in MI patients was however taken from within the 
infarct area, and an average of infarct and remote myocardial tissue would yield a 
lower value. Given the less intense anticipated inflammation in our 3 cohorts, we 
estimate an increase in R2* value of at least 10s-1 when compared to controls giving 
an R2* value least 51s-1. Assuming a two-sided 5% level of significance and 80% 
power, we would require a sample size of 18 in each group. 
